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ABSTRACT 
Problems associated with the inefficient or ineffective use of medicines at the 
interface between primary and secondary health care are well recognised and remain 
largely unresolved. Attempts to resolve difficulties at the interface have, to date, 
focused on national guidance with a view to improving communication between 
health care professionals. The research presented in this thesis examines the root 
causes of problems with the management of medicines with a view to reappraise 
traditional definitions of the interface and to learn of the perspectives of the main 
stakeholders - community phannacists, hospital phannacists, general medical 
practitioners and hospital medical consultants. The objectives of the research were: 1. 
To describe and categorise problems relating to the care transfer process that lead to a 
deterioration in medicines management, 2. To critically appraise the local 
interpretation and implementation of health policy, 3. To describe staff 
communication and decision-making processes and 4. To explore reasons why 
guidance is not put into practice. 
The research was conducted in a district general hospital whilst the researcher was 
employed as an Interface Phannacist. Qualitative methods of data collection were 
deployed as follows. First, 87 case study examples of interface issues were collected 
from reports made by doctors and phannacists in primary and secondary care and 
those identified by the researcher. A root cause analysis of each case showed how 
deficiencies in medicines management processes could contribute to problems and 
difficulties. The medicines management processes relevant when patients are 
transferred between primary and secondary care, together with the root causes of 
interface issues were mapped. The next stage ofthe research involved conducting 
focus group and semi-structured interviews with seven community phannacists, 
sixteen hospital pharmacists, nine general practitioners and two hospital medical 
consultants. Content analysis, based on qualitative research theory, showed 
participants' perspectives of medicines management across the interface. The 
perspectives of patients were gained through semi-structured interviews with 101 
patients attending hospital outpatient clinics and eight medical inpatients. Patients 
were followed up after the hospital episode to detennine whether they had 
experienced any difficulties with their medicines. 
Three key outcomes emerged from the research. First, an improved understanding of 
the types of medicines management issues that arise when patient care is transferred 
across the interface. Second, four causes of sub-optimal medicines management 
across the interface were identified, a lack of awareness or misunderstanding of 
policy, inadequate inter- or intra-professional collaboration, impracticable or 
inflexible policy or flagrant violation of policy. Change management theory was 
utilised in order to confirm the presence of barriers that prevent medicines from being 
managed effectively at the interface and demonstrate why guidance has failed to 
improve the situation. Finally, this research has led to an improved understanding of 
the interface and its constituent dimensions which helps appreciation of the type of 
interventions that may be necessary in order to improve seamless care. 
Xl 
ACKNOWLEDGEMENTS 
I would like to take this opportunity to thank the many people whose help made this 
thesis possible. 
First of all thanks go to Dr Malcolm Partridge, Chief Pharmacist at the Derby City 
General Hospital at the start of the research. Without his vision there would not have 
been an Interface Pharmacist post at the hospital and I would not have had the 
opportunity to undertake this research. 
Special thanks also to my Director of Studies, Dr Peter Rivers, for excellent advice 
and support and helping me to see the way forward. Also, to Dr David Gerrett, my 
second supervisor, for encouragement and offering alternative perspectives and Dr 
Ruth Goldstein for her supervision at the start of the research. 
To my fellow research students, Hazel, Sharon, Adrian, Paul and Asiya I would like 
to say thank you for sharing the experience and raising a smile when things seemed 
impossible. 
Finally, Neil, I couldn't have done this without you. 
xii 
CHAPTER ONE 
COMPOSITION OF THE PRIMARY / SECONDARY CARE INTERFACE 
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2 
CHAPTER ONE 
COMPOSITION OF THE PRIMARY / SECONDARY CARE INTERFACE 
1.1 INTRODUCTION 
This thesis is concerned with the numerous processes and interactions between health 
care professionals that take place when the care of patients is transferred from the 
hospital environment to that of primary care. The transition of care that takes place 
each time a patient is discharged from hospital does not involve the passage through 
any real physical barrier. However, the separate managerial processes that have, over 
the years, developed into two essentially separate and independent organisations, has 
resulted in a theoretical barrier that has come to be known as the 'interface' between 
primary and secondary care. 
There are many reports in the literature of problems with the use of medicines 
occurring when the responsibility for patient care is transferred between health care 
professionals in primary and secondary care. Research, to date, concentrates on the 
miscommunication that occurs between health care professionals across the interface 
resulting in compromised patient care. To the present day, however, despite the 
publication of national guidance over a period of approximately 20 years, 
communication problems persist and continue to result in inconvenience, inefficiency 
and in rarer, but important instances, morbidity and mortality. 
Whilst the primary / secondary care interface has been blamed for poor patient 
outcomes, much of the research does not adequately take account of the complexity of 
the interface nor explain why so many problems relating to the interface result in 
detrimental patient care. Current thinking is that it is a theoretical transitional state 
that patients must cross in order for care to be transferred efficiently between primary 
and secondary care. This chapter focuses on a comprehensive exploration of the 
interface in order to illustrate its specific elements and how they have a direct impact 
on the well-being of patients. 
In the first two chapters of this thesis two substantial bodies of literature will be 
reviewed. First, the structure and process ofNHS health care will be considered in 
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terms of how it relates to the interface and its constituent components. Management 
arrangements together with resource allocation and policy making will be taken into 
account with particular regard to policies relating to the use of medicines. The roles 
of health care professionals who provide NHS care will be discussed from both an 
inter- and intra-professional perspective. 
After exploring the structure and process of health care and the wider, more complex 
dimensions of the interface, the second chapter will specifically consider the problems 
with medicines that arise when patients are transferred between primary and 
secondary care settings. This will provide an understanding of the primary / 
secondary care interface and the type of medicine problems created and exacerbated 
as a result of it. Then, in Chapter Three, the major organisation change management 
theories are outlined. An appreciation of change management theory is necessary in 
order to understand how improvements in the management of medicines can be 
brought about. 
The aim of the present study was to identify and contextualise difficulties and 
deficiencies which may compromise the effective delivery of medicines management 
when patients are transferred between primary and secondary care environments in 
the Southern Derbyshire health economy. The specific objectives were, first, to 
describe and categorise medicine management problems occurring when patients were 
transferred and the associated communication and decision making processes. Then, 
to appraise the local interpretation and implementation of policy relevant to the 
management of medicines across the interface and explore reasons why policy had not 
been put into practice. 
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1.2 DEFINING THE PRIMARY / SECONDARY HEALTH CARE 
INTERFACE 
First, an explanation is required of what is meant by primary and secondary health 
care and the concept of the primary / secondary care interface. The structural 
components of the NHS as defined by Donabedian (1980) will be discussed in order 
to demonstrate how changes over time affect the way medicines are used. Structural 
components relate to management structures and lines of accountability, resource 
allocation and the policy making and implementation process. It is important to 
appreciate that external factors such as the marketing of medicines by the 
pharmaceutical industry also have an impact on policies relating to the primary / 
secondary care interface. Later, when discussing the process of care, the roles and 
responsibilities of health care professionals within and between disciplines in primary 
and secondary care will be considered. Inter- and intra-professional relations will be 
explored, including communication channels. Finally, a summary is provided of how 
these different components interact to produce the primary / secondary care interface 
which impacts on the quality of patient care. For simplicity the primary / secondary 
care interface will, from now on in this thesis, be referred to as the 'interface'. 
Consultation with a general medical practitioner (OP) is normally the first point of 
contact of a patient with the health care system, hence the term 'primary care' . 
Ultimately, OPs are responsible for patients in primary care but not all care is 
provided by doctors. Practice and community nurses, community pharmacists and 
other professions allied to medicine play important roles. As will be shown later 
however, the role of the community pharmacist within the primary health care team is 
tenuous and may result in gaps in the continuity of care that adversely affect 
medicines management processes. 
Secondary care is largely hospital-based and access is generally via OP referral. Once 
a care plan has been agreed it is normal practice and recommended NHS policy for 
the responsibility for patient care to be transferred back to OPs (NHS Modernisation 
Agency,2004a). There is no capacity within secondary care for patients with 
common conditions to be followed up, either to monitor their progress or to issue 
repeat prescriptions. The secondary care system attempts to make the best use of 
hospital medical consultants' time by ensuring that the patients they see require a 
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specialist's expertise. However, this system is often not adhered to with the result that 
many patients seen in outpatient clinics are in 'follow-up' (Burkey et ai, 1997). Then, 
when hospital clinics are taken up with patients who should be followed up in primary 
care, new patients have to wait longer for an appointment with a hospital medical 
consultant. 
Many previous researchers have investigated the impact of the interface on health care 
but few definitions of the interface have been attempted. Baker et al (1999) defined 
care across the interface as 'beginning at the point of referral from a general 
practitioner, and including outpatient, inpatient and post-discharge care'. However, 
this does not fully explore the interface to determine how it is constructed and impacts 
on patient care. For the purposes of this thesis the interface is defined as: 
'The state that patients must pass through when responsibility for their care transfers 
from primary to secondary health care professionals and vice versa.' 
It is perhaps easier to understand the concept of the interface by showing it 
diagrammatically as in Figure 1.1. 
Figure 1.1 The primary / secondary care interface 
Community setting 
Primary care 
INTERFACE 1 
Secondary care 
Hospital setting 
6 
GP Community / practice 
Hospital 
doctor 
nurse 
Hospital 
nurse 
Community 
pharmacist 
Hospital 
pharmacist 
The interface may at first appear to be a theoretical transitional state that patients pass 
through when transferred between the care of primary and secondary professionals. 
However, from Figure 1.1, above, it can be seen that, not only are primary and 
secondary care services provided from different settings, but the health care 
professionals who provide care generally work solely in either primary or secondary 
care. In addition, there are different policies operating within primary and secondary 
care. This means that, despite being part of the same National Health Service, 
primary and secondary care at times effectively operate as separate organisations with 
objectives that are sometimes complementary but are often detrimental to the other 
side. Now the elements making up the interface will be examined in detail to 
demonstrate how the interface has both physical and non-physical characteristics that 
interact to create a situation whereby patient care can be adversely affected. First, 
however, Donabedian's (1980) theory about how the structure and process of health 
care impact on quality will be discussed. 
Donabedian (1980) argues that the most direct assessment of the quality of health care 
is to examine the process of care. The process of care refers to activities that take 
place within and between health care professionals and patients when care is 
provided. The reason for examining the process of care is because it has a direct 
effect on the 'outcome' of health care. The outcome of care is a change in a patient's 
current and future health status that can be attributed to health care. The definition of 
outcome also includes improvements in the physical and psychological well being of 
a patient, patient satisfaction with the care provided and changes in health-related 
knowledge and behaviour. The impact of the interface on patient outcomes with 
respect to medicines will be considered in Chapter Two. 
Whilst the process of care impacts on the outcome, the process is also influenced by 
the structure of health care. Linking these concepts together produces a relationship 
whereby the structural characteristics of the care settings influence the process of care 
so that its quality is improved or reduced. The structure of health care includes 
characteristics such as the physical setting and size of health care organisations and 
the human, physical and financial resources. Donabedian's work was based around 
the American health care system so it is appreciated that structural characteristics such 
as health insurance are not relevant to the NHS in the UK. However, consideration 
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does need to be given to how the NHS is financed and the mechanisms to control 
expenditure. 
1.3 STRUCTURE OF PRIMARY AND SECONDARY HEALTH CARE 
The structure of the NHS health care system and how it has evolved over the last 
thirty years has had a major impact upon the ways in which medicines are used within 
the NHS. Over the last 30 years there have been several major structural 
reorganisations in attempts to improve the managerial control and efficiency. 
Reorganisation was necessary because, whilst the initial philosophy of the NHS was 
to provide healthcare that was free at the point of contact, it soon became clear that 
this was not affordable. The changing management structures of the NHS from 
before 1989 to the present day are shown in Figures 1.2 and 1.3. 
The structural changes that are most relevant to this thesis were introduced in 1989. 
At this time the NHS was experiencing severe financial problems and services and 
facilities were being withdrawn in an attempt to reduce expenditure. It was felt that 
efficiency could be improved by developing the NHS into a market economy (Levitt 
& Wall, 1992). The implementation of the National Health Service and Community 
Care Act in 1990 brought about important changes to the management of the NHS 
that are illustrated in Figure 1.2 (DoH, 1990). 
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Figure 1.2 Changing NHS management structure up to the internal market 
Pre- internal market (up to 1989) 
I Department of heaHh I 
I 
I Regional heaHh authority I 
District heaHh authority I Family pract~ioner committee 
Hosp~als Community GPs Commun~y Dentists Optometrists 
heaHh ph arm acists 
services 
Internal Market (1990 - 1996) 
Internal market - dissolution ofFHSAs (April 1996 - April 1999) 
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Figure 1.3 NHS management structure following the internal market 
Primary care groups introduced (April 1999 - October 2002) 
I Department of health I 
I 
NHS e>eecutive 
regional 
outposts 
Health Hospital 
authority trusts 
Primary care Community Optometrists Dentists Community 
groups I truats pharmacists health 
services 
~ 
Dissolution of HAs (October 2002 - current) 
I Department of health I 
I 
Strategic 
health 
authority 
Primary Hospital 
care trusts 
trust 
GP. Commlrity Optometrists Dentists Commlrity 
pharmacists health 
services 
Until 1989 District Health Authorities (DHAs) were responsible for purchasing 
hospital and community health services for their residents and for the management of 
services provided by NHS hospitals. Family Practitioner Committees (FPCs) 
undertook administration relating to primary care contractors (OPs, dentists, 
community pharmacists and optometrists). The first change brought about by the 
NHS and Community Care Act affected secondary care. Hospitals were allowed to 
apply for self-governing status and their managers took over responsibility for running 
day-to-day health care from DHAs. These self-governing hospitals became known as 
NHS Hospital Trusts and were directly accountable to new NHS executive regional 
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outposts. The second change affected primary care. In a similar way to which 
hospitals were able to apply for self-governing status, GPs were able to apply for 
fundholding status. If accepted, GP practices were allocated practice budgets for 
prescribing, hospital and community services and general medical services. General 
practices had to manage within their allocated budgets to maintain their status as 
fundholders and their hospital referral and prescribing patterns were monitored. 
Practices that did not become fundholders were given indicative budgets which they 
were requested to adhere to despite there being no penalties for overspending. At this 
time FPCs were renamed as Family Health Services Authorities (FHSAs) but kept the 
same responsibilities for primary care contractors. In 1996 the DHAs and FHSAs 
merged to fonn Health Authorities (HAs) responsible for both the primary care 
contractors and commissioning hospital services. 
It is important to appreciate that changes introduced with the NHS and Community 
Care Act made GPs more accountable for health care expenditure. Whilst the internal 
NHS market was set up to increase efficiency it created tensions between primary and 
secondary health care professionals as they implemented strategies to manage their 
own medicines expenditure. Some of these strategies led to an adverse impact on 
medicines expenditure in primary care. This will be discussed in more detail later 
when NHS resources are considered. 
The internal market was dissolved in 1999 by the incoming Labour government and 
Primary Care Groups (PCGs) were introduced acting as subcommittees of HAs and 
taking on varying levels of budgetary and health care planning responsibility. In 
April 2000 some PCGs evolved into Primary Care Trusts (PCTs) to become 
freestanding commissioners responsible for the provision of health care services for 
their population. In October 2002, following further NHS reorganisation, all PCGs 
became PCTs. Health Authorities were dissolved and their responsibilities devolved 
to PCTs. Strategic Health Authorities (StHAs) were put in place to monitor and 
manage the perfonnance ofPCTs. 
In this section it has been shown how the primary and secondary care sectors have 
developed with different management structures. The continually evolving changes in 
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management particularly over the last fifteen years have had considerable impact 
upon the ways in which medicines are managed within the NHS. In particular the 
need to control costs and eventual enforcement of cash-limited budgets means that 
health care professionals and patients have had to come to terms with the finite 
availability of expensive medicines. Before considering this more fully, the issues of 
resource allocation in the NHS will be discussed to provide a fuller explanation of 
how expenditure on medicines fits into the overall NHS budget. 
1.4 RESOURCE ALLOCATION IN THE NHS 
In order to appreciate the current method of funding of NHS prescription medicines 
there needs to be conversance with the way overall resources are allocated in the 
NHS. The procedures in place to control finances have a profound impact on the 
management of medicines and it is important to be aware that there are significant 
differences between primary and secondary care. 
The Department of Health (DoH) provides the majority of the finance needed for 
NHS services. This comes in the form of revenue expenditure for the running costs of 
the NHS and capital expenditure for new buildings. Discretionary capital allocations 
are paid to Strategic Health Authorities whilst block capital allocations are paid to 
PCTs and NHS Hospital Trusts. Revenue allocations are made direct to PCTs. Until 
the introduction of PCTs an upper limit was imposed on NHS hospital expenditure 
whilst the family health service expenditure, that is the primary care element of the 
NHS, remained non-cash limited. This difference in funding was to have an 
important impact on medicines management across the interface as hospitals 
introduced measures to control expenditure and this will be explored later. 
The revenue allocation is made up of three elements; the hospital and community 
health services budget (HCHS), the general medical services (GMS) budget and the 
primary care prescribing budget. Primary Care Trusts are responsible for contracting 
with NHS trusts to provide secondary care services for their population. This is 
funded out of the HCHS element of the budget along with community health services, 
such as district nursing, which are now provided by PCTs. Until the formation of 
peTs, moving funds between the different elements of the revenue budget was illegal. 
The new legislation permitting the NHS reorganisation stated that a unified budget 
would be allocated for prescribing, hospital and community health services and 
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general medical services. This is of great significance because it allows the transfer of 
money between budgets provided the overall cash limit is not exceeded. The positive 
side of this is that money can be taken from the prescribing budget to pay for planned 
developments in hospital services. However, on the negative side it means that if 
there is an unplanned overspend, for example on the prescribing budget, resources 
have to be taken from other budgets in order to achieve financial balance. In the past 
overspends by individual primary care organisations were made good by the 
Department of Health. This means that there is now more emphasis on budgetary 
management within NHS organisations in both primary and secondary care. 
It is important to point out a fundamental difference between the primary and 
secondary care budgetary arrangements. Within primary care there is a separate 
allocation for prescribing whilst in secondary care this is included in the total 
allocation and so there is no funding specifically earmarked for medicines. 
Prescribing costs in hospital have to compete against other priorities and consequently 
the proportion of hospital expenditure spent on medicines has fallen over time (NPC, 
1997). 
The changes to NHS structure implemented since 1989 had significant implications 
for medicines management. The most important change was the introduction of cash-
limited budgets to primary care. Until the advent of the internal market there had 
been no real restriction on NHS spending at GP practice level. However, practices that 
became fundholders were allocated cash limited budgets with penalties and incentives 
to encourage them to manage within this resource. The penalty for overspending 
prescribing budgets was that overspends had to be funded out of other budgets, hence 
restricting the amount of community health care or routine operations that could be 
purchased. Perhaps more important were the incentives to manage within allocated 
budgets. Practices were allowed to keep savings to purchase equipment or services to 
improve patient care. Particularly in the first few years of fundholding, the potential 
financial incentives were large. Whilst there were no penalties against non-
fundholders for overspending, they were also given financial incentives to encourage 
them to manage their indicative prescribing budgets. The incentives to manage 
practice prescribing budgets may have given GPs a motive to resist requests to 
prescribe expensive medicines requested by hospital doctors. This needs to be taken 
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into account later when considering the tactics implemented by hospitals to manage 
their own prescribing expenditure. 
Another significant change occurred when PCGs and PCTs were introduced. The 
enabling legislation removed restrictions on moving funds from one part of the 
primary care budget to another. The reality of this was that it was only really possible 
to move funds from the prescribing budget or the HCHS budget because the GMS 
budget had been protected within legislation. This means that, in theory, the 
prescribing budget could be reduced to fund planned increases in hospital or primary 
health care services. However, this is unlikely to happen in practice given the high 
proportion ofNHS resources allocated to medicines and the rate at which it is 
increasing. 
So far in this section the managerial structure of the NHS has been considered and 
how this has changed over the last thirty years. Resource allocation within the NHS 
has been explained, showing key differences between primary and secondary care and 
how NHS management changes have impacted on resource management. The final 
part of this section will turn to policy development and implementation which is the 
third aspect of the structure ofNHS healthcare. 
1.5 HEALTH CARE POLICY IN THE NHS 
So far the management structure within the NHS has been considered and changes 
over the last thirty years impacting on the management of medicines highlighted. The 
implementation of the NHS internal market introduced cash-limited prescribing 
budgets to primary care whilst budgets in secondary care had long been cash-limited. 
This section will consider policies that have been introduced in both primary and 
secondary care to control medicines expenditure. Two other policy areas are also 
important within the context of medicines management at the interface and these 
relate to the quality agenda from the perspective of reducing medication errors and 
policies specifically aimed at improving medicines management at the interface. 
Health care professionals' decisions are influenced by these policies and conversely 
health care professionals can change the spirit of a policy by the way it is interpreted. 
Before considering specific policies relating to medicines management, it is 
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appropriate first to consider the policy-making process with regard to its 
dissemination and implementation by health care professionals. 
The Department of Health, with the Secretary of State for health at its head, is 
responsible for the planning of services, setting overall policy on all health issues, 
allocating resources, monitoring the performance of organisations and holding them to 
account. Whilst the Secretary of State is accountable for the provision of health 
services the responsibility for ensuring the actual provision of services is actually 
devolved down to NHS organisations such as PCTs, Hospital Trusts and Strategic 
Health Authorities. 
Within NHS organisations it is the responsibility of chief executives to ensure that 
policies laid out in DoH guidance are implemented. However, it is important to 
appreciate that policy guidance from the DoH is often very general and as such is 
open to interpretation by both NHS organisations and the people who work within 
them. NHS organisations do not exist simply to carry out the wishes of the Secretary 
of State but are required to develop local policy in the context of a national strategy. 
This effectively means that policies are modified during the process of 
implementation which can lead to a variance between the intended national strategy 
and how individual health care organisations or professionals act under given 
circumstances. Ham (1992) suggests three reasons why policies are not implemented. 
First, there may be historical differences between local services and national policies 
and so the policy may not suit local circumstances. Second, local policymakers may 
want to prioritise differently to DoH proposals and, third, there may be difficulties in 
persuading service providers to accept national and local priorities. Examples of each 
of these circumstances will be given as appropriate in the following section. 
In addition to the difficulties experienced at an organisational level there are also 
difficulties created by individual members of staff as successful policy 
implementation relies on the compliance of staff. Conflict between NHS management 
and health care professionals may provide a barrier to policy implementation 
particularly if this impinges on a professional's clinical freedom. 
Although there are many DoH policies with relevance to medicines management, 
three areas are important within the context of this thesis. These policy areas relate to 
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the financial control of medicines expenditure, quality of health care and specific 
policies relating to medicines use at the interface. Each of these areas will now be 
considered from both a national policy perspective and how individual health care 
organisations have interpreted and implemented them. 
1.5.1 Policies concerning the financial aspeds of medicines management 
National Health Service expenditure on medicines continues to escalate, increasing 
the financial burden to the NHS and making it even more difficult to develop cost-
limiting mechanisms without compromising patient care or equity. Resource 
allocation and the importance of managing expenditure on medicines within cash-
limited budgets were explained earlier. One of the most important elements of 
resource management is that overspends on medicines must be balanced by reducing 
expenditure in another component of an NHS organisation's budget. This may leave 
services without sufficient funding and so be detrimental to patient care. 
Given the importance of budgetary control, the growth in expenditure on and volume 
of medicines and the factors within the NHS that influence this need to be considered. 
This leads to the strategies introduced in secondary and primary care in order to 
manage the growth in medicines expenditure. Lastly, factors originating from outside 
the NHS, namely the phannaceutical industry, will be discussed with respect to how 
they influence NHS medicines expenditure. 
1.5.1.1 Increasing expenditure on and volume o/medlcines 
The administration of a medicine is the most common therapeutic intervention in the 
NHS (NPC & NPCRDC, 2002). It is not surprising, then, that medicines consume a 
large proportion ofNHS resources. Within the last decade the escalation in demand 
for medicines and appliances in primary care resulted in a huge cost that, in 2003, was 
£7.5 billion for England alone (Table 1.1). In the same year a total of 650 million 
prescription items were dispensed which was, on average. nearly 13 items per head of 
population. This represents a 5.3% increase in the number of items dispensed and a 
9.7% increase in expenditure compared to the previous year (DoH, 2004). This 
increase in demand is consequently leading to escalating expenditure which is fast 
outstripping the available NHS resources. Over the last ten years there has been a 
134% increase in NHS medicines expenditure (see Table 1.1). 
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Table 1.1 Cost and volume of primary care prescriptions 1992 - 2003 (DoH, 2003b; 
DoH,2004) 
Total cost Items dispensed Increase since ~revious ~ear 
(£billion) (million) Cost Items 
Year 
2003 7.5 650 10.3% 5.3% 
2002 6.8 617 11.5% 5.1% 
2001 6.1 587 8.9% 6.3% 
2000 5.6 552 5.7% 4.2% 
1999 5.3 530 12.8% 3.3% 
1998 4.7 513 6.8% 2.6% 
1997 4.4 500 10% 3.1% 
1996 4.0 485 8.1% 2.5% 
1995 3.7 473 8.8% 3.7% 
1994 3.4 456 6.3% 2.5% 
1993 3.2 445 10.3% 4.7% 
1992 2.9 425 
In 2003 the primary care prescribing expenditure represented around one tenth of the 
total NHS expenditure for that year. It is important that expenditure on medicines is 
controlled because the total NHS budget is cash-limited and any unplanned increase 
in medicines expenditure will result in the diversion of resources from other areas of 
healthcare (NHS executive, 1994). 
The growth in prescribing expenditure is largely driven by the implementation of 
National Service Frameworks (NSFs) which aim to raise standards of treatment in 
specific therapeutic areas. The impact of the coronary heart disease (NICE, 2000) and 
diabetes (NICE, 1999) NSFs on prescribing expenditure is illustrated by the growth of 
over 25% in the expenditure on lipid-regulating drugs between 2002 and 2003 and an 
increase of over 16% on drugs for diabetes (DoH, 2003; DoH 2004). Later in this 
chapter the effects of NSF implementation on the quality of patient care will be 
discussed. 
Publication and uptake of new research also has an impact on medicines expenditure 
as illustrated by the increase of 11 % in expenditure on antiplatelet drugs over a five 
year period with only a two-fold increase in the number of items dispensed (PPA, 
2004a). Newer and more expensive antiplatelet drugs such as clopidogrel are 
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replacing aspirin following the publication of clinical trials showing benefits in certain 
patient groups (CURE trial investigators, 2000). 
National information on the cost and number of prescriptions dispensed in NHS 
hospitals is less readily available. However, sixteen hospitals experienced a 5% rise 
in total annual medicines expenditure between 1997 and 1998 (Walker & Jackson, 
2000). This illustrates that although the increase in medicines expenditure is not as 
high as in primary care it is still a significant factor for hospital management to 
consider. Therefore, expenditure on medicines is a priority for both primary and 
secondary care sectors and the strategies in both sectors need to be understood. 
Secondary care strategies will be considered first because these are historically more 
advanced than primary care strategies for managing medicines expenditure. 
1.5.1.2 Secondary care strategies/or managing medicines expenditure 
There is an important difference in financial management between primary and 
secondary care. Traditionally hospital budgets have been cash-limited whereas 
primary care budgets only became completely cash-limited with the introduction of 
PCTs. The result is that hospitals have developed more refined and sophisticated 
mechanisms for managing expenditure on medicines. These mechanisms sometimes 
have an adverse effect on primary care budgets because hospitals are mainly 
concerned with managing their own expenditure rather than those of the whole health 
economy. These mechanisms work by controlling the choice of medicines available 
for prescribing within hospitals, substitution of more cost-effective medicines and 
transferring the cost of prescribing to the primary care budget. These three processes 
will now be discussed in detail. 
Drug and Therapeutics Committees were established in United Kingdom hospitals 
over 30 years ago to provide guidance to prescribers on safe and cost-effective 
prescribing (Leach & Leach, 1994). This reflects the fact that hospital budgets have 
been cash-limited since the 1950s and the appreciation that the expenditure on 
medicines must be managed to prevent overspending. The majority of Drug and 
Therapeutics Committees have encouraged safe and cost-effective prescribing by the 
production of a medicines formulary (Leach & Leach, 1994). A formulary is 'any list 
of selected drugs from which hospital doctors are encouraged or required to prescribe' 
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(Joshi et aI, 1994). However, drug policy in some hospitals has evolved so that 
formularies reflect the needs of individual clinical directorates rather than applying 
across a whole hospital (Cotter & McKee, 1997). The most important reasons for 
formulary development are to improve the quality of prescribing and to contain costs 
(Joshi et aI, 1994). 
Another important function of Drug and Therapeutics Committees is to control the 
introduction of new medicines into hospitals (Fitzpatrick, 1997). This is because new 
medicines are often expensive and may offer no real advantages over medicines 
already included in a formulary. In some hospitals it would seem that this function is 
ineffective as over 50% of Drug and Therapeutics Committees only make formulary 
adherence compulsory for junior doctors and voluntary for consultants and about a 
quarter of hospitals do not monitor formulary compliance (Joshi et aI, 1994). Despite 
involving GPs in Drug and Therapeutics Committees they are still mainly concerned 
with secondary care budgets and prescribing (Leach & Leach, 1994) although changes 
in the NHS have made hospital Drug and Therapeutics Committees more sensitive to 
the needs of primary care (Fitzpatrick, 1997). This is an example of where it could be 
difficult to persuade service providers to accept national or local priorities. A local 
Drug and Therapeutics Committee may reject a new medicine application on the 
grounds that the additional expense of the new medicine is not justified by additional 
clinical benefit. However, a medical consultant who submits an application may 
disagree with the decision and be reluctant to accept that the new medicine cannot be 
prescribed. Some hospital medical consultants perceive Drug and Therapeutics 
Committees as a barrier that may discourage the introduction of new drugs and there 
is a loophole that is often exploited by requesting GPs to prescribe new medicines that 
are not included in a hospital formulary (Jones et ai, 2001). There is also a lack of 
awareness amongst hospital clinicians of the role of Drug and Therapeutics 
Committees and a perception exists that formularies are purely about cost-restriction 
(El-Beik & Elliott, 2002). These misperceptions may again reduce their effectiveness 
by reducing compliance. 
Within the context of hospital strategies to manage medicines expenditure it is 
important to appreciate that hospitals are often tempted to take advantage of 
pharmaceutical company marketing strategies. By accepting offers of discounted 
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medicines from pharmaceutical companies, hospitals can purchase more medicines 
within limited budgets. These discounted medicines have been termed 'loss leaders' 
because they often cost substantially more when prescribed in primary care (Orme, 
1991) and so there is no overall saving to the NHS. On the contrary the total cost may 
be more as a direct result of purchasing discounted medicines if the hospital pharmacy 
department bases the choice of medicine on a discounted price and does not take the 
primary care price into consideration. This is compounded when prescribing 
recommendations are made to GPs as hospital doctors may not be aware of the full list 
prices of drugs (Audit Commission, 1994). 
In the recent past, pharmaceutical companies actively pursued 'loss leader' marketing 
strategies because they are likely to benefit through increasing their sales of medicines 
in the primary care sector. However, a questionnaire survey of 100 GPs found that 
38% of the respondents were not satisfied with hospitals initiating medicines that 
were cheap for hospitals to purchase but expensive in the community (Bennett, 1994). 
It will, therefore, be appreciated that these perceptions and practices can have an 
adverse effect on the primary care prescribing budget and lead to frustration that the 
purchase of medicines on prescription is not being done efficiently. This approach 
has not gone unnoticed as the promotion of loss leaders to hospitals has recently been 
raised by the Office of Fair Trading as anti competitive practice (Anon, 2001). 
Interestingly, on appeal it was decided that the promotion of loss leaders was not 
against competition law but the company was still fined for 'predatory pricing' (Anon, 
2002a). 
This is an example of where historical differences between national strategy and local 
policies may make policy implementation difficult. It may be difficult to persuade 
hospital management to accept that they need to taken into account the total medicine 
costs to the whole health economy, that is to both primary and secondary care, when 
they have long used loss leaders to enable them to purchase more medicines from 
their allocated resources. On the other hand, the prevention of loss leader strategies 
will increase medicine costs for hospitals resulting in the need for alternative 
strategies for managing hospital medicine budgets. 
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Another method of reducing the financial burden of medicines to hospitals is to 
transfer prescribing costs to the primary care budget (Orme, 1991). This has been 
achieved by reducing the quantity of drugs prescribed for patients when they visit 
hospital outpatient clinics with a resulting increase in GP prescribing (Wilkie ef ai, 
1992a) or by transferring prescribing responsibility, and therefore the cost of the 
medicine, to the GP. This practice of' cost shifting' which happens when 'a hospital 
doctor initiates a course of treatment, but the prescription for the drug is written by the 
general practitioner' (Anderson, 1992) will be discussed in more detail in Chapter 
Two as one of the specific problems relating to medicines management at the 
interface. Whilst GPs have expressed concerns about taking responsibility for certain 
medicines (Sibbald ef ai, 1992) there is nothing in the literature to suggest that this 
practice was not acceptable to GPs before the advent of fundholding and indicative 
prescribing budgets. 
The final method of managing expenditure on medicines by hospitals is to encourage 
a policy of using generic, and hence cheaper, medicines. It is common practice for 
hospital pharmacies to substitute the generic equivalent for a prescription written for a 
brand of medicine. This practice is not legally permitted in primary care because 
community pharmacists must dispense the exact brand prescribed. 
1.5.1.3 Primary care strategies/or managing medicines expenditure 
The strategies introduced into hospitals had begun to successfully reduce the 
increasing cost of medicines, or at least to prevent further increases, but until 
relatively recently there had been few constraints on prescribing in primary care. The 
attempts to control medicines expenditure started with the 'selected list' and moved 
onto the provision of comparative prescribing data and incentives to encourage GPs to 
prescribe more rationally. These strategies will now be considered in tum. 
The NHS 'blacklist' was introduced by the DoH in 1985 and restricted NHS 
reimbursement of certain categories of medicines, for example anxiolytics and 
hypnotics and antacids. A limited number of medicines within each category was 
available for NHS prescribing and so the list effectively reduced the prescribing of the 
higher cost medicines. Community pharmacists cannot be reimbursed if they 
dispense blacklisted items so there is a good incentive for them to enforce the list. 
The selected list was extended in 1992 to include other categories of medicines. 
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Whilst some new medicines have been added, for example those to treat impotence 
and male-pattern baldness, the list remains small. 
Professional self-regulation of primary care prescribing was introduced in 1988 when 
the Prescription Pricing Authority started sending GPs Prescribing Analysis and Cost 
Trend (PACT) data (Bevan, 1996). Each GP is currently sent a quarterly practice 
PACT report that includes the number of items dispensed and the cost for six 
therapeutic categories. The report also shows the top twenty most expensive 
medicines and the top 40 most expensive groups of medicines prescribed. Initially 
there were no restrictions on the medicines prescribed. Prescribing Analysis and Cost 
Trend data simply enabled GPs to compare their prescribing with other practices both 
locally and nationally. 
When the internal market was introduced, further steps were taken in an attempt to 
control NHS medicines expenditure (Secretary of State for Health et ai, 1989). 
General practices given fundholding status were allocated cash-limited prescribing 
budgets and, although the non-fundholders' budgets were not strictly cash-limited, 
they were still advised to adhere to them if possible and given financial incentives to 
do so (Bennett, 1994; Anderson, 1992). Fundholding had some impact on controlling 
prescribing costs and this was by therapeutic substitution with medicines of equal 
effectiveness rather than by restricting the uptake of newer, more expensive medicines 
(Wilson et ai, 1999). Prescribing incentive schemes, where practices could keep 
prescribing savings to spend on their patients, have also helped to control prescribing 
costs in non-fundholding practices (Bateman e/ ai, 1996). 
The early 1990s saw the introduction of Pharmaceutical Advisers to FHSAs and HAs. 
Their role was to assist with the analysis of PACT data and advise practices how the 
quality and cost-effectiveness of prescribing could be improved. At this time there 
was evidence of inefficient prescribing through the over-prescribing of ulcer-healing 
medicines, antibiotics and anti-inflammatory medicines and the use of expensive 
combination products (Audit Commission, 1994). 
Cantrill and Leese (2001) found that most peGs received prescribing advice in some 
form. Despite access to prescribing advice it can be difficult to change prescribing 
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patterns not least because primary care organisations have little power to force GPs to 
prescribe in a particular way because of their status as independent contractors rather 
than NHS employees. Change in prescribing has been achieved in certain areas. For 
example, Braybrook and Walker (1996) found that face-to-face meetings between 
GPs and a health authority prescribing adviser improved GPs' antibiotic prescribing 
decisions. Bradley et al (2000) investigated the effect of a rational prescribing 
intervention that included the provision of practice prescribing data to be discussed at 
a practice away-day facilitated by pharmacists trained as educators. This intervention 
proved successful in changing practice by reducing the quantity of modified-release 
non-steroidal anti-inflammatory drugs prescribed and increasing the proportion of 
bendrofluazide prescribed at a daily dose of2.5mg. 
Towards the end of the 1980s FHSAs and DHAs were encouraged by the DoH to 
develop joint formularies to facilitate continuity of treatment when patients are 
transferred between primary and secondary care (Secretary of State for Health et ai, 
1989). Joint formularies contain medicines chosen for their cost benefits to both 
primary and secondary care and have the added advantage that, if a patient is admitted 
to hospital, the medicines will be stocked by the hospital pharmacy department 
(Ferrow et ai, 1997). Joint formularies have been in existence in Scotland for several 
years (Ferrow et ai, 1997) but generally across the United Kingdom development of 
joint formularies has been slow with only two out of 59 acute / general hospitals 
stating that their formulary was a joint one (Joshi et ai, 1994). A more recent review 
found few examples of successful joint formularies (Duerden & Walley, 1999). 
Enforcing adherence to a joint formulary may be difficult because, although hospital 
pharmacists may intervene if a non-formulary drug is prescribed in hospitals, 
adherence in primary care is voluntary and not enforced by community pharmacists 
(Ferrow et ai, 1997). This is in contrast to the NHS blacklist, described earlier, which 
is a national non-formulary list that community pharmacists have a good incentive to 
enforce. Unless there are good relationships between community pharmacists and 
local GPs, community pharmacists may not feel able to question non-formulary 
prescribing. Moreover, community pharmacists are not paid for providing such 
advice and therefore there is little incentive to do so. This may change with the 
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implementation of the new phannaceutical services contract for community phannacy 
introduced in April 2005 (DoH, 2005). 
Whilst the uptake of joint fonnularies has not been high joint prescribing committees 
have been set up following guidance to Health Authorities to implement strategies to 
improve prescribing at the interface (NHS executive, 1994). The purpose of these 
committees is to reduce prescribing problems at the interface, consider the 
appropriateness of hospital-led prescribing and manage the entry of new drugs 
(Wakeman & Leach, 1997). 
1.5.1.4 Influence of the pharmaceutical industry on the use of medicines within the 
NHS 
The mechanisms introduced in primary and secondary care to manage expenditure on 
medicines have been explored. However, the NHS does not exist in isolation from 
outside influences. In particular it is important to consider the influence that the 
phannaceutical industry has over the medicines that are used within the NHS. 
Although many medicines developed over the last twenty years have reduced 
mortality and morbidity, the phannaceutical industry cannot be considered to be 
wholly altruistic in this task. After all, phannaceutical companies are profit-making 
organisations and so have a motive to develop treatments for diseases where there will 
be maximum profits. An example of this is the development of medicines to treat 
obesity by reducing appetite and hence food intake or reducing fat absorption from the 
gastrointestinal tract (NPC & UKMI, 1998). Left untreated, obesity contributes to the 
development of coronary heart disease and diabetes. However, this does not 
necessarily mean that drug treatments are required to treat obesity. This condition 
may also be treated non-phannacologically by reducing energy intake in the form of 
food or increasing energy utilisation in the fonn of exercise. These non-
pharmacological treatments require people to change their lifestyles and are perhaps 
not as attractive to patients as taking medicines. Therefore, given the proportion of 
the population who are obese there are large profits to be made from developing 
medicines to combat this. 
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Pharmaceutical companies also have extensive resources available to protect their 
profits. Take, for example, the situation when the patent on omeprazole, a proton 
pump inhibitor, was due to expire. Lawyers for the manufacturer of the original 
medicine, Losec®, took their battle through the courts arguing that although the 
original patent was due to expire, there was another patent on a co-existing molecule 
of the drug and it was impossible to make them separately hence breaking patent laws 
(Anon,2002b). Once the patent on a medicine has expired, the way is open for other 
manufacturers to produce generic versions ofthe original medicine. Since these are 
usually cheaper they are often prescribed in place of the original branded medicine. 
An important aspect of medicines management within the NHS is ensuring value for 
money. By encouraging generic prescribing the NHS automatically makes savings 
once the patent on a medicine has expired and cheaper generic versions are produced. 
There has been a recent trend for pharmaceutical companies to maintain market 
exclusivity of medicines as the patent expiry date approaches by withdrawing the 
original medicine from the market and bringing out either a new formulation or an 
isomer of the original medicine (WeMeReC, 2003). With no alternatives on the 
market the prescriber has little choice but to switch to the new product or use a 
different medicine. Parallel imported medicines could be used as an alternative but 
only if the licence is equivalent and the product is readily available (MeReC, 2001). 
This means that, by the time a patent expires, most patients will already have been 
switched to an alternative product and so the pharmaceutical company maintains its 
profit on an alternative branded product and the NHS does not benefit from generic 
savings. The next section will consider the NHS quality agenda and how medicines 
management fits into this. 
1.5.2 Policies concerning quality and governance issues in the NHS 
Quality has been brought to the forefront of the NHS and chief executives may be 
held accountable for this. A framework of clinical governance has been put in place 
to ensure that the quality of health care is continually reviewed and improved upon 
(DoH, 1998). Variations in standards and access to health care across the country are 
no longer acceptable and these problems are being tackled through a series of 
National Service Frameworks (NSFs). The clinical and cost-effectiveness of new and 
existing medicines and procedures are being reviewed by the National Institute of 
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Clinical Excellence (NICE). This section introduces the framework in place to 
continuously improve the quality of care within the NHS and policies around reducing 
medication errors. 
With the introduction ofPCGs and PCTs came a ten year plan for improving the NHS 
through a process of evolutionary change (DoH, 2000a). These changes were 
'designed to deliver a better service to patients, through improved quality and 
efficiency, offering prompt high quality treatment and care built around the needs of 
individuals'. A series of lapses in the quality of health care had received considerable 
publicity so the restoration of public confidence in the NHS by improving quality was 
a high priority. The process by which quality was to be improved involved a system 
of clinical governance, standard setting and monitoring (DoH, 1998). 
1.5.2.1 Clinical governance 
Clinical governance is 'a framework through which NHS organisations are 
accountable for continuously improving the quality of their services and safeguarding 
high standards of care by creating an environment in which excellence in clinical care 
will flourish'. The introduction of clinical governance into the NHS makes chief 
executives ofNHS organisations accountable for assuring the quality of services in 
addition to meeting statutory financial duties. 
Within the clinical governance framework are several different approaches for 
improving quality in the NHS. One of these is ensuring employees are participating 
in continuing professional development. In addition to addressing each individual's 
learning needs this also meets the service development needs of the NHS. Another 
approach involves the setting up of systems for identifying and managing risk and 
identifying and remedying poor performance. This is achieved through a process of 
critical incident reporting, effective complaints procedures and mechanisms to enable 
staff to report their concerns about their colleagues' professional performance. This is 
where medicines management fits in particularly with a view to documenting and 
rectifying medication errors. 
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1.5.2.2 Standard setting 
Historically there was inequity in service provision within the NHS whereby the 
services a patient received depended upon the priorities of the local Health Authority. 
This meant that patients may not have been able to access services available to others 
in neighbouring HAs. There had also been variations in standards in the quality of 
care between HAs. This is no longer acceptable and so national standards have been 
established through the publication of National Service Frameworks and guidance 
from the National Institute for Clinical Excellence (NICE). 
National service frameworks (NSFs) are cost-effective, evidence-based models of 
service provision for major care areas and disease groups. National service 
frameworks aim to ensure that there is consistency in the availability and quality of 
services across the NHS. Each NSF defines national standards and perfonnance 
measures so that progress can be monitored. National service frameworks address 
whole systems of care and so require partnerships to be forged between health care 
providers, local authorities, social care providers and the voluntary sector. Earlier on 
in this section it was explained how the implementation ofNSFs, particularly for 
coronary heart disease and diabetes, was contributing to the increase in medicines 
expenditure. So whilst the quality of care is improved, the cost of care increases too. 
This makes strategies for reducing unnecessary medicines expenditure even more 
important. 
NICE was established as a special health authority in 1999 to produce and disseminate 
clinical guidelines. Guidelines are published on both existing medicines and 
procedures. These are developed using clinical and cost-effectiveness evidence from 
a variety of sources. Following the evidence review process NICE makes 
recommendations on where the therapy fits into the NHS. 
NICE is only responsible for producing and disseminating the guidance. It is not 
responsible for ensuring implementation or monitoring that the guidance has been 
implemented. It is expected that the guidance will be implemented consistently across 
the NHS through the clinical governance process and will remove unacceptable 
variations in patient care. NICE recommendations supporting the use of specific 
medicines within the NHS put cost pressures on individual health care organisations. 
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Thus, there may be conflict between the work of Area Prescribing Committees, 
described earlier, to manage the introduction of new medicines and the requirement to 
implement NICE guidance within a certain time frame. 
The principles behind NICE and NSFs are that medicines of proven efficacy and cost-
effectiveness will be used and the provision of care and medicines will be consistent 
across the NHS. Therefore, there is the need for a monitoring agency to check that 
standards are being adhered to. This is the role of the Healthcare Commission which 
has previously been known as the Commission for Health Improvement and Audit 
(CHAI) and before that the Commission for Health Improvement (CHI). 
1.5.2.3 Medication e"ors 
The DoH has set a target to reduce serious medication errors by 40% by 2005 (DoH, 
2000a). The strategy to improve the quality of care through reducing errors also 
includes investigating 'near misses', those occasions which might potentially have 
resulted in patient harm. In the following chapter the impact of the interface on 
medication errors will be discussed. 
As this thesis is concerned specifically with medicines management across the 
interface it is now important to consider specific DoH policies that have been issued 
about this topic. 
1.5.3 Department of Health policies concerning medicines use at the interface 
One of the most important principles concerning medicines management across the 
interface is that the doctor who has clinical responsibility for a patient should 
undertake any necessary prescribing. This principle was included in guidance on 
prescribing policy issued in 1987 by Sir Leonard Peach, the acting Chairman of the 
NHS Management Board, and reinforced by the DoH in 1991 (NHS Management 
Executive, 1991). The reason for reinforcing the principle at this time was that 
indicative prescribing budgets for GPs had just been introduced and GPs were 
concerned about the effects of outpatient prescribing on their own prescribing costs. 
However, GPs also had concerns about taking clinical responsibility for unfamiliar 
treatment and hospital medical consultants had concerns about prescribing medicines 
for which there was no budgetary allocation. A working group ofNHS professionals 
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and managers was set up in 1990 to examine the main issues concerning prescribing 
across the interface. Their conclusions were enhanced by research conducted by a 
team from St. George's Hospital Medical School and the guidance 'Responsibility for 
prescribing between hospitals and GPs' was issued in November 1991 (NHS 
Management Executive, 1991). 
One of the purposes of this guidance was to stop the practice of 'cost shifting' which 
was described earlier. This refers to the inappropriate transfer of prescribing 
responsibility from hospitals to GPs for budgetary management purposes rather than 
patient benefits. Despite the 1987 guidance, issued by Sir Leonard Peach, 'cost 
shifting' was still occurring and causing difficulty to patients, GPs and hospital 
medical consultants (NHS Management Executive, 1991). The 1991 guidance re-
affirmed the principle that prescribing responsibility should continue to be based on 
clinical responsibility and specified the minimum amounts of medicines that should 
be supplied by hospital pharmacy departments to patients discharged from hospital or 
attending outpatient clinics or accident and emergency departments. The concept of 
shared care was described and when it would be appropriate for a hospital doctor and 
GP to share the responsibility of a particular aspect of a patient's care. Situations 
when hospital medical consultants should retain prescribing responsibility were also 
specified. Responsibility for ensuring that patient care was seamless and that local 
policies were compatible with this guidance was given to Regional Health 
Authorities. 
Recognition of the influence of secondary care prescribing on GPs' prescribing and 
the impact this can have on managing the drugs bill led to guidance on the cost-
effectiveness of prescribing across the interface (NHS executive, 1994). This 
included the appropriateness of hospital-led prescribing, that is taking into account the 
total costs of medicines to the NHS and not just the secondary care aspect and so 
considering groups of medicines used as loss leaders. It also covered managing the 
entry of new drugs into the NHS and taking into account the evidence of clinical and 
cost-effectiveness. This guidance also advised purchasers within the NHS, that is 
FHSAs and GP fundholders, to use the contracting process to ensure that the 
recommendations in the guidance were implemented and monitored. Again Regional 
Health Authorities were expected to monitor the implementation through their 
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performance management arrangements. This guidance also specified the need to 
have local agreement over which hospital initiated medicines GPs should not be asked 
to accept prescribing responsibility for and which medicines they might be able to 
transfer under approved circumstances. 
'Discharge from Hospital' (DoH, 1989) covered all aspects of the discharge process 
and not just medicines. However, it is important to consider it here because much of 
what was stated about general communication also applies to medicines. Before 
patients are discharged from hospital, proper arrangements should be made for their 
return home and for any necessary continuing care. In particular GPs, community 
nursing services and social services should be informed of patients' potential needs in 
time for them to be met. Hospital medical consultants are required to notify GPs of 
the discharge date, diagnosis, medicines, the degree of patient management required 
and any follow-up arrangements made. Ward sisters must ensure that patients are 
provided with any necessary dressings or medicines and that they understand the 
instructions. Two good practice guidance documents have been issued since 
'Discharge from hospital', most recently in 2003. This latest guidance specifically 
acknowledges that difficulties with medicines management can contribute to delayed 
hospital discharges and that poor communication about medicines can result in 
medication errors (DoH, 2003a). A section on the importance of medicines 
management is included. It recognises the importance of up-to-date information for 
GPs so that medicine regimens can be continued. The document focuses on patient 
centred schemes such as one-stop dispensing and discharging patients with at least 
fourteen days' worth of medicines, rather than the seven days specified in 'Purchasing 
and Prescribing' ( NHS executive, 1994), to ensure that there is sufficient time for 
communication to reach the OP. 
As explained at the beginning of this section, whilst the DoH issues guidance, it is the 
responsibility of individual NHS organisations to implement it. This relies on 
employees following and complying with local implementation plans. The 
relationships between and within health care professions and NHS managers will be 
discussed later in this chapter. 
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1.6 SUMMARY OF THE STRUCTURE OF NHS HEALTH CARE RELEVANT 
TO THE INTERFACE 
This chapter started with an introduction to the concept of the primary / secondary 
care interface. It was proposed that the interface is not simply a theoretical 
transitional state but is constructed from both physical and non-physical 
characteristics that interact to adversely affect patient care. The components of the 
structure and process of health care were examined to show how the interface is 
constructed. This included an examination of the respective responsibilities of 
primary and secondary care and the lines of managerial responsibility between the 
DoH and individual health care organisations. Recent changes to the structure of 
NHS health care and their relevance to medicines management have been highlighted. 
One of the most relevant is the introduction of cash-limited budgets to primary care. 
The result of this being that some secondary care strategies for managing medicines 
expenditure, such as the use of loss leader medicines and transferring the prescribing 
of medicines to GPs, are no longer acceptable to primary care. 
Department of Health policies relevant to this thesis have been described. More 
specifically, policies relating to the effective discharge of patients from hospital have 
been explored. These highlight the need for effective communication between health 
care professionals in primary and secondary care. Communication is also a strong 
theme within guidance specifically relating to prescribing and the use of medicines 
across the interface. However, there are other issues to be considered not least 
ensuring that the doctor who has clinical responsibility for a patient prescribes any 
necessary medicines. Additionally, efficient use of medicines requires consideration 
of the total costs to the NHS and their clinical and cost effectiveness before new 
medicines are introduced. Successful policy implementation, however, relies upon 
the compliance of individual members of health care staff. 
It is now appropriate to consider the 'process' of patient care and the contribution 
made by different professional groups. This will help our understanding of how 
individual staff members influence positively and negatively, the implementation of 
policy. 
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1.7 PROCESS OF HEALTH CARE WITHIN THE NHS 
Donabedian described the process of care as the activities that take place within and 
between health care professionals when care is provided. The process of care impacts 
on patient outcomes and so the process of patient care within and across both primary 
and secondary care will be considered in this section. It will be appreciated that the 
complexity of the NHS necessitates good communication and collaboration between 
professionals both within and across primary and secondary care in order that care 
does not break down across the interface. First the usual processes of care and 
responsibilities of different professionals will be discussed and how they 
communicate with each other. As this thesis concerns medicines management at the 
interface the major players that will be considered are doctors and pharmacists 
responsible for prescribing and supplying medicines. Whilst nurses now have 
prescribing rights, the number and cost of items they prescribe is still an extremely 
small proportion of overall prescribing (DoH, 2004). The general communication 
channels between primary and secondary care will be examined to show how 
communication is inadequate both from the perspective of the quality and timing of 
the infonnation of the infonnation that is transferred. Then, because health care 
professionals influence both the utilisation of resources and the quality of 
communication, the process of care and interprofessional relations will be considered. 
1. 7.1 Process of care from different disciplines 
It is acknowledged that OPs perfonn a 'gatekeeper' role in referring patients to 
secondary care services. There are several reasons why OPs may refer patients to a 
secondary care specialist. First, when patients require major surgical intervention, 
this can only be carried out in hospital. Second, a OP may require specialist expertise 
in diagnosing a patient's condition. A hospital specialist can provide this and often 
has access to sophisticated diagnostic techniques and equipment that are not available 
in primary care. Third, there may be a need for a 'second opinion' to reassure either 
the patient or the OP that the correct diagnosis has been made. Finally, for conditions 
where the management is difficult a OP may refer for specialist advice. 
When a patient is referred to inpatient secondary care services, a hospital medical 
consultant assumes responsibility for patient care. If treatment is on an outpatient 
basis, a hospital medical consultant takes responsibility for the aspect of care 
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necessitating the referral but a GP retains responsibility for the overall care of a 
patient. Following completion of secondary care treatment responsibility for patient 
care is transferred back to the GP. However, for certain generally more complicated 
conditions a hospital specialist may prefer to follow up a patient at regular intervals, 
thus care is effectively shared between the hospital specialist and the GP. 
This sharing or partnership of responsibilities between the GP and hospital specialist 
in many ways provides a good continuation of support and expertise that is in the 
patient's interests. However, the very sharing of responsibilities, itself may give rise 
to difficulties, usually when the communication channels between the two health 
professionals break down. 
Almost half of hospital inpatient episodes involve medical rather than surgical 
treatment (DoH, 2003a) and so patients are likely to require ongoing treatment with 
medicines. The importance of medicines management from both a resource 
management and safety perspective means that the pharmacist, as an expert in 
medicines, has an important role to play. Along with advances in therapeutics over 
the last few decades the role of the pharmacist has also developed. Due to the 
development of the commercial pharmaceutical industry the majority of prescriptions 
dispensed in primary care are for medicines that are available from pharmaceutical 
wholesalers (Candlish et ai, 2003). Only a small proportion of medicines are now 
extemporaneously prepared in community pharmacies which means that it will be 
difficult for pharmacists and their staff to maintain competence and expertise in this 
line of work (Rennison & Portlock, 2003a). Another argument against 
extemporaneous dispensing in community pharmacies is the lack of evidence of 
efficacy of such products (Rennison & Portlock, 2003b). The development of a 
pharmacist's role from a compounder and dispenser of medicines to an adviser on the 
use of medicines has been particularly apparent within secondary care. This move 
from a product-orientated service to a patient-orientated service became known as 
'clinical pharmacy'. 
1.7.2 Development of clinical pbarmacy services in secondary care 
Over the last 30 years several pharmaceutical services review committees have 
endorsed the developing role of pharmacists from dispensers of medicines to members 
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of health professional teams ensuring the effective, safe and economical use of 
medicines (Department of health and social security et at, 1970; Nuffield Foundation, 
1986). Appropriate skill mix within pharmacies enables pharmacists to devote more 
time to undertaking those tasks that can only be carried out by a pharmacist (Nuffield 
Foundation, 1986). However, community pharmacists are still held back from 
developing their role because of the legal requirement that pharmacies must be under 
the supervision of a pharmacist at all times when prescriptions are being dispensed or 
pharmacy medicines sold. In reality this means that the pharmacist must be on the 
pharmacy premises (Anon, 2004). This ties community pharmacists to their 
pharmacies and means that they cannot provide medicines management services to 
patients off the premises unless a locum is employed to supervise the pharmacy or the 
pharmacy is closed. This effectively limits the provision of medicines management 
services provided by community pharmacists. 
A more recent review also endorsed the central role of hospital pharmacists in 
managing medicines effectively (Audit Commission, 2001). The review found that 
less than optimal use of medicines led to medication errors, poor compliance and 
wastage. There was also a recommendation to elevate the profile and status of 
hospital pharmacy services and to review skill mix to ensure the best use of the 
available staff, particularly pharmacists who should concentrate on their clinical roles. 
The point was made how the management of medicines across the whole health 
economy, rather than only in secondary care, would lead to significant quality 
improvements for patients and reduced costs. This report demonstrates that despite 
developments in clinical pharmacy services over the past 30 years medicines 
management is still unsatisfactory. 
Clinical pharmacy activities can be divided into those that occur either before hospital 
admission or when patients have been admitted to hospital, those that occur during the 
inpatient stay and those that occur when patients are discharged from hospital. Whilst 
there are some similarities in the services provided at each stage ofeare there are 
some differences and so these will now be separately described. 
For elective admissions clinical pharmacy activities may be carried out at a pre-
admission clinic. Clinical tasks include drug history taking, checking patients' own 
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drugs for use in hospital, transcribing patients' medicines onto inpatient prescription 
charts, documenting allergies and non-prescribed medicines, pre-ordering of 
discharge medicines, counselling patients about their medicines and making 
recommendations about changing non-formulary medicines to formulary ones (Bhanji 
et aI, 1993; Jay, 1998; Crowley et aI, 1997; McIntyre & Manson, 2004). The benefits 
of pharmacist involvement at this stage include a reduction in ward staff time spent on 
the medicine supply process, a reduction in discrepancies on inpatient prescriptions 
and less prescribed medicine doses omitted (Crowley et ai, 1997). Other patient 
benefits include clarification of medicine dose or frequency (Bhanj i et ai, 1993). 
Clarifying the prescription at a pre-admission clinic should ensure that the inpatient 
card is written correctly and reduce either missed doses of medicine or medication 
errors. 
Clinical pharmacists have also developed a role on hospital admissions wards. 
Activities include drug history clarification, ordering medicines, counselling patients 
and producing ongoing medicines management care plans to ensure continuity of care 
(Foster, 1995; Price, 1998; Doyle et ai, 1998). Benefits to patients of interventions at 
this point are patient education, clarification of the dose or frequency of medicines 
and prevention of adverse drug reactions, including allergic reactions (Foster, 1995; 
Price & Rogers, 2000). Ward staff benefit from reduced time spent on the medicine 
supply process (Doyle et ai, 1998). 
Clinical activities provided to inpatients mainly involve prescription monitoring and 
patient counselling. Following prescription monitoring, pharmacists intervene to 
ensure that the choice of medicine, dose and duration of therapy are appropriate 
(Boardman & Fitzpatrick, 1998a). Hawkey et ai (1990) found that the commonest 
type of reactive intervention undertaken by pharmacists related to the dose of 
medicines. However, the clinical pharmacy role is developing from a reactive model 
to a proactive one as recommended by Cousins and Luscombe (1996) so, rather than 
simply identifying problems once a prescription has been written, pharmacists are 
making recommendations for additional therapy (Slee et ai, 1998). Pharmacists also 
have a role to ensure that medicines are used cost-effectively and this is demonstrated 
by the substitution of expensive medicines for cheaper ones with the same therapeutic 
effect (Wake et ai, 1998). Freedom to make amendments to patients' prescriptions 
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without reference to a doctor first is not universal throughout NHS hospitals 
(Boardman & Fitzpatrick, 1998b) reflecting the legislative framework that 
pharmacists currently work within. The introduction of pharmacist supplementary 
prescribing gives pharmacists more freedom to act without reference to a doctor. 
However, supplementary prescribers can only act within a clinical management plan 
previously agreed with the patient and a doctor and so pharmacists are still not 
autonomous practitioners (NHS Modernisation Agency, 2005). 
Pharmacists are also developing specific roles to undertake when patients are 
discharged from hospital. These new roles may enhance patient safety, for example 
by improving the identification of problems on discharge prescriptions (Maguiness et 
ai, 1992; Elfellah & Jappy, 1996). The pharmacists' role when patients are 
discharged from hospital has developed further to include responsibilities such as 
writing discharge prescriptions, patient counselling and checking that patients' own 
medicines are suitable for reuse. These new roles reduce the time junior doctors 
spend writing discharge prescriptions, expenditure on hospital discharge medicines 
and the time patients wait for discharge medicines to be prepared (Dobrzanski & 
Reidy, 1993; Elfellah & Jappy, 1996; Culshaw & Dawes, 1998; Milliken & Rea, 
1997; Jacklin et ai, 2001). 
1. 7.3 Development of community pharmacy clinical services 
It is important to appreciate that whilst hospital pharmacists have embraced the 
philosophy of clinical pharmacy and now spend a high proportion of their time on 
clinical rather than technical duties (Audit Commission, 2001) the same cannot be 
said of community pharmacists. The role of community pharmacists is still orientated 
towards a supply service. An extended role for community pharmacists has been 
promoted over recent years (Nuffield Foundation, 1986; DoH, 2000c). This extended 
role includes the supply of prescription only medicines under patient group directions 
(O'Brien & Gray, 2000), medication review services (Goldstein et ai, 1998; Granas & 
Bates, 1999), treatment of minor ailments (Hassell, K. et ai, 2001) and point of 
dispensing intervention schemes (Ansell, 2002; Leach et ai, 2003). 
A major constraint to the development of the extended role has been the 
Pharmaceutical Services contract that specifies the remuneration of community 
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pharmacists. Within the contract pharmacists are remunerated solely for dispensing 
prescriptions and extended roles have to be paid for locally by PCTs. The new 
contract, implemented in April 2005, may improve the provision of extended roles. 
However, there are other barriers to overcome, not least the perceptions that other 
professionals and patients have about the role of the community pharmacist, and these 
will be discussed later. In addition to this, whilst community pharmacists currently 
feel that their skills are under-used they recognise that training will be necessary to 
enable them to provide extended roles under the new pharmacy contract (Tweedie et 
al,2004). Community pharmacists may be better equipped to provide a more clinical 
service if they had better access to patients' clinical data (Moody et ai, 2004). There 
is evidence however, that hospital pharmacists are providing clinical medicines 
management services to primary care (Cotter et ai, 1994; Burtonwood et ai, 1998). 
Extending hospital pharmacists' roles into a community setting may further widen the 
gap between the roles of the two groups of pharmacists by limiting community 
pharmacists to technical activities such as dispensing. 
Pharmacists have a role to not only dispense medicines according to a doctor's 
prescription but to ensure that the medicine is appropriate for a particular patient and 
that the patient knows how to take it. It is clear, then, to enable them to carry out this 
role, good communication channels are essential between pharmacists and doctors on 
both sides of the interface. However, in the next section we will see that 
communication is often inadequate. First the methods of communication between 
primary and secondary care will be considered. Then communication within and 
between professions across the interface will be discussed. 
1.8 COMMUNICATION BETWEEN PRIMARY AND SECONDARY CARE 
It is well known that methods of communicating information between secondary and 
primary care are often unsatisfactory. The major problems concern the timing of the 
information, that is, it often arrives too late to be of any real use and that the content is 
not relevant to the receiver's needs. 
It is normally the responsibility of a house officer to prepare an 'interim discharge 
summary' when a patient is well enough to be discharged from hospital. This 
contains information to update the OP on hospital treatment given and should help to 
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ensure that treatment initiated in hospital is continued without a break when a patient 
gets home. Following a patient's discharge a more formal discharge summary is 
sometimes written to the GP. Putting this in the context of medicines, ideally any 
information about a patient's hospital treatment including any changes to the medicine 
regimen should reach the GP before the patient requests a further supply of medicine. 
Delays in the receipt of discharge information have been continuously reported over 
at least 30 years and do not appear to be improving. Whilst delays are more widely 
recognised in formal discharge summaries, interim summaries are more important to 
GPs because they include information vital to enable the continuity of care in the 
immediate post-discharge period. Mottram et al (1994) found an average delay in the 
receipt of formal discharge letters of22 and 33 days and Mageean (1986) found a 
median delay of 24 days. Mottram et al (1994) were optimistic in reporting that 95% 
of interim discharge summaries were received by GPs within five days of patients' 
discharges but Mageean (1986) found that over half of patients had contacted their GP 
before an interim discharge letter had been received. 
Combining an interim discharge summary with a discharge prescription has enabled 
GPs to receive discharge information much more rapidly (Kendrick & Hindmarsh, 
1989) and resolved the problem of absence of information about medicines supplied 
on discharge (Tulloch et ai, 1975). This type of combined form is now commonly 
used (Argyle & Newman, 1996). However, even with a combined summary 14% of 
patients contacted their GP before any information had been received (Kendrick & 
Hindmarsh, 1989). Giving patients a copy of the summary to deliver to GPs by hand 
has helped to speed up the passing of information from secondary to primary care. 
Sandler and Mitchell (1987) found that there was a mean delivery time of two days 
using this method, however, Penney (1988) still found that it took an average of 4.3 
days for GPs to receive the information even when it was hand-delivered. More 
recently Coleman et al (2001) found that most patients did not contact OP surgeries 
before discharge advice notes or outpatient letters were received. This perhaps 
reflects the fact that patients were given fourteen days supply of medicines on 
discharge from hospital and one month's supply from outpatient clinics. This length . 
of supply may well be longer than that given from other hospitals. They did find that 
information required for appropriate prescribing was missing from 11 % of immediate 
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discharge notes and 15% of discharge letters and that a third of discharge notes and 
the subsequent discharge letters for the same patient differed in their content. 
The OP receives no information at all for a significant number of patients who are 
discharged from hospital. This is despite attempts to improve communication from 
secondary to primary care by the use of patient delivered summaries and combining 
interim summaries with prescriptions. Mageean (1986) found eight weeks after 
discharge no information had been received for 11 % of patients; Williams and Fitton 
(1990) found 17% and Penney (1988) found 25% of summaries were never received 
despite data collection continuing for over three months. 
The content of discharge communications has also been reported to be inadequate. 
Patient details such as name and address are included but information such as the date 
of birth, hospital attended and follow-up treatment are often missing (Mottram et aI, 
1994; Mageean, 1986). Although these pieces of information may seem obvious or 
unimportant to hospital staff it makes querying prescriptions much more difficult for 
OPs because of not knowing which hospital or ward department to contact. The 
exclusion of information relating to what the patient has been told also results in a 
conflict of information provided by the OP undermining the patient's faith in the 
doctors (Tullock et aI, 1975). Formal discharge letters tend to be more accurate 
(Mottram et aI, 1994) but are of little value if they do not arrive before the 
information is needed. 
Attempts have been made to improve the content of discharge communications to 
reflect what OPs need to know. However, there is disagreement between what OPs 
actually find useful. Philp et al (1988) found that OPs wanted to know about the 
functional status of patients and services or equipment arranged whereas Solomon et 
al (1995) found that the functional ability of patients was ranked, low in the list of 
items that should be included in discharge summaries, perhaps because OPs were 
already aware of this. Munday et al (1997) found that OPs need to be informed of 
reasons why medicine therapies have been changed whilst patients were treated in 
hospital. 
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Part of the problem with unsatisfactory discharge communication seems to be that 
even when hospital doctors provide information on structured pre-printed discharge 
forms there are often important omissions (Sandler et ai, 1989). A survey of GPs 
found that whilst they preferred structured letters about patients few hospital doctors 
wrote such letters (Rawal et ai, 1993). There is therefore a certain lack of insight by 
hospital doctors regarding the importance of discharge information for GPs to ensure 
the continuity of care. 
So far the problems associated with communication from hospital to GPs have been 
discussed. In Chapter Two it will be demonstrated how poor communication 
contributes to medication errors when patients are transferred from secondary to 
primary care. If the information is not received by the GP before the patient requests 
a further supply of medicine, the GP will not know if any changes are necessary to a 
patient's medicine regimen. Incomplete information may also contribute to 
medication errors. For example, the discharge information may include a complete 
list of a patient's current medicine regimen but exclude any medicines discontinued 
during the hospital stay. There is the risk, therefore, that medicines that were 
discontinued could be restarted inappropriately. 
General practitioners themselves are also responsible for poor communication when 
making referrals to secondary care. Only 48% of acute medical admission referral 
letters were written by the patient's own GP, 41 % by a practice partner and 11 % by a 
locum or 'radio' doctor (Todd et al. 1984). This suggests that part of the problem 
with the content of referral' letters may be due to the doctor writing the letter not being 
familiar with the patient. However, even for patients referred to a medical outpatients 
clinic one study reported that 36% of letters contained no information about the 
patient's drug therapy (Holmes et al. 1984). These letters were written with less 
urgency and illustrate a lack of understanding of the type of information hospital 
doctors require. 
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1.8.1 Communication between and within professions 
In the previous section it was explained that the majority of communication across the 
interface is between the medical professions and that communication is often 
inadequate either because the information is incomplete or that it arrives too late to 
provide any benefit to patient care. Now it is appropriate to consider the 
communication between community pharmacists and their medical and 
pharmaceutical colleagues on both sides of the interface. 
The first important point to consider is that community pharmacists are unlikely to 
receive information about a patient's hospital episode and may not even be aware that 
a patient has been in contact with hospital services (Brown & Brown, 1997; Oborne & 
Dodds, 1994). Attempts have been made to increase the communication between 
hospital and community pharmacists through the use of admission and discharge 
checklist forms (RPSGP, 1993) but there has been little uptake of these (Cairns, 1994; 
Argyle & Newman, 1996). More recently, Sexton et at (2000) found that community 
pharmacists were not contacted about most patients discharged from hospital. It is 
clear then that the concept of 'pharmacy discharge' as proposed by Jackson, Rowe 
and Lea (1993) has not been taken up. They proposed a preliminary definition of 
pharmacy discharge as 'the process whereby a patient is moved from one care 
environment to another with the assurance that all pharmaceutical requirements, 
including information, can be communicated and maintained in a safe, timely, 
efficient and user-friendly way'. However, successful liaison between hospital and 
community pharmacists has been achieved in specialist areas where patient 
throughput is lower, for example heart or lung transplant patients (Eadon, 1994). In 
such clinical areas pharmacists may have time to complete referral forms whereas in 
areas with higher patient throughput the high workload associated with completing 
referral forms may provide a barrier to their use (Pegrum, 1995). Clinical areas with 
high patient throughput have a higher number of patient admissions and discharges 
each day and as the forms have to be completed manually this could potentially be a 
time consuming task if a form was completed for each patient. There are, however, 
other factors preventing effective information transfer between primary and secondary 
care. 
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One of the barriers deterring secondary care services from providing information to 
community pharmacists is the perception that patients do not consistently use a 
regular pharmacy (Cairns, 1994). Therefore, there is a strong likelihood that 
information would not reach the pharmacist for whom it was intended. This 
perception cannot be dismissed because whilst several studies have shown that over 
80% of patients do use the same community pharmacy for prescription dispensing 
services, (Brackenborough, 1997; Cook, 1995; Cannon & Hughes, 1999) others have 
shown that loyalty to a single pharmacy may be as low as around 60% (Oborne & 
Dodds, 1994; Choo & Cook, 1997). This may be explained by the locations where 
studies were conducted. In rural areas patients may have less choice of pharmacy and 
therefore be more likely to routinely use one community pharmacy. A relative or 
carer may also collect post-discharge medicines although Cook (1995) found that they 
were unlikely to use a different pharmacy. Research in this area tends to be 
inconclusive because what people say and do may be different. A lack of confidence 
of the data arising from such studies may be one reason why strategies to improve the 
transfer of information have not been pursued. 
One way of overcoming the workload issue associated with providing information to 
community pharmacists would be t~ restrict this to certain patient groups. However, 
whilst guidance on medication discharge planning recommends that hospital 
pharmacists should liaise with colleagues in primary care there is no indication as to 
which patients would benefit from such liaison (Coombes & Home, 1994). Cairns 
(1994) did prioritise patients for whom the exchange of information was important. 
These patient groups were the elderly, patients on complex treatments, patients on 
'specials' and patients who had experienced adverse drug reactions, although this was 
not backed up by evidence of usefulness in these patients. 
I.S.1 Inter-professional eommunieation 
Inter-professional, as opposed to intra-professional, communication across the 
interface is unusual although pilot studies have investigated communication between 
hospital pharmacists and GPs (Cromarty et al, 1998; Norris et ai, 2001). However, 
the value of this needs to be considered as results of studies are conflicting. Cromarty 
et al (1998) reported that GPs found no use for a pharmacy information letter given to 
elderly patients on discharge whilst Norris et a/ (2001) reported that GPs thought a 
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discharge letter produced by a hospital pharmacist was beneficial. Other researchers 
have also shown that GPs value communication from pharmacists as interactions with 
community pharmacists have been well received by GPs under different 
circumstances (Blenkinsopp et ai, 1991; Watson & Sharp, 2001). 
Communication about medicines across the interface is particularly important as a 
high proportion of patients experience changes to their medicine regimens whilst in 
hospital (Gonski et ai, 1993; Cantrill & Clark, 1992). In the next section of this 
chapter we will see that this restriction of communication may actually compound 
some of the issues that arise because of the interface and leave practitioners less 
equipped to carry out their roles successfully. Poor communication may be related to 
poor inter-professional relations and so this will now be considered. 
1.9 HIERARCHY AND CONFLICTS WITHIN AND BETWEEN 
PROFESSIONALS 
Before considering internal hierarchies within the medical profession it is important to 
consider the dominance of the medical profession as a whole over other health care 
professionals and health care managers. This is in part sustained by the dominance of 
the biomedical model of health care within the NHS. The biomedical model of health 
care defines health as the absence of disease and not as the possession of healthy 
attributes. Doctors have a central role in the provision of health care and hospital 
treatment plays a major part. Being a non-smoker or exercising regularly are 
considered to be 'healthy attributes'. Health promotion activities, such as smoking 
cessation support, help people to gain healthy attributes and are generally provided 
within primary care. This is perhaps why the biomedical model is less dominant in 
primary care than in secondary care and could be a reason why secondary care doctors 
have historically had dominance over GPs. 
Baggott (1998) provides four explanations for the dominance of the medical 
profession within health care. First, the social background of the profession in that it 
is male-dominated with the majority coming from upper-middle class backgrounds. 
From a Marxist perspective this means that those of the higher classes, hence with 
more money and therefore power, dominate those from the lower classes. Second, 
doctors provide legitimation of health and illness and controlling this prevents the 
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social system being undermined by ensuring that malingerers are separated from those 
who are genuinely ill. The medical profession also has more political influence than 
other professional groups. This is demonstrated by medical organisations such as the 
British Medical Association and the Royal Colleges being consulted by the 
Department of Health for their views on policy. The fourth explanation is most 
important in the context of medicines management and this is that the medical 
profession dominates because of the autonomy under which it operates. 
The medical profession has autonomy in that the doctor takes responsibility of the 
diagnosis of the patient and hence determines what laboratory tests are required and 
ultimately how patients are treated. General practitioners decide which patients to 
refer to secondary care and, whilst there are different referral patterns between GPs, 
there has been little success in controlling this by management (O'Donnell, 2000). 
Doctors working from hospitals make decisions about admitting patients and 
determine when they should be discharged. Thus doctors in primary and secondary 
care largely determine the fate of patients. Whilst attempts have been made to make 
doctors more managerially accountable (Baggott, 1998) this has largely been resisted 
with the result that doctors still control the majority ofNHS resources hence 
maintaining a substantial power base. Furthermore, the medical profession enjoys 
self-regulatory status via the General Medical Council. 
1.9.1 Relationships between hospital doctors and GPs 
To better understand why there may be difficulties with communication between 
hospital doctors and GPs we first need to appreciate how they might not fully 
understand each other's roles. It is important to appreciate that whilst all medical 
doctors must pass the same undergraduate degree their subsequent education and 
training depends on whether they decide to follow a primary or secondary care career 
path. Following successful completion of an undergraduate medical degree 
provisional registration from the General Medical Council is obtained and following a 
year working as a pre-registration house officer in a hospital full registration is 
awarded. At this point doctors wishing to become general practitioners undertake a 
three year course consisting of two years working in hospitals followed by a year 
working in a training general practice. Hospital doctors progress through posts as 
junior doctors leading to the award of Certificate of Completion of Specialist Training 
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making the holder eligible for a consultant appointment (Baggott, 1998). This is 
important because, currently, whilst all doctors gain hospital experience, only those 
who choose to follow a general practice career gain experience in primary care. It is 
clear then that hospital doctors in particular may not understand how their primary 
care colleagues operate. Another important point is that GPs refer to hospital 
consultants when they require specialist advice as to the management of a patient. 
However, as explained earlier, once the hospital doctor has given his opinion and 
recommendations for treatment, clinical responsibility usually transfers back to the 
GP. It is evident therefore, that there is the potential for GPs to be asked to take 
clinical responsibility for treatments that they have little knowledge or experience of. 
There have been suggestions that the changing role of GPs to purchasers of hospital 
services has brought about a shift in the balance of power between specialists and GPs 
(Baggott, 1998). However, there are still misunderstandings and difficulties between 
the two areas of the profession as demonstrated in their complaints about poor 
communication and lack of understanding. Marshall (1998) found that whilst there 
was a high level of mutual respect and co-operation between GPs and hospital 
medical consultants there were still areas of significant disagreement. For example, 
consultants felt that GPs did not understand the pressures they worked under and that 
GPs were sometimes over-concerned about managerial and financial issues. General 
practitioners complaints about their secondary care colleagues focused on their poor 
communication with patients and their perception that hospital doctors were resistant 
to change. Relationships between specialists and GPs tended to be built up over a 
period of time and were important in how each perceived the other. They used this 
knowledge of each other to amend how patients were referred or treated. 
1.9.2 Inter-professional relationships between doctors and pharmacists 
Despite a plea for pharmacists to be integrated into the primary health care team 
(Nuffield Foundation, 1986; DoH, 2000c; DoH, 2003c) this has not yet been 
successfully achieved. Although projects have been initiated to improve 
communication and collaboration between GPs and community pharmacists 
(Blenkinsopp et ai, 1991; Schneider & Barber, 1996) and educational outreach visits 
from community pharmacists have been well received by GPs (Watson & Sharp, 
2001) this is not yet routine practice. Hughes and McCann (2003) identified barriers 
45 
to greater collaboration between the two professions which would have to be 
overcome before inter professional liaison could be fully achieved. The main barriers 
for the GPs were the 'shopkeeper' image of community pharmacy and the perceived 
conflict between business and health care. The community pharmacists felt these 
perceptions affected their position in the health care professional hierarchy. 
Additional barriers experienced by the pharmacists were the difficulty in accessing 
GPs mainly due to the gate-keeping role of practice receptionists. Some GPs see 
extended community pharmacist roles as a threat and respond by trying to reinforce 
the existing division between pharmacy and medicine. Whilst GPs are happy to 
delegate difficult or mundane medicines management tasks to pharmacists they ensure 
that they maintain overall control (Edmunds & Calnan, 2001). 
1.10 SUMMARY OF THE CONSTITUENTS OF THE INTERFACE 
The process of health care within the NHS describes the activities that take place 
within and between health care professionals when care is provided. The roles of 
doctors and pharmacists, with respect to medicines management, in primary and 
secondary care are quite different. In particular, whilst hospital pharmacists undertake 
a clinical pharmacy role, this is less well developed within oommunity pharmacy 
practice. There are still barriers to overcome before community pharmacists can 
successfully undertake clinical roles, not least the perceptions of GPs who consider 
there is a conflict between business and 'health care. Relationships between hospital 
doctors and GPs are also not always favourable. 
Communication both within and between professional groups across the interface is 
less than satisfac~ory. In the next chapter it will be demonstrated how poor 
communication across the interface may lead to medicine related problems. However, 
first it is appropriate to consider how the elements of process and structure of health 
care, which have been explored in this chapter, interact. 
At the start of this chapter it was proposed that the interface was not simply a 
theoretical transitional state that patients pass through when responsibility for their 
care is transferred between primary and secondary care. To demonstrate this the 
separate components of the interface were examined using Donabedian's (1988) 
definitions of the structure and process of health care. This chapter finishes with a 
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summary of the structural and process components of health care demonstrating their 
contribution to making the interface a real entity with the potential to impact on the 
quality of patient care. 
Within the structure of health care the environments where primary and secondary 
care are provided, managerial lines of accountability, resource allocation and policy 
implementation were considered. As secondary care is generally provided in 
hospitals and primary care is provided in a community setting good communication 
between health care professionals on either side of the interface is essential to 
preserve the quality of care. However, communication between primary and 
secondary health care professionals is poor and this may partly be due to a lack of 
appreciation of the information requirements of colleagues on the opposite side of the 
interface. 
Changes in NHS management structure over the last twenty years have aimed to make 
the NHS more efficient through the development of a market economy. However, in 
reality what this has done is put pressure on both primary and secondary care to limit 
expenditure as much as possible. Whilst this has been achieved partially by 
restricting the use of new expensive medicines and ensuring medicines are used in 
appropriate circumstances some tactics rather than controlling medicines expenditure 
simply transferred the costs of prescribed medicines across the interface. This is 
particularly true from secondary to primary care, perhaps because hospitals had 
limited budgets long before these were introduced to primary care. However, GPs 
may also resist the transfer of prescribing responsibilities because of the cost of a 
medicine rather than any clinical concerns. The lack of concern about the cost to the 
whole NHS of medicines can be exploited by external agencies such as the 
pharmaceutical industry. Taking up offers of discounted medicines may mean that 
either primary or secondary care can achieve financial balance but may have an 
adverse impact on expenditure on the other side of the interface. 
The third structural component of the interface relates to the policy process. It was 
explained how primary and secondary care are under separate management structures 
and as such there will be chief executives on each side responsible for implementing a 
particular policy in their sector. It was explained how policy from the DoH was often 
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not rigid and so could be changed whilst it was implemented. This means that 
policies about the same subject may be interpreted differently in primary and 
secondary care to reflect their individual concerns and priorities. Some policies may 
not apply across both primary and secondary care. An example of this is the NHS 
'blacklist' which is strictly enforced in primary care but may not be adhered to at all 
in secondary care. Conversely hospitals are better able to restrict the range of 
medicines used than primary care organisations. 
Finally, the fourth component of the interface comes from the process of care and the 
health care professionals providing that care. The first important point to appreciate is 
that health care professionals tend to work only in primary or secondary care. This 
means that, not only are professionals from either side of the interface unlikely to 
meet, but they may also not appreciate the concerns of their colleagues on the 'other 
side'. This is compounded firstly by the fact that doctors and pharmacists generally 
decide their future career paths soon after finishing university and whilst GPs will 
have hospital experience, community and hospital pharmacists and hospital doctors 
may have never worked on the opposite side of the interface. This raises the question 
as to how health care professionals can appreciate each other's needs and thus 
facilitate the continuity of care across the interface. Pharmacists' roles develop 
differently, with hospital pharmacists pursuing a clinical, interventional role and 
community pharmacists still mainly undertaking a technical, supply role. Hospital 
pharmacists may develop roles in particular specialities whilst community pharmacies 
provide a general service. Similarly, hospital doctors develop specialist knowledge in 
particular disease areas and GPs maintain a general knowledge although they may 
develop special interests. This gives the potential for a mismatch between the 
information needs of a GP when asked to prescribe a particular medicine and the 
information provide by hospital specialists. 
Now that an explanation of how the interface has been proffered and the components 
that make it real rather than theoretical have been described it is appropriate to 
consider the problems this may cause. In the next chapter an overview is provided of 
existing knowledge about medicines related problems when patient care is transferred 
across the interface. 
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CHAPTER TWO 
MEDICINES RELATED PROBLEMS AT THE INTERFACE 
2.1 INTRODUCTION 
In Chapter One it was shown how the interface is constructed from components of the 
structure and process of health care. This demonstrates that the interface is not simply 
a theoretical state that patients pass through when responsibility for their care is 
transferred between primary and secondary care. The interface has physical and non-
physical characteristics that interact to create a situation whereby patient care can be 
adversely affected. Three structural elements making the interface tangible were 
identified. The first of these is the environment where health care is provided. 
Physical separation of primary and secondary care services means that effective 
communication is necessary to ensure that care transfer is smooth. The second relates 
to resources and strategies introduced in secondary and primary care to manage 
expenditure on medicines were described. It was shown how strategies introduced on 
one side of the interface could adversely impact on medicines expenditure on the 
other side. Thirdly, the NHS policy making and implementation process was 
discussed to demonstrate how policies from the DoH can be interpreted by NHS 
health care organisations as they are implemented. Sometimes contlict between 
different policies means that some policies are incompletely implemented. The 
process element of the interface relates to health care professionals. It was shown 
how, even within professions, there are likely to be misunderstandings about roles and 
information needs. 
Within this chapter, the literature relating to problems with medicines when 
responsibility for patient care is transferred across the interface will be reviewed. The 
problems will be covered under three themes: medication errors, financial issues and 
clinical responsibility issues. However, before considering problems with medicines 
it is important to appreciate the ideal situations with regard to both patient transfer and 
control of medicines across the interface. Therefore, first the concept of 'seamless 
care' will be described and how medicines can be used safely, effectively and 
efficiently within the NHS through a system of medicines management. 
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2.2 SEAMLESS CARE 
The efficient functioning of the NHS relies on patients being transferred from one 
care setting to another. The increased expense of hospital based services means that 
this is particularly relevant for transfer from secondary care back to primary care once 
patients no longer require acute care. The term 'seamless care' has been used to 
encapsulate an ideal world in which professional and managerial boundaries within 
the NHS are made invisible or 'seamless' to patients. Thus the continuity of care is 
maintained within this extremely complex organisation. 
'A seamless service is one where services which individuals need are co-ordinated 
and integrated across the health and social care system, including primary care and 
social care' (DoH, 1996). 
Roberts et al (1997) expanded the DoH definition of seamless care from a 
pharmaceutical perspective to clarify the main aims of a seamless service. That is, a 
service enabling patients to receive uninterrupted treatment and care whenever they 
are prescribed medication, dressings or medical and surgical devices and one that 
allows each health care professional involved in the treatment and care of patients to 
have sufficient information to carry out their role effectively and efficiently. 
In many respects, this ideal of seamless care is rarely achieved. The difficulties with 
the continuity and quality of care with respect to medicines when patients are 
transferred between primary and secondary care will be discussed in this section. 
However, first we need to consider the concept of medicines management. This is a 
term used to describe how the use of medicines within the NHS should be controlled 
to ensure safety, efficacy and efficiency. 
2.3 MEDICINES MANAGEMENT 
The development of pharmacy practice, particularly in hospitals, from a product 
orientated medicine supply service to a clinical pharmacy service was described in 
Chapter One. The aim of clinical pharmacy is to reduce medication errors and to 
improve the cost-effectiveness of medicines use. However, although clinical 
pharmacy concentrates the efforts of pharmacists on improving medicines use rather 
than medicines supply it is still task and process driven. Therefore, clinical pharmacy 
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services were developed into pharmaceutical care services. The difference between 
clinical pharmacy and pharmaceutical care is that, in the former, the majority of 
services are provided to other health care professionals whereas pharmaceutical care 
puts the patient at the centre and aims to address the medicines needs of patients. 
Another important difference is that pharmaceutical care requires definite 
improvements in patient outcomes through the use of medicines (Hepler & Strand, 
1990). Hepler and Strand (1990) defined four outcomes that should result from 
effective pharmaceutical care provision. These are cure of disease; elimination or 
reduction of symptoms; stopping or slowing of disease progression and prevention of 
disease or symptoms. 
It is clear that the philosophy of pharmaceutical care is important to ensure that 
patients' health is improved through the use of medicines. However, the emphasis is 
on the needs of individual patients rather than improving the health of the general 
population. Barber (1996) argued that this philosophy could be detrimental to public 
health if medicines were used inappropriately or resources were used inefficiently. 
Therefore, there was a need for an overarching philosophy for medicines use within 
the NHS taking into account safety, effectiveness and efficiency. These three factors 
have been combined into a single term 'medicines management' although there has 
been some debate about the meaning of this term. Tweedie and Jones (2001) describe 
medicines management in a similar way to pharmaceutical care but include the 
efficient use of medicines. Barber (2001) describes how the concept of medicines 
management originated from health care organisations that paid for medicines and so 
needed to control or manage their use in some way. This means that the use of 
medicines is rationalised to improve effectiveness and efficiency. In this way the 
medicines that are available to patients are controlled and so medicines management 
benefits health care organisations by reducing both expenditure and wastage of 
medicines. This is opposed to pharmaceutical care which puts the patient at the centre 
and aims to provide benefits for individual patients. Simpson (2001) comments that 
some medicines management services being explored,are really models of 
pharmaceutical care. However, he explains that whilst pharmaceutical care is one 
aspect of medicines management there are other aspects, such as formulary 
development. Formulary development can be considered as a medicines management 
service but not a pharmaceutical care service. This is because pharmaceutical care is 
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about optimising medicines use for individual patients whereas medicines 
management also includes medicines issues affecting the greater public health. For 
the purposes of this thesis the following definition will be used. 
'Medicines management is a system of processes and-behaviours that determines how 
medicines are used by patients and by the NHS' (NPC & NPCRDC, 2002). 
This definition includes all aspects of the supply and use of medicines from the 
perspective of individual patients and health care organisations. Effective medicines 
management aims to improve health, improve patient care and satisfaction, make 
better use of professional skills, deliver effective clinical governance and maximise 
the effective use of resources available (NPC & NPCRDC, 2002). This means that 
whilst the ultimate aim of using medicines is to improve the health of patients, this 
must be done within allocated resources. Therefore systems must be in place to 
ensure that effective medicines are used but that the costs and benefits are considered. 
Hence, dilemmas arise in terms of the medicines patients or health care professionals 
want to use, contrasting with what can be provided at an organisational level in order 
to achieve financial balance. In addition to concerns about expenditure, medicines 
management also considers the safety perspectives of medicines use and this includes 
reducing patient harms associated with medicines. 
The remainder of this chapter will concentrate on an exploration of problems 
associated with medicines management within the NHS. Once medicines 
management problems to the whole NHS have been considered specific problems 
when patients are transferred between primary and secondary care will be discussed. 
2.4 PROBLEMS ASSOCIATED WITH MEDICINES MANAGEMENT 
The problems associated with medicines management can be categorised into three 
major themes: problems associated with medication errors, financial issues and 
clinical responsibility issues. Each of these categories will now be discussed. 
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2.4.1 Medication errors 
A medication error is 'any preventable event that may cause or lead to inappropriate 
medication use or patient harm' (ASHSP, 1998). Not every medication error results 
in harm to the patient but those that do are termed adverse drug events, that is 'injury 
from a medicine (or lack of an intended medicine), (ASHSP, 1998). 
Researchers in the United States of America found that 3.7% of hospital patients 
experienced disabling injuries caused by medical treatment (Leape et ai, 1991). This 
contrasts with a study in a British hospital which determined that nearly 11 % of 
patients e:xperienced an adverse event (Vincent et ai, 2001). Both of these studies 
were retrospective and would probably have underestimated the true adverse event 
rate because they were limited by what was documented (Barber & Dean, 1998). This 
is confirmed by a prospective study which found that 18% of patients experienced at 
least one serious adverse event (Andrews et ai, 1997). Leape et al (1991) established 
that drug complications were the most common type of adverse event causing 19% of 
the total. A covert, observational study of medicine administration in an NHS 
hospital found an overall error rate of 3.5% (Ridge et ai, 1995). Again the error rate 
in the prospective study by Ridge et al (1995) is higher than that in the retrospective 
study by Leape et al (1991). In addition Ridge et al (1995) only looked at medicine 
administration errors rather than the whole spectrum of adverse drug events. 
Therefore, it would be expected that a prospective study looking at all adverse drug 
events would show a higher event rate. Dean et al (2002) found that prescribing 
errors were identified in 1.5% of medication orders for hospital inpatients with half of 
them associated with the dose of medicine. It is clear then that medication errors have 
the potential to cause considerable harm to patients in hospital. As many adverse drug 
events experienced by hospital inpatients are preventable (Bates et ai, 1995) much can 
be done to reduce them. 
Less research has been undertaken to determine the medication error rate in primary 
care, although it would be logical to assume that som~ errors in secondary care will 
perpetuate on discharge into primary care. A study of OP prescribing errors found an 
error rate of 7%, over a third of which related to the directions for taking the medicine 
(Shah et ai, 2001). The practice of two thirds of community pharmacists is to label a 
medicine as stated on the prescription even when the prescriber's directions are 
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unspecific, for example, 'as before' or 'as directed' (Rogers & Rees, 1997). This 
could leave patients confused as to how much and how frequently medicines are 
meant to be taken. The National Medicines Management Services Collaborative has 
highlighted this important aspect of patient care by making it one of their specific 
areas for improvement in medicines management in primary care (NPC, 2002a). 
Hawksworth et al (1999) however, found that community pharmacists made clinical 
interventions on 0.75% of prescription items. This is a lower figure than that found 
by Shah et al (2001) and may be because the focus of Hawks worth's study was to . 
assess community pharmacists' ability to undertake clinical interventions rather than 
to specifically look for medication errors. However, it does show that medication 
errors are also a problem in primary care. Plans are being developed to include 
community pharmacies in medication error reporting schemes (Obome et ai, 2002). 
Medication errors that arise when patient care is transferred between primary and 
secondary care settings have been researched more extensively. It is reasonable to 
assume that the medicines prescribed by a OP subsequent to a patient's discharge 
from hospital would correspond with those prescribed by the hospital doctor at the 
point of discharge. However, numerous discrepancies between the medicines 
prescribed on discharge from hospital and those subsequently prescribed by OPs have 
been reported. Cochrane et al (1992) found that for 45 out of 50 elderly patients' 
medicine regimens there were differences between the medicines prescribed on 
discharge from hospital and those subsequently prescribed by OPs. The changes 
discovered included medicines stopped, medicines started, dose changes and dose 
instruction changes. Binyon (1994) found similar changes and that 17% of medicine 
names, 15% of doses and 39% of directions were changed. High levels of direction 
changes is partially accounted for by the fact that the hospital labelled medicines with 
specific times to be taken, for example at breakfast time, rather than just once daily. 
Bums et al (1992) found that only 37% of medicines prescribed for elderly patients 
had no changes between the discharge medicines and the OP prescribed medicines. 
Changes also included directions being changed from specific to non-specific 
directions, for example 'as directed' and container closures changed to child resistant 
versions. These changes may hinder elderly patients in taking their medicines 
correctly by limiting the accessibility of medicines or reducing the available 
information. Omori et al (1991) found that 32% of patients' medicine regimens had 
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deletion or addition errors and 18% had dosage errors. Duggan et al (1996) 
categorised medicine changes following discharge from hospital into intentional 
changes, that is those that had been made following health care professional review , 
and unintentional changes. They found unintentional changes in 11 % of medicines 
one week after discharge and in 46% of medicines six weeks after discharge. 
Unintentional changes found included change in dose or dose instructions, change of 
medicine name, change in form or brand of medicine, absence or presence of warning 
labels and medicines added or discontinued. 
Differences between hospital discharge medicines and those subsequently prescribed 
by OPs may be explained by the action of GPs reviewing patients and making 
appropriate changes according to clinical condition. However, few patients see their 
OP following hospital discharge (Williams & Fitton, 1990; Obome & Dodds, 1994) 
which has led researchers to conclude that many of the differences are unintentional 
rather than following a clinical decision to amend the regimen (Duggan et ai, 1996; 
Pegrum, 1995; Bums et ai, 1992; Cochrane et ai, 1992). Whilst delays in 
communication described in Chapter One may contribute to the discrepancies found, 
the management of information received by OP practices may also contribute. 
Coleman et al (2001) found that transcription errors occurred when information from 
hospital discharge letters was transferred to primary care records. Errors that were 
made included old medicines not stopped, duplication of drug, class or action and 
recommended change not implemented. These problems are not unexpected given the 
poor control of computer prescribing systems in general practice especially when we 
consider that staff with little knowledge of medicines may make amendments to 
patients' records without supervision (Zermansky, 1996). It is easy to see how 
someone with little knowledge of medicines may not recognise that a new medicine 
on a discharge letter is from the same class of medicines as one on a patient's repeat 
medicines list. 
The consequences of discrepancies between medicines prescribed on discharge and 
those subsequently prescribed by OPs are difficult to assess because adverse drug 
events reSUlting from interface problems are infrequently reported. However, when a 
doctor assessed the interventions made by pharmacists when prescribing was 
transferred between primary and secondary care 68% of interventions were judged to 
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be clinically significant (Pegrum, 1995). Interventions made included clarification of 
medicine regimen to prevent inappropriate medicines being prescribed or 
discontinued. 
Research has identified that liaison between hospital and community pharmacists can 
be beneficial in terms of enabling a reduction in unintentional medicine changes in 
elderly patients (Binyon, 1994; Law et ai, 1994; Pegrum, 1995) and in general 
medical patients (Choo & Cook, 1997; Duggan et ai, 1998) and a reduction in 
medicine related problems once home (Cromarty et ai, 1998). However, the evidence 
on the effectiveness of liaison between hospital and community pharmacists is 
conflicting. Binyon (1994) found that changes to medicine regimens that could not be 
explained by a clinical review still occurred despite pharmaceutical care plans being 
sent to OPs and community pharmacists. Choo and Cook (1997) reported that only 
33 interface events were identified by three community pharmacists over a three-
month period. Law et al (1994) found that, despite documenting differences between 
the medicines supplied on discharge and those subsequently prescribed by OPs, 
community pharmacists made no intervention for almost half the problems identified. 
This suggests that community pharmacists may face uncertainty about how to manage 
information to which they do not normally have access. Duggan et al (1998) found 
more positive effects of increased liaison between hospital and community 
pharmacists and that unintentional discrepancies were reduced. The success of their 
intervention may have been because patients were asked to deliver a copy of a letter 
listing the medicines prescribed on discharge from hospital to the community 
pharmacist when they went to obtain their subsequent OP prescription. Law et al 
(1994) and Binyon (1994) posted information to community pharmacies and Choo 
and Cook (1997) faxed information. These methods of communication could result in 
the information being sent to the wrong pharmacy. Alternatively, because the 
information is not immediately present when discharged patients bring in OP 
prescriptions it may not be referred to. These differences in communication methods 
could partially explain the different success rates of community pharmacy interface 
intervention schemes. This type of information transfer between hospital and 
community pharmacists is not yet common practice (Sexton et ai, 2000). Wilcock 
and Lawrence (2004) also found that drug histories taken by hospital clinical 
pharmacists on patients' admission to hospital were not substantially improved by 
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obtaining information from patient medication records held by community 
pharmacists. 
In addition to this, although pharmacists' interventions have led to a reduction in 
medication errors across the interface, the fact that community pharmacists are 
intervening means that 'near misses' are actually occurring and should be reported. 
Therefore, systems need to be put in place to prevent medication errors occurring in 
the first place rather than simply expecting community pharmacists to bridge the gap 
of poor information transfer (Cook et ai, 2000). This is because, if a community 
pharmacist fails to intervene for any reason, a patient may be harmed. Another 
important factor is that community pharmacist intervention schemes are not uniformly 
provided across the NHS. The commissioning and provision of this type of service is 
patchy and dependent on local priorities, 'vision' and funding. 
2.4.2 Financial problems 
It was explained in Chapter One that the high and escalating expenditure on medicines 
in the NHS is a cause for concern. This is because pressure is put on the overall NHS 
budget which potentially leads to restrictions being imposed on other areas of health 
care in order to achieve financial balance. The drivers for the increase in medicines 
expenditure were explored and included NSFs, implementation of research findings 
and the impact of the marketing strategies of the pharmaceutical industry. 
Whilst it is important to implement the findings of successful research it is also 
important to ensure that cost-effectiveness is taken into account. In order to manage 
cash-limited budgets, new, more expensive medicines should only be used in those 
patients who will benefit most rather than switching all prescribing to the new 
medicine. An example of this is in the treatment of dyspepsia where the newer more 
expensive proton pump inhibitors (PPIs) have taken the place of the cheaper H2 
receptor antagonists. Despite evidence that PPIs are over-prescribed (NICE, 2000b) 
expenditure on ulcer healing drugs is still growing (PP A 2004b). 
An increase in expenditure on medicines does not necessarily result in improved 
patient outcomes. Two reports by the Audit Commission nine years apart have 
reported similar findings around inefficiencies in medicines use within primary care 
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(Audit Commision, 1994; Audit Commission, 2003). Many areas were highlighted 
where prescribing could be rationalised and savings released. Examples of how this 
could be achieved include the substitution of cheaper yet equally effective medicines, 
such as those of a modified-release formulation, and the reduction in prescribing of 
medicines of limited clinical value, such as cough mixtures. 
In addition to the problem of managing total NHS expenditure on medicines there are 
three problems specific to the interface. These are: 
• the impact of hospital prescribing patterns on GPs' prescribing patterns; 
• the use of discounted medicines by hospitals and 
• the practice of hospital doctors asking GPs to prescribe expensive treatments 
instead of prescribing themselves. 
Prescribing advisers perceive that hospital prescribing policies cause significant 
problems in their attempts to improve GPs' prescribing performance (Baines et ai, 
2000). These perceptions are confirmed by studies investigating the influence of 
hospital doctors' prescribing patterns on those of GPs (Audit Commission, 1994; 
Eccles et ai, 1996; Allery et ai, 1997). More than half of non-fundholding practices 
responding to a postal questionnaire reported that hospital prescribing was an 
important influence on GP prescribing patterns in the areas of schizophrenia, 
ischaemic heart disease, diabetes and peptic ulceration. Even for therapeutic areas 
commonly managed in primary care, such as asthma and hypertension, around 40% of 
respondents felt that their prescribing was influenced by hospital patterns (Eccles et 
ai, 1996). Allery et al (1997) tried to ascertain reasons for GPs changing their clinical 
practice. General practitioners reported hospital medical consultants being one of the 
factors that influenced them to change their practice. Edgar and Girvin (1999) 
attempted to quantify the impact of hospital doctors' prescribing decisions on 
cardiovascular medicines expenditure in one GP practice. They investigated the 
initiating doctor for the ten highest expenditure cardiovascular medicines within the 
practice and found that hospital-led prescribing decisions were responsible for 74% of 
their cost. Whilst GPs commented that these were not their usual choice of medicines 
this was not specifically addressed by the study nor did the authors address the 
appropriateness of the top ten medicines. Patients who are seen by hospital doctors 
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may have more severe disease than those cared for solely by GPs. Therefore, the 
medicines chosen by hospital doctors may have been appropriate for those patients 
they had seen but inappropriate in patients cared for solely by GPs. 
The influence of hospital doctors' prescribing on GPs may be particularly problematic 
When new medicines are introduced. General practitioners may prescribe new 
medicines following prescription requests from consultants or may follow the 
example of consultants when starting to use new medicines because this gives a 
medicine acceptability (Jones et ai, 2001). This endorses what Armstrong et al (1996) 
found in that GPs were influenced by consultants if they trusted or respected them. 
This is particularly a problem for medicines that are not available for prescribing in 
hospitals. Almost half of hospital consultants reported that they asked GPs to 
prescribe such medicines (Jones et ai, 2000). This may be influenced by hospital 
policies for the introduction of new medicines. When asked to rate the ease of 
introduction of new medicines, 38% of medical consultants rated this as either 
'difficult' or 'very difficult' (Jones et ai, 2000) and so it may be easier to ask GPs to 
prescribe rather than to try to obtain medicines via a lengthy hospital application 
process. It is important, therefore, that hospitals have robust mechanisms for 
controlling both the medicines used within hospitals and the prescribing 
recommendations that hospital staff make to GPs. Without these mechanisms the 
introduction of new medicines into hospitals can also have a significant impact on 
primary care prescribing (Pryce et ai, 1996). 
The practice whereby a hospital doctor makes the decision to initiate a course of 
treatment but where the prescription is written by a GP has become know as 'cost 
shifting' (Anderson, 1992). Often the medicines that GPs are asked to prescribe are 
not normally used within primary care and can be considered as 'specialist' 
medicines. Cost shifting became customary hospital practice and this is demonstrated 
by many hospitals reporting that GPs are routinely asked to prescribe specialist 
medicines (Wilkie et a/1992b; O'Brien et ai, 1996). However, the study by O'Brien 
et al (1996) needs to be taken in the context of the period when it was carried out. For 
example, within this study proton pump inhibitors were classified as specialist 
medicines but ten years later are now commonly prescribed in primary care. 
Similarly, dialysis fluids were also included and these are now no longer prescribed 
61 
by GPs following DoH guidance (NHS executive, 1995). The practice of cost shifting 
is unacceptable in primary care particularly when the cost of the medicine is high 
(Sibbald et 01, 1992) and is an ongoing problem (Jones et 01, 2000). In the previous 
chapter, strategies introduced into hospitals to reduce medicines expenditure were 
discussed and one of these was to transfer prescribing costs to primary care (Orme, 
1991). Crump et 01 (1995) identified two financial problems with this strategy. The 
first is that medical consultants are effectively given access to GPs' prescribing 
budgets and so do not have to make rationing decisions to manage prescribing 
expenditure. The second is that many expensive medicines form part of a hospital-led 
service and if the cost of medicines is not included in the service contract price 
commissioners may agree to purchase more services than if the medicine costs were 
included. This means that commissioners may be unaware of the real costs of a 
service. As well as shifting the cost of expensive medicines, hospitals sometimes 
transfer the cost of medicines to primary care by restricting the quantities of 
medicines supplied to outpatients and on discharge from hospital (Wilkie et 01, 
1992a). 
The third financial problem with medicines management at the interface arises from 
the ability of hospitals to take advantage of lower prices. Pharmaceutical companies 
offer discounted medicines to hospitals to encourage their use (Audit Commission, 
1994). These medicines can be significantly more expensive when prescribed in 
primary care and are described as 'loss leaders'. Whilst there may be advantages to 
hospital budgets, GPs are concerned about the impact of continued prescribing on 
their own prescribing budgets (Bennett, 1994). 
The financial problems associated with the use of medicines across the interface have 
been described. These are hospital influences on GP prescribing, 'cost shifting' and 
the use of 'loss leaders'. However, cost is not the only issue when prescribing is 
transferred because there is also a need for clear lines of clinical responsibility. 
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2.4.3 Clinical responsibility 
Concerns about taking clinical responsibility for prescribing a medicine evolve from 
the legal framework of medicines administration. Liability for adverse consequences 
resulting from medicines administration is affected by the circumstances within which 
the medicines are used. The manufacturer is liable if a medicine is of defective 
quality either because of inadequacies in the manufacturing process or the storage 
conditions. If, however, a patient suffers because an incorrect diagnosis results in the 
wrong medicine being prescribed, the liability for the use of a product lies with the 
prescriber and not the manufacturer (Harman, 2003). There is a similar situation if a 
medicine is used outside the terms of its product licence. The product licence holder 
is liable for any adverse effects resulting from the licensed use of their product 
(Wingfield et ai, 1997). However, if a product is used outside the terms of the 
product licence the liability for use rests with the prescriber (Harman, 2003). 
Disagreements over clinical responsibility have been compounded because over time 
medicines available to treat patients have become more efficacious but also 
increasingly complicated and expensive. It has already been explained how GPs have 
been expected to prescribe medicines which are specialist and rarely used in primary 
care so that hospital prescribing budgets are managed (Wilkie et ai, 1992a). General 
practitioners feel unable to take clinical responsibility for certain medicines because 
of difficulties in detecting side-effects, uncertainty about explaining treatments to 
patients and difficulty monitoring dosages. However, as stated earlier, their concerns 
are sometimes clouded by the high cost of certain medicines (Sibbald et ai, 1992). 
The problems with transfer of clinical responsibility may be related to the quality of 
information that is provided when patient care is transferred. Even for newly 
marketed medicines, medical consultants give GPs a minimum amount of 
information. The expectation is that GPs will already know about new medicines or 
they will be able to find out more information if necessary (Jones et ai, 2001). The 
introduction of shared care guidelines has been recommended as a way forward to 
address concerns over clinical responsibility (NHS Management Executive, 1991). 
Despite this, GPs still feel dissatisfied with arrangements for prescribing specialist 
medicines because they see this as a cost shifting exercise (Duggan et ai, 2001; Horne 
et ai, 200 I). O'Brien et al (1996) found that over half of hospitals surveyed had no 
written shared care policies for the specialist medicines they asked GPs to prescribe 
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although the situation may have improved since this study was carried out. Shared 
care guidelines may not solve all difficulties associated with the transfer of clinical 
responsibility as GPs may be unaware of changes made to patients' medicine 
regimens despite a shared care policy being in place (Ashcroft et ai, 1998). 
Clinical responsibility has been defined by the National Prescribing Centre (NPC, 
1999, P 40). 
'Whichever individual signs a prescription generally carries the legal liability for the 
consequences of prescribing the drug or item. This cannot be delegated to another 
individual. It may be shared on occasion depending on contractual arrangements, for 
example with assistants or locums. ' 
It is clear, therefore, that a GP who prescribes a specialist medicine under the terms of 
a shared care guideline is liable in law for any adverse consequences. It is therefore 
understandable why GPs feel uncomfortable about prescribing medicines under 
shared care guidelines because they have to trust the medical consultant to make the 
correct diagnosis and prescribe appropriately. The prescribing GP must also ensure 
that any necessary monitoring has been carried out so that the medicine is used safely. 
Any unfamiliarity with a medicine may require a significant amount of research into 
both the disease and its treatment to ensme that prescribing is underpinned by the 
necessary knowledge and information. It is important to recognise that GPs' concerns 
about taking clinical responsibility for unfamiliar medicines are genuine because 
medication errors made by doctors have been associated with a lack of knowledge of 
medicines (Lesar et ai, 1997). 
General practitioners are not alone in their concerns about managing specialist 
medicines that have been initiated in hospital. These are shared with community 
pharmacists who feel that some specialist medicines would be more appropriately 
dispensed in hospital pharmacies (Wilkie et ai, 1992b). However, the main problem 
raised was with procurement difficulties and it is interesting to note that only a tenth 
of those questioned said they were concerned about the legal responsibility for 
dispensing these medicines (Wilkie et ai, 1992b). 
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2.5 SUMMARY 
This chapter started with a description of 'seamless care' as the ideal situation when 
patient care is transferred across the interface. Then it was explained how clinical 
pharmacy services had developed into pharmaceutical care services provided to 
patients by phannacists. Whilst pharmaceutical care fulfils the needs of individual 
patients with respect to their medicines there is a need to ensure that enhancing the 
care of individuals does not adversely impact on the health of the general population 
through the inefficient use of medicines. Therefore, a new concept of 'medicines 
management' evolved to describe the processes and behaviours used by patients and 
the NHS to ensure that the use of medicines is safe, effective and efficient. The three 
problem areas with medicines management were then considered with regard to care 
being transferred between the primary and secondary care sectors. These were 
identified as medication errors, financial issues and clinical responsibility issues. 
These problem areas can result in reduced patient safety through medication errors , 
inefficient use of medicines because of poor systems for controlling medicines use 
and difficulties with the transfer of prescribing responsibilities across the interface. 
These are not new problems as there are reports in the literature going back more than 
fifteen years. In the first chapter it was described how the DoH had published 
guidance aimed at improving medicines management across the interface. Whilst 
some strategies and interventions have been introduced it is clear this has not been 
achieved across the whole NHS as problems continue to be reported up until the 
present day. Despite the publication of DoH guidance there are still problems with 
medicines management across the interface. Improving medicines management 
across the interface requires health care professionals to change professional practice. 
Therefore, in order to understand why this has not happened an appreciation of 
change management theories is necessary. The major theories relating to change 
management will be discussed in the next chapter. 
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CHAPTER THREE 
CHANGE MANAGEMENT THEORY AND ITS APPLICATION TO 
MEDICINES MANAGEMENT 
3.1 INTRODUCTION 
In the previous chapter 'seamless care' was described as the ideal situation when 
responsibility for patient care is transferred across the interface. The concept of 
medicines management was introduced and how medicines management systems 
should ensure that medicines are used safely, effectively and efficiently. The 
literature relating to medicines management problems across the interface was 
reviewed. Problems could be categorised according to whether they were related to 
communication, financial issues or clinical responsibility issues. Although there are 
reports in the literature of interventions which improve medicines management at the 
interface, problems are still being reported to this day. This is despite the pUblication 
of national guidance specifying how medicines should be managed across the 
interface. In order to identify reasons why medicines management at the interface has 
not improved over the last fifteen years an understanding of organisational change 
theory is necessary. This is because the NHS is one of the largest organisations in the 
UK with over a million employees (Hicks et ai, 2005). 
This chapter starts with the description and application of a model for diagnosis of a 
problem requiring change. Unless the exact nature of a problem is determined there is 
a risk that it will not be resolved. An overview of organisational change management 
theory will then be given. There will be an explanation of how driving and restraining 
forces interact to prevent change happening and how this can be overcome. Then the 
development of change management models will be discussed from Lewin's three 
stage model developed in the 1940s to modern models of organisational development. 
A model for diagnosing a change situation will be explored to show how the real 
source of a problem can be determined. The importance of considering how different 
Parts of the NHS interact when trying to improve the process of care, that is 'systems 
thinking' will be demonstrated. Finally this chapter will end with a review of the 
literature on changing health care professionals' behaviour, with particular emphasis 
on prescribing and medicines management. 
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3.2 DIAGNOSIS OF A PROBLEM REQUIRING CHANGE 
Cummings and Worley (2001) describe the diagnosis of a problem requiring change 
as 'the process of assessing the functioning of the organisation, department, group or 
job to discover the sources of problems and areas for improvement'. A thorough 
diagnosis should provide an understanding of the situation in its current state and any 
information needed before a change programme can be initiated. Whilst several 
different models have been developed to aid the diagnosis of organisations, Nadler 
and Tushman's (1977) model will be described because this has previously been used 
to diagnose NHS care systems (Martin & Henderson, 2001). This model is also 
particularly relevant to medicines management systems because it highlights the 
influence of the external environment on the system under review. The external 
factors that impact on medicines management were described in Chapter One. The 
model is also relevant as it considers the system as a whole and how each constituent 
part interacts with others. This 'whole systems' approach recognises that each part of 
a system influences, and is influenced by, other parts and is in keeping with Senge's 
(1993) concept of 'systems thinking' which will be discussed later on in this chapter. 
In addition, changes made in one part of the system impact on other parts and this 
needs to be taken into account when designing a change programme. The 'whole 
systems' approach has been adopted by the NHS Modernisation Agency as the 
method to improve the experience and care of patients within the NHS through a 
series of change programmes (NHS Modernisation Agency, 2004b). 
Nadler and Tushman's model consists of seven components. The model separates the 
components of an organisation to increase our understanding of the current situation, 
how components relate to each other and what changes might be needed. Four of the 
components represent the organisation itself and although the other three components 
are external they influence the organisation and are influenced by it. 
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The four organisational components are:-
1. Tasks - this represents the nature and content of the work or service that is 
provided by the organisation. 
ii. Formal organisational arrangements - that is lines of accountability, information 
systems, monitoring and control mechanisms, operating policies, meeting 
structures, management arrangements. 
iii. Informal culture - this is important because it represents 'the way we do things 
around here', the values, power bases, political and informal networks and often 
drives the organisation. The informal culture can be very strong and difficult to 
change. 
IV. Individuals - these are the members of the organisation who perform the tasks 
and make choices about what they do and how they do it. 
The external components are: 
1. Shared vision - this is the same definition as used by Senge, that is a picture of 
how things will look for the better in the future. 
u. Leadership - how the senior personnel within the organisation are moving 
towards the goal of the shared vision. 
iii. Environment - there is a need to fit the organisation within the context of the 
environment within which it exists. These external factors or relationships must 
be considered (e.g. government directives). 
The four organisational components of the model are in a state of dynamic 
equilibrium with each other and their environment. As one component changes the 
others must also change to rebalance the equilibrium. 
The model allows a deeper understanding of an organisation to be gained through a 
process of describing, defining and exploring each constituent component and the 
relationships between them. Showing where components do not fit well with each 
other may identify areas for change to make an organisation more effective. An 
example of two components that do not fit well together would be if the individuals 
Were not properly skilled to carry out the tasks. This model may also be used to 
detect barriers to change and to predict how an organisation might react to an 
intervention. This deeper understanding of the organisation also ensures that a 
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solution to the real problem is developed. Sometimes what initially appears to be the 
problem is not the real problem at all. If the problem were solved in its initial form 
the solution may be inappropriate and therefore fail or result in unnecessary changes, 
thus wasting time and resources. 
Nadler and Tushman's model will now be applied to medicines management at the 
interface to identify and describe the relevant components (Table 3.1). The gaps in 
this table reflect where the information does not exist in the literature and therefore 
requires to be addressed by research. 
Table 3.1 Components of medicines management across the interface 
Component 
Organisational 
1. Tasks 
2. Formal organisational arrangements 
3. Informal culture 
4. Individuals 
External 
1. Shared vision 
2. Leadership 
3. Environment 
Description 
Prescribing, procurement, dispensing & 
administration of medicines for patients 
Formularies (including the NHS blacklist) 
Drug & Therapeutics Committees 
Area Prescribing Committees 
Prescribing budgets 
Patients 
GPs 
Community pharmacists 
Hospital doctors 
Hospital pharmacists 
DoH guidance 
Pharmaceutical industry 
Table 3.1 above outlines the researcher's interpretation of the internal and external 
components contributing to medicines management at the interface as defined by 
Nadler and Tushman. The tasks that are relevant for this thesis are those associated 
with the prescribing, procurement, dispensing and administration of medicines. As 
outlined in Chapter Two these need to be undertaken with regard to safety, efficacy 
and efficiency. The formal organisational arrangements relate to those concerned 
with the cost-effectiveness of prescribing, such as resource allocation and control of 
use of new medicines through formularies and Drug and Therapeutics Committees. 
The individuals we are concerned with are firstly patients. This is because they are 
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potentially affected most by problems with medicines management at the interface 
through medication errors and difficulties in obtaining medicines. Doctors in hospital 
and primary care prescribe medicines and their prescribing decisions can impact on 
medicines management across the interface as was demonstrated in the previous two 
chapters. Similarly, pharmacists on either side of the interface are affected through 
poor communication about the medicines patients are taking. The component that is 
not clear from the literature is the informal culture or 'the way things are done around 
here'. Previous literature relates to the formal ways of doing things rather than how 
and why they were actually carried out. 
It has already been explained that the ideal situation is one of 'seamless care' when 
medicines management is transferred across the interface. However, it is not clear 
Whether the individuals, that is the doctors and pharmacists, providing medicines 
management across the interface, understand or acknowledge this vision. It is also not 
clear whether there is leadership within NHS organisations to achieve this vision 
despite a clear message being disseminated in the form of DoH guidance (NHS 
Management Executive, 1991; NHS Executive, 1994). However, the external 
environment is clear and factors contributing to this include the pharmaceutical 
industry and, as this is being considered within a single health economy, the 
overarching policies and guidance of the DoH. 
3.3 OVERVIEW OF ORGANISATIONAL CHANGE MANAGEMENT 
THEORY 
There is a large body of literature relating to organisational change theory with 
Contributions from several academic disciplines. For the purposes of this thesis an 
appreciation is required of the key change management theories and how these can be 
applied to medicines management at the interface. Therefore this chapter will provide 
an overview of the development of change management theory starting with the 
theories of Lewin in the 1940s and showing how these have been adapted and 
modified to the present day. 
Kurt Lewin is one of the early prominent figures in change management theory. He 
Contributed two major theories to change management which are still applicable today 
and have been developed by more modem change management proponents. Firstly, 
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Lewin (1947) proposed a three-step model for implementing change. Ackoff(1993) 
developed this further into a theory describing how problems can be dissolved by 
redesigning the system containing a problem so the problem is removed. This type of 
approach has since been termed organisational development (Paton & McCalman, 
2000; Senior, 2002). Senge (1993) took organisational development a step further 
and proposed that organisations become learning organisations in order to ensure that 
they constantly improve towards a vision of a better future shared by all members of 
the organisation. 
The change models described are suitable for use in 'soft' systems which have a large 
human rather than technological dimension. It will be appreciated that first a situation 
will have to be assessed to determine whether the system containing the problem is 
mainly 'soft' or 'hard'. This is because application of the incorrect type of change 
management model may result in failure or incomplete change implementation. 
The second of Lewin's major contributions to change management theory is the force 
field theory (Lewin, 1947). This can be used to explain why change is difficult to 
implement and how various factors interact to prevent change happening. This has 
been developed further by Carnall (1999) into the 'change equation'. These theories 
are important as they help to show whether it will be possible to implement a change 
and so they will be discussed before considering models of change implementation. 
3.3.1 Resistanee to ehange 
Lewin's (1947) 'force field' theory describes how driving and restraining forces 
interact in a situation to prevent change happening. The driving forces are those 
which make a change happen and the restraining forces oppose it. The theory is that 
for every force driving a change there will be an equal and opposite force. Therefore, 
for change to happen either the driving forces must be made stronger or the 
restraining forces made weaker. It is important to point out that the forces are as 
people perceive them and therefore they may not be factually correct but if people 
believe them they will influence the change process (Martin & Henderson, 2001). 
The forces can be shown diagrammatically as in Figure 3.1 using arrows to show the 
direction and relative strength of the forces. This model helps to determine which 
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driving forces may be taken advantage of and which restraining forces can be 
removed. Producing a force field diagram for each person, group or task affected by 
change will allow assessment of the relative strengths of opposing forces. 
Figure 3.1 Forces driving and restraining change (as described by Lewin, 1947) 
Driving forces Restraining forces 
Equilibrium 
Progress in a change programme will only be made if the driving forces are greater 
than the restraining forces. Whilst it may seem preferable to use driving forces to 
'win' by exerting pressure on people who oppose the change it is often better to focus 
on the weakening or removal of the objections of the opposite side (Martin & 
Henderson, 2001). This is because what tends to happen when a driving force is 
increased is that the restraining forces increase proportionately too and this prevents 
any movement towards change. Drawing up a force field diagram helps to identify 
Which restraining forces it is possible to remove in order to allow the change to take 
place. 
Camall (1999) expanded on force field analysis and developed the change equation 
Which is expressed as follows: 
EC = A x B x D 
'EC' is the energy for change, 'A' represents dissatisfaction with the present situation, 
'B' is the level of knowledge of the first steps to take towards change and 'D' is the 
shared vision of what the future will look like following the change. Change will only 
happen if A, Band D are greater than zero. There is an additional factor in that the 
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energy for change must be greater than the perceived cost of making the change. This 
aspect is similar to Lewin's theory in that the energy for change could be considered 
as the forces driving change and the costs of making the change as the restraining 
forces. 
It is important to identify factors that could prevent change happening. This is 
because identification of these factors helps to determine, firstly, whether it is feasible 
to attempt to introduce change and, secondly, the most effective way of bringing 
about change. Change can be introduced either by removing the resisting forces, as in 
Lewin's model, or by modification of the factors in Camall' s (1999) change equation. 
For example, highlighting specific problems and difficulties could increase 
dissatisfaction with the current situation. Alternatively, a clear vision of how things 
could look better in the future could be disseminated and people shown what steps 
they could take to make this happen. However, it is important to remember that some 
situations are too difficult to change because the restraining forces cannot be 
overcome. Assessing these before introducing change prevents time and resources 
being wasted on trying to introduce impossible change. Models for implementing 
change specifically in organisations will now be discussed. 
3.3.2 Implementation of ebange 
Lewin (1947) proposed a model describing how change could be implemented. 
Whilst this model is over 50 years old it has been described as 'one of the simplest 
and most useful' (Nicholson, 1993) and is still used as the basis for organisational 
development theory. Lewin (1947) identified three stages in every change process: 
unfreezing, moving and refreezing. 
3.3.2.1 Stage one - unfreezing 
The first step, 'unfreezing', is the stage when work is undertaken to acknowledge that 
there is a need for change. This is one way of overcoming resistance to change and 
making people more accepting of the change process. It was explained earlier how 
Lewin proposed that opposing forces for and against change produce an equilibrium 
to prevent change from happening. In order for change to happen then there needs to 
be an incident that interferes with the equilibrium. Senior (2002) describes such 
incidents as triggers for change. Triggers are important because they identify what is 
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causing a need for change and understanding the nature of a trigger may help 
management of the change process. 
Triggers can be considered internal, that is originating from within the organisation, 
or external, whereby outside factors trigger the change to happen. In reality, however, 
it is difficult to completely separate internal from external triggers. Within the NHS 
recruiting a new hospital consultant or redesigning the delivery of a service could be 
considered internal triggers for change. External triggers can be divided into the 
political, economic, technologic and socio-cultural factors influencing an organisation 
(Senior,2002). Table 3.2 illustrates how this categorisation can be applied to 
medicines management across the interface in a single health economy. 
Table 3.2 External triggers for change 
Jactor 
Political 
Economic 
Technological 
Socio-cultural 
Example of triggers 
Government ideology (e.g. Care in the 
community) 
DoH guidance 
DoH performance targets (e.g. waiting 
lists) 
Medicines legislation 
Prescribing allocations 
Cost shifting 
Availability of loss leader medicines 
Development of new medicines 
Use of information technology in 
prescribing and communication 
Improved patient access to information 
through the internet 
Skills availability 
Demographic trends (e.g. Increase In 
elderly people) 
Political triggers for change are those that originate from government. The most 
obvious example of this is when there is a change in government and hence 
ideologies. This happened when a Labour government was elected in the mid-1990s. 
The internal NHS market created by the previous Conservative government was 
dissolved and replaced with Primary Care Groups and Trusts. It was discussed in the 
first chapter how this introduced changes in resource allocation so that, theoretically 
at least, funds could be transferred more easily between primary and secondary care 
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budgets. Other government policies also fit into this category. The implementation of 
Caring for People (DoH, 1990), for example, impacted on medicines management 
across the interface because it meant that more people were cared for within homely 
environments in the community rather than in hospital. Therefore, there was a 
resulting increase in medicines expenditure in primary care for these people. 
Methods of resource allocation and the need to control medicines expenditure can be 
classified as economic triggers for change. Downward pressure on cash limited 
hospital prescribing budgets triggered the introduction of strategies to control 
medicines expenditure. 'Cost shifting' and the use of 'loss leader' medicines are 
examples of these strategies and were discussed in Chapter One. Wilkie et al (1992a) 
found that hospitals seemed to be moving towards policies restricting the quantities of 
medicines supplied to outpatients. The result of these policies is that GPs prescribe 
instead of hospital doctors and so the cost of medicines is moved to the primary care 
budget. This supports the view that 'cost shifting' was triggered by downward 
pressure on hospital prescribing budgets and will be discussed further in Chapter Six. 
Technological triggers for change relate to the development of new medicines and 
also changes in information technology. As new medicines are developed they may 
change how patient care is provided. The Mirena® interuterine device is a highly 
effective contraceptive (Guillebaud, 1999). Use of this device could result in less 
women being admitted to hospital for sterilisation operations. However, this affects 
the interface because GPs may be expected to prescribe the device. 
Socio-cultural triggers for change impacting on medicines management at the 
interface include the fact that the population is aging. This means that more 
medicines will be prescribed with a resulting increase in expenditure. There may also 
be a need to provide more assistance to older people to enable them to take their 
medicines (NICE, 2001). 
The unfreezing stage may also include demonstrating that there is that there is an 
inconsistency between, for example, care provision at the current time and the quality 
of care that an organisation is aiming for. This helps to show people why change is 
necessary and helps to create dissatisfaction with the current situation. Dissatisfaction 
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with the current situation was one of the components of Carnell's (1999) change 
equation described in the previous section. Without dissatisfaction with the current 
situation, change will not take place. 
In Some situations, however, there may be no time to wait for an unfreezing event to 
trigger the change and so it will be necessary to intervene to improve the current 
situation. In such circumstances, potential sources of resistance to the proposed 
change need to be identified and resolved so that they do not impede the change 
process. 
3.2.2.2 Stage two - moving 
The second stage of Lewin's change model is known as 'moving'. During this stage 
the changes that will move the organisation to the desired future state are 
implemented. In particular, people who will be negatively impacted by the change 
should be observed because they are likely to provide the strongest resistance to the 
change (Paton & McCalman, 2000). This stage may also involve the development of 
new structures and systems to ensure that the new ways of doing things are protected. 
3.2.2.3 Stage three - refreezing 
'Refreezing' is the final phase of the change model when the new practices introduced 
become part of normal behaviour. This requires putting systems into place to ensure 
that practices do not revert to the previous way of doing things. Following the 
refreezing phase other changes may be necessary, for example, in the monitoring 
arrangements or changes to the organisational culture. 
The refreezing phase of Lewin's change model has been criticised. This is because, 
whilst it is necessary to prevent reverting back to previous behaviour, organisations 
now should be continuously changing and moving forward rather than standing still 
after a change programme (Senior, 2002). Lewin's model is perhaps over-simplistic 
and more recent change management experts have developed more detailed models of 
organisational development. Therefore it will now be discussed how Lewin's simple 
three stage model has developed into a change management model called 
'organisational development' which takes into account the need for organisations to 
be constantly improving. However, organisational development is a change model 
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effective for specific situations called 'soft' systems. Therefore an appreciation of the 
difference between 'soft' and 'hard' systems is necessary before considering methods 
of introducing change. 
3.3.3 Categorisation of change situations 
Problems can be divided into those that are mainly related to work systems and 
technology and these are commonly referred to as 'hard' systems (Paton & 
McCalman, 2000). Conversely, those problems with a mainly human dimension are 
referred to as 'soft' systems (Paton & McCalman, 2000). It is quite difficult to 
differentiate between hard and soft problems although hard problems tend to be quite 
contained and limited whilst soft problems are larger and more difficult to solve. 
Usually problems do not wholly fit into either the soft or hard categories but there is a 
scale along which problems can be placed depending on whether they have a tendency 
towards hard or soft complexity. Hard and soft problems require different types of 
solutions to resolve them. Categorisation of problems in this way allows the 
development of an appropriate solution which is more likely to be successful. 
Paton and McCalman (2000) devised the 'Tropics' test to aid the categorisation of 
problems into hard or soft complexity. The title is a mnemonic using the first letters 
of the issues taken into consideration. These are time scales, resources, Qbjectives, 
nerceptions, interest, £ontrol and §.ource.· Issues likely to be found in hard situations 
are put on one side of a line with soft situations on the other side. The test is applied 
by marking the line according to whether the situation is nearer to one end or the 
other. For example, if the times scales were clearly defined and within the short to 
medium-term, the issue would be considered to be nearer the hard end of the spectrum 
than if the time scales were poorly defined and the change was expected to occur over 
the medium to long-term. Similarly if the resources for the change were clearly 
identified this would be nearer the hard end of the spectrum than if the necessary 
resources were uncertain. Table 3.3 shows the how the Tropics test can be applied to 
changing medicines management at the interface. 
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Table 3.3 Application of the 'Tropics' test to medicines management across the 
interface 
Issue 
Time scales 
Resources 
Objectives 
Perceptions 
Interest 
Control 
Source 
Description 
No time limit given for implementation of DoH 
guidance around medicines management at the 
interface. 
No specific resources allocated. 
Mainly subjective but some objective 
improvement measures could be put in place e.g. 
timing of discharge communication. 
Some differing perceptions across the interface 
between health care professionals. 
Widespread because medicines management 
impacts on other areas of health care e.g. due to 
high expenditure on medicines. 
Impact on other areas of health care means that 
control is not limited to health care professionals 
dealing with medicines e.g. requirement to 
achieve waiting list targets. 
Originates externally through DoH guidance. 
Complexity 
(hard or soft) 
Soft 
Soft 
Soft 
Soft 
Soft 
Soft 
Soft 
The above assessment of the interface medicines management system shows that it is 
one of 'soft' complexity. Change management models that have developed from 
Lewin's three-stage models and are appropriate for use in 'soft' situations will now be 
described. 
3.3.4 Development from Lewin's three stage model to organisational 
development 
Ackoff (1993) stated that problems could be 'resolved', 'solved' or 'dissolved'. 
'Resolving' a problem is an approach that uses previous experience of what has 
worked in the past to determine a solution to the problem. This is a subjective method 
and so it is difficult to determine whether the objectives of the change have been met 
due to the lack of thoroughness in developing objectives and methods of evaluation. 
'Solving' a problem is a much more objective approach and relies on research-based 
scientific methods. However, this may not be a very effective approach in a soft 
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system because of the complexity of several problems interacting with each other. 
Breaking a system into its individual problems to deal with each individually would 
result in the loss of the vital properties of the whole system. In contrast, 'dissolving' a 
problem involves redesigning the whole system containing the problem so that it is 
removed. This type of solution has been termed organisational development and has 
been defined by Paton and McCalman (2000) as 'an ongoing process of change aimed 
at resolving issues through the effective diagnosis and management of the 
organization's culture'. Senior (2002) offers an alternative definition of 
organisational development as 'a process of facilitation of organisational change and 
renewal'. What is important within both these definitions is that organisational 
development is a long-term process for implementing change that takes into account 
the complex nature of many problems and also recognises that individuals within an 
organisation are key to successful change implementation. Change will not happen 
simply by issuing guidelines or changing policies, individuals need to be engaged and 
understand and be willing to collaborate with the change. 
Organisational development aims to dissolve problems, that is design them out of the 
system, rather than simply resolving or solving them. Within the organisational 
development process are a series of stages taking an organisation from its current state 
to its desired future state (Senior, 2000). 
3.3.4.1 Stage one - development 0/ a vision and the need/or change 
The first stage of organisational development has two parts, the development of a 
vision that the organisation is aiming for and a diagnosis of the organisation's current 
position. Either p~ can be carried out first but in reality they tend to be carried out 
simultaneously with each part informing the other as it proceeds. Diagnosis takes into 
account the political, economic, technological and socio-cultural factors impacting on 
the organisation and internal and external triggers for change. Data is collected at the 
individual, work group and organisational level to gather a complete picture of how 
the organisation functions, including the organisational culture, relationships, 
leadership styles and individuals' motivation and commitment to both their work and 
the organisation. At this stage barriers to organisational performance and factors 
contributing to organisational success are identified. Data is verified during 
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discussions with those who provided the information. This helps to develop a vision 
for change. 
3.3.4.2 Stage two - gaining commitment to the vision 
The second stage involves gaining commitment to the vision and the need for change. 
This is why feedback from the first stage is important because unless the people who 
are going to be affected by the change are consulted and have already participated in 
the process in stage one they will have little incentive or desire to accept the new 
vision and the associated change process. Therefore, resistance to change must be 
managed through discussion, negotiation and active participation of those people who 
will have to make the changes. Communication is important at this stage and the 
influence of formal and informal group leaders and organisational culture needs to be 
taken into account. 
3.3.4.3 Stage three - action planning 
An action plan for managing the transition from the current state to the desired future 
state is developed in stage three. Whilst effort should still be put into gaining 
commitment to the vision at this stage there is also a move towards selling how the 
vision can be brought about. 
3.3.4.3 Stages/our andflve - change implementation and assessment 
Stage four is when the change is implemented. Then stage five involves 
reinforcement of the change and assessment of efficacy. This is to find out whether 
the change has been successful. This may be difficult to assess, particularly if the 
Change involved changes in attitudes or organisational culture, but can be done by 
surveys or interviews. Changes need to be reinforced by updating any necessary 
policies and systems 
So far organisational development has been described as an appropriate method of 
introducing change to problems of soft complexity. This theory has been further 
developed by Senge (1993) and will now be discussed. 
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3.3.5 Development from organisational development to 'learning organisations' 
Senge (1993) takes organisational development a step further and describes 
organisations undergoing this process as 'learning organisations'. This is a process 
whereby organisations move towards a shared vision of the future and ongoing 
change is necessary to achieve the vision. The shared vision is one of five 
components, or learning disciplines, which Senge believes must be present in a 
successful organisation. The absence of one or more of these learning disciplines can 
act as a barrier to change so it is important that they are taken into account when 
planning change implementation. The theory is that all people within the organisation 
excel and learn because they are all committed to achieving the vision of how the 
organisation will be in the future. The four other learning disciplines will now be 
described. 
'Systems thinking' is the component that integrates all the other disciplines and 'fuses 
them into a coherent body of theory and practice' and so is perhaps the most 
important component. Systems thinking describes a conceptual framework that 
requires considering the whole of a system in order to understand it rather than just 
one individual aspect. This is because each part of the system has an influence on 
other parts of the system, although the effects of this might not always be obvious. 
Systems thinking allows these interrelationships to be seen more clearly and helps to 
show where changes need to be engineered in the system to make it more effective. 
Applied to the NHS, systems thinking is quite a daunting prospect given that the NHS 
is one of the largest organisations in the UK. However, this type of approach is being 
undertaken by the NHS Modernisation Agency (2004b) to improve patient care. 
Two of the disciplines are associated with learning at an individual and team level. 
'Personal mastery' describes a commitment by people within an organisation to their 
own lifelong learning. This is important because, if individuals do not learn, an 
organisation as a whole cannot develop and improve. Lifelong learning has recently 
become important within the NHS as a part of the clinical governance framework for 
improving quality. 'Teamlearning' involves looking at how individuals in teams 
interact and identifying patterns that can prevent learning. Again without this 
discipline the organisation as a whole cannot learn and therefore change. Both of 
these disciplines help to develop the skills of people within organisations to look for 
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the larger picture that lies beyond individual perspectives and how their actions 
impact on the world they operate within. 
'Mental models' are deeply ingrained assumptions that influence how people 
understand the world and how they act. These models are often subconscious and 
people may not be aware of how they affect their behaviour. It is important to 
consider mental models when looking at change management because this is one of 
the learning disciplines that can be a barrier to successful change if the mental model 
conflicts with the change being proposed. In order for change to take place it may be 
necessary to evaluate individual's mental models and expose them to other people's 
influences. 
This section has described how change implementation theory has moved from 
Lewin's simple three-step model to a more complex model of organisational 
development. These models are useful when considering 'soft' systems, that is those 
with a large human element. It has already been shown that medicines management 
across the interface represents a soft system. Therefore, within the context of this 
thesis a complete understanding of hard systems models of change is not necessary. 
However, it is important to appreciate that there are two fundamental differences 
between hard systems models of change and those created for soft systems. 
1. Hard systems models of change tend to be one-off projects which end when 
the change has been completed. Soft systems models of change, particularly 
as they have evolved into organisational development are an integral part of 
organisational life and therefore a continuous process. 
2. Organisational development recognises the importance of individuals within 
an organisation and that in order for change to be successful they must be 
involved in the decision-making processes. Hard systems models of change 
tend to involve projects planned and implemented by managers without 
consulting the individuals who will be expected to undertake the changes. 
There is an assumption that they will automatically go along with the changes. 
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This makes it easier to appreciate why attempting to implement a change in a soft 
system using a hard system approach is likely to fail because the human factors are 
not taken into account. As Paton and McCalman (2000) stated 'The most 
fundamental step in achieving successful implementation of change is obtaining a 
shared perception of those affected' and without this change is likely to fail. This 
statement highlights the importance of individuals working within an organisation 
when any change programme is being considered. 
So far, a model has been discussed for diagnosis of a problem requiring change and 
organisational change management theories relevant to medicines management at the 
interface. It has been demonstrated how driving and restraining forces interact to 
prevent change happening and how these can be overcome by the choice of an 
appropriate change management model. Change implementation may fail if the 
human factors are not taken into account and so it is now appropriate to consider the 
literature on changing individual health care professionals' behaviour. 
3.4 CHANGING HEALTH CARE PROFESSIONALS' BEHAVIOUR 
The models outlined previously focus on the concept of organisational change. 
However, it is important to recognise that individual health care professionals also 
playa major role in any change process within the NHS. In order to improve 
medicines management at the interface liealth care professionals need to change the 
way they behave so that actions that do not contribute to good medicines management 
are replaced with those that do. Whilst the vast literature around the theory of 
changing professional behaviour will not be covered in depth the finding that passive 
dissemination of guidelines alone is not an effective method of introducing 
behavioural change is important within the context of this thesis. 
Oxman et al (1995) investigated the impact of interventions on improving the general 
delivery of health care. They found that passive dissemination resulted in little or no 
change in behaviour. Similarly, research that has focused on improving prescribing 
behaviour has found that dissemination of printed educational materials alone does 
not improve prescribing behaviour (Grimshaw et ai, 2001; Anderson & Lexchin, 
1996; Avom & Soumerai, 1983). This is supported by a systematic literature review 
regarding the adoption of clinical practice guidelines by Davis and Taylor-Vaisey 
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(1997) who found that mailing out or publication of clinical guidelines in professional 
journals had only weak effects on implementation. Davis and Taylor-Vaisey found a 
number of factors affected the success of implementation of guidelines. These were 
the quality of the guideline, characteristics of the health care professional and their 
practice setting, financial or legal incentives and patient factors such as demographic 
characteristics. A consideration of organisational change theory may provide some 
insight into why passive dissemination of guidelines is ineffective at producing 
change. This may be because the receivers of the guidelines may be unaware firstly 
of the need to change their current behaviour and also they may not appreciate the 
'shared vision' of how change could improve patient outcomes. 
There is evidence that clinical guidelines can have a positive impact on both the 
process of care and patient outcomes. However, effects of guidelines on clinical 
practice are often weak or have an impact on only one of several possible outcomes 
being measured. The size of the effect on changing clinical practice is also related to 
the intensity of the intervention with provision of information alone reSUlting in less 
change than complex interventions (Grimshaw & Russell, 1993). Braybrook and 
Walker (1996) found that GPs provided with printed material detailing their current 
antibiotic prescribing trends and a workbook to facilitate discussion about antibiotic 
prescribing showed greater improvements in antibiotic prescribing than a control 
group of GPs. However, even greater improvements were shown when a Health 
Authority Prescribing Adviser facilitated the discussion. This supports the positive 
effect of written material on changing behaviour. However, the benefits were not due 
to simply mailing out written information because the GPs were expected to hold a 
discussion within their practice about their current antibiotic prescribing and how this 
could be improved. These discussions may have helped demonstrate why change was 
needed or to induce dissatisfaction with the current situation. Freemantle ef al (2002) 
also found that this type of educational outreach was effective in changing prescribing 
behaviour in line with clinical guidelines in small practices but the impact was not as 
great in larger practices. Systematic reviews of interventions to change doctors' 
behaviour have also found that educational outreach is effective (Grimshaw et ai, 
2001; Davis ef ai, 1995). Education outreach has been termed 'academic detailing' 
and uses a specific format to introduce behavioural change. Initially, baseline 
knowledge and motivations for current behaviour are investigated and then clear 
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educational and behavioural objectives are defined. Unbiased and authoritative 
sources of information are presented to doctors covering both sides of controversial 
issues. Essential messages are highlighted and repeated and positive reinforcement of 
improved practice is given in follow-up visits (Soumerai & A vorn, 1990). 
Educational outreach is not dissimilar to a soft system model of organisational change 
in that it starts with identification of barriers to change (unfreezing), followed by an 
explanation of how current behaviour should be changed (moving) and finally 
reinforcement of positive changes made (refreezing). 
Lewin's force field theory was described earlier to explain why change is difficult to 
implement and how barriers to change need to be overcome. When considering why 
change in clinical practice does not occur, it is also important to consider the barriers 
to change. Cabana et al (1999) reviewed the barriers to physician adherence to 
clinical practice guidelines. The barriers identified were organised into a framework 
according to their effect on physician knowledge, attitudes or behaviour. The 
knowledge section included such barriers as lack of knowledge of, or familiarity with, 
a guideline. Attitudes included barriers such as a lack of agreement with the principle 
of guidelines and disagreement with a specific guideline. Barriers allocated to the 
behaviour section included time restraints, guideline factors and external barriers. 
Whilst some of the literature concerning changing health care professionals' practice 
is applicable within the context of improving medicines management at the interface, 
some of the wider issues around medicines management systems have not been 
addressed. The research around changing prescribing behaviour focuses on increasing 
the prescribing of evidence-based medicines and decreasing prescribing of those 
medicines without a robust evidence-base (Bradley et ai, 2001; Schwarz et ai, 1989; 
Rogers et ai, 2000; NHS Centre for Reviews & Dissemination, 1999; Anderson & 
Lexchin, 1996; Avom & Soumerai, 1983) rather than considering changing the 
systems within which medicines are used. 
Health care changes necessitated by guidelines will not be brought about by simple 
passive dissemination techniques and so proper organisational change techniques need 
to be introduced including determining and addressing any resistance to change 
(Garside, 1998). Whilst Cabana et al (1999) considered barriers to successful 
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implementation of clinical practice guidelines changing practice at the interface may 
provide different barriers and so it is important that these are identified and overcome 
in any change programme. Additionally, a understanding of health care professionals' 
current behaviour is necessary before trying to change practice (Cook et ai, 2004). 
3.5 SUMMARY 
An understanding of change management theory is necessary to appreciate why 
medicines management at the interface has not improved over the last fifteen years. 
In this chapter the development of change management theory and how this can be 
related to medicines management has been discussed. Change management models 
have been described and how these have developed from Lewin's simple three stage 
model into more complex organisational development models. An appreciation of the 
factors which can prevent change happening has been given. This chapter also 
discusses the importance of determining the true nature of a problem so that the actual 
problem is addressed and the choice of change management model is appropriate. 
The chapter culminated with a review of the literature relating to changing health care 
professionals' behaviour. This showed that passive dissemination of information is 
not an effective strategy for changing behaviour. It is important to consider this when 
designing interventions that aim to improve medicines management at the interface. 
Improving medicines management at the interface relies on health care professionals 
changing the way they practice. This is unlikely to happen if they are not aware of or 
disagree with the reasons why they have to change. 
The next chapter introduces the aim and objectives of the present study and describes 
and justifies the methods used for data collection. 
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CHAPTER FOUR 
METHODS 
4.1 INTRODUCTION 
This chapter starts with a brief synopsis of the literature reviewed in Chapters One to 
Three and explains the relevance of this to the present study. This then leads onto the 
specific aim and objectives of the present study. The study is considered to be located 
within a constructivist paradigm. Before explaining the reasons for locating the 
research within a constructivist paradigm, consideration will be given to the location 
of the researcher within the study. This is because, within the constructivist 
paradigm, the researcher is considered to interact with study subjects. Therefore, it is 
important to appreciate how the researcher's perspectives might impact on the study 
outcomes. Following on from this an explanation is given for the choice of qualitative 
data collection methods and then the ethical considerations for the present study are 
discussed. The remainder of this chapter describes the specific methods used for data 
Collection and analysis. 
4.2 LITERA TURE RELEVANT TO MEDICINES MANAGEMENT AT THE 
INTERFACE 
In the previous three chapters, three substantial bodies of evidence were reviewed. 
The first showed how the primary / secondary care interface is constructed from 
elements of the structure and process of primary and secondary health care. The 
different environments in which care is carried out and the different staff providing 
care in primary and secondary care mean that effective communication is vital to 
ensure continuity of care. Other factors such as management structures and policies 
also contribute to the interface, making it a complex entity that may adversely impact 
on patient care. 
In Chapter Two the ideal situation of 'seamless care' was described and the 
importance of managing the use of medicines within the NHS. Following on from 
this, the literature relating to problems with medicines management at the interface 
Was discussed. The problems identified related to medication errors, financial 
difficulties and difficulties with transfer of clinical responsibilities. It was shown how 
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the interface may contribute to medication errors, particularly when patients are 
discharged from hospital to the care of GPs. Financial problems were related to how 
hospital policies or prescribing patterns adversely affect prescribing expenditure in 
primary care. Lastly, the current research about difficulties in transferring clinical 
responsibilities from secondary to primary care doctors was considered. 
The problems described with medicines management at the interface are serious and 
ongoing. This is despite the publication over the last fifteen years of several pieces of 
national guidance aiming to improve medicines management at the interface. 
Improving medicines management at the interface requires health care professionals 
to change the way they practise. An appreciation of change management theory is 
therefore necessary to understand why change has not happened. In Chapter Three 
the major change management theories were reviewed in their context to medicines 
management. 
In addition to understanding the reasons why national guidance has not produced the 
changes necessary to improve medicines management at the interface it is also 
important to improve understanding of the reasons why interface problems occur. 
Previous researchers have identified poor communication as a cause of medication 
errors when patients are transferred between primary and secondary care. However, 
this has not identified reasons for poor communication about medicines across the 
interface. Interventions involving communication with community pharmacists have 
reduced the number of medication errors that actually reach patients. These should 
still be considered 'near misses' and so the root causes for errors must be identified in 
order to design effective solutions. It is therefore clear that there is a need for a better 
understanding of medicines management at the interface, and the difficulties caused, 
before effective solutions can be designed. 
94 
4.3 AIM 
The aim of the present study was to identify and contextualise difficulties and 
deficiencies which may compromise the effective delivery of medicines management 
when patients are transferred between primary and secondary care in Southern 
Derbyshire Health Authority. 
4.4 OBJECTIVES 
The specific objectives of the study were:-
1. To describe and categorise problems relating to the care transfer process that 
lead to a deterioration in medicines management. 
2. To critically appraise the local interpretation and implementation of health 
policy relevant to the needs of patients when clinical responsibility is 
transferred between primary and secondary care. 
3. To describe the staff communication and decision-making processes when 
responsibility for care transfers from primary to secondary care and vice versa. 
4. To explore reasons why Department of Health guidance regarding the 
management of medicines across the interface is not put into practice. 
Before describing the methods used to meet the research aims it is important to locate 
the researcher within the research study. Following on from this explanations are 
given for locating the research within a constructivist paradigm and justification for 
the choice of data collection methods. Each stage of data collection and analysis will 
then be described. 
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4.5 LOCATING THE RESEARCHER WITHIN THE RESEARCH STUDY 
This research is considered to fit within a constructivist paradigm and so the 
researcher's personal views may impact on the data generated. First the researcher's 
position within the research area and relationships with the research subjects will be 
described. 
Before starting the research I was a qualified pharmacist with a hospital clinical 
background. I had spent fifteen months in the position of Assistant Pharmaceutical 
Adviser to a health authority. My health authority background had given me the 
perspective that the interface was still contributing to many medicines management 
problems. However, I understood this mainly from the perspective of GPs, because 
they raised medicines management problems that I had to resolve. As I had spent 
several years as a hospital clinical pharmacist I could also relate to the interface from 
the perspective of hospital pharmacists. 
At the start of this research study I was employed as the primary care liaison 
pharmacist at Derby City General Hospital pharmacy department. The aim of the role 
was to uncover and resolve medicines management problems occurring because of the 
interface. General practitioners, hospital medical consultants, community pharmacists 
and hospital colleagues were encouraged to contact me with any interface issues. 
However, I also performed a clinical role to various medical wards within the 
hospital. This allowed me to observe at first-hand the medicines management 
processes that went on within the hospital. Following on from that, I continued to 
practise as a Primary Care Group (Gloucestershire), and then Primary Care Trust 
(Manchester), Prescribing Adviser. 
It is important to mention my relationship with the participants because this could 
have affected responses to the questions. At the time of the focus groups with the 
pharmacists I was employed as the primary care liaison pharmacist by the hospital 
pharmacy department. Whilst this meant that I interviewed some of my own 
colleagues I felt that the nature of the topic was such that they were unlikely to be 
inhibited by this. Part of my role was to improve communication with primary care 
and the community pharmacists saw this as an opportunity to air their grievances with 
difficulties caused by the interface and again did not seem to be inhibited by my 
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presence. When I carried out the GP focus groups I was acting as their Primary Care 
Group Prescribing Adviser. However, I made it clear that this was a completely 
separate exercise to that role although any useful comments would be raised with the 
peG with their permission. All focus group participants were reassured of the 
confidential nature of their comments outside the group. I did not have any 
professional relationship with the hospital medical consultants interviewed. 
It should also be mentioned that I was not acting purely as a researcher but as a 
clinician too. During the collection of case study examples of interface issues it was 
necessary to separate data collected for the purposes of uncovering and resolving 
interface medicines management issues, the primary care liaison pharmacist role, and 
that collected for the current research. Data collected for the primary care liaison 
pharmacist role was used to resolve interface issues for individual patients or groups 
of patents. Only data about the nature of the issue and any interventions made were 
documented for research purposes. Also, during the interviews with health care 
professionals and patients, I intervened if I felt it was necessary on a professional 
basis. This may have been to explain a misperception at the end of an interview or to 
encourage a patient to seek further advice. However, I do not feel that this was 
detrimental to my role in collecting data without bias. 
4.6 LOCATION OF THE RESEARCH WITHIN AN EPISTEMOLOGICAL 
PARADIGM 
This study concerns the organisational structures and communication between health 
care professionals working on each side of the interface. The components and 
complexity of the interface relevant to medicines management were identified in 
Chapter One. Any research carried out within such a complex environment presents 
Considerable challenges in finding a methodology that is practical and reaches the 
heart of the problem. 
Four major paradigms may be used to describe the beliefs a researcher has about the 
nature of reality and truth. These are positivism, post-positivism, critical theory and 
constructivism. These terms encompass different beliefs about ontology, 
epistemology and the methodology used to gain knowledge about a subject (Denzin & 
Lincoln, 1994). Each paradigm and the differences between them will now be 
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appraised in order to demonstrate and explain within which paradigm the research is 
located. 
Positivists adopt an ontological stance know as realism in that research is believed to 
determine the true state of affairs. The researcher and subject of enquiry are 
independent entities. This means that an objective view is achieved because the 
researcher does not influence or be influenced by the subject (Guba & Lincoln, 1994). 
Experiments are designed to test hypotheses ensuring that confounding factors that 
may influence the outcome are controlled for. A positive result supporting the 
research hypothesis is considered to be the truth. However, negative results are also 
acceptable. 
Post-positivists also believe that reality exists but differ from positivists in that reality 
is only partially understood (Denzin & Lincoln, 1994). Within the post-positivist 
paradigm is the belief that a finding is probably true if it can be replicated (Guba & 
Lincoln, 1994). However, rather than setting out to prove a hypothesis, post-
positivists develop a null-hypothesis to test against. This is because of the belief that 
positivists, through concentrating their efforts on finding evidence to prove a 
hypothesis, could miss evidence that disproved it. Again the researcher and the 
subject are thought to be independent. 
There are two reasons why the positivist and post-positivist paradigms do not fit with 
the objectives of the present study. Firstly, one of the study objectives was to describe 
and categorise medicines management problems relating to the care transfer process. 
This required an in-depth exploration of peoples' perceptions and experiences in order 
to find out how problems affected people and how they dealt with them. 
Additionally, data was required to show how implementation of health policy was 
impacted on by individual health care professionals. It was felt that this type of data 
would be difficult to obtain empirically. Therefore, in order to uncover information in 
sufficient depth about what interface problems meant to the subjects and why they 
were caused, it was felt that an interactive approach between the researcher and the 
subjects was required. As both the positivist and post-positivist paradigms require the 
researcher and subject to be independent entities that do not influence each other these 
were considered incompatible with the study aim and objectives. Secondly, positivist 
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and post-positivist approaches require hypothesis testing. The study aimed to uncover 
the issues relating to medicines management as perceived by the subjects and so there 
was no preconceived hypothesis to test. Additionally, identification of causal factors 
and providing explanations for existence of the problems, so that potential solutions 
can be devised, was not compatible with a preconceived hypothesis. 
Critical theory is based on historical realism, the belief that it is possible to apprehend 
a reality by taking into account that over time this has been shaped by various factors. 
These factors may be, for example, social, political, cultural, economic, ethnic or 
gender related. Structures are then formed that are inappropriately taken as being real, 
hence this is described as a virtual or historical reality. Gaps in knowledge or 
misapprehensions are filled through research and so knowledge about a particular 
subject grows and changes (Guba & Lincoln, 1994). The epistemological view of 
critical theorists is more subjective than that of positivists or post-positivists in that 
the researcher interacts with the subjects. The reason that the critical theory paradigm 
Was rejected is that within this paradigm the researcher's own values influence the 
research. Whilst it is acknowledged that the researcher has values of her own, an 
attempt was made for these not to influence the outcome of the study because the 
study aimed to find out the views of the participants. For example, if the researcher 
Was asked a specific question about medicines management during the interviews she 
answered the question after the interview had been closed. This meant that 
misperceptions were not explained during the interview process. 
Constructivism takes a relativist ontological stance (Guba & Lincoln, 1994) whereby 
an understanding is developed of the lived experience from the point of view of those 
Who live in it. Fundamentally, constructivism implies that interpretation is necessary 
in order to understand these lived experiences (Schwandt, 1994). As with critical 
theory, the researcher and the subject are interactively linked. However, with 
constructivism the findings are created as the research proceeds. The mental 
constructs of the subjects are interpreted and knowledge is considered to consist of 
those constructions about which different researchers achieve consensus (Guba & 
Lincoln, 1994). This paradigm fits with the aims of the present study because the 
researcher was interested in the views of the subjects and these would be determined 
by interaction between the researcher and the subjects. However, this interaction 
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would be as an orchestrator and facilitator rather than to influence the outcomes 
(Guba & Lincoln, 1994). 
Both quantitative and qualitative methodologies may be used to collect data for 
studies located within any of the four paradigms (Guba & Lincoln, 1994). However, 
it is more usual for positivist and post-positivist researchers to utilise quantitative 
methods and for critical theory and constructivist researchers to adopt qualitative 
methods. The reasons for locating the current research within the constructivist 
paradigm have been discussed. Now an explanation will be given why qualitative 
methodology offers an appropriate approach in the context of this research. 
4.7 QUALITATIVE METHODS 
Qualitative research involves an interpretive, naturalistic approach to the subject 
matter whereby things are studied in their natural settings and attempts are made to 
make sense of, or interpret, phenomena in terms of the meanings people bring to them 
(Denzin & Lincoln, 1994). This is in contrast to quantitative research which is 
concerned with providing enumerated answers to research questions through 
experimentation (pope & Mays, 1995). Miles and Huberman (1994) identify one of 
the strengths of qualitative data as providing a good idea of what 'real life' is like and 
finding out how and why things happen as they do. One of the fundamental 
differences between the two domains is that quantitative methods are held to be 
deductive (akin to hypothesis testing) whereas qualitative research is inductive or 
hypothesis generating (Pope & Mays, 1995). There are, however, circumstances 
whereby qualitative data maybe generated for the purpose of testing hypotheses. 
Validity is the extent to which a measurement accurately reflects the concept to which 
it is supposed to be referring (Bryman, 1988). This is also referred to as 'internal 
validity' in contrast to 'external validity' which refers to the degree to which findings 
can be generalised to other similar settings (Denzin & Lincoln, 1994). Reliability is 
the extent to which a measurement gives the same answer each time it is undertaken 
(Mays & Pope, 1995). Britten and Fisher (1993) summed up a polarised description 
of quantitative and qualitative research in stating that 'quantitative methods are 
reliable but not valid' and that 'qualitative methods are valid but not reliable'. 
Qualitative research has been criticised for its lack of generalisability and reliability 
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(Mays & Pope, 1995). However Marshall and Rossman (1995) argue that poor 
reliability is not a failing because qualitative research cannot be replicated when the 
real world evolves and changes. As a qualitative researcher is attempting to 
determine and record what the real world is like then results will change as the world 
changes. Use of theoretical sampling whereby the range oflikely responses are 
included greatly increases the generalisability of qualitative research (Greenhalgh & 
Taylor, 1997) and Parahoo (1997) considers that by studying the typical rather than 
the unusual the findings of qualitative research can have wider implications than for 
the specific population and setting under study. The perceived disadvantages of a 
lack of reliability are balanced against increased internal validity, that is gaining a 
deep understanding of the situation being researched. Therefore, the choice of 
qualitative or quantitative methods is determined by the question the researcher is 
trying to answer. The reasons for choosing qualitative methods for the present study 
will now be discussed. 
4.7.1 Reasons for choice of qualitative methodology 
Previously, the value of qualitative research in answering questions about why things 
happen and what they mean to people was highlighted. This is in contrast to 
quantitative research which is able to answer questions about how often an event 
happens or how much a factor is changed. The aim of this study was not to collect 
data of the absolute numbers of interface problems arising but to find out why they 
occurred and how practitioners detected and dealt with them. It was hoped that 
finding out why things happen would inform the development of solutions to resolve 
the many medication problems and difficulties associated with the interface. 
Chapter Two highlighted the occurrence of medication errors that were associated 
with the management of medicines at the interface. Previous researchers have 
identified the frequency of medication errors when patients are transferred across the 
interface and concluded that poor communication about medicines is a contributing 
factor (Omori et ai, 1991; Bums et ai, 1992; Cochrane et ai, 1992; Binyon, 1994; 
Duggan et ai, 1996; Choo & Cook, 1997). Whilst this demonstrates that there is a 
problem that needs addressing to improve patient safety, it does not explain why 
Communication continues to be poor. Without knowing why things happen the way 
they do it is difficult to design strategies to improve medicines management systems. 
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Other researchers have investigated specific aspects of the interface, such as transfer 
of clinical responsibility (Sibbald et ai, 1992) and shared care (Home et ai, 2001). 
The study by Sibbald et al was quantitative and GP respondents were given a list of 
options to explain why they felt unable to take over clinical responsibility for patients 
who had been in contact with hospital services. This may have led the respondents to 
give particular answers, whereas a qualitative study would have allowed them to come 
up with their own reasons. The study by Home et al was qualitative but only 
considered shared care which represents only a small part of the medicines 
management process associated with the interface. Whilst Home's study provided an 
interesting insight into the issues around shared care, it did not take into account the 
wider range of issues concerning medicines management across the interface. It was 
felt that qualitative data collection methods would be most appropriate for the present 
study to fill the gaps in knowledge about how the interface impacts on practitioners 
and how they deal with issues. Insight would also be gained into why practitioners 
act the way they do through asking for the experiences and views of the participants 
rather than presuming what the issues are. 
Another reason for giving preference to qualitative methods is in view of interface 
issues arising infrequently. This perception was backed up during initial discussions 
with practitioners who confirmed that, whilst interface issues occurred infrequently, 
they had the potential to cause much disruption. The problem for health care 
professionals was trying to resolve the issues themselves rather than the frequency 
with which they occurred. The low frequency of interface issues also meant that the 
collection of appropriate numbers to allow quantitative analysis was not feasible given 
the amount of time allocated for data collection. It would take too long to obtain 
sufficient numbers of issues that could show statistically significant differences. 
More importantly, however, such an approach would not have provided any insight 
into the reasons why interface issues arose and how they were dealt with. 
A qualitative exploration of beliefs and understandings has been suggested as an 
appropriate method of finding out why the results of research are not implemented in 
clinical practice (Haines & Jones, 1994). Whilst the present study aims to investigate 
the implementation of good practice guidance, rather than clinical research, it can be 
appreciated that these are similar situations that could fail for similar reasons. 
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Another reason for choosing qualitative methods is because they are particularly 
suited to research that seeks to explore where and why policy and local knowledge 
and practice are at odds (Marshall & Rossman, 1995). One of the objectives of this 
study was to explore the implementation of DoH guidance associated with medicines 
management at the interface and to try to provide explanations as to why the guidance 
is not put into practice. This, again, gave support to a qualitative approach. 
The final reason for choosing qualitative methods is that qualitative data preserves the 
chronological flow allowing us to see precisely which events led to which 
consequences (Miles & Hubennan, 1994). This was felt to be important within the 
context of the present study particularly as the researcher was interested in the causes 
of interface issues. By gaining a better understanding of the causes of interface issues 
it was hoped that new improved strategies for improving the management of 
medicines could be put forward. 
So far, some important differences between quantitative and qualitative research have 
been discussed and reasons given for the choice of qualitative methods for the present 
study. Now a description will be given of how the data were collected and analysed. 
Data were collected both prospectively, through the collection of interface issues as 
they arose, and through the use of a questionnaire for patients attending hospital. 
Focus groups and semi-structured interviews were also held with GPs, hospital 
medical consultants and community and hospital phannacists. The plan of field work 
is shown in Table 4.1. Before describing the data collection methods used at each 
step the ethical considerations raised by the present research will be discussed. 
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Table 4.1 Field work plan with links to study objectives 
Collection of case study 
examples of interface issues 
Mapping of medicines 
management process 
Focus group and semi-
structured interviews with 
health care professionals 
Structured interviews with 
patients 
Justification 
Identification of interface problems. 
Determination of organisational 
implementation of interface policy. 
Identification of factors facilitating or 
impeding change in medicines 
management processes. 
Determination of health care professional 
communication channels. 
Identification of weaknesses in the 
medicines management 'system'. 
Identification of interface problems. 
Appraisal of health care professionals' 
implementation of interface policy. 
Determination of communication 
channels and decision making processes. 
Identification of barriers to changing 
existing situation. 
Identification of patients' perceptions 
and difficulties with medicines 
management when care is transferred. 
4.8 ETHICAL CONSIDERATIONS 
Objective 
(see 4.4) 
1 
2 
4 
3 
1 
2 
3 
4 
In the absence of any definition of research ethics by the Royal Pharmaceutical 
Society of Great Britain reference to a definition offered by the Royal College of 
Nursing is appropriate. The Royal College of Nursing (2004) outlines three main 
areas that must be addressed to ensure that research'with human subjects is ethical. 
These are ensuring consent, protecting confidentiality and balancing the risk of harm 
against potential benefits. Each of these areas will now be discussed in the context of 
the present study. Data collection for the current study was undertaken between 1997 
and 2000 and at this time there was no requirement for ethical committee approval to 
be gained for research involving health care professionals, who, it was assumed, could 
make their own decisions whether or not to partake in research studies. However, 
whilst this covers the consent aspect of research ethics it does not take into account 
the wider issues regarding research governance. Research that duplicates other work 
unnecessarily or which is not of sufficient quality to make a useful contribution to 
existing knowledge is in itself unethical because it wastes valuable resources such as 
NHS staff time. Therefore the DoH now requires that all research involving NHS 
staff recruited as research participants by virtue of their professional role is 
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independently reviewed by a Research Ethics Committee to ensure it meets the 
required ethical standards (COREC, 2001). 
4.8.1 Collection of case study examples of interface issues 
For the purposes of the present research, only information relating to the nature of the 
interface issue and any interventions made to resolve the issue was documented. Data 
Was collected from discussions with health care professionals who had complained or 
been involved in an interface issue and from reviewing relevant policy documents. 
For this stage of the research no patient data was collected either from health care 
professionals or from patients directly. 
4.8.2 Focus group and semi-structured interviews with health care professionals 
Whilst it was not a requirement to obtain ethics committee approval before 
undertaking this part of the data collection, ethical principles were still taken into 
consideration. Health care professionals were informed of the nature of the study 
When invited to participate. Written consent was not obtained but the fact that the 
participants voluntarily attended for the interviews implies that they agreed to 
participate. Before each interview started participants were asked whether they would 
agree to an audio recording being made. The confidentiality of data given by the 
participants was maintained by storing audiotapes in a locked cabinet and by not 
recording the names of participants on the tape cassettes. Furthermore, the 
Participants were not referred to by name within the transcripts. 
4.8.3 Structured interviews with patients 
Informed consent requires that patients are empowered to enable them to decide about 
Whether or not to take part in a research study in the full knowledge of the purpose of 
the study and without any form of coercion by the researcher. In the present study 
this was ensured by giving potential participants a full explanation of the purpose of 
the study and what taking part would entail. Patients were informed that their care 
would not be affected whatever their decision. A written log of consent given or 
refused was recorded each time a patient was approached. Patients were also 
provided with written information about the study that also explained how they could 
find further information and that they could withdraw from the study at any time 
Without any impact on the quality of their care (Appendix 1). To ensure that consent 
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was continued patients were asked at follow up interviews whether they still wished to 
take part. Those who refused were withdrawn from the study from that point 
onwards. Confidentiality was ensured by storing all patient identifiable information 
in a locked cabinet. A copy of the research proposal for this phase of data collection 
along with the patient information leaflets and interview schedules was submitted to 
the Local Research Ethics Committee. A copy of the Research Ethics Committee's 
approval letter is included in Appendix One. 
4.9 COLLECTION OF CASE STUDY EXAMPLES OF INTERFACE ISSUES 
Choo and Cook (1997) defined interface problems as 'situations which disrupted the 
smooth transfer of care from the secondary to primary sector. These were mainly to 
do with difficulties, for whatever reason, encountered when dispensing the recently 
discharged patient's FP I 0 prescription'. This definition was appropriate for Choo and 
Cook's study because they were specifically investigating liaison between hospital 
and community pharmacists but there are three limitations to this definition within the 
context of the present study. Firstly, it only considers problems caused when patients 
are transferred from secondary to primary care. Secondly, it only includes interface 
problems encountered by community pharmacists. Thirdly, the term 'interface 
problem' infers that something has gone wrong to cause an event to be recorded and 
that incidents will be difficult to resolve. In the present study, the researcher preferred 
the term 'interface issue' because it was ftlt that this had fewer associations with error 
and would allow the inclusion of issues that were resolved simply but still caused 
frustrations. On this basis, the following definition was developed: 
An interface Issue was defined as occurring when a health care professional took 
specific action, such as to make a complaint, to enable pharmaceutical care to be 
maintained between care settings. 
Although the interface issues are described as case studies it needs to be appreciated 
that this does not fit with the traditional description of case study research. Within the 
context of qualitative research a 'case' is normally defined as 'a single unit in a study' 
and a case study investigates intensively the characteristics of that single case, or a 
small number of cases (Bowling, 1997; Pope & Mays, 1995). During the present 
study, however, a larger number of cases than would normally be necessary for case 
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study research were collected and they were investigated in less depth. Investigating 
a large number of cases in less detail provided more information about the range of 
interface issues that could occur. It was felt the benefit of this outweighed the depth 
of information that researching a smaller number of cases intensively would have 
provided. 
The stages of data collection and analysis for this phase of the current study will now 
be described. 
4.9.1 Advertisement of the role of the primary care liaison pharmacist to 
promote reporting of interface issues 
It was anticipated that the primary care liaison pharmacist would identify interface 
issues directly through practice as a pharmacist and via reports from other health care 
professionals. In order to ensure reporting of issues by other health care professionals 
the researcher wrote to all general practices, hospital medical consultants and 
community pharmacists explaining the nature of the role and asking them to report 
any difficulties they experienced with transfer of patient care with respect to 
medicines across the interface. Hospital pharmacy staffwere informed verbally of the 
role and also requested to report any arising issues. 
4.9.2 Development of a standard data collection form 
A data collection form was developed to record the complainant's contact details, a 
Summary of the complaint, further information gained from other sources and any 
Possible actions and how these could be implemented. An example of the interface 
issue reporting form is included in Appendix Two. Each time an interface issue was 
encountered an interface issue reporting form was completed. 
4.9.3 Development of an interface issue reporting card 
FOllowing a suggestion from a GP that a reporting form similar to the 'yellow card' 
for reporting adverse drug reactions might aid reporting, an 'interface issue reporting 
card' was developed (Appendix 3). One side of the pre-printed form prompted 
reporters to complete a brief description of the issue and their contact details in case 
further information was required. Patient details were not requested on the form for 
confidentiality reasons. The form was printed on one side of A5 paper with the name 
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and address of the Health Authority Pharmaceutical Adviser on the reverse to allow 
for ease of reporting. This made it easy for the health care professional to complete 
the details of the issue and put the card in the post-bag for collection by the Health 
Authority post van. Reporting via the Health Authority meant that no postage stamp 
would be required. It was hoped that reducing the effort and cost required to report 
issues would lead to an increase in reporting. The cards were returned to the 
Pharmaceutical Adviser with a view to increase the awareness of the role of the 
adviser in working together to resolve interface issues. It was hoped that this would 
increase confidence in the value of reporting issues. Interface issue reporting cards 
were distributed with a Health Authority prescribing newsletter. On receipt of an 
interface issue reporting card the details were completed onto an interface issue 
reporting form. 
4.9.4 Administration of interface issue reports 
All interface issues reported to the researcher were reviewed but some did not require 
any action. An example of an issue that would not have been dealt with is if a patient 
was admitted on a non-formulary medicine and discharged with less than the fourteen 
days supply of medicines specified in the hospital policy. Provided the patient had 
enough tablets until they could get a repeat prescription from the OP then the issue 
was not acted upon. The discharge prescription was endorsed with an explanation in 
case of future queries. However, the rese~cher's assessment of issues determined 
whether or not they were taken further. Other people may have disagreed with this 
assessment although it was felt that the researcher, as primary care liaison pharmacist, 
was in a good position to judge the issues. 
The process for dealing with interface issue reports varied slightly depending on 
whether the issue was reported directly to the researcher or whether it came on an 
interface issue reporting card. The processes are outlined below. 
4.9.4.1 Issues reported directly to the primary care liaison pharmacist 
As much detail as possible was collected about the nature of each interface issue from 
complainants. The medicines management systems and policies and procedures were 
investigated to determine if any of these impacted on the interface issue raised. This 
included reviewing Drug and Therapeutics Committee minutes to check the formulary 
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status of a medicine; checking the quantity of medicines supplied against a patient's 
discharge prescription or determining the source or formula of an unusual or 
extemporaneous medicine from pharmacy records. Relevant health care professionals 
Were contacted for more information as necessary. All information was logged on an 
interface issue reporting form. 
4.9.4.2 Issues reported by interface issue reporting card 
When an interface issue reporting card was received from the primary care sector, an 
assessment was made as to whether the information was about a specific patient or 
incident which was ongoing and needed dealing with, or if it was a general complaint 
about the quality of patient care at the interface. If more information was required the 
complainant was contacted and asked for more information. Options were then drawn 
up as to how the situation could be resolved. At this point, appropriate practitioners 
within the hospital were contacted for their views on how the problem could be 
tackled. Minor issues such as those associated with a lack of knowledge about 
interface issues could be dealt with 'in-house' by providing staff education. The more 
major issues were dealt with by more extensive consultation, such as with the Area 
Prescribing Committee. Complainants were informed, by letter or telephone, of how 
their problem was being dealt with. 
4.9.5 Resolution of cases 
Part of the role of the primary care liaison pharmacist was to resolve interface issues 
in addition to investigating them. Therefore, any necessary action was taken to ensure 
that issues were satisfactorily resolved. Sometimes resolution of interface issues was 
Simple and involved, for example, writing a letter to a health care professional to 
Correct misunderstandings about an agreed medicines management process. Other 
more complex issues could not easily be resolved and required substantial changes to 
medicines management systems. For example, resolution of one case (Appendix 5, 
Table 16, Case 2) involved the removal of modified-release nitrates from the district 
formulary. The process involved determining a therapeutically equivalent dose of 
standard-release nitrates, agreement by hospital cardiologists and approval by the 
hospital Drug and Therapeutics Committee. Hospital pharmacists were then infomled 
of the change and how they would proceed with amending patients' prescription 
charts and educating patients and hospital doctors. 
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4.9.6 Qualitative analysis of case studies 
The epistemological stance adopted during this study has previously been outlined. It 
will, therefore, be appreciated that a qualitative analysis was most appropriate to 
consider the types of issues that arose, reasons for issues occurring and explanations 
for the action taken, or not taken, by health care professionals. 
The analysis was undertaken in three stages. In the first stage, a content analysis was 
carried out of the difficulties identified in transferring patient care. The second stage 
involved a deeper analysis of the difficulties with transferring care. The third and 
final stage was undertaken to uncover the root causes of the interface issues. The 
processes involved in carrying out each of these stages will now be described in 
detail. 
4.9.6.1 Stage one 
Each case was analysed to identify the cause of the difficulty in transferring care. 
When approximately 40 cases had been collected a content analysis was performed 
and the emerging pattern was that issues could be categorised under the following 
themes. 
• Issues which resulted from unsatisfactory communication between primary 
and secondary health care professionals. 
• Issues associated with disagreemeht or confusion over financial responsibility. 
• Issues associated with disagreement or confusion over clinical responsibility. 
The results of this initial content analysis were used as a basis for the topics to be 
included in the focus group discussions and interviews. However, as more cases were 
collected it became clear that the above categorisation was too simple and did not 
provide insight into why interface issues arose. The content analysis was repeated 
and refined in stage two of the analysis. 
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4.9.6.2 Stage two 
During stage two of the case study analysis, reasons for the occurrence of interface 
issues emerged from the data. These are listed below. 
• Lack of awareness or misunderstanding of policy 
• Lack of inter- and intra-professional collaboration 
• Impracticable or inflexible policy 
• Flagrant violation of policy 
The first two stages of data analysis concentrated on the emerging interface issues. 
However, there was a suspicion that, despite issues appearing superficially to be quite 
similar, they might have quite distinct root causes. This was an important discovery 
because without getting to the root cause of issues the causative factors could not be 
identified in order to prevent a recurrence. Therefore, in stage three, a root cause 
analysis of the cases was undertaken to find out how the issues originated. 
4.9.6.3 Stage three 
Root cause analysis is a tool that has been advocated for the investigation of patient 
safety incidents (NPSA, 2003a). By learning how and why incidents happen through 
root cause analysis it is hoped that measures can be put in place to prevent similar 
incidents occurring. Wilson (2002) outlined seven steps involved in root cause 
analysis. 
1. Outline sequence of events. 
2. Find and record each pertinent event. 
3. Avoid early judgement, blame or attribution. 
4. Concentrate on the facts. 
5. Look at why the incident occurred - causation. 
6. Look at how the incident occurred - system faults, active errors, latent 
failures, flawed defences. 
7. Situational factors - distractions, circumstances, triggers for latent failures. 
Latent conditions are the underlying organisational problems that can contribute to the 
causes of clinical errors, for example, high workload and fatigue or inadequate staff 
training (Wilson, 2002). Active failures are the actions that can lead to immediate 
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poor outcomes for patients, such as, staff memory lapses or mistakes, slips or failures, 
for example misreading the label on a medicine, and violations that are unintentional 
deviations from safe practices. Systems failures are due to organisational problems 
such as the lack of shared goals throughout an organisation and poor communication. 
In Wilson's (2002) root cause analysis model, determination of the cause of the 
incident comes before consideration of how the error occurred. In the model 
recommended by the National Patient Safety Agency (NPSA, 2003b), outlined below, 
a full investigation of all contributing factors is carried out before determining the root 
cause of an incident. However, both models share the need to define the scope of the 
analysis before mapping the actions leading up to the incident and data gathering. 
The National Patient Safety Agency (NPSA, 2003b) recommends the follpwing steps. 
1. Scoping the patient safety incident. 
2. Data gathering. 
3. Information mapping. 
4. Identifying problems. 
S. Analysing problems for contributory factors. 
6. Agreeing to the root causes. 
7. Recommending and reporting. 
Root cause analysis was felt to be an appropriate tool for the investigation of interface 
issues because it concentrates on problems with the system within which the incident 
has happened. This method does not attempt to blame individuals for incidents. 
However, it is a tool for investigating serious patient safety incidents and not all the 
interface issues raised could be considered to be putting patients at risk. Additionally, 
root cause analysis is usually carried out with a team of investigators (NPSA, 2003b) 
whereas the researcher in the present study investigated interface issues alone. 
Therefore, the two models described above were combined and modified to take into 
account the reduced seriousness of some of the interface issues and that a single 
person investigated them. The process that was adopted will now be described and is 
illustrated in Figure 4.1. 
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Figure 4.1 Process of root cause analysis for case study examples 
l1. Interface issue identified and described J 
I 2. Data gathering I 
Obtain further details from Review relevant 
complainant or others 
I- policies and procedures 
• 
Review relevant meeting 
minutes 
, 
3. Work backwards from interface issue 
to find out why each previous step 
happened. Continue until no further 
underlying causes are identified 
I 
4. Identification of other contributing 
factors 
I 
5. Plot pOint at which root causes appear 
onto medicines management process map 
1. Interface issue identified and described. 
2. Data gathering to find relevant policies and procedures relating to the issue 
including for example, searching minutes of Drug and Therapeutics 
Committee meetings. Obtaining further information through discussions with 
the complainant or other health care professionals involved with the patient 
regarding the interface issue. 
3. Working backwards down the medicines management system map to 
determine at each step why things happened as they did. The 'five whys' 
approach was used. This involves asking why something happened the way it 
did until no further underlying causes are forthcoming and it is thought that the 
root cause has been identified (Howard, 2004). 
4. Identification of medicines management system contributions to the interface 
issue. 
5. Plotting the point at which root causes occurred on the medicines management 
process map. 
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Consideration was also given to the use of 'cascade analysis' for analysing the case 
study examples (Woolf et al, 2004). This method was rejected because, whilst it 
considers the chain of events preceding medical error, causation between errors and 
the final incident has to be shown. This means that only errors are considered, rather 
than also taking into account other predisposing factors. Root cause analysis was 
preferred for the present study because it takes into account factors that do not 
necessarily cause errors to occur but do contribute to creating an environment 
whereby an interface issue can arise. 
4.10 DEVELOPMENT OF A TECHNIQUE TO ENABLE MAPPING OF THE 
MEDICINES MANAGEMENT PROCESS 
The medicines management process across the primary / secondary care interface was 
mapped in order to gain a deeper understanding of how medicines management fits 
into the wider construct of patient care, especially at the interface. Process mapping is 
promoted by the NHS Modernisation Agency (2002) as a starting point for the 
redesign of patient services to improve efficiency and match capacity to demand by 
reducing the number of steps a patient has to go through. The present study was 
concerned with identifying gaps in processes that might lead to the breakdown of 
communication or continuity resulting in poor management of medicines. 
First of all the scope for the mapping process was defined as starting from when a 
patient was referred to hospital. The process was defmed as ending when a patient or 
carer obtained medicines prescribed by a OP following a hospital episode. All.· 
patients would be included in the process map but taking into account that this would 
reflect the process .that occurs the majority of the time and not variations that happen 
for individual patients or on individual wards. 
The process map was developed by gathering information from the literature and from 
the researcher's discussions and observations whilst practising as a clinical 
pharmacist. As the map was built up, the steps were confirmed with new contributors 
and any gaps in the process filled. Local and national policy documents relating to 
medicines management across the interface were also collected and reviewed during 
this phase. Local procedures for the addition of new medicines onto the district 
formulary through the Drug and Therapeutics and Area Prescribing Committees were 
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also mapped. This map was then used to identify common locations for interface 
issues in the medicines management process. 
4.11 FOCUS GROUP AND SEMI-STRUCTURED INTERVIEWS WITH 
HEALTH CARE PROFESSIONALS 
Focus group interviewing was chosen for data collection because it allows a larger 
amount of information to be collected than through interviews of single people. One 
premise underpinning the use of focus groups is that people need to listen to other 
people's ideas and attitudes before forming their own (Marshall & Rossman, 1995). 
This aspect certainly became clear when running the groups because several 
participants commented that they would not have anything to say when invited to join 
the discussion. However, when the time came, ideas raised by other participants 
helped them to recall similar situations they had experienced and there was plenty of 
discussion. 
4.11.1 Focus group preparation 
There were three stages of preparation for running the focus groups. The first stage 
involved preparing the researcher to facilitate the groups to ensure that relevant data 
Was collected. The second stage was the development of an interview schedule to 
outline the broad concepts to be explored within the focus groups. During the third 
stage of preparation the operational aspects of running the groups were organised. 
Each of these will now be considered in tum. 
Facilitation of focus group discussions is usually a task for an experienced interviewer 
(Marshall & Rossman, 1995). However, the researcher had no previous experience of 
facilitating focus group discussions. To resolve the problem of the researcher's 
inexperience a practise session was run with research colleagues as the participants. 
This enabled the researcher to develop confidence in facilitating the generation of 
discussion and the use of techniques to encourage quieter members of the group 
. whilst moderating more vociferous members. As the focus groups were to be 
audiotaped the researcher had to find suitable equipment for recording the focus 
groups. 
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The second stage of preparation for the focus groups was the development of an 
interview schedule. The quality of questions in a focus group discussion is very 
important in order to ensure that data generated is informative. The focus group 
questions were designed following Krueger's (1994) focus group interview schedule. 
Within this there are three main types of questions. Introductory questions are used to 
introduce the general topic of discussion and give participants an opportunity to 
reflect on past experiences concerning the overall topic. These questions are intended 
to promote interaction and conversation between the participants. Transition 
questions are then used to move the conversation into the key questions that are the 
main focus of the study. They act as a link between the introductory questions and the 
key questions. The key questions form the majority of the discussion. Generally, 
between two and five key questions are developed. An interview schedule was 
developed for each of the three professional groups included in the focus group 
discussions, hospital pharmacists, community pharmacists and GPs. This was 
because whilst the broad topic areas would be the same for each group it was expected 
that different groups would have different perspectives on medicines management 
across the interface and so this was taken into account when phrasing questions. 
It is not possible to pilot test focus group interviews in the same way as questionnaire 
surveys. However, this can be accomplished by expert review of the questioning 
route and potential probes, reflecting on the wording and sequencing of the questions 
after the first focus group (Krueger, 1994). For these focus groups selected 
representatives were not asked to comment on the questions because of the 
recruitment problems experienced. 
The final stage of preparation involved the operational aspects of running the focus 
groups. Times and venues were chosen that would be convenient for participants. 
The community pharmacist focus group was held in the evening, after usual pharmacy 
closing times, and light refreshments were provided. An evening was chosen because 
community pharmacists often find it difficult to attend meetings during the working 
day due to pharmacy supervisory requirements. The groups were held in the neutral 
territory of the hospital post-graduate education centre, rather than the hospital 
pharmacy department, so that the participants were less likely to be intimidated. For 
hospital pharmacists the groups were held at lunchtime and were held in the pharmacy . 
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seminar room of each hospital. The GP focus groups were held at lunchtime, after 
morning surgery, and light refreshments were provided. The groups were held in a 
seminar room shared by five large group practices. In the next section recruitment to 
the focus groups will be explained, 
4.11.2 Recruitment of health care professionals 
Two focus groups were held for each of the health care professional groups 
considered important within the context of this study. These professional groups were 
general practitioners, community pharmacists and hospital pharmacists. It was aimed 
to recruit between four and eight participants to each focus group as this is considered 
to be the optimum number of participants (Kitzinger, 1995). Recruitment for each of 
the professional groups differed and so this will now be explained in more detail. 
4.11.2.1 Recruitment of community pharmacists 
It was felt that the perceptions of a pharmacist employed by a multiple community 
pharmacy might differ from those of an independent community pharmacist and so it 
was attempted to recruit a cross-section of pharmacists from both sectors. Using a 
theoretical sampling frame in this way rather than a convenience sample increases the 
generalisability of results from qualitative studies (Greenhalgh & Taylor, 1995; Mays 
& Pope, 1995). The Health Authority Community Pharmacy Adviser provided a list 
of community pharmacists who might be interested in taking part. These were 
pharmacists known to have been involved in projects in the past. Other pharmacists 
were chosen from the area using the telephone directory. Participants in a focus group 
should, ideally, be unfamiliar with each other (Krueger, 1994) and so pharmacists 
were chosen from different localities within the Health Authority boundary in an 
attempt to avoid the participants knowing each other well. Each pharmacist was 
telephoned and the purpose of the focus group explained. When the venue and date of 
the focus group had been set a letter with further details was sent to each pharmacist 
who had expressed an interest. The letter included a tear-off slip to return indicating 
whether or not they would attend. The week before the interviews, pharmacists were 
telephoned again in an attempt to generate more interest. 
Recruitment was difficult, partly, because the community pharmacists felt that they 
already spent a significant amount of their spare time on work related issues. An 
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additional problem with recruitment to the first session was that the date coincided 
with an event run by the Centre for Pharmacy Postgraduate Education (CPPE). 
For the first session three participants attended. A fourth participant withdrew at short 
notice due to unforeseen family commitments. Three participants would not normally 
be sufficient, but on this occasion an enormous amount of discussion was generated. 
Four participants attended the second session. 
4.11.2.2 Recruitment o/hospital pharmacists 
Recruitment was easier to this group because one of the interviews was held during a 
pre-scheduled lunchtime education meeting. The other group was held with 
colleagues from the hospital pharmacy department. Participants with a range of 
specialities and experiences were included. 
4.11.2.3 Recruitment 0/ general practitioners 
Letters were sent to every GP within the Southern Derbyshire Health Authority area. 
General practitioners who had contacted the researcher in her role as primary care 
liaison pharmacist, because of a specific issue with prescribing across the interface, 
were also contacted by telephone. The meetings were discussed with the GP post-
graduate education tutor and accredited for post-graduate education allowance points. 
Despite this, only four GPs stated that they would attend one of the meetings. Even 
with reminders, only one actually turned up on the day. The second meeting was 
cancelled due to lack of interest. 
A further two focus groups were set up within the Gloucestershire Health Authority 
area. The reason for the change in locality was that the researcher had moved from 
Derbyshire for work purposes and was now employed as a PCG Prescribing Adviser 
within Gloucestershire. General practitioner prescribing leads from practices in one 
Primary Care Group area were invited to participate. There were small numbers who 
would attend each group and so all participants were asked.to attend the first group 
and a second group was arranged at a later date. 
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4.11.3 Running the focus groups 
Each focus group was set up to allow a short period of time for taking refreshments if 
provided and for late arrivals. Once all participants had arrived they were asked to sit 
on chairs laid out in a circular formation. The researcher explained that the focus 
group was being conducted as part of a research project. At this point participants 
Were asked if they consented to an audio recording being taken of the discussion on 
the understanding that the tapes would be transcribed and then erased. Participants 
Were informed that comments made could be published but that the identity of 
Participants would remain confidential. The tape recorder was then switched on. 
The researcher facilitated the discussion using the interview schedule as a guide. 
Questions were directed to the group as a whole rather than to individual participants. 
When necessary the researcher used probing questions to encourage participants to 
expand on issues raised or to ask other group members for similar experiences. Brief 
notes were taken of main themes raised during the discussion to allow the researcher 
to summarise the issues discussed. The main themes raised in the focus groups were 
summarised at the end of each discussion to allow participants to verify the accuracy 
and completeness of the data (Krueger, 1994). 
At the end of each focus group the tape recorder was switched off and participants 
were thanked for their time and contributions. Immediately after each group the 
recording was checked to ensure that it had recorded successfully. A verbatim 
transcript was made of each tape by the researcher. 
4.11.4 Semi-structured interviews with hospital medical consultants 
Semi-structured interviews were chosen for the hospital medical consultants because 
it was felt that, given the difficulties with recruiting to focus groups for the other 
groups of health care professionals, the medical consultants would prove almost 
impossible. 
The hospital medical consultants were approached opportunistically by the researcher 
and asked if they would be willing to take part in the study. The semi-structured 
interviews followed a similar planning schedule to the focus group interviews. 
Initially an interview schedule was developed to keep the interview focused. Then 
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once agreement for inclusion had been obtained a convenient time and venue was 
chosen for participants. At the start of each interview the purpose of the study was 
explained and consent for audio recording the interview gained. The interview was 
undertaken following the interview schedule and using prompts when necessary to 
clarify or expand on issues raised. Following each interview the audio recording was 
checked and the tapes transcribed verbatim. One of the hospital medical consultants 
was employed within Gloucestershire Health Authority and the other within 
Manchester Health Authority, where the researcher had taken up a post as a PCG / 
PCT Prescribing Adviser. 
4.11.5 Analysis of focus group and semi-structured interviews 
Transcripts and field notes form the raw data of qualitative research and provide a 
descriptive record of the research. Explanations may only be provided through the 
analysis and interpretation of the data (Pope et ai, 2000). Bryman and Burgess (1994) 
demonstrate that there is a range of approaches to analysing qualitative data in their 
collection of different researchers' strategies. Examples from this text were used 
along with recommendations from Krueger (1994), Miles and Huberman (1994) and 
Marshall and Rossman (1995) to develop the following analytical process for dealing 
with data from the focus group and semi-structured interviews with health care 
professionals. 
1. The first step of analysis was for the researcher to familiarise herself with the data 
by listening to the interview tapes and reading the transcripts several times. Key 
areas and recurrent themes were noted. This step helped to ensure that when the 
data was reduced in the later stages of analysis the context underpinning 
interviewees' statements was not misinterpreted. 
2. Open coding is the first stage of data organisation. Descriptive codes were 
applied to each segment of transcribed text. The aim was to code all segments of 
data apart from the fillers that appeared in the interview that were unrelated to the 
topic. Constant comparison was used to check each segment of coded data against 
the rest of the data to establish analytical categories (pope et ai, 2000). A 
common code index was used for all professional groups to help identify both 
common and divergent themes. 
120 
3. The list of codes was then reviewed and refined by grouping together similar 
themes under broader codes to reduce the total number of codes. The codes used 
were internally consistent but divergent from each other (Marshall & Rossman, 
1995). The list of codes was revised to remove repetitious or similar headings. 
4. The data was searched for deviant or negative cases, for example where one 
interviewee responded in a dissimilar way to other interviewees (Marshall & 
Rossman, 1995). 
5. Distilled summaries of interviewees' views and experiences were rearranged onto 
a single meta-matrix to aid identification of patterns and interpretation of the data 
(Miles and Huberman, 1994). 
6. As is usual within qualitative research, verbatim quotations that encapsulated each 
of the themes discovered were extracted from the transcripts to illustrate the 
findings (Greenhalgh & Taylor, 1997). Each quotation was referenced to allow 
them to be traced back to an identifiable subject and setting. 
4.11.6 Change management analysis 
Once the initial content analysis of the interviews had been finalised, the transcripts 
were searched again looking for data relating to change management theory. 
Evidence of driving and restraining forces for change, dissatisfaction with the current 
state, shared vision of an improved interface medicines management system and 
knowledge of the first steps towards this were extracted from the data. Summaries of 
these extracts were tabulated according to the professional group from which the 
information came. 
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4.12 STRUCTURED INTERVIEWS WITH PATIENTS 
Four outpatient clinic settings were chosen (urology, gynaecology, general medical 
and paediatric medical). Patients were approached in the waiting room, the study 
explained and an information leaflet provided (Appendix 1). Patients were then asked 
whether they gave consent to being included in the study and informed what that 
would entail. They were assured of the confidentially of all data provided. 
The interviews were carried out following a structured schedule (Appendix 4). 
Patients were asked about how they currently obtained their prescription medicines 
and their expectations for their medication regimen to be changed at the outpatient 
consultation. 
At the end of each interview patients were asked if it would be possible to contact 
them again. Patients who gave consent to this, and who had a telephone, were 
followed up by telephone at least two weeks following the initial interview. Patients 
were reminded who the interviewer was and asked if it was a convenient time to talk. 
Patients were given the opportunity to withdraw from the study at this point. During 
the interview they were asked if any changes had been made to their medicine 
regimen at the outpatient appointment and if they had been given a hospital 
prescription or asked to obtain a prescription through their OP. They were asked if 
they had experienced any difficulties in obtaining medicines. Patients who had been 
given a hospital prescription but had not yet obtained a further supply from their OP 
were asked if they could be contacted again to find out their experience of this stage 
of the process. This group of patients were again contacted by telephone after at least 
two weeks to find out if they had experienced any difficulties in obtaining a further 
supply of medicines. All data were recorded on a pre-printed interview schedule 
(Appendix 4). 
A similar process was followed for patients about to be discharged from hospital. 
Patients were interviewed on a hospital ward and then followed up by telephone at 
least four weeks after discharge. It was expected that at this time patients would have 
had to obtain a further supply of medicines from their OPs. 
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4.12.1 Analysis of patient interviews 
Simple quantitative analysis was undertaken to calculate the percentage of patients 
giving specific responses to questions. Statistical analysis was not appropriate due to 
the small numbers of patients interviewed. Comments relating to difficulties 
experienced with the medicines management process were recorded to illustrate the 
problems. There was insufficient data to undertake a detailed content analysis but the 
comments provided some insight into the difficulties associated with medicines 
experienced by patients. 
4.13 A CRITICAL EVALUATION OF THE RESEARCH PROCESS 
The present study considered medicines management at the interface both 
prospectively, through the collection of case study examples of interface issues, and 
retrospectively, through interviews with health care professionals in primary and 
secondary care. This has allowed medicines management across the interface to be 
considered from the perspective of how it impacts on health care professionals and 
has allowed the identification of a range of medicines management problems. 
However, there are a number of issues related to the research process and these will 
be discussed in this section. 
The prospective part of this study, the collection of case study examples of interface 
issues, relied on reports being given to the researcher. Therefore, it is likely that 
many other interface issues arose during the period of data collection than were 
identified by the researcher. There are several reasons why interface issues may have 
not been reported. Health care professionals in primary and secondary care may not 
have been aware of the researcher's role and therefore that there was a mechanism to 
report such issues. Individual health care professionals may also have been reluctant 
to complain about an issue or perceived that it was insignificant and so did not 
warrant reporting. Every effort was made to advertise the role of the 'primary care 
liaison pharmacist' in identifying and resolving interface issues. This was done by 
writing to hospital medical consultants, GPs and community pharmacists and 
reinforcing this with information in the health authority'S prescribing newsletter. 
Hospital pharmacy colleagues were also encouraged to report interface issues they 
encountered whilst in the dispensary or on wards. An interface issue reporting card 
was also sent to GPs and community pharmacists to provide an easy method of 
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reporting. Despite these efforts it is likely that many interface issues were missed. 
However, the range of problems identified through the collection of case study 
examples was backed up through data obtained from interviews with health care 
professionals and in the literature. As the current study set out to categorise interface 
issues, rather than quantify them, the fact that individual issues may have been missed 
is of less significance. 
The researcher was employed as the 'primary care liaison pharmacist' by the hospital 
in the health authority where the pharmacists were interviewed and as a prescribing 
adviser to the Primary Care Group where the GPs and hospital medical consultants 
were interviewed. Therefore, there was a relationship between the researcher and the 
participants that could have affected their responses to questions. However, the focus 
of the research was to determine deficiencies in the systems and processes of health 
care across the interface that caused problems to emerge, rather than apportioning 
blame to individuals for their actions. Therefore, it was felt that participants were not 
restricted from responding truthfully despite having a professional relationship with 
the researcher. 
It is also necessary to comment on the selection of participants in the community 
pharmacist and GP focus groups. The Health Authority Community Pharmacy 
Adviser helped to recruit community phaimacists to the focus groups by providing a 
list of pharmacists who had been involved in previous projects. This means that they 
may represent a particularly progressive group of pharmacists who are keen to be 
involved in moving the profession forward. This was not considered to be 
problematic though because, even though the participants may not have been 
representative of community pharmacists as a whole, the study aimed to identify 
difficulties that may compromise the effective delivery of medicines management 
when patient care is transferred. Less active pharmacists may give less consideration 
to the issues that they encounter. Therefore, they may dispense medicines with little 
thought for the consequences or turn patients away if prescriptions cannot be 
dispensed without further enquiries being made. In fact, from the case study 
examples, it was clear that other pharmacists did act in this manner by not considering 
whether patients would be able to administer medicines or refusing to dispense 
prescriptions. The GPs who participated in the focus groups took an active role in the 
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management of prescribing within their practices. Again, this may mean that they are 
more aware of interface medicines management issues that GPs as a whole. However, 
having a group of GPs who were interested in prescribing meant that they were 
acutely aware of the problems that arise and were keen to talk about the dilemmas 
they faced. 
As a final consideration, the majority of data collected during the present study 
focused around the management of medicines within a single English Health 
Authority, Southern Derbyshire, although the GP focus groups were undertaken in 
Gloucestershire and the hospital medical consultants interviewed worked in 
Gloucestershire and Manchester. This was not felt to be detrimental to the research 
process because all NHS hospitals must comply with the same set of regulations. 
Whilst, guidance may be interpreted and implemented slightly differently in 
individual hospitals, it is unlikely that this would affect the range of interface issues 
that arise. Similarly, whilst there may be differences in the structure and process of 
care within individual hospitals, these are likely to be minor differences, and so this 
should not mean that similar interface issues will not arise throughout NHS hospitals. 
Therefore it was a typical situation that was being researched which adds weight to 
the generalisability of the findings (Parahoo, 1997). Additionally the use of 
theoretical sampling methods to recruit participants to the focus groups to reflect the 
range of likely responses also increases the generalisability of the findings. 
Triangulation of multiple sources of data can also enhance a study'S generalisability 
(Marshall & Rossman, 1995). This was achieved in the present study by collecting 
the views of pharmacists and doctors in primary and secondary care. Whilst their 
views were often conflicting in terms of their own goals they complemented and 
substantiated each other. It should also not be forgotten that there is a large literature 
base relating to medicines management across the interface. This demonstrates that 
the issues identified in the present study are similar to those identified in other studies 
across the whole of England (Sibbald et ai, 1992; Wilkie et ai, 1992a; Wilkie et ai, 
1992b), the North of England (Cochrane et aI, 1992; Coleman et aI, 2001), the South 
of England (Duggan et ai, 1996; Home et ai, 2001), Scotland (Bums et ai, 1992; 
Cromarty et ai, 1998) and Wales (Pegrum, 1995). Therefore, although data collection 
was concentrated within specific areas in England the findings may be generalised to 
other NHS settings. 
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CHAPTER FIVE 
RESULTS 
5.1 INTRODUCTION 
In this chapter the findings of the present study are presented in three parts as shown 
in Figure 5.1. 
Figure 5.1 Structure of Results Chapter 
Section One Section One Section Two 
Part A Part B Interviews with 
Analysis of case ... Mapping of .. health care 
study examples of 
... 
interface medicines 
.... 
professionals and 
interface issues management patients adds to the 
allows description processes enables description of 
and categorisation of consideration of root interface problems. 
interface problems causes in context of Informs about the 
and assessment of whole process and communication and 
root causes. identification of decision making 
weak points. processes with 
respect to medicines 
management. 
In Section One Part A, case study examples of interface issues are presented, 
categorised and analysed. Root cause analysis of a selection of case study examples is 
presented to show where there were weaknesses in existing medicines management 
processes thus enabling interface issues to be generated. The remaining complement 
of case study examples in their initial descriptive form and following root cause 
analysis are included in Appendices Five and Six. 
In order to appreciate how interface issues are generated, it is necessary to understand 
the whole process relating to medicines management across the interface. Therefore, 
in Part B of Section One the relevant medicines management processes are mapped. 
This allows the root causes found in Part A to be considered within the context of the 
complete medicines management process. 
Health care professionals in primary and secondary care are responsible for the 
decision making and communication processes that affect effective medicines 
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management when patients are transferred across the interface. Therefore, in Section 
Two the perspectives of health care professionals and patients of medicines 
management across the interface are presented. This adds to the description and 
categorisation of interface problems and also provides additional data for the appraisal 
of the implementation ofinterface policy. Finally, this allows the perceptions of 
health care professionals of communication and decision making processes relevant to 
the interface to be described. A summary of the data collection period and locations 
is shown in Table 5.1. 
Table 5.1 Summary of data collected 
Data collected Number Data collection Place of data 
induded period collection 
Case study examples of 87 Jan '97 - Aug '99 Southern Derbyshire 
interface issues Health Authority 
Mapping of medicines Jan '97 - Aug '99 Derby City General 
management processes Hospital 
Community pharmacist 3 24.09.98 Southern Derbyshire 
focus group 1 Health Authority 
Community pharmacist 4 11.11.98 Southern Derbyshire 
focus group 2 Health Authority 
Hospital pharmacist 10 27.04.99 Southern Derbyshire 
focus group 1 Health Authority 
Hospital pharmacist 6 12.08.99 Southern Derbyshire 
focus group 2 Health Authority 
GP focus group 1 4 22.03.00 Gloucestershire 
Health Authority 
GP focus group 2 5 26.07.00 Gloucestershire 
Health Authority 
Hospital medical 1 08.08.00 Gloucestershire 
consultant interview 1 Health Authority 
Hospital medical 1 28.11.00 Manchester Health 
consultant interview 2 Authority 
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RESULTS 
SECTION ONE - PART A 
5.2 CATEGORISATION OF INTERFACE PROBLEMS AND 
DETERMINATION OF THEIR ROOT CAUSES 
5.2.1 Description and categorisation of interface issues from case study examples 
Initial content analysis, described in Chapter Four, of the case study examples showed 
that these could be categorised according to whether the issue was associated with: 
1. Communication 
2. Financial aspects of medicines management 
3. Clinical responsibility 
The 'communication' category reflects instances when information was poorly 
transferred between primary and secondary care practitioners. The 'financial' 
category illustrated cases associated with difficulties transferring prescribing 
responsibilities between primary and secondary care doctors because of financial 
issues. Problems relating to national systems for the control of medicines 
expenditure, such as the NHS 'blacklist' are included within this category. The 
'clinical responsibility' category contains examples where GPs felt uncomfortable in 
accepting responsibility for prescribing because of their lack of knowledge or 
experience. Table 5.2 shows the categorisation of cases into the three categories. 
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Table 5.2 Categorisation of case study examples of interface issues 
Description of issue 
Communication 
Difficulties obtaining further 
supplies of medicines in primary 
care 
Poor information on admission 
to hospital 
Poor information on discharge 
from hospital 
Financial 
Supply not permitted in primary 
care 
Insufficient supply of medicines 
on discharge from hospital or 
following outpatient attendance 
Loss leaders 
Cost shifting 
Formulary non-compliance 
GP refusing to prescribe 
formulary medicine 
Community pharmacist refuses 
to dispense prescription 
Hospital doctor recommending 
expensive formulations when 
cheaper versions are more 
appropriate 
Clinical responsibility 
GP feels uncomfortable 
prescribing unusual medicine 
GP feels uncomfortable 
prescribing unlicensed or 'off-
label' medicine 
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Examples of issues 
Community pharmacist not informed of 
supplier / formula / medicine not listed on 
GP computer picking list 
Medication errors / drug history queries 
No explanation given for initiation of non-
formulary or unusual medicine / patient not 
informed that community pharmacy may 
not keep medicine in stock 
Community pharmacy cannot dispense due 
to NHS 'blacklist' 
Less than 28 days supply dispensed / 
hospital doctors not issuing prescriptions 
for 'repeat' medicines / hospital pharmacy 
not dispensing medicines for outpatients 
Hospital initiating medicines which cost 
significantly more when prescribed in 
primary care 
Attempts to transfer the costs of expensive 
medicines to the primary care prescribing 
budget 
Hospital doctors asking GPs to prescribe 
medicines which either have not been 
considered or .have been rejected by Drug 
& Therapeutics Committee 
Refusal to prescribe when consensus of 
Area Prescribing Committee is that 
medicine is suitable for GP prescribing 
Patient gi ven FP 1 O(HP) prescription for 
erythropoietin which community 
pharmacist will not dispense because of 
delay between purchase and reimbursement 
Enteric coated preparation initiated instead 
of standard formulation 
OP refuses to prescribe because no 
previous experience of medicine / medicine 
requires specialist monitoring 
GP refuses to prescribe medicine for 'off-
label' indication 
Case reference 
(Appendix 5) 
(Table number. case 
number 
e.g. 7.2 refers to 
Table 7. Case 2) 
7.2, 7.3, 7.4, 7.5, 7.6, 
7.7,9.2,9.3 
8.1,8.2,8.3,8.4,8.5, 
9.4 
3.5,5.1,5.2, 
6.1, 6.2, 6.4, 6.5, 
7.8,9.1,13.1 
10.6,10.7, 
11.1, 11.2 
1.1, 1.2, 1.5,3.1, 
4.1,4.2, 
12.1, 12.2, 12.3, 
12.4, 12.5 
4.3,7.1, 
10.1, 14.1 
1.3,2.1,2.2,15.1, 
16.1,16.3,16.4, 
16.5,17.1,17.2, 
17.3,17.4,17.5, 
17.6, 17.7, 17.8, 
18.3,19.1, 19.2 
3.2,3.3,3.4 
21.1 
16.2,20.1,20.2 
1.4,6.6, 10.2, 10.3, 
10.4, 18.1, 18.2 
6.3, 10.5, 18.4, 18.5 
So far it has been shown that interface issues can be categorised into those associated 
with communication difficulties, financial responsibility or clinical responsibility 
issues. However, during the initial analysis it became clear that this categorisation 
framework was too simplistic and did not provide any insight into why problems 
occurred. Therefore, further analysis was undertaken as described in Chapter Four 
(Methods). This showed that apparent reasons for the occurrence of interface issues 
could be categorised as follows. A full description of the cases within these 
categories is provided in Appendix Five. 
1. Lack of awareness or misunderstanding of policy 
This theme describes cases where prescribing policy had not been followed and 
was due to a misunderstanding of the policy rather than a will to deliberately 
violate a policy. Cases were included if the complainant had misunderstood a 
policy and incorrectly assumed that it had been violated. 
2. Inadequate inter- or intra-professional collaboration 
Cases were put into this category if the problem appeared to be caused by 
miscommunication or a failure on the part of professionals to collaborate. 
3. Impracticable or inflexible policy 
Sometimes practitioners attempted to follow correct policy within their sector but 
encountered difficulties in so doing. Problems arose due to differences in policy 
between primary and secondary care and rigid policy adherence. For example, a 
hospital policy specified that patients had to be given a specific quantity of 
medicines. This meant that patients had to return to hospital to collect incomplete 
supplies despite this being inconvenient. 
4. Flagrant violation of policy 
The majority of issues fitting the flagrant violation of policy category had resulted 
from practitioners refusing to be compliant with a district formulary. For 
example, there was a tendency for hospital doctors to ask GPs to prescribe 
medicines that had either not been considered or had been rejected by the Drug 
and Therapeutics Committee. Cases were included in this category when the 
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initiator of the problem was aware that a medicine was not included in the 
formulary and had deliberately decided to ignore the policy. 
In Chapter Three it was explained that an initial thorough assessment of situations 
ensures that any solutions devised are targeted to address real problems and not just 
apparent problems. Whilst the second step of the categorisation process showed why 
interface issues were occurring this approach only gave a superficial assessment of the 
cause. It is difficult to propose effective solutions to interface medicines management 
problems without first determining the origin of each problem or issue. Therefore, the 
case studies were further analysed to identify the root causes of interface issues. 
5.2.2 Presentation of root causes of interface issues 
A full description of the process undertaken to determine root causes of interface 
issues is given in Chapter Four, but for convenience, will be briefly summarised as 
follows (see also Figure 4.1). 
• Data is gathered about incidents starting with the identification and description of 
an incident. 
• Each step of a process is examined to determine why it occurred. 
• Additional factors that may contribute to incidents are then taken into account. 
It is not appropriate to present the complete set of root cause analyses because the 
amount of data would provide a confusing picture. Therefore, illustrative examples 
are presented showing the typical scenarios. They illustrate examples of interface 
issues with root causes at particularly problematic steps of the medicines management 
process. Root cause analyses derived from the remaining cases are shown in 
Appendix Six. 
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Poor inter- / intra-professional collaboration on discharge results in inability of 
patient to take medicines at home (Case 5.1) 
A baby was discharged from the special care baby unit taking Niferex® elixir, an iron 
supplement. The mother returned to the ward complaining that she could not 
administer the medicine to her baby. The medicine had been dispensed by a 
community pharmacist and was labelled correctly but a dropper had not been 
provided. 
Problem 
A mother was unable to administer Niferex® elixir to her baby without a dropper. 
Arising questions 
• Why could the elixir not be administered? 
The community pharmacist had dispensed a standard lOOml bottle of elixir which 
has no administration dropper. 
• Why did the community pharmacist dispense 100ml bottle? 
The 30ml dropper bottle is only available on the NHS under the' Selected List 
Scheme' (SLS) for the prophylaxis and treatment of iron deficiency in infants 
born prematurely. The GP had not endorsed the prescription 'SLS' to confirm 
that the patient fitted these criteria. 
• Why was the prescription not returned to the GP for endorsement? 
The community pharmacist dispensed the prescription as written and did not take 
the patients' needs into consideration. 
• Why? 
The community pharmacist followed the rule of dispensing without considering 
the needs of the patient. 
Review of multifactorial dimensions of case 
• Lack of awareness on the part of hospital pharmacists of the need to endorse 
prescriptions in the community. 
• No communication between hospital and community pharmacists to ensure 
continuity of medicine supplies. 
• Rigid application of rules by community pharmacist without considering how 
mother would administer the drops to her baby. 
• If the community pharmacist had dispensed a 30ml dropper bottle without 
endorsement, the Prescription Prescribing Authority would have refused the 
prescription for payment. 
• Community pharmacist may have been ignorant of the 'SLS' prescribing rules. 
• GP may have been unaware of the specific indication for the Niferex® elixir. 
• GP appeared unaware of the need to endorse the prescription 'SLS' to confirm 
that the infant fitted the criteria of the selected list scheme. 
Root cause 
Poor collaboration when patient was discharged with the result that the information to 
the GP did not specify to endorse prescriptions with 'SLS'. 
Figure 5.3 Step 7 
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General practitioner asked to prescribe a non-formulary medicine (Case 6.1) 
A OP complained that he had received a letter from a hospital pharmacist asking him 
to prescribe olsalazine for a patient seen at a hospital outpatient clinic. Olsalazine was 
not included in the district formulary. 
Problem 
A OP objected to being asked to prescribe a non-formulary medicine. 
Arising questions 
• Why was a non-formulary medicine chosen? 
The patient had previously tried mesalazine, which was the formulary choice, but 
could not tolerate it due to side-effects. 
• Why is the GP complaining? 
He was not provided with a valid reason for the choice of a non-formulary 
medicine. 
• Why? 
A hospital pharmacist wrote a note to the OP asking him to prescribe olsalazine as 
it was not stocked by the hospital pharmacy without explaining why this was a 
reasonable choice. 
• Why did the hospital pharmacist write to the GP? 
The patient presented a prescription for olsalazine at the hospital pharmacy. This 
could not be dispensed because olsalazine was non-formulary and therefore not 
stocked by the hospital pharmacy. The pharmacist contacted the hospital doctor to 
inform him that the prescription could not be dispensed. The hospital doctor 
asked the pharmacist to write a note for the patient to deliver to the OP so that the 
patient did not have to return to the outpatient clinic which was some distance 
away. 
Review of multifactorial dimensions of case 
• Clinical factors. Some patients cannot tolerate formulary medicines. 
• The hospital doctor was not aware that olsalazine was not stocked by the hospital 
pharmacy. 
• The hospital doctor asked the hospital pharmacist to write a note for the OP so that 
the patient did not have to return to the outpatient clinic. 
• The hospital pharmacist did not explain to the OP the reasons for a non-formulary 
choice of medicine. 
• It is unusual, but not unreasonable, for hospital pharmacists to communicate with 
OPs in this way. 
• The OP assumed that the request for a non-formulary medicine was due to a 
violation of policy rather than an identified clinical need. This led to annoyance. 
Root cause 
When a hospital doctor did not appreciate that olsalazine was non-formulary and 
therefore a prescription could not be dispensed at the hospital pharmacy. This meant 
that the usual communication channels were not followed. 
Figure 5.4 Step 4a 
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Hospital discharge procedure did not consider medication supply difficulties in 
primary care (Case 9.1) 
A child was discharged from hospital taking phenobarbitone mixture. The hospital 
pharmacy department had been making the mixture as an extemporaneous 
preparation. The child's mother contacted the hospital pharmacy a few weeks after 
her child's discharge from hospital complaining that she was having difficulty 
obtaining a further supply from a community pharmacy. 
Problem 
A mother experienced difficulties obtaining a further supply of phenobarbitone 
mixture in the community. 
Arising questions 
• Why can the mother not obtain a further supply? 
The mother obtained a prescription from her GP and took this to a community 
pharmacy for dispensing. She was informed that the prescription would take 
approximately one week to dispense. 
• Why? 
Many community pharmacists purchase extemporaneous preparations from 
'specials' manufacturers instead of making them in the pharmacy. 
• Why do community pharmacists not make extemporaneous preparations 
Good practice recommends that medicines should be purchased from licensed 
manufacturers whenever possible. 
• Why will the prescription take so long to dispense? 
Some 'specials' are manufactured only when an order is received. This introduces 
an additional time delay compared to a preparation that is ready manufactured and 
simply picked from a warehouse shelf. 
Review of multifactorial dimensions of case 
• The hospital pharmacist was not aware that community pharmacists do not make 
extemporaneous preparations on the premises and hence the extended lag time to 
dispense prescriptions. 
• The mother was not warned that obtaining a further supply might take longer than 
usual to obtain. 
• Unwillingness of community pharmacist to help maintain continuity of medicine 
supplies. 
Root cause 
Lack of awareness on the part of the hospital pharmacist meant that the mother was 
inadequately counselled when her child was discharged from hospital and no liaison 
between hospital and community pharmacists to ensure continuity of supply. 
Figure 5.3 Step 8b 
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Problems transferring prescribing responsibility for an unlicensed medicine 
(Case 10.5) 
A consultant paediatrician had initiated cisapride for a five-year-old child with gastro-
oesophageal reflux. The child's GP had been issuing repeat prescriptions over a 
period of six months. However, on an occasion when the GP was not available to 
sign the prescription, a colleague in the practice refused to prescribe cisapride because 
it was unlicensed for use in children and concerns about side-effects had been 
published. The child was referred back to the paediatrician who asked a hospital 
pharmacist for help in resolving the issue. 
Problem 
A mother can no longer obtain prescriptions for cisapride for her child from her GP. 
Arising questions 
• Why? 
A GP is refusing to prescribe cisapride. 
• Why? 
Cisapride is unlicensed for use in children and the GP is concerned about side-
effects. Prescribers take full responsibility for adverse consequences of medicines 
when they are used outside the terms of their product licenses. 
• Many medicines are not licensed for use in children, is there a particular 
problem with cisapride? 
A Committee on Safety of Medicines warning has been issued about cardiac side-
effects. 
Review of multifactorial dimensions of case 
• There are no systems in place to continue prescribing in hospital if GPs refuse. 
• Even if one GP feels comfortable prescribing a particular medicine another GP 
might disagree. There will be occasions, such as annual leave, when patients' 
own GPs are not available to sign repeat prescriptions. 
• Liability for adverse consequences of unlicensed medicines rests with the person 
who signs the prescription. 
Root cause 
When prescribing responsibility was transferred from secondary to primary care. 
Agreement was not reached with all GPs in the practice who might be asked to 
prescribe cisapride. 
Figure 5.4 Step 7 
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Inadequate medicines management plans on admission to hospital (Case 12.2) 
It is recommended that patients taking modified-release diltiazem remain on the same 
brand due to differences in bioavailablity between preparations. This is because 
different modified-release preparations may not have the same clinical effects. The 
hospital pharmacy kept a limited range of modified-release diltiazem preparations. 
Patients admitted on different preparations would use their own medicines during the 
inpatient stay and further supplies would be purchased for individual patients if 
necessary. 
Problem 
A GP complained that the relatives of an inpatient had written requesting a repeat 
prescription for modified-release diltiazem. The GP considers that this is in breach of 
the hospital contract which states that all medicines for inpatients will be provided by 
the hospital pharmacy. 
Arising questions 
• Why did the relatives write to the GP? 
The patient was due to be discharged and only had nine days supply of diltiazem 
left. The relatives were advised to order a repeat prescription for the patient to 
ensure continuity of supplies. 
• Why was this a problem if the patient was at home? 
Firstly, the hospital contract states that at least fourteen days supply of medicines 
will be given on discharge from hospital. Secondly, the patient became unwell 
and so the discharge was delayed. The relatives had already sent the letter 
requesting a repeat prescription. 
• Why was patient going to be discharged with less than fourteen days supply? 
The brand that the patient was taking was not stocked by the hospital pharmacy. 
The ward pharmacist anticipated that the patient's own supply would be sufficient 
for both the inpatient stay and the discharge prescription. 
• Why was a further supply not ordered at the appropriate time? 
The patient was due to be discharged and the ward pharmacist felt that there was 
sufficient time to obtain a repeat supply from the GP. 
Review of multifactorial dimensions of case 
• The process for ordering non-formulary medicines within the pharmacy 
department was such that this should only be done as a last resort. This deterred 
the hospital pharmacist from ordering the medicine. 
• The hospital pharmacist had not taken into account the possibility that the 
patient's discharge could be delayed when calculating whether the patient had 
sufficient medicines. 
• Individual health care professionals may modify policies as they are applied. 
• The brand of diltiazem was not the one recommended in the district formulary 
illustrating lack of compliance with the formulary in primary care. 
Root cause 
When the hospital pharmacist violated policy by not ordering a further supply of 
diltiazem at the time stated in the policy. 
Figure 5.2 Step 4c 
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Loophole in the process for managed introduction of new medicines whereby 
hospital doctors may ask GPs to prescribe non-formulary medicines (Case 17.5) 
A patient was admitted on moxonidine which is an antihypertensive medicine which 
was not included in the district formulary. 
Problem 
A patient was admitted to hospital taking a non-formulary medicine. The quantities 
of medicines the patient had brought into hospital were insufficient to last throughout 
the inpatient stay and on discharge from hospital. 
Arising questions 
• Why is this a problem? 
The hospital pharmacist had to decide whether to purchase a supply of 
moxonidine for the patient. The purchase of non-formulary medicines was only 
allowed when there were no other suitable options. 
• Could the patient be switched onto another equivalent medicine? 
No, because moxonidine is a novel medicine. 
• Why did the GP prescribe moxonidine when it was non-formulary? 
The OP prescribed moxonidine on the recommendation of a hospital doctor after 
the patient had been seen at a hospital outpatient clinic. The hospital doctor used 
a medicines advice note to ask the OP to prescribe moxonidine. 
Review of multifactorial dimensions of case 
• There is no hospital pharmacist input when hospital doctors write medicines 
advice notes asking OPs to prescribe medicines. This means that hospital 
pharmacists cannot intervene if OPs are asked to prescribe non-formulary 
medicines. 
• Hospital doctors may use this loophole in the medicines management process to 
avoid applying for approval for new medicines through Drug and Therapeutics 
Committees. 
• Community pharmacists do not enforce the district formulary in the same way as 
hospital pharmacists. This means that they will not intervene if OPs prescribe 
non-formulary medicines. 
Root cause 
When the hospital doctor violated the policy by asking a OP to prescribe a non-
formulary medicine. 
Figure S.4 Step 4b 
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Similarities between the root causes became apparent in that they seemed to occur at 
similar places during the medicines management processes. In order to identify weak 
points in the medicines processes that allow interface issues to arise it is necessary to 
understand the whole process relating to medicines management across the interface. 
Therefore, based on the case study examples and the researcher's knowledge as a 
practising hospital pharmacist, the overall process was mapped. These steps include 
the decisions made by prescribers, organisational arrangements for discharge, for 
example, arranging transport, and communication mechanisms. The resulting 
diagrams portray a comprehensive map of the communication processes both within 
primary and secondary care, and crucially where communication must take place 
across the primary / secondary divide. These are described in Section One, Part B. 
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RESULTS 
SECTION ONE - PART B 
5.3 MAPPING OF MEDICINES MANAGEMENT PROCESSES RELEVANT 
TO THE PRIMARY I SECONDARY CARE INTERFACE 
In this second part of results, the medicines management process maps for patients 
admitted to Derby District General Hospital and attending outpatient clinics are 
shown in Figures 5.2, 5.3 and 5.4. These start with referral to hospital and end when 
patients are discharged from hospital. Figure 5.5 shows the process relating to 
medicines management within primary care when patients have been discharged from 
hospital or following an outpatient appointment. Figure 5.6 shows the process for the 
introduction of new medicines within the Southern Derbyshire health economy. This 
takes into account consideration by the hospital Drug and Therapeutics Committee 
and the Southern Derbyshire joint primary I secondary care Area Prescribing 
Committee. 
The stars on the diagrams indicate the points where root causes of interface issues 
were identified. The numbers within the stars indicate the number of case study 
examples with a root cause at this point from a total of 87 case study examples 
collected. Eleven of the cases are not included on the maps because they were 
associated with inadequate policy development rather than the day-to-day medicines 
management processes that occur when patient care is transferred across the interface 
(e.g. Case 4.3). 
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Figure 5.2 Process map of communication and medicines management for patients 
admitted to hospital 
1 a. GP refers patient to 
hospital 
Referral letter may include 
• Presenting complaint 
• Past medical history 
• Drug history 
2. Patient seen by nurse +----"1. 
3. Patient seen by doctor 
• History 
• Drug history 
• Examination 
• Diagnosis 
4a. Patient admitted to 
ward 
1 b. Self-referral 
through Accident & 
Emergency 
department 
Referral to social 
services if necessary 
4b. Prescription 
written 
1 c.Patient brought in 
by ambulance 
Primary care 
Secondary care 
4c. Medicines management 
by pharmacy 
• Drug history 
• Prescription review 
Sa. Daily review, investigation and 
monitoring of patient by:-
• Patient's own drugs 
• Supply 
• Counselling 
• Medical staff 
• Nursing staff 
• Pharmacist 
As necessary by: 
• Social services 
• Physiotherapy 
• Dietician 
• Occupational therapist 
1 
etc. 
5b. Dose of medicine 
altered or new medicine 
-. prescribed 
W Key The stars indicate the point at which root causes of interface issues occurred. The 7 numbers within the stars indicate the number of case study examples with a root cause at this point from a total of 87 case study examples collected. 
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Figure 5.3 Process map of communication and medicines management leading up to 
discharge from hospital 
6a. Consultant decides patient is 
ready for discharge from hospital & 
patient informed 
6b. Nurse contacts 
community nurses if 
necessary 
6c. JHO writes combined 
interim discharge 
ummary / prescription 
7. Discharge medicines 
prepared by pharmacy 
6d. Receptionist 
• Books transport & outpatient 
appointments if necessary 
• Sends notes to medical 
secretary 
9. Consultant / SpR / SHO 
collects notes & dictates formal 
6e. Social services 
involved if support 
needed at home or 
residential care 
identified earlier in the 
process 
discharge summary ~ 
L..-__________ -J 10. Formal summary , 
typed & posted to 
OP 
8a. Nurse discharges 
patient 
8c. Patient's copy of 
.---~ interim discharge 
11. Patient has nearly completed 
hospital supply of med icines 
summary 
8d. Copy of interim 
discharge summary 
for OP in envelope 
12. Interim summary 
received by practice 
Secondary care 
Primary care 
13. Formal summary 
received by practice 
W Key The stars indicate the point at which root causes of interface issues occurred. The 7 numbers within the stars indicate the number of case study examples with a root cause at this point from a total of 87 case study examples collected. 
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Figure 5.4 Process map of communication and medicines management for patients 
attending outpatient clinics 
Primary care 
1. GP refers patient to hospital 
Referral letter may include 
• Presenting complaint 
• Past medical history 
• Drug history 
----------------------------------------- -----------------------------------------------
Secondary care 
During clinic 
4a. Urgent treatment or 
'hospital only' medicine 
Bospital prescription written 
. Patient takes prescription 
to hospital pharmacy 
for dispensing 
6, Prescription checked by 
pharmacist & dispensed 
care 
b 10. Patient has nearly 
ompleted hospital supply of 
medicines 
2. Patient seen in outpatient clinic 
• History 
• Examination 
• Diagnosis 
3. Drug treatment 
appropriate 
4b. Non-urgent treatment 
Medicines advice note written 
11. Patient delivers 
medicines advice note to 
surgery 
1 
Following clinic 
summary dictated 
including prescribing 
advice 
9. Summary posted to 
GP 
12. Formal summary 
received by practice 
1 
W Key The stars indicate the point at which root causes of interface issues occurred. The 7 numbers within the stars indicate the number of case study examples with a root cause at this point from a total of 87 case study examples collected. 
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Figure 5.5 Process map of communication and medicines management in primary 
care 
-------1:----------------------------------------------1:------------------------~;;:;:.;~~~~~::':.- 1. 
1 a. Patient has nearly completed 
hospital supply of medicines 
1 
2. Patient requests repeat 
prescription 
Key The stars indicate the point at 
which root causes of interface issues 
occurred. The numbers within the 
stars indicate the number of case 
study examples with a root cause at 
this point from a total of 87 case 
study examples collected. 
1 b. Patient delivers medicines 
advice note / interim discharge 
summary to surgery 
3. Medication changes 
updated on computer by OP 
or receptionist 
1 
4. Prescription printed 
and signed by doctor 
5. Patient collects 
prescription & takes to 
community pharmacy 
lc. Formal summary receh 
by practice 
7. Discrepancies queried with 
patient / carer / OP 
6. Regular community 
pharmacy. 
8. Prescription dispensed 
9. Patient / carer 
counselled .. ~ 
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Prescription checked 
against patient medication 
records 
10. Patient takes medicine as 
prescribed 
Figure 5.6 Process map for introduction of new medicines 
Application rejected' 
~ 
Applicant informed 
Impact on primary care 
medicines budget too 
Referred to Area 
Prescribing Committee 
Area Prescribing 
Committee considers 
application 
Approved Rejected 
Consultant submits new 
medicine application to chair of 
Drug & Therapeutics Committee 
Drug & Therapeutics 
Committee considers 
application 
Yes 
.... 
Impact only in 
secondary care 
Referred to clinical 
director for consideration 
of funding issues 
Funding not 
approved 
Key The stars indicate the point at 
which root causes of interface issues 
occurred. The numbers within the 
stars indicate the number of case 
study examples with a root cause at 
this point from a total of 87 case 
study examples collected. 
Application approved 
on clinical grounds 
Assessment of whether 
additional resources 
will be necessary 
No 
Applicant & other 
prescribers informed 
that medicine has been 
added to formulary 
Funding 
approved 
~ ,r '.----A-P-p-li-ca.....ln~t-in:tl--O-rm-e-d----', 
Applicant & other preSCribe~~S 
informed that medicine has 2 
been added to formulary 
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5.4 SUMMARY 
The analysis of case study examples of interface issues found that they arose because 
of one of the following four reasons: 
• A lack of awareness or misunderstanding of policy. 
• Inadequate inter- or intra-professional collaboration. 
• Impracticable or inflexible policy. 
• Flagrant violation of policy. 
Superficially, the causes of interface issues seemed relatively simple. However, root 
cause analysis revealed that there were contributing factors to each case which were 
termed the multifactorial dimensions of the case. The combination of the 
multifactorial dimensions created an environment whereby an interface issue could 
emerge. Root cause analysis revealed the point within a medicines management 
process when an incident took place to start a chain of events resulting in the 
occurrence of an interface issue. Unless the multifactorial dimensions of the case 
were also present it is likely that the emergence of many incidents may have been 
prevented further down the medicines management process. 
Plotting the point at which the root causes happened on maps of the various medicines 
management processes shows where there are weak spots in the medicines 
management processes for the development of interface issues. It is possible that 
redesigning processes at these points could prevent interface issues arising. In the 
next section difficulties and problems experienced by health care professionals and 
patients with regard to medicines management across the interface will be 
demonstrated. 
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RESULTS 
SECTION TWO 
5.5 IMPACT OF THE PRIMARY I SECONDARY CARE INTERFACE ON 
EFFECTIVE MEDICINES MANAGEMENT 
The medicines management processes when patients are transferred between primary 
and secondary care were mapped in the previous section of this chapter. This 
mapping process demonstrates the complexity of medicines management across the 
interface by showing the number of steps and personnel involved to ensure that 
patients can access the medicines they need. In this section problems caused by the 
complexity of, and deficiencies in, the interface medicines management processes 
were determined from the perspective of both health care professionals and patients. 
Interviews with secondary care hospital consultants and pharmacists and primary care 
GPs and community pharmacists provided insight into how health care professionals 
contribute to medicines management processes. In particular, these professionals 
illustrated the importance of communication processes and the quality of information 
transferred across the interface. Health care professionals' perspectives of medicines 
management across the interface are described under the four themes identified in 
Section One of this chapter. 
• Lack of awareness or misunderstanding of policy 
• Inadequate inter- or intra-professional collaboration 
• Impracticable or inflexible policy 
• Flagrant violation of policy 
This section is structured by first considering the views of GPs, then community 
pharmacists, followed by hospital pharmacists and finally hospital consultants. The 
reason for considering primary care health professionals first is that GPs and 
community pharmacists seemed to encounter more medicines management difficulties 
associated with the interface than their hospital colleagues. Conversely, whilst 
hospital practitioners were frustrated by some aspects of the interface medicines 
management processes, these did not seem to impact on them as much in their day-to-
day practice. It was felt most appropriate to start with GPs' perceptions because this 
would uncover the difficulties associated with issuing prescriptions in primary care 
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following discharge of patients from hospital. Although this is not always the case, 
interface medicines management difficulties tend to impact on community 
pharmacists after a prescription has been written by a OP. The findings are illustrated 
with quotations extracted from the focus group and interview transcripts. A 
condensed version of the transcripts is included in Appendix 7. The appendix and 
paragraph number for each quotation are given as a reference in brackets. 
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5.5.1 General practitioners' perspectives of medicines management across the 
interface 
General practitioners' perspectives are presented starting with issues raised within the 
theme 'inadequate inter- or intra-professional collaboration'. This theme is 
considered first as it seemed to be the one causing most difficulties for GPs. 
5.5.1.1 Inadequate inter- or intra-professional collaboration 
General practitioners raised issues relating to the general poor quality of information 
about patients from secondary to primary care and this will be discussed first. What 
emerged from the focus groups was an appreciation of the difficulties that poor 
communication across the interface caused for GPs. General practitioners were 
frustrated, not only by the lack of information about patients, but also the lack of 
involvement in the decision making process when patients were prescribed new or 
unusual medicines. The dilemmas that GPs face through this lack of inter-
professional collaboration will be discussed. 
General practitioners require information about patients' medical conditions and 
ongoing treatment plans in order to continue patient care initiated by hospital 
practitioners. The accuracy and manner in which this is communicated is crucial to 
successful medicines management. General practitioners may express dissatisfaction 
with the quality of information received from hospital practitioners and that often it is 
received too late to be of any benefit. 
It's quite frustrating sometimes that you get patients asking for repeat prescriptions of 
their discharge medications before you've got any notification through of what they 
were discharged on. 
GP 1 (App. 7.1, para. 2) 
General practitioners perceive that delays in information transfer compromise their 
relationships with patients. They feel embarrassed if they do riot have access to 
information about hospital episodes and that patients are not sympathetic to 
inadequacies in transmission of information from hospitals. This is particularly true if 
hospital practitioners lead patients to expect that information will be there at the 
surgery. This demonstrates that hospital doctors and pharmacists may be unaware 
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that patients often present at a primary care surgery or pharmacy before the hospital 
discharge information has been received. 
It is so unrealistic the expectation, 'Oh, go and see your doctor, the letter will be there 
next week'. You feel a real prat sitting there. 
GP 9 CAppo 7.2, para. 104) 
Even when discharge information does arrive in surgeries it is often poorly written. 
There is a perception amongst GPs that hospital doctors give insufficient importance 
to writing discharge summaries with the result that they are of poor quality. General 
practice reception staff may be asked to enter information from hospital discharge 
summaries into patients' records. Therefore, unless information is accurate and clear 
incorrect changes may be made to patients' medicine regimens. 
Poor discharge summaries that are incomplete due to the absence of key decisions and 
explanations may prevent GPs from obtaining a complete picture of what has 
happened to patients during hospital episodes. This makes it difficult for GPs to plan 
ongoing care. 
Even when you get a proper discharge summary, there's often none of the ... thought 
processes, the decision making processes" that have gone on to end up with that list of 
drugs. 
OP 2 (App. 7.1, para. 15) 
In particular, it m~y be unclear whether medicines should be continued long-term. 
Patients are often unsure whether a further supply of medicine is necessary and so 
contact their GPs for advice. General practitioners are sometimes unable to advise 
patients if the information from the hospital is unclear or has not been received. This 
may result in medicines being continued inappropriately in primary care. Also, unlesS 
directions for making planned changes to medicine regimens are added to GP 
computer systems when medicine records are amended, it is unlikely that these will be 
carried out in the future. Therefore, medicines may continue to be prescribed for 
longer than necessary. 
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Sometimes patients have no idea ... and some things that we consider it's obvious they 
are going to want to continue, like aspirin, beta-blockers post-infarct or something. 
Other things may not be so obvious, proton pump inhibitors if they've had a 
gastroscopy ... ... and the patient hasn't been told. 
OP 6 (App. 7.2, para. 24) 
General practitioners expressed irritation when hospital practitioners communicate 
poorly because it means that they waste time looking for information that could easily 
be provided to them. 
Time costs money as well, ......... it's having to scout around to find useful or relevant 
information prior to seeing someone. 
GP 6 (App. 7.2, para. 35) 
So far it has been demonstrated that GPs are dissatisfied with the timing and quality of 
information they receive from their secondary care colleagues. However, the problem 
is more than one of simple communication, the lack of collaboration between 
professionals across the interface poses dilemmas for GPs particularly regarding 
whether they should accept the transfer of clinical responsibility. For example, when 
medicines are used outside the terms of their product licences prescribers take full 
responsibility for any associated adverse outcomes. General practitioners may be 
uncomfortable accepting clinical responsibility for prescribing such medicines if it is 
unclear whether patients are aware of, and willing to accept, the associated risks. In 
the following example the GP is describing her concerns about prescribing hormone 
replacement therapy (HRT) for a woman with breast cancer. Hormone replacement 
therapy is contraindicated for use in women with breast cancer because the oestrogen 
component might accelerate the cancer growth. However, it was unclear in the 
information that the GP received from the hospital doctor whether the patient was 
willing to accept these risks. 
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HRT, treatment of breast cancer ... ... ... ....... If a letter came saying '/ have discussed 
with the patient the pros and cons and whilst it is recognised that ... [there are risks 
associated with the use of HRT in women with breast cancer but the patient is willing 
to accept the risks} " gave you the extra information. 
GP 6 (App. 7.2, para. 98) 
A similar situation may occur if GPs are not aware that the contraindications for a 
particular group of medicines have changed. Beta-blockers were, until recently, 
contraindicated in patients with peripheral vascular disease but current opinion is that 
they may be given to specific groups of patients with this condition. 
We've just had a guy who IS got severe peripheral vascular disease ......... / just felt 
really uncomfortable about putting him on a beta blocker. 
GP 7 (App. 7.2, para. 91) 
The two examples above demonstrate that GPs do not have sufficient information to 
allow them to prescribe confidently. It seems that hospital doctors simply expect GPs 
to prescribe what they have recommended without the need to provide any 
justification for the medicine regimen. Whilst this might be acceptable for medicines 
that are commonly prescribed by GPs it is clear that for medicines used outside their 
licensed indications, or in relatively nove'l situations, further information or discussion 
would be beneficial. The lack of two-way dialogue between GPs and hospital doctors 
across the interface creates difficulties for GPs in assessing whether it is appropriate 
to prescribe a particular medicine. 
Similarly, GPs may also feel uncomfortable prescribing new or uncommon medicines 
they are unfamiliar with. Medicines that are new on the market can be particularly 
problematic for GPs due to the lack of even basic information such as the dose or 
contraindications. This is of concern to OPs because the doctor who signs a 
prescription takes legal responsibility for any adverse outcomes. 
Mibefradil ..... I'd never heard of it, it had only just been launched ......... and yet / 
was, you know, having to take the responsibility for carrying on with the drug. 
OP 4 (App. 7.1, para. 149), 
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General practitioners experience a similar dilemma when asked to prescribe specialist 
medicines which are uncommon in primary care. Requests to prescribe such 
medicines may contain insufficient detail as to the dose, side-effects and monitoring 
requirements to allow OPs to confidently accept clinical responsibility. In the 
example below the hospital consultant expected the OP to prescribe subcutaneous 
methotrexate injections for a child with rheumatoid arthritis. The OP had not 
prescribed this before and the patient had not had methotrexate injections. Therefore, 
the OP was concerned that the patient could have experienced an adverse reaction for 
which she could have been held responsible. As the OP had no previous experience 
of this medicine she was unaware of, and concerned about, the potential problems that 
could arise. 
J've got a girl ...... and she's on subcutaneous methotrexate ...... I've written to the 
professor before now and said, you know, II am worried about this '. .. ....... I gave 
the first injection. 
GP 5 (App. 7.2, para. 243, 262) 
General practitioners have to decide whether to prescribe medicines that they feel 
uncomfortable taking clinical responsibility for. Several factors were raised which 
GPs felt put pressure on them to prescribe medicines when they felt they had 
insufficient knowledge or experience to prescribe safely. The first factor occurs when 
hospital practitioners lead patients to believe that OPs will prescribe specific 
medicines. In such cases there may be no prior consultation with GPs who are left 
unsure whether to prescribe. Without prior consultation GPs are unable to research a 
medicine before patients present requesting prescriptions. Discussing individual cases 
with colleagues helps GPs refuse the pressure to prescribe unfamiliar medicines. 
The patient was rather hoping, he was told, that his GP would be able to prescribe it 
[erythropoietin). And at a practice meeting we decided that this wasn't acceptable. 
OP 3 (App. 7.1, para. 125) 
Another factor which encourages GPs to prescribe medicines despite having clinical 
responsibility concerns is the perception that patients may not be able to access 
medicines through any other route. Whilst secondary care medical consultants may 
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continue to follow up patients at intervals, GPs are expected to undertake almost all 
prescribing. General practitioners comply with requests to prescribe because they feel 
there is no alternative. Patient factors also influenced whether GPs were willing to 
prescribe, for example, if travelling to hospital to obtain medicines would be difficult. 
If I'd have said, 'No we're not doing this' then either she'd have to go to London 
every week to have her injection which clearly is, you know, impossible because she's 
got such disabling disease or she wouldn't have had it. 
GP 5 CAppo 7.2, para. 275) 
There is a feeling that clinical responsibility issues are self-perpetuating because 
although GPs have concerns about prescribing certain medicines there seems to be no 
alternative. 
It leaves a bad taste in everybody's mouth ...... You can't win, you can't establish the 
fact that you are unhappy and reluctant to prescribe and it should be done differently 
because there is no alternative if you don't do it. 
OP 7 CAppo 7.2, para. 76) 
5.5.1.2 Flagrant violation o/policy 
General practitioners' frustrations with hospital professionals' tactics to manage 
secondary care expenditure on medicines and poor management of patients' own 
medicines on admission to hospital are described under this theme. Some of the 
tactics used by hospital staff to manage secondary care medicines expenditure are in 
direct contravention of national guidance on medicines management across the 
interface. These tactics include the use of 'loss leader' medicines which are cheap in 
hospital but expensive when prescribed in primary care, 'cost shifting' the cost of 
expensive medicines from secondary to primary care and giving small supplies of 
medicines following hospital attendance. This is considered to be violation of policy 
because hospital managers, including within pharmacy departments, allow this 
situation to persist despite DoH guidance recommending that the total costs of 
medicines to the NHS (NHS executive, 1994), and not just the costs to secondary 
care, should be taken into account when choosing medicines. Some loss leader 
medicines may have been included on hospital formularies for many years and it 
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seems that there has been a lack of action on the part of hospitals to review the 
medicines included in formularies to ensure that they are cost-effective across whole 
health economies. 
General practitioners were concerned that the choice of medicines within hospitals is 
heavily influenced by the discounts that they are able to negotiate with suppliers and 
the marketing strategies of pharmaceutical companies. This makes particular brands 
of medicines attractive to hospital professionals because they can purchase more 
medicines out of limited budgets. 
One knows full well that it is only done because the hospital are getting it at a real 
knock-down price compared to, you know, general practice. 
GP 7 (App. 7.2, para. 132) 
General practitioners are frustrated with hospital use of loss leaders because it is 
difficult to change patients to cheaper formulations. The result of this is that there is 
an on-going cost to individual GP practices but also to the NHS. 
Half of them we change ......... but a lot of them you just never can so you end up with 
these repeat prescriptions year on year. 
GP 7 (App. 7.2, para. 132) 
General practitioners perceive that cost shifting happens for two reasons. First, the 
enforcement of formularies by hospital pharmacy staff means that hospital doctors 
may only use non-formulary medicines if they ask to GPs to prescribe on their behalf. 
The second reason for cost shifting is to manage hospital prescribing budgets by 
transferring the cost of a medicine from the secondary to the primary care budget. 
The family planning clinic's askingfor the prescription for Mirena because they 
haven't got any funding. 
GP 4 (App. 7.2, para. 217) 
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General practitioners also consider that cost shifting occurs when they are expected to 
prescribe medicines for patients which whom they have no clinical involvement. 
A cystic [fibrosis patient] ...... I never see her from one year's end to the next, but 
every month I get these letters from Dr (name of paediatrician] saying, 'Please will I 
prescribe this, this, this, this, this and this?' It's cost-shifting. 
GP 5 CAppo 7.2, para. 245) 
The letters that GPs receive from hospital medical consultants asking them to 
prescribe medicines do offer GPs a choice. However, in reality GPs are reluctant to 
refuse such requests. 
She'll ask you to provide the prescription, if you are willing, it's not a demand, it's a 
polite request, it's really difficult to turn it down. I haven't felt able to turn it down. 
GP 1 CAppo 7.1, para. 221) 
However, other GPs seem able to confidently decline requests they feel are 
inappropriate. There is a perception that declining inappropriate requests to prescribe 
actually stops hospital medical consultants making similar requests in the future. 
Conversely, there is awareness that complying with inappropriate prescription 
requests perpetuates the problem and repeated requests are received. 
We are all quite happy just to write these prescriptions for things purely to endorse 
them when really we shouldn't be. 
GP 7 CAppo 7.2, para. 192) 
It is not only doctors who ask GPs to prescribe non-formulary medicines. Specialist 
nurses, such as continence advisers, also hold outpatient clinics and write to GPs 
requesting the prescribing of specific medicines. 
She hasn't normally mentioned the name to the patient but she will often put it in the 
letter saying she wants Detrusitol as opposed to what we might start with. 
GP 2 CAppo 7.1, para. 57) 
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General practitioners were aware that patients need to take their medicines into 
hospital with them to aid the drug history taking process. However, they complained 
that not only do hospitals give patients short supplies of medicines on discharge but 
they also do not manage patients' own medicines effectively and so these often 
disappear. This means that GPs have to issue further prescriptions and so 
consequently there is an increased expenditure on primary care prescribing budgets. 
They can go in with a full bottle of aspirin and come out with just days worth. 
GP 2 (App. 7.1, para. 81) 
5.5.1.3 Impracticable or inflexible policy 
General practitioners raised three issues when impracticable or inflexible policy 
adversely impacted on medicines management across the interface. 
• Difficulties in moving money between hospital budgets means that it may be 
easier to transfer the prescribing, and cost, of medicines to primary care rather 
than fund new medicines internally within secondary care. 
• Rigid hospital formularies mean that patients' medicines are often changed simply 
to ensure compliance with hospital formularies rather than for any clinical 
benefits. 
• The short supplies of medicines given to patients on discharge from hospital 
means that patients use up their medicines before GPs have received discharge 
information. 
General practitioners are sometimes frustrated that for some transferred medicines 
there will be a subsequent reduction in other areas of hospital expenditure and that 
funds should be transferred between hospital budgets instead of transferring the cost 
of the prescription to the primary care prescribing budget. The use of Mirena® 
intrauterine devices provides an example of such a situation because use of this device 
should reduce expenditure associated with female sterilisation operations. General 
practitioners felt that funds could be moved between the hospital surgery and 
prescribing budgets to accommodate increased prescribing expenditure. More 
flexibility in managing hospital budgets could perhaps resolve cost shifting issues of 
this type. 
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The cost of a Mirena is going to be cheaper than the sterilisation. If it's a cost issue 
the hospital should be looking at that and changing their budget allowance rather 
than trying to shove it back onto us, 
GP 2 (App, 7,1, para, 226) 
General practitioners experience difficulties when hospital formularies differ from 
their own. This is particularly frustrating ifpatients' medicines are changed on 
hospital admission to a hospital formulary choice. The perception is that continuity is 
disrupted for the sake offitting in with the hospital formulary. General practitioners 
feel that this confuses patients and presents them with a dilemma whether to change 
patients back to the original medicine. Unless there is a clinical reason for changing 
patients' medicines GPs feel that hospitals should maintain patients on their existing 
medicines. 
They go in on, say felodipine, and, because the hospital don't have it in their 
formulary perhaps, they'll come out on a different calcium channel blocker. 
GP 3 (App. 7.1, para. 97) 
Differences between primary and secondary care formularies also cause problems 
when hospital practitioners recommend medicines that are not in GP practice 
formularies. This is particularly difficult'to deal with when patients have been led to 
expect a specific medicine. 
But it is awkward because they've been given the impression that there is something 
else that they could try and if I am going to turn round and say, 'Well, I am sorry this 
is not in the practice formulary' or 'I don't actually want you to have anything 
different' it's quite a difficult situation. 
GP 1 (App. 7.1, para. 60) 
The limited quantities of medicines provided to patients on discharge from hospital or 
following outpatient appointments compounds the problems that GPs have with poor 
collaboration. This is because information about patients is often not received before 
they need a further supply of medicines. 
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Seven day prescribingfrom outpatients is even more irritating than seven day 
prescribingfrom inpatients because there is no way in heaven that you are going to 
get the clinic letter within the time that the patient has been given the tablets to last. 
OP 5 (App. 7.2, para. 44) 
5.5.2 Summary of general practitioners' perspectives of medicines management 
across the interface 
The findings derived from focus group interviews with OPs show that they are 
concerned with three main issues. First, inadequate inter-professional collaboration 
across the interface is frustrating for OPs superficially because communication about 
patients is often of a poor quality or arrives too late to be of any use. This means that 
incorrect changes may be made to patients' medicine regimens, OPs waste time trying 
to find out information and their ability to plan ongoing care for patients is limited. 
However, when this issue is considered more deeply it appears that inadequate inter-
professional collaboration creates larger dilemmas for GPs. Lack of involvement in 
the decision making processes when patients are prescribed medicines leaves GPs 
uncertain about whether they should take over prescribing, and therefore clinical, 
responsibility. This dilemma is further complicated by GPs' concerns that patients 
may not easily obtain their medicines any other way. 
Second, the violation of policy regarding medicines management across the interface, 
particularly concerning how hospital professionals manage their budgets, means that 
there is an increased expenditure on medicines in primary care. General practitioners 
frustrations about this relate to the difficulties that they have changing patients to 
more cost-effective medicines or having to reissue prescriptions for patients' 
medicines which have been lost during inpatient hospital stays. 
Finally, OPs raised problems associated with inflexible or impracticable medicines 
management policies within secondary care. In particular rigid application of hospital 
budgets means that hospital doctors may sometimes only obtain the medicines 
patients need by transferring the responsibility for prescribing, and hence the cost, to 
GPs. General practitioners feel that the needs of patients are sometimes over-ridden 
by the need to manage hospital budgets, for example by changing patients' medicines 
to hospital formulary choices and giving small supplies of medicines to patients even 
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though this means that they may run out before GPs have received discharge 
summaries. In the next section the perspectives of community pharmacists will be 
considered. 
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5.5.3 Community pharmacists' perspectives of medicines management across the 
interrace 
Community pharmacists' perspectives are considered under the same four themes as 
GPs' perspectives. 
• Lack of awareness or misunderstanding of policy 
• Inadequate inter- or intra-professional collaboration 
• Impracticable or inflexible policy 
• Flagrant violation of policy 
Inadequate inter- or intra-professional collaboration will be considered first because 
the community pharmacists highlighted this as being particularly problematic. 
5.5.3.1 Inadequate inter- or intra- professional collaboration 
Community pharmacists are relatively isolated from other health care professionals, 
both within primary care and across the interface, which means that issues relating to 
access to information about patients are particularly pertinent to them. Community 
pharmacists obtain the majority of information about patients from GP prescriptions 
or through talking to patients or carers. Even when dealing with surgeries, contacts 
are normally with receptionists rather than GPs. Community pharmacists may prefer 
to work with practice receptionists if they think GPs are too busy to deal with their 
queries or not interested in queries from pharmacists. 
We found it was a waste of time trying to contact any doctors .................... " 
whereas if you could get the receptionist who normally churns out the prescriptions, if 
you can get her on side ... 
CP 3 (App. 7.3, para. 70) 
Community pharmacists, because they work within primary care, will naturally more 
easily be able to get in touch with GPs. Therefore, queries with prescriptions 
originating from hospital doctors are usually clarified by speaking to GPs. However, 
community pharmacists feel that GPs are sometimes unwilling to accept advice from 
them if it contradicts advice given by a hospital doctor. Community pharmacists may 
therefore feel that OP colleagues undervalue their contribution to patient care. 
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The number of times that I've had a prescription ... ... straight from the GP and 
you've looked at it and looked at their past records and realised that there's a 
contraindication or an interaction ... and you ring up the GP , Oh yes, it's initiated 
by the hospital, it's got to be alright '. 
CP 5 (App. 7.4, para. 127) 
The most conscientious of community pharmacists take a lot of trouble to contract 
secondary care prescribers in order to prevent medication errors reaching patients. 
I got a prescription for what was an overdose so I went back to the GP and the GP 
said ' Oh that's what the hospital said' so I was so unhappy about it I actually 
managed to get hold of the hospital and check the dose with them ............ I felt like I 
was going over the GP's head. 
CP 7 (App. 7.4, para 149) 
In so doing, community pharmacists may feel that they are damaging relations with 
local GPs. This may deter community pharmacists from contacting GPs to discuss 
medicines issues especially when they are not party to a full medical history. 
That's the problem. It's all tied in with communication. Are we confident enough to 
challenge the GP with that prescribing? And unfortunately we're not because we 
don't have the whole picture and that's why we find it very diffiCUlt to challenge the 
GP. 
CP 6 (App. 7.4, para. 343) 
Community pharmacists feel that their time is wasted searching for information about 
patients or trying to resolve issues. Lack of information about patients causes 
difficulties when community pharmacists find discrepancies between the medicines 
patients were taking when discharged from hospital compared with the medicines they 
were previously taking. It is difficult for community pharmacists to resolve these 
issues because of the paucity of information they have about patients. 
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One thing she was on was lithium, the Camcolit brand ......... She was admitted to 
hospital, when she came out a week later it had been swapped to Priadel but nobody 
seemed to know why. And then it was left to me. 
CP 3 (App. 7.3, para. 74) 
Another activity that takes up community pharmacists' time is the procurement of 
unusual items, particularly 'specials'. There is a perception amongst community 
pharmacists that information about specials suppliers could easily be provided 
proactively by hospitals. 
It was a 'special' antibiotic mixture for eye drops, A & E didn't issue a prescription 
presumably because the pharmacy was shut, they'd been told to go to the GP to get 
this prescription written up ........ and I said I'd have to order it specially made. Of 
course then Ifound out that it's actually a special that the [name of hospital] keep in. 
CP 5 (App. 7.4, para. 168) 
In addition to the time wasted resolving prescription queries there are also financial 
consequences for community pharmacists resulting from poor collaboration across the 
interface. This is because the remuneration framework for dispensing NHS 
prescriptions does not reimburse community pharmacists for expenses incurred on 
prescription interventions through telephone calls to GPs or postage charges when 
prescriptions are returned to GPs for amendments. The opinion of community 
pharmacists is that the current level of dispensing remuneration is insufficient to cover 
the time, telephone calls and stamps used when making prescription interventions. 
I think they don't realise the time it takes, in community 'phone calls cost as well and 
it's, if you 'phone from a GP 's practice the health authority pay for it. Ifwe 'phone it 
comes from our bills. 
CP 6 (App. 7.4, para. 158) 
Along with community pharmacists' frustrations about the financial consequences of 
poor communication there are potentially serious consequences for patient care. In 
particular community pharmacists may be unaware of patients' complete medicine 
regimens if some medicines are being supplied by hospital pharmacies. 
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She's also on azathioprine that for some reason she has to get from the hospital 
......... if the parent hadn't told me I wouldn't even know that she was on azathioprine 
......... '" I do find that disturbing. I mean for something like azathioprine I really 
think I ought to know that a six year old child is on it. Definitely. 
CP 2 CAppo 7.3, para. 77) 
Unless community pharmacists practise good pharmaceutical care and talk to patients 
they may not be aware of complete medicine regimens. This means that interacting 
medicines could be inadvertently dispensed. This is potentially dangerous for certain 
combinations of medicines. 
Lack of collaboration with other health care professionals in primary care and across 
the interface may leave community pharmacists relatively isolated, resulting in their 
inability to properly carry out the following aspects of their professional role. 
• Advising patients how to take their medicines 
• Ensuring that patients are able to maintain a continuous supply of medicines 
• Helping patients to be compliant with their medicine regimens 
Despite community pharmacists' perceptions that OPs do not find their input 
necessary or useful, patients clearly hold a different view. Patients ask community 
phannacists for advice about which medicines they should take or why particular 
medicines have been started. Community pharmacists may find it difficult to help 
such patients if they do not have sufficient information about patients discharged from 
hospital. 
The patient was at home at this stage .......... the husband was really in a frenzy 
because he didn't know what to do. He came to our door wanting help. 
CP 6 (App. 7.4, para. 209) 
Community pharmacists provide a role as an advocate for patients and the holistic 
knowledge that they gain about patients' social circumstances helps them to 
understand how patients cope with their medicines in their home environments. This 
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means that they are in a good position to advise on ways of modifying medicine 
regimens to make them easier for patients to manage. 
I think perhaps [hospital medical consultants] don't see the problems that families 
have to cope with at home. 
CP 2 (App. 7.3, para. 153) 
However, the knowledge that community pharmacists have about how patients 
manage their medicines is not currently utilised and so patients may be prescribed 
medicines that they have difficulty taking. Community pharmacists also feel that 
some solutions to medicines management problems devised in secondary care are 
unworkable in primary care. Formulations were felt to be inappropriate for 
dispensing in primary care if the constituents were not stocked in community 
pharmacies or required complicated manipulation of ingredients. Involving 
community pharmacists when solutions are being devised could prevent this 
happening. 
The biggest 'faj!, was she was on omeprazole 10 dissolved in two and a half mls of 
sodium bicarbonate 8.4% solution. So I rang up and said 'How are you making 
this? ' 
CP 1 (App. 7.3, para. 154) 
Another area where community pharmacists have a holistic view of patients is related 
to their compliance difficulties. Community pharmacists are frustrated that hospital 
staff do not seem to take compliance into account when changing medicine regimens. 
This particularly seems to be a problem with patients whose medicines are packaged 
in monitored dosage systems (MDS) to overcome compliance difficulties. Patients 
using MDS whilst at home may be discharged from hospital with their tablets 
dispensed in standard packaging. 
I've got one chap that comes in quite regularly, he'll then come out [from hospital] 
with his 28 days supply, he doesn't read and he won't take anything unless it's in a 
compliance aid so, you know, usually all this gets wasted. 
CP 2 (App. 7.3, para. 10) 
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Some community pharmacists have similar concerns to OPs about their liability for 
dispensing unfamiliar medicines or those used outside their licensed indications. 
Dilemmas are sometimes raised between the potential of a medicine to cause serious 
adverse effects and the fact that patients can gain real clinical benefits. 
We have a very young child with GORD [gastro-oesophageal reflux disease}, who's 
on ... cisapride and because we've had that letter come round from the CSM 
[Committee on Safety of Medicines} ......... I do wish they'd go somewhere else ..... I 
really feel awkward about it ........ , I really feel I should say something but I could 
destroy the trust that the patient has with the consultant because the child is so much 
better at the moment. 
CP 1 (App. 7.3, para. 204) 
This particular community pharmacist was uncomfortable because she was aware of 
the risks associated with cisapride but did not seem confident to raise her concerns 
with the patient's OP. However, this may not be a common predicament because 
community pharmacists feel that because of the lack of information they have about 
patients they can do little more than dispense medicines as they are prescribed. 
I suppose that does make it a sort of ethical issue but legally it's not an issue because 
the doctor has signed to say that he is happy to give that and I think..... as long as 
we are happy that the dose is correct for that person, it isn't going to do them any 
harm, then I think that's all we can do with the information that we know at present. 
CP 4 (App. 7.4, para. 342) 
Even with unlicensed medicines community pharmacists feel that the responsibility 
would lie with the prescribing OP should something go wrong and so are not overly 
worried about the clinical responsibility aspects of dispensing. This was particularly 
true if there was a history of usage for a particular indication and if there had not been 
any specific warnings about its use. This may reflect a misunderstanding of the 
responsibilities associated with dispensing prescriptions. In the following example 
the community pharmacist is talking about the use of doxycycline for malaria 
prophylaxis. 
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.... there's a recommendation for [doxycycline for malaria prophylaxis 1 '" and [the 
BNFJ says it's unlicensed for that recommendation so it's acceptable to do it. 
Providing the doctor has signed the prescription and therefore he's taking the clinical 
responsibility. 
CP 5 (App. 7.4, para. 340) 
Community pharmacists' concerns about unusual medicines were allayed if they 
knew that there had been no specific warnings about their use, for example from the 
Committee on Safety of Medicines. Community pharmacists also consider that they 
do not have the time to get deeply involved in questioning whether medicines are 
being prescribed appropriately. Some community pharmacists consider that this is not 
Part of their role. 
Like everyone else we have limited time . ...... Now to myself, finding out whether 
someone's being monitored on something, unfortunately is not a priority ... ..... the 
actual monitoring etcetera would be down to the GP and the consultant. 
CP 4 (App. 7.4, para. 439) 
Lack of time is one explanation why community pharmacists do not intervene on 
prescriptions despite being aware that particular medicines require monitoring to 
ensure patient safety. However, a lack of clinical information about patients also 
makes it difficult for community pharmacists to develop a more clinical role and 
become more involved in monitoring outcomes, both beneficial and harmful, to 
medicines. 
This is taking clinical pharmacy into the community but we actually haven't been 
given the responsibility to do it. You know if someone comes in and they take 
allopurinol, do we ring up the GP 'Have you done a creatinine clearance?' You 
know, 'Have you adjusted the dose?' you know, how far do you take it? 
CP 6 (App. 7.4, para. 442) 
This role dilemma is also raised in the following example when a pharmacist 
demonstrated her lack of confidence with recommending changes to a prescription 
despite the fact that the current prescription was not optimal for the patient. 
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I was in the back of my mind thinking, 'Oh, if this change is made on my insistence " 
you know, you've got to carry the can and pharmacists ...... aren't used to carrying 
the can for that extent. 
CP 2 (App. 7.3, para. 156) 
5.5.3.2 Flagrant violation of policy 
Previously it has been highlighted how GPs are frustrated when patients' own 
medicines are not returned on discharge from hospital. This is because it wastes NHS 
resources and GPs' time when they have to issue further prescriptions. The 
mismanagement of patients' own medicines also impacts on community pharmacists 
particularly if medicines are dispensed in monitored dosage systems. This is because 
pharmacists purchase MDS packaging which has to be replaced at the pharmacists' 
expense if it goes missing whilst patients are in hospital. Pharmacists find it difficult 
to keep track of MDS packs particularly because hospital policies on the reuse of 
patients' own medicines encourage patients to bring their own medicines into hospital 
with them. These policies include the ambulance service and so ambulance staff are 
instructed to collect patients' own medicines when picking up patients. 
I've told my nursing homes that they're not to hand anything over to the ambulance 
drivers ......... I basically said, 'It's my property' ...... as far as I am concerned it is 
my property. It does not go in the ambulance. 
CP 4 (App. 7.4, para. 287) 
However, hospital professionals may experience difficulties in obtaining accurate 
medicine histories if patients are prevented by community pharmacists from taking 
their medicines into hospital with them. 
Although recommendations from hospital doctors to GPs to prescribe non-formulary 
medicines do not impact on community pharmacists directly they were aware that this 
might pose a dilemma for GPs. This supports what GPs said about the difficulty they 
had changing hospital doctors' recommendations especially when patients had been 
led to expect a particular medicine. 
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GPs can be very reluctant to change hospital's recommendations, very reluctant. You 
know when one does for good reason you really do feel like applauding them. 
CP 2 CAppo 7.3, para. 209) 
It is not part of the community pharmacists' role to enforce formulary compliance. 
The result of this is that GPs often prescribe non-formulary medicines requested by 
hospital practitioners who choose not to adhere to formularies. This is because, 
although community pharmacists may be aware that a medicine prescribed by a GP is 
not included in a formulary, they have contractual obligations to dispense what is 
requested. In the long term this means that it is difficult to manage medicines 
expenditure across primary and secondary care because formulary enforcement is 
incomplete. 
Ethically what do we do? ...... it's not blacklisted so we can't refuse it. 
CP 6 CAppo 7.4, para. 420) 
5.5.3.3 Impracticable or inflexible policy 
The different cost containment policies operational in primary and secondary care 
cause problems for community pharmacists when patients are discharged from 
hospital. Within primary care pharmacists are only reimbursed for appliances, such as 
dressings, that are included in the Drug Tariff. This effectively restricts the use of 
expensive products in primary care but is not applicable in secondary care. Patients 
are sometimes initiated on items in hospital which are not included in the Drug Tariff. 
If GPs are not aware of Drug Tariff exclusions they may issue prescriptions that 
community pharmacists are unable to dispense. Community pharmacists are then left 
to explain to patients why certain items cannot be dispensed in primary care. 
You could expand the dressings to include all non-drug tariff lines because hospitals 
..... might use things that are blacklisted and it can leave you in a situation when the 
patient doesn't understand why they have to get it from the hospital. 
CP 1 CAppo 7.3, para. 194) 
Restrictive budgets for ward stocks means that hospital practitioners are reluctant to 
supply items to discharged patients and may insist that the items are provided in 
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primary care. This may leave patients in a situation where it is impossible to obtain 
the items they need for their care. Again community pharmacists may be left to 
resolve the issue. 
We had a child on Hickman line chemotherapy transferred to do five days at home 
..... this fraught, frantic district nurse comes running in wanting Opsite Veneguard 
dressings and I said, 'Well you won't get them on an FP 10' and the ward that had 
discharged the child to go home for a home visit said 'No, no, we can't give you those 
out of our budget. Get the doctor to prescribe them.' So we were trapped in this 
loop. 
CP 1 (App. 7.3, para. 76) 
5.5.3.4 Lack o/awareness /misunderstanding o/policy 
Community pharmacists appreciate that NHS resources are wasted through the use of 
expensive branded medicines in primary care when cheaper generic medicines could 
be used with equal effect. This is more of a frustration than a problem for community 
pharmacists because it does not directly impact on them financially. The substitution 
of prescriptions written for branded medicines with generic medicines is encouraged 
in hospital pharmacy departments. Conversely, community pharmacists are legally 
obliged to dispense the exact brand of medicines prescribed. 
A branded prescription that's written in GP land will be, the patient will be issued 
with Tenormin ifTenormin is written, whereas in hospital the registrar can write a 
brand product but whatever's kept in the pharmacy gets given. 
CP 6 (App. 7.4, para. 26) 
Again, this means that there may be increased expenditure in primary care if 
proprietary medicines are written on discharge summaries and these are transcribed to 
patients' primary care records without changing to the generic equivalent. 
172 
5.5.4 Summary of community pharmacists' perspectives of medicines 
management across the interface 
Many of the problems that community pharmacists experience when patients have 
been in contact with hospital services can be traced back to their relative isolation 
from other health care professionals within both primary and secondary care. Even in 
primary care they deal mainly with receptionists rather than GPs and so it is clear that 
they are not yet fully integrated members of the primary health care team. The lack of 
inter- and intra-professional collaboration limits the ability of community pharmacists 
to fully undertake their role particularly with respect to reducing medication errors 
and helping patients to take their medicines. However, it also means that the 
knowledge that community pharmacists have about how patients manage their 
medicines within their own homes is not utilised. 
Under the theme 'flagrant violation of policy' community pharmacists were 
concerned about the inability of hospital staff to manage patients' own medicines 
brought into hospital. This was because ofthe financial impact to community 
pharmacists of having to replace monitored dosage packaging not returned to patients 
on hospital discharge. However, they also highlighted the difficulties in primary care 
of enforcing formulary compliance, with the possibility for increased medicines 
expenditure, because hospital professionals may ask GPs to prescribe non-formulary 
medicines and it is not within the remit of community pharmacists to question this. 
Differences in medicines policies between primary and secondary care, such as the 
NHs blacklist, creates problems for community pharmacists in explaining why 
medicines or appliances prescribed in hospital cannot be dispensed in primary care. 
Additionally the contractual obligation on community pharmacists to dispense 
prescriptions exactly as written can have an adverse impact on medicines expenditure 
if expensive proprietary medicines are prescribed. In the next section the perspectives 
of hospital pharmacists will be considered. 
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5.5.5 Hospital pharmacists' perspectives of medicines management across the 
interface 
In this section the perceptions of hospital pharmacists of poor inter- and intra-
professional collaboration will be considered. Hospital pharmacists highlighted the 
difficulties this creates when taking drug histories from patients and they also provide 
some insight into the reasons why they fail to collaborate with their community 
colleagues. Hospital pharmacists perceive that different policies across the interface 
may contribute to medicines management problems either through a lack of awareness 
of policies or a will on the part of health care professionals to intentionally violate 
them. 
5.5.5.1 Inadequate inter- or intra-professional collaboration 
Hospital pharmacists experience difficulties determining patients' correct medicine 
regimens because of poor information from primary care. These difficulties are 
compounded if patients do not bring their own medicines into hospital with them. 
Sometimes the medicines patients are actually taking are different to those included in 
the information provided by OPs. This could have serious consequences for patient 
safety if a vital medicine is missed when a drug history is being taken, particularly if 
the patient is unconscious and so unable to provide details of medicines, as in the 
example below relating to corticosteroids. 
They're as flat as a pancake and they're on steroids or something and they [the 
medicines} go missingfor days ... patients should register with a community 
pharmacist in the same way as they do with GPs and so you've got someone to refer 
to so you've got an up-to-date list. 
HP 11 (App. 7.6, para. 124) 
Hospital pharmacists are also concerned about poor handwriting on OP admission 
letters. Again this can have serious consequences for patients if the information is 
misread and incorrect medicines prescribed for patients. 
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Very inadequate GP letters. That example of, was it thyroxine? That looked like 
something totally different and so for days [the patient] got [a different medicine] 
because it looked like that and we had no way of checking their drugs over the 
weekend. 
HP 13 CAppo 7.6, para. 111) 
Hospital phannacists use patient's own medicines as an aid to the drug history taking 
process. However, these are of limited use if there are no specific directions for the 
dose and frequency on the medicine container. During the drug history taking process 
hospital pharmacists sometimes find discrepancies between what GPs thought patients 
were taking and the medicines patients said they were taking. 
Sometimes the prescription that the doctor writes bears absolutely no resemblance to 
what the patient ...... is actually doing. 
HP 7 CAppo 7.5, para. 88) 
Hospital pharmacists identified similar problems to those raised by community 
phannacists in contacting GPs. This creates difficulties for hospital pharmacists when 
trying to check patients' medicine regimens. Firstly, they experience problems 
accessing GPs because surgery opening hours are different to hospital pharmacy 
opening times. Secondly, they perceive that receptionists act as a barrier to speaking 
directly with GPs. 
Very frequently the receptionist won't actually let you speak to the GP. 
HP 6 CAppo 7.5, para. 280) 
Even when hospital phannacists do manage to speak to someone at a surgery, usually 
a receptionist, they are uncertain as to the accuracy of the infonnation given. 
However, unlike their community colleagues, hospital pharmacists are not always 
satisfied discussing medicines issues with unqualified receptionists. They have 
developed tactics to ensure that receptionists allow them to speak to GPs directly. 
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What I've found is totally bamboozle them with something ..... and you make it sound 
so technical that they say, 'Oh, I'll put you through to the doctor '. 
HP 10 (App. 7.5, para. 281) 
Hospital pharmacists appreciate that community pharmacists are more accessible than 
GPs. However, two issues deter them from communicating directly with community 
pharmacists. First, they have difficulties identifying the community pharmacists that 
individual patients use. Second, hospital pharmacists perceive that patients do not 
generally use a single pharmacy. 
I'm having problems getting hold of community chemists and find out which chemist 
they are to direct the information to. 
HP 13 (App. 7.6, para 157) 
Hospital pharmacists appreciate that poor communication from secondary to primary 
care may cause problems when patients need changes to their medicine regimens 
following hospital discharge. Medicines requiring dose reduction after a period of 
time, for example proton pump inhibitors, may not be reviewed. It is felt that this is 
due to a lack of information in discharge communications specifying when dose 
changes should be undertaken. Whilst maintaining patients on high doses of PPIs has 
cost implications it is probably not detrimental to patients. However, hospital 
pharmacists are also concerned that failing to increase the dose of certain medicines 
might actually be detrimental to patient care through not achieving a clinically 
therapeutic dose. 
There's no communication one way or the other as to what the long-term plan is 
................... things lilce ACE inhibitors and statins, is there really any intention to 
increase the dose? Is there any intention with H2 antagonists or with PPIs to actually 
reduce the dose when the patient is controlled? .... ........... so we end up with people 
on ACE inhibitors who are on low doses and never actually achieve a clinically 
Significant dose. 
HP 9 (App. 7.5, para. 227) 
176 
Whilst communication about patients' medicines across the interface is not solely the 
responsibility of hospital pharmacists, they provided some insight into why 
communication between hospital and community pharmacists is so poor. Firstly, 
hospital pharmacists feel that the need to discharge patients rapidly, particularly 
during times when there are bed shortages, impacts on the quality of the discharge 
process. Sometimes it is impossible to counsel patients about their medicines before 
hospital discharge due to workload or time constraints. In addition to these concerns 
they also acknowledge that on particular wards pharmacists never see patients who 
are admitted and discharged quickly. Some wards keep 'pre-packed' medicines, 
ready labelled for discharge, which are supplied by nurses and so there is no need for 
prescriptions to be dispensed by the pharmacy department. This limits the ability of 
hospital pharmacists to intervene and perhaps initiate communication with primary 
care. 
The discharge .... you know it wasn't planned, there's a bed crisis and you go up the 
next day and they've gone, so you've never even had the opportunity to intervene. 
HP 6 (App. 7.5, para. 249) 
Hospital pharmacists claim they do communicate with community pharmacists, 
although they often use patients as messengers. However, the lack of triggers to 
prompt communication with community pharmacists means that this often does not 
happen. This is because many of the medicines that community pharmacists might 
experience difficulties obtaining are readily available in hospital pharmacies rather 
than having to be specially ordered. This is particularly a problem for medicines that 
have a long lag time between ordering and supply. If community pharmacists are 
given insufficient notice of unusual medicines that patients need then they may not be 
able to obtain them before the hospital discharge supply runs out. This can lead to 
discontinuities of patients' medicines supplies. 
1 think we're very good at thinking about it if it's obvious, like we've stood there 
crushing the tablets down but if it comes in a box or is in blister packs I think we just 
tend to assume that [the community pharmacist] will get hold of it. 
HP 13 (App. 7.6, para. 64) 
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Another factor which seems to prevent the transfer of information from hospital to 
community pharmacists is a lack of awareness of what community pharmacists need 
to know. 
We kind of need more information from them to know what they need to know about. 
HP 16 (App. 7.6, para. 249) 
Hospital pharmacists feel that community pharmacists should enforce formulary 
adherence in the way that they do. They feel this would be advantageous to 
community pharmacists through reducing stocks of medicines. However, this perhaps 
demonstrates a lack of insight on the part of hospital pharmacists of their community 
colleagues' role and that formulary enforcement is a task that they are not neither 
remunerated for, nor really permitted to do, under their terms of service. 
I think community pharmacists should try and enforce it more. I think that should be 
part of their role. But then they could keep a narrower number of drugs couldn't 
they, they wouldn't have to keep all these hundreds of obscure things that keep going 
out of date and throwing them away. 
HP 11 (App. 7.6, para. 285) 
5.5.5.2 Impracticable or inflexible policy 
The ideal situation, and the one specified in hospital discharge policies, is that 
discharge planning should start on the day a patient is admitted to hospital and is a 
continuing process throughout the hospital stay. However, hospital pharmacists felt 
that some aspects of discharge policy were impracticable and were not always 
followed particularly if there was a shortage of beds for new patients within the 
hospital. Ordering discharge medicines could either be forgotten in the rush to 
discharge patients or patients were discharged without the pharmacy department being 
notified. 
It's haphazard isn 't it? If [the medicines are] coming from the ward it's the last 
thing on their mind to get them out, and they suddenly realise that the ambulance is 
on its way and they go 'Erh, we need medicines '. 
HP 13 (App. 7.6, para. 23) 
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Hospital pharmacists said that they tried to counsel patients about their medicines 
before they were discharged from hospital but sometimes this proved impossible due 
to workload or time constraints. 
In an ideal world it would be nice to think all that way ahead but you've just got so 
many patients that it's difficult to do. 
HP 1 CAppo 7.5, para. 248) 
The need to discharge patients with a specific quantity of medicines was 
impracticable for patients who used monitored dosage systems to help them manage 
their medicines. This poses a dilemma for hospital pharmacists whether to adhere to 
the policy and supply fourteen days worth of medicines or to supply no medicines 
because they knew that patients would not be able to take them unless they were 
packaged in a monitored dosage system. 
You can supply the medicines but .......... there's no point in us giving boxes and 
bottles because they can't really use them. 
HP 2 CAppo 7.5, para. 106) 
5.5.5.3 Flagrant violation o/policy 
Hospital pharmacists were aware that enforcing compliance with a medicine 
formulary was hindered because of a loophole in the system for the managed entry of 
new medicines whereby hospital doctors can ask GPs to prescribe non-formulary 
medicines. 
There's the other issue of hospital doctors thinking they can get round the formulary 
by saying that the GP can prescribe a non{ormulary drug when in actual fact they 
shouldn't. 
HP 16 CAppo 7.6, para. 455) 
Hospital pharmacists may attempt to educate hospital doctors but they are unable to 
stop hospital doctors asking GPs to prescribe non-formulary medicines. Hospital 
doctors may have good reasons for choosing non-formulary medicines, although it 
may be contentious whether the benefits are perceived or true clinical benefits. For 
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medicines considered by Drug and Therapeutics Committees these potential benefits 
over existing medicines should have been taken into account. 
I said to him [hospital doctor], 'You know we use this instead' and he said, 'Oh well, 
just tell the patient, give the patient a note and send them to their GP and tell them 
that this is what I want them to prescribe' 
HP 16 (App. 7.6, para. 226) 
However, it is not only hospital doctors who flaunt policies relating to non-formulary 
medicines, hospital pharmacists seem to do this too. In particular hospital 
pharmacists experienced problems when patients were admitted on non-formulary 
medicines. They were left in a dilemma whether to recommend an alternative 
medicine or to purchase a supply of the non-formulary medicine. This was a problem 
particularly if the medicine was new and either had not been considered by the Drug 
and Therapeutics Committee or had been considered and rejected. 
I think you make a value judgement as to the medication and as I say if it was blood 
pressure or depression, something serious then I think we would make every attempt 
to continue it. But if it was something say for symptomatic relief .... then we would 
probably change them. 
HP 6 (App. 7.5, para. 122) 
This also demonstrates that hospital pharmacists interpret hospital policy and make 
decisions whether it is applicable in a particular situation. Similarly, if patients 
continue on their own non-formulary medicines hospital pharmacists may make the 
decision to discharge patients on less than the agreed quantity of medicines. This is 
perhaps because it is easier to do this than to go through a complex process in order to 
purchase a non-formulary medicine. It appears that hospital medicines management 
policies give greater emphasis to controlling secondary care expenditure on medicines 
than ensuring seamless care for patients. 
Most of the patients are alright if you explain that it's something that we don't keep 
routinely and if they have got a means of getting more when they get back home. 
HP 9 (App. 7.5, para. 126) 
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It has already been discussed how hospital pharmacists feel that the pressure to 
discharge patients sometimes results in patients being discharged before anyone has 
had the time to counsel them fully about their medicines. Hospital pharmacists also 
felt that in the rush to discharge patients ward staff might decide to discharge patients 
from hospital with less than the agreed quantity of medicines. This then means that 
patients will need to obtain a further supply from their GPs more quickly than if the 
specified quantity of medicines had been supplied. 
Depending on their need for the bed they may discharge them with less than the 
optimum amount (of medicines] if there 's a bed crisis. 
HP 6 CAppo 7.5, para. 60) 
Hospital pharmacists also perceived that GPs sometimes violate policies when they 
refuse to prescribe medicines under the pretext of being unable to take clinical 
responsibility when the real issue is one of cost. 
The GP yeah, they pass it off as, '/ don't know enough about this drug or this 
condition, we'd sooner have the hospital at least get people started on it' but there is 
an element of it's an expensive product and they don't want it on their budget. 
HP 9 CAppo 7.5, para. 212) 
5.5.5.4 Lack o/awareness or misunderstanding o/policy 
Hospital pharmacists expressed different views about whether hospitals should be 
restricted to using only medicines and appliances that are available in the community. 
Hospital pharmacists did not seem to be particularly aware of what was included in 
the Drug Tariff and therefore which medicines or appliances could not be dispensed in 
primary care. 
I'm not aware really a/what'S not on the Drug Tariff. 
HP I CAppo 7.5, para. 257) 
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5.5.6 Summary of hospital pharmacists' perspectives of medicines management 
across the interface 
Poor collaboration between health care professionals across the interface causes 
difficulties when hospital pharmacists try to determine patients' drug histories and 
may result in patients being prescribed incorrect medicines. Similarly, poor 
collaboration when patients are discharged from hospital may result in medicine doses 
not being optimised in primary care. A lack of triggers to prompt communication 
explains why hospital pharmacists do not liaise with their community pharmacist 
colleagues when patients are prescribed unusual medicines. Whilst hospital 
pharmacists do intervene when hospital doctors prescribe non-formulary medicines 
they are often powerless to stop hospital doctors asking GPs to prescribe non-
formulary medicines. This helps to explain why enforcing formulary adherence is 
difficult. However, the hospital pharmacists felt that community pharmacists should 
intervene to enforce formulary compliance which reflects a lack of understanding of 
the role of community pharmacists. Hospital pharmacists also seem unaware of the 
different policies under which community pharmacists operate, such as the NHS 
blacklist, which also may prevent them intervening when patients are discharged from 
hospital on medicines or appliances which cannot be dispensed in primary care. 
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5.5.7 Hospital medical consultants' perspectives of medicines management across 
the interface 
Hospital medical consultants' perspectives of medicines management across the 
interface are described under the same four themes as the other groups of health care 
professionals. Hospital medical consultants also provide some insight into why 
information on discharge summaries is poor as well as describing the difficulties they 
experience with poor information from primary care. They describe how they decide 
how much information to provide to GPs when prescribing responsibility is 
transferred. Difficulties created by impracticable or inflexible policies, particularly 
regarding processes for the managed entry of new medicines, and the limitations put 
on medicines quantities that may be prescribed are discussed. 
5.5.7.1 Inadequate inter- or intra-professional collaboration 
Hospital medical consultants were concerned about the poor quality of information 
provided by GPs when patients are admitted or referred to hospital. In their opinion, 
admission letters often do not contain sufficient information about why patients are 
referred to hospital. Therefore, hospital medical consultants are unaware of what 
treatments have been tried in primary care. It has already been explained that hospital 
pharmacists do not always trust information provided by GP receptionists. Similarly, 
hospital consultants check information provided by GPs to ensure it is accurate. 
I think the standard of information in lots of referral letters in primary care is not 
high ...... I'd say probably 50% o/referralletters don't contain adequate information 
about why the patient has been referred or about specifics with regard to the drugs 
that they 're taking. 
HC 2 (App. 7.8, para. 59) 
Hospital medical consultants perceive that GPs are unaware of the information that 
should be included in referral letters. Some referral letters contain too much detail 
which hospital medical consultants will find out themselves during the history taking 
process. Conversely some vital information is missed such as how patients cope at 
home and whether they have support from carers. 
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Particularly psychosocial information's often left out of the GP's letter because that 
very much helps to put the patient in their context. 
HC 2 CAppo 7.8, para. 14) 
Whilst hospital medical consultants are irritated by poor communication they do not 
seem overly concerned with this. Their main frustration, similar to other health care 
professionals, is that time is wasted time trying to find information that could easily 
have been provided for them. 
It wastes my time but, in a busy clinic you can more usefully spend your time doing 
something other than trying to dig out the details of what it might be relatively easy to 
provide anyway. 
HC 2 CAppo 7.8, para. 61) 
Hospital medical consultants provided insight into why communication from hospital 
to primary care was so poor. Hospital medical consultants consider both the type of 
medicine and the individual OP when deciding when to transfer prescribing 
responsibility and what information to provide. Less information is sent for well" 
established medicines than for newer medicines. This decision is also influenced by 
consultants' previous experiences of patient transfers to individual OPs. 
It depends on the drug, ...... Ifeel that most GPs are unlikely to befamiliar with 
leflunomide so I'd probably do the initial prescribing ... GPs are more likely to be 
familiar with, for example, methotrexate, so I would often ask the GP to prescribe 
methotrexate. Although that would depend on the GP as well, I mean I know that 
some GPs would be very happy with that .... and other GPs would be less happy so 
that would depend on personal knowledge. 
He 2 CAppo 7.8, para. 26) 
Hospital medical consultants feel that the quality of information sent by hospital 
doctors to GPs is influenced by the fact that junior medical staff are usually 
responsible for preparing discharge summaries and they might not be fully aware of 
what has actually happened to patients. There is also a feeling that because junior 
doctors move around different hospitals they do not have to deal with the 
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consequences of their own poor communication so there is less incentive to get it 
right. 
You know a lot of the time some of the junior staff have only got a rough idea ofwhat 
the admission's all about. .. ..... they don't have this feeling of responsibility, you 
know, they've dealt with the acute episode and their responsibility ends there ... if this 
doesn't work out well for the patient then they, you know, 'It's not my problem, it's 
going to be someone else's problem '. 
He 1 (App. 7.7, para. 24) 
Similar to hospital pharmacists, hospital medical consultants seem not to have clinical 
responsibility issues of their own. However, hospital medical consultants do have 
views why GPs sometimes refuse to prescribe certain medicines. They appreciate that 
sometimes GPs refuse to prescribe because they are unhappy taking clinical 
responsibility for prescribing a medicine. 
You know they'll not perhaps have their name on a prescription for a drug when 
they're not familiar with that drug's actions, it's side-effects, monitoring, which I 
think is reasonable, very reasonable. 
He 2 (App. 7.8, para 63) 
Hospital medical consultants are also aware that GPs may be reluctant to prescribe 
medicines because they feel that either the wrong medicine has been chosen or that 
the decision to treat was wrong. 
They may also feel that the drug that you're prescribing, that they may be familiar 
with, is not appropriate, that the wrong decision's been made. 
He 2 (App. 7.8, para 63) 
Hospital medical consultants recognise that, when patient care is shared with GPs, 
there can be problems both gaining agreement and sharing monitoring information 
across the interface. What is appreciated, though, is the need to consult with GPs 
about handing over clinical responsibility rather than just assuming GPs will accept it. 
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What we're doing with the methotrexate is a bit more organised because we've got an 
advanced nurse practitioner to sort it out for us. And that is that any patient 
commenced on methotrexate, the GPs would be sent an information leaflet ... and that 
we would not pass over care without getting their permission first. 
He 1 (App. 7.7, para. 60) 
There is awareness that hospital practitioners should not assume that GPs will 
prescribe medicines. However, if GPs do accept prescribing responsibility then they 
should have sufficient information to be able to monitor the effects of treatment too. 
Aligning prescribing and monitoring responsibilities is complicated if systems are not 
in place to allow GPs access to patient results. This means that there is a risk that GPs 
could issue repeat prescriptions without knowing whether monitoring has been 
undertaken or the results indicate toxicity. 
I think it's going to have to be the case that in future that the person who prescribes 
actually is able to have sight of the results. It may be that that means that the GPs, if 
they're going to prescribe, have to do more of the monitoring, it may mean that we 
have to do more of the prescriptions. 
He 2 (App. 7.8, para. 32) 
5.5.7.2 Flagrant violation of policy 
Although hospital medical consultants seemed to appreciate that some GPs have 
genuine reasons for not wishing to prescribe certain medicines they were also aware 
that the cost of some medicines might be the real reason why GPs refuse to prescribe 
them. 
I don't think I've ever had a GP query, I can't remember when they queried a script 
that wasn't for financial reasons. 
Hel (App. 7.7, para. 72) 
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5.5.7.3 Impracticable or inflexible policy 
Hospital medical consultants appreciate that new medicines are often expensive and 
so it is necessary to manage their introduction onto a formulary. They are aware that 
the NHS has a limited amount of funding and that financial balance had to be 
achieved and so if expenditure on medicines increases there will be a subsequent 
reduction in the amount of money available for other areas of health care. Sometimes 
non-pharmacological treatments produce greater patient benefits than increasing the 
use of expensive medicines. 
Within a given financial year you've only got a given amount of money to work with 
and if you spend more on Cox II inhibitors, or whatever, then you're going to have 
less money to spend on other things. 
HC 2 (App. 7.8, para. 55) 
Whilst hospital medical consultants understand the reasons for controlling the use of 
medicines there is some frustration about how this impacts on their clinical freedom. 
You can't just write a script for it and so you know that's a bit of a nuisance, but it's 
fair enough because you are signing a cheque for so much money. 
HC 1 (App. 7.7, para. 88) 
Hospital medical consultants feel that processes for inclusion of new medicines onto 
formularies are prohibitive and unnecessarily time-consuming and bureaucratic. The 
inflexibility of the processes is particularly exasperating. These were acceptable 
when considering the use of medicines for general use in a specific patient popUlation. 
However, for individual patients when a new medicine might be the only available 
treatment the processes were felt to be obstructive. Whilst hospital medical 
consultants eventually manage to obtain medicines they request for individual patients 
they feel this takes an unnecessarily long time and that perhaps there should be a 'fast-
track' system when there is an urgent need for a particular medicine for an individual 
patient. 
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There are sort of committees that it has to go through ........ we have to go through all 
these hoops. 
He 1 (App. 7.7, para. 86) 
This may explain why some hospital doctors choose to violate policies for the 
managed entry of new medicines rather than going through the proper processes. 
Some insight was given into why consultants are not more proactive about changing 
their prescribing behaviour to improve cost-effectiveness. This was because the 
available rewards, if any, are not sufficient to encourage them to do it. They 
understand the need to consider the costs to the whole NHS but sometimes it is easier 
to carry on as before. 
The question is, 'Is there a big enough pay-back for the effort of changing people's 
practice?' And very often there isn't. 
He 1 (App. 7.7, para. 90) 
Another aspect of medicines management that frustrates hospital medical consultants 
is the rigid policies determining the quantities of medicines to be supplied from 
hospital pharmacy departments. They find it difficult to accept restrictions on the 
quantities of medicines they may prescribe for patients attending outpatient clinics. 
There was an underlying appreciation of how this impacts on patients who will have 
to make another journey to their OP practice to obtain a further prescription in a short 
period of time. The need to manage medicines expen4iture separately in both primary 
and secondary care demonstrates that primary and secondary care tend to function as 
separate organisations rather than as a single NHS organisation in which the total 
expenditure on medicines is considered. 
If a patient needs to be restocked with their su/fasalazine and they would normally get 
a months script from their GP, why can I only give them two weeks? It's anomalous 
really and it's a nuisance for them. 
He 1 (App. 7.7, para. 96) 
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5.5.8 Summary of hospital medical consultants' perspectives of medicines 
management across the interface 
Hospital medical consultants perceive that inter-professional collaboration across the 
interface is poor and their needs are not fulfilled. In particular information is lacking 
about patients' social circumstances and clear reasons why patients have been referred 
to hospital. This makes it difficult for them consider patients holistically. Hospital 
medical consultants identified a reason for the poor quality of discharge summaries. 
This was because discharge summaries are written by junior medical staff who may 
not be clear about what has happened during a patient's hospital episode. 
Additionally, they make decisions about what information individual GPs require 
depending on their knowledge of individual GPs and the medicines they are 
prescribing. Hospital medical consultants are aware of the need for policies to control 
medicines expenditure. However, these can cause frustration due to the lengthy 
processes involved which may delay appropriate patient care. Additionally, the need 
to manage medicines expenditure in primary and secondary care sometimes leads to 
policies that are overly restrictive and inconvenient to patients. 
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5.6 PATIENTS' EXPERIENCES OF OBTAINING MEDICINES FOLLOWING 
HOSPITAL EPISODES 
5.6.1 Hospital outpatients 
One hundred and one patients were interviewed face-to-face immediately prior to an 
outpatient appointment using a structured interview schedule (Appendix 4). Patients 
who consented to be interviewed were followed up by telephone at least two weeks 
after the appointment. For most patients this was not their first visit to an outpatient 
clinic. A third of the gynaecology and paediatric patients, two thirds of urology 
patients and four fifths of medical patients were currently taking prescribed 
medicines. Most medicines were prescribed by patients' OPs with only one 
gynaecology patient and three urology patients indicating that their OP and a hospital 
doctor prescribed medicines. The majority of patients did not expect any changes to 
be made to their medicine regimens during the outpatient clinic although lower 
numbers of urology and medical patients held this view. Eight of the medical 
patients, four of the gynaecology and urology patients and two of the paediatric 
patients actually had changes made to their medicines. Less than half of the patients 
were given a hospital prescription. The results of patients' experiences of changes to 
their medicines following attendance at an outpatient clinic are summarised in Table 
5.3. 
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Table 5.3 Medication processes and patients' expectations at outpatient clinics 
Gynaecology Paediatrics Urology Medicine 
(n = 26) (n = 25) (n = 25) (n = 25) 
Number of patients 26 25 32 28 
approached 
Consent to interview 26 25 25 25 
Sex Male 0 15 20 9 
Female 26 10 5 16 
First visit to 3 8 5 11 
outpatient clinic 
Currently on 9 9 17 20 
medicines 
Current GP 8 7 13 19 
prescriber Hosp Dr 0 I 1 1 
Both 1 0 3 0 
OTC 0 1 0 0 
Expecting No 8 7 10 13 
change Do not 0 0 5 4 
know 
Maybe 0 2 2 3 
Yes 1 0 0 
Expecting No 22 13 13 15 
new Do not 3 8 9 6 
medicine know 
Maybe 1 2 I 2 
Yes 0 2 2 2 
Number of patients 24A 226 23c 25 
followed up 
4D 2E 4E 8F Changes to 
medicines 
Hospital prescription 0 3 2 
given 
Patients who said they were currently taking medicines were also questioned about 
how they managed their medicines. This included asking them whether they had any 
help with their medicines, knew the duration of the medicines and how they obtained 
a further supply. Table 5.4 below shows how patients managed their medicines. 
A Two patients lost to follow up, one did not have a telephone and one could not be contacted. 
B Three patients could not be contacted by telephone. 
C One patient specifically requested no follow up and one was admitted to hospital. 
o Changes made were:- dose change; advice to restart previous medicine; buy over the counter 
medicine; GP to prescribe new medicine. 
E One patient had to obtain a prescription from the GP. 
F Six patients had new medicines initiated, one patient had a dose change and three patients had 
medicines discontinued. 
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Table 5.4 Patients' management of their medicines 
Gynaecology Paediatrics Urology Medicine 
(n=9) (n=9) (n = 17) (n = 20) 
Re~ort hel~ with medicines 0 0 1 6 
Does not know duration of 0 0 0 2 
medicines 
Does not know when to get 0 0 0 0 
further su~~II 
Repeat 6 5 15 16 
~rescri~tion 
GP 0 
Obtaining consultation 
further Repeat & 2 2 0 2 
supplt GP 
consultation 
Home visit 0 0 0 1 
Hos~ital 0 0 1 0 
Patient 8 5 10 9 
Who orders Carer 0 0 0 1 
repeats Relative 0 0 1 1 
CP 0 0 0 8 
Dispensing 1 0 4 1 
doctor 
Patient 7 5 10 9 
Who takes Carer 0 0 1 
to Relative 0 1 1 
community CP collects 1 0 0 8 
pharmacy Dispensing 1 0 4 1 
doctor 
Table 5.4 shows that most patients did not receive any help with managing their 
medicines either from a carer or health care professional. Almost all of the patients 
interviewed knew the duration of their medicines and all knew when to obtain a 
further supply. Most patients obtained further supplies of their medicines through a 
repeat prescription system without having a consultation with their GP. Most patients 
ordered their own repeat prescriptions and took this to a community pharmacy for 
dispensing although around half of the medical patients used a community pharmacy 
prescription collection service. 
A For patients attending paediatric outpatient clinic the figures in this row are not the same as the 
numbers currently taking medicines because one patient was taking an over the counter medicine and 
one had not yet had to obtain a further supply. 
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5.6.2 Subsequent interviews with patients following outpatient clinic attendance 
Patients were contacted by telephone at least two weeks after their initial outpatient 
clinic attendance. This was to determine whether any changes were made to their 
medicines at the outpatient clinic and find out if they had experienced any difficulties 
obtaining medicines. Patients who were given a hospital prescription were followed 
up again by telephone when it was expected that the medicines supplied against the 
hospital prescription would have been used up. A full description of the methods used 
is provided in Chapter Four. 
Generally patients were able to obtain further supplies of medicines without 
experiencing any difficulties. However, a few patients did experience problems and 
these are described below. 
5.6.2.1 Delay in updating patient records in primary care/ollowing receipt 0/ 
in/ormation from secondary care causes delay in obtaining medicines 
(Case study 1) 
A hospital doctor recommended adding senna liquid to the lactulose liquid already 
prescribed by a GP for a child. The child's mother had to return to the GP surgery 
several times before a prescription was issued. The mother thought that the problem 
was that the surgery had received the letter from the paediatrician but the additional 
medicine had not been added to her daughter's record. 
This case demonstrates that: 
• The mismanagement of communication received in surgeries may cause 
difficulties for patients when trying to obtain further supplies of medicines. 
• This may result in supply discontinuities. 
5.6.2.2 Patient discharged/rom a hospital outpatient clinic when not ready to self-
administer medicines (Case study 2) 
A male patient was attending the urology clinic for an impotence problem. He had 
visited the hospital twice, the first time a nurse administered a 5mg Viradal® 
injection. Next time he saw a doctor who gave him a prescription for 1 Omg injections 
to administer himself. The patient did not feel ready to self-administer the injections 
at this point. Additionally, the effects of the increased dose lasted too long and he 
was too embarrassed to contact the hospital for advice. A community pharmacist 
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obtained a prescription for the 5mg strength for him but it was in the form of a powder 
requiring reconstitution rather than the simple injection device that he had been 
trained to use. This case raises several issues: 
• The patient was discharged from a hospital clinic when he did not feel confident 
administering his own injections. 
• When the effects of his medicine lasted too long he felt unable to contact the 
hospital as advised. 
These two issues meant that the patient resulted in the patient not using the medicine 
he had been prescribed for his condition. 
• It demonstrates how community pharmacists may be left to resolve patients' 
problems with medicines initiated by hospital clinicians. 
5.6.2.3 De/ay in preparation 0/ outpatient summary causes delay in optimising 
medicine regimen (Case study 3) 
A female patient attended a medical outpatient clinic for assessment of a cardiac 
complaint. One month after the clinic appointment she did not know if her medicines 
would be changed because her OP was still waiting for a letter from the hospital 
registrar. The woman said that the registrar told her that he thought her heart tablet 
could be reduced but until the letter arrived this could not be implemented. 
This demonstrates that: 
• Patients may be told that changes are required to their medicines but have to wait 
significant lengths of time for these to be implemented due to slow 
communication across the interface. 
• This has the potential to cause anxiety in patients. 
• Delays in preparation of outpatient summaries means that patients' medicines are 
not optimised and therefore their disease is not fully controlled. This may mean 
that patients suffer unnecessary symptoms or adverse consequences of their 
disease. 
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5.6.3 Hospital inpatients 
Eight patients were interviewed about their medicines whilst hospital inpatients and 
then by telephone following discharge from hospital. All patients had changes made 
to their medicine regimens whilst in hospital and four reported problems with their 
medicines following hospital discharge. These problems are described below. 
5.6.3.1 Failure to optimise medicine regimen results in problems post-discharge 
(Case study 4) 
A female patient was admitted to hospital for treatment of an asthma exacerbation 
although she also had ischaemic heart disease. She became unwell following 
discharge from hospital which she believed was because the hospital doctor had 
prescribed a reducing dose of corticosteroids that was too rapid. Her GP decided to 
restart a medicine that had been discontinued during her hospital admission. She also 
felt that her asthma had been poorly controlled since her discharge from hospital. It is 
not unreasonable to expect that patients' medicines are optimised during inpatient 
stays. However, this case demonstrates that: 
• Medicine regimens are not always optimised when patients are in hospital 
resulting in patients' medicines being changed back on discharge from hospital. 
• Patients' acute problems may be resolved during hospital admissions but 
sometimes too little attention is paid to how diseases should be managed 
chronically. 
• Unless discharge summaries include details of why medicines have been 
discontinued by hospital doctors, GPs may find it difficult to deal with patient's 
problems when they are discharged from hospital. 
5.6.3.2 Failure to counsel patient about generic medicines results in confusion 
(Case study 5) 
This case demonstrates how patients may be confused if their medicines are not 
adequately explained to them. A female patient was prescribed atenolol but was 
confused when she obtained a further supply because it was a different generic 
preparation. No one explained to her that, although the medicines looked different, 
they were the same. 
195 
5.6.3.3 Failure to counsel patient about the need/or ongoing medicines results in 
anxiety (Case study 6) 
This illustrates how patients may misunderstand their treatment regimens if they are 
not counselled adequately on hospital discharge. A male patient had been taking 
cartons of food supplements whilst in hospital. He seemed concerned that his OP 
would not prescribe a further supply following his discharge from hospital. Whilst 
the food supplements were probably no longer required once the patient was eating 
properly, this had not been explained to him when he was discharged from hospital. 
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5.7 SUMMARY OF HEALTH CARE PROFESSIONALS' AND PATIENTS' 
PERSPECTIVES OF MEDICINES MANAGEMENT ACROSS THE 
INTERFACE 
This section has considered the perspectives of health care professionals and patients 
of medicines management across the interface. To conclude this section the issues 
raised will now be summarised under the four themes identified: lack of awareness or 
misunderstanding of policy; inadequate inter- or intra-professional collaboration; 
impracticable or inflexible policy and flagrant violation of policy. 
5.7.1 Lack of awareness or misunderstanding of policy 
Issues raised under the theme 'lack of awareness or misunderstanding of policy' 
related to the different medicines management systems in place in primary and 
secondary care. Community pharmacists are contractually obliged to adhere to the 
NHS blacklist and are not remunerated for any blacklisted medicines dispensed. This 
does not apply to hospital pharmacy departments and so patients may be prescribed 
medicines by hospital doctors that cannot be continued in primary care. Hospital 
pharmacists, because they do not have to abide by the NHS blacklist, seem relatively 
unaware of medicines that may not be dispensed in primary care. This may explain 
their failure to intervene before patients are discharged from hospital on blacklisted 
medicines or appliances. Hospital pharmacists are allowed to 'generically substitute' 
medicines prescribed by proprietary name for the generic equivalent. Conversely, 
community pharmacists must dispense the exact medicine prescribed. The inclusion 
of proprietary medicines in discharge information may mean that proprietary 
medicines are prescribed and dispensed. As generic medicines are generally less 
expensive than proprietary medicines there will be a financial cost to the NHS. 
5.7.2 Inadequate inter- or intra-professional collaboration 
Inadequate inter- or intra-professional collaboration caused difficulties for patients 
and all groups of health care professionals interviewed. Patients were inconvenienced 
when outpatient summaries took a long time to reach OP surgeries or if OP practice 
staff failed to implement the recommendations. This was because it caused a delay in 
making changes to medicine regimens which could make patients anxious. If patients 
are not fully informed about their medicines on discharge from hospital they may 
contact their OP or community pharmacist for advice. However, it is difficult for OPs 
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and community pharmacists to advise patients if they have not been fully informed of 
what has happened to a patient during a hospital episode. The failure to involve GPs 
when prescribing decisions are made means that GPs experience dilemmas about 
whether they should take over responsibility for ongoing prescribing of certain 
medicines. Similarly, for community pharmacists, this lack of involvement means 
that sometimes impractical solutions to medicines management problems are 
developed. Perhaps more importantly, community pharmacists are isolated from 
other health care professionals in primary and secondary care. This means that the 
wealth of information that they gather about how patients manage their own 
medicines in their home environments is not utilised by GPs or hospital professionals. 
Some explanations for poor communication across the interface arose during the 
interviews. First, there was a lack of awareness of the information requirements of 
health care professionals working on the opposite side of the interface. Second, junior 
doctors, who are responsible for preparing interim discharge summaries, may not be 
fully aware of what has happened during a patient's inpatient episode. Third, hospital 
pharmacists report a lack of time and the absence of triggers to prompt them to 
communicate with their community pharmacist colleagues. Additionally, they 
experience difficulty identifying which community pharmacists to liase with. 
5.7.3 Impracticable or inflexible policy 
The theme 'impracticable or inflexible policy' may be used to categorise some of the 
mechanisms for controlling medicines expenditure in hospitals, particularly the limit 
on the quantities of medicines dispensed by hospital pharmacy departments. This was 
frustrating for both GPs and hospital medical consultants. For GPs, short supplies of 
medicines given following outpatient appointments or discharge from hospital meant 
that they could be expected to issue a further prescription before they had received 
information about the hospital episode. Hospital medical consultants felt that it was 
inconvenient for patients to have to obtain prescriptions from GPs rather than a 
hospital prescription being issued during the outpatient consultation. Rigid 
application of medicine quantity policies could also result in wastage of medicines. 
This was the case when patients were discharged from hospital with their medicines 
dispensed in standard packaging rather than in monitored dosage systems. This 
seemed to happen despite hospital practitioners being aware that patients were unable 
to take their medicines unless they were dispensed in a monitored dosage system. 
198 
Strict adherence to hospital medicine formularies meant that patients' medicines were 
sometimes changed simply to ensure compliance with the hospital formulary rather 
than for any clinical reasons. It seems clear then that rigid application of medicines 
management policies, which are impracticable or inflexible, can inconvenience 
patients or cause confusion about which medicines they should be taking. 
5.7.4 Flagrant violation of policy 
Issues included in the 'flagrant violation of policy' theme were mainly related to 
hospital doctors choosing not to adhere to systems for medicines formulary control. 
General practitioners, hospital and community pharmacists all stated that hospital 
doctors would sometimes ask GPs to prescribe non-formulary medicines. General 
practitioners are generally reluctant to refuse requests to prescribe medicines from 
hospital doctors and it is not within the role of community pharmacists to enforce 
formularies. This means that patients often do receive non-formulary medicines. 
This can cause a problem if patients are subsequently admitted to hospital if their 
medicines are then changed to a formulary choice. This is confusing for patients and 
creates extra work for hospital staff. The hospital medical consultants interviewed felt 
that the systems for the managed entry of new medicines were unnecessarily 
bureaucratic and complicated. This may explain why some hospital doctors choose to 
bypass such systems by asking GPs to prescribe non-formulary medicines without 
being aware of the consequences. 
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~.8 OVERALL SUMMARY OF FINDINGS 
The findings of this study have been presented in this chapter and the main features 
are summarised as follows:-
• The interface is still contributing to difficulties in the management of medicines 
when patients are transferred between primary and secondary care. This results in 
difficulties in maintaining continuity of care and inefficient medicines 
management. These difficulties have been categorised and described. 
• The present research has illustrated numerous instances whereby doctors and 
pharmacists in primary and secondary care have not put Department of Health 
guidance on medicines management across the interface into practice. 
• Some of the dilemmas that health care professionals, on both sides of the 
interface, deal with when considering the transfer of patient care have been 
identified. Poor medicines management across the interface impacts differently 
on different groups of health care professionals. General practitioners' concerns 
are related to accepting the transfer of clinical responsibility for some patients. 
Community pharmacists' difficulties are associated with poor communication 
about medicines across the interface and the impact this has on their ability to 
undertake their role effectively. Hospital medical consultants and hospital 
pharmacists, although raising some frustrations with medicines management 
across the interface, did not seem to be ~ffected as much as GPs and community 
pharmacists. Resolving the issues identified by GPs and community pharmacists 
requires hospital consultants and hospital pharmacists to more fully understand 
and appreciate each other's roles. 
In the following chapter these findings will be discussed in terms of how they help to 
explain why medicines management problems still exist despite the existence of a 
large evidence base showing how the interface contributes to poor medicines 
management. 
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CHAPTER SIX 
DISCUSSION 
6.1 OVERVIEW 
This chapter begins with a review of the three main areas of literature that are relevant 
to this thesis. The first key area is the structure and process ofNHS health care and 
how this affects the interface and medicines management issues in relation to patient 
care. Next, the existing literature is re-visited in relation to problems associated with 
medicines management at the interface. This ends with a summary of the main 
theories relevant to organisational change and changing health care professionals' 
behaviour. It is important to recognise that change has a major impact on the process 
of managing medicines at the interface, both from the perspective ofNHS 
organisations and individual health care professionals. 
Against this theoretical background the findings of the present study will be 
introduced in order to gain a better understanding of the problems associated with 
medicines management. In particular, the focus will be on the perspectives of doctors 
and pharmacists in primary and secondary care and how these influence inter- and 
intra-professional communication at the interface. The arguments brought to bear in 
this section help to develop our understanding of how the structure and process of 
NHS health care has a direct impact on medicines management problems. Later in the 
chapter national policies affecting medicines management at the interface will be 
appraised in the light of insights gained from the mind-sets of primary and secondary 
health care professionals acquired from the present study. 
Then the findings are considered in the context of change management theory. This 
will help to explain why medicines management at the interface continues to be 
problematic despite the extensive publication of national guidance on this subject. 
More importantly, this leads to an appreciation of what needs to be done to improve 
medicines management at the interface. The latter part of this discussion is devoted to 
a consideration of the key outcomes of the present study which shows how the study's 
original aim and objectives have been achieved. 
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6.2 RESUME OF LITERATURE 
The purpose of this resume is to draw together the three main areas of literature that 
were covered in detail in the first three chapters of this thesis. This will provide the 
context within which the findings from the present study can be discussed. The 
primary / secondary care interface has traditionally been considered as a theoretical 
barrier that patients pass through when responsibility for their care is transferred. 
However, this simple concept of the interface does not show how the interface 
impacts on the ability of health care professionals to provide quality patient care. In 
the introductory chapters of this thesis, it is argued that, although the interface is a 
theoretical concept it is constituted of a wide variety of factors, human, physical and 
organisational, all of which may impact adversely on the quality of patient care. 
6.2.1 Impact of the structure and process of care on the management of 
medicines 
Donabedian's (1980) definitions of the structure and process of care are helpful in 
describing the components of the interface because they remind us why management 
arrangements, resource allocation and policy-making affect the use of medicines. In 
addition to being physically separated, primary and secondary care organisations are 
also managerially separate. This can lead to conflicts between what managers in 
primary and secondary care are trying to ~chieve (Ham, 1992). This is particularly 
relevant when considering expenditure on medicines because strategies introduced 
into hospitals to control medicines expenditure may adversely impact on medicines 
expenditure in primary care. Before the introduction of cash limited budgets in 
primary care, the use of 'loss leader' medicines by hospitals and transferring 
prescribing responsibility to GPs in order to transfer the cost of medicines might have 
been acceptable. However, since the introduction of GP fundholding, and more 
recently, Primary Care Trusts, these practices are no longer tolerated because they 
increase expenditure on medicines in primary care (Sibbald et ai, 1992; Bennett, 
1994; Jones et ai, 2000). It is noted that the Department of Health recommends that 
this practice should be stopped (NHS management executive, 1991) though it is clear 
that this guidance has not been effectively implemented (Crump et ai, 1995; Edgar 
and Girvin, 1999). This may be partly explained by the fact that DoH guidance is 
open to interpretation both by managers within NHS organisations and the health care 
professionals who provide patient care. Therefore, such guidance may only be 
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partially implemented if it conflicts with an NHS organisation's objectives or an 
individual health care professional's beliefs. This argument will be re-visited later 
when the results from the present study are taken into account. 
The process of care is mainly concerned with the roles of health care professionals 
who provide NHS care and the relationships between them. General practitioners are 
responsible for overall patient care and refer patients to their hospital colleagues when 
specialist advice or treatment is necessary. However, the roles of hospital and 
community pharmacists are quite different. Hospital pharmacists provide a mainly 
clinical service whereas community pharmacists still spend much time on technical 
tasks, such as dispensing. It is well known that communication from hospital doctors 
to GPs is unsatisfactory (Coleman et ai, 2001) and it is not routine practice to provide 
information for community pharmacists when patients have been in contact with 
hospital services (Sexton et ai, 2000). In addition to poor communication between 
health care professionals across the interface there is also evidence from the literature 
that intra- and inter-professional relationships need to be improved. General 
practitioners and hospital medical consultants are not fully satisfied with their 
relationships (Marshall, 1998). Relationships between GPs and community 
pharmacists are also less than ideal (Hughes & McCann, 2003). 
In summary, the literature relating to structure and process of care reminds us of the 
importance of the separation of managerial responsibility for medicines expenditure 
and the separate overarching management structures resulting in different 
interpretation and implementation of national policies. Finally, this literature 
illustrates the importance of the intra- and inter-professional relationships between 
doctors and pharmacists who provide patient care. 
6.2.2 Medicines related problems at the interface 
The notion of seamlessness when patient care is transferred across the interface was 
outlined in Chapter Two. Ideally, patient care should be uninterrupted and all health 
care professionals have access to sufficient information to carry out their roles 
effectively and efficiently. The importance of medicines management within the 
NHS was also discussed from the perspective of ensuring that patients receive 
appropriate medicines within allocated resources. This led onto a discussion of the 
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current literature regarding medicines management problems at the interface. First it 
has been shown that the interface may be a factor contributing to medication errors 
when patient care is transferred (Duggan et ai, 1996). Second, financial problems 
arise because GPs' prescribing patterns are influenced by those of hospital doctors 
(Audit Commission, 1994; Edgar & Girvin, 1999) and the cost of expensive 
medicines may be transferred onto GPs' prescribing budgets (Wilkie et ai, 1992b; 
Sibbald et ai, 1992; Jones et ai, 2000). Hospitals also take advantage of 'loss leader' 
medicines, which are offered at significantly discounted prices in order to encourage 
use, but cost significantly more when prescribed in primary care. The third problem 
category relates to the transfer of clinical responsibility for prescribing from hospital 
doctors to GPs. This is because GPs feel they may have difficulty in detecting side-
effects, explaining treatments to patients and monitoring dosages (Sibbald et ai, 
1992). Shared care guidelines have been recommended as a way forward to address 
GPs' clinical responsibility concerns (NHS executive, 1991) but GPs consider that 
transferring prescribing responsibility is really about transferring the costs of 
expensive medicines (Horne et ai, 2000; Duggan et ai, 2001). 
6.2.3 Impact of organisational change on the management of medicines 
Organisational change theory helps us to appreciate the importance of assessing a 
situation before implementing a change prc;>gramme. This helps to ensure that 
solutions address actual problems rather than perceived problems and the type of 
problem is determined so that an appropriate solution is chosen. Application of a 
diagnostic test to medicines management at the interface showed that this is a problem 
of 'soft complexity' (Paton & McCalman, 2000). Change models suitable for dealing 
with soft problems have developed from Lewin's (1947) three stage model into an 
organisational development model (Senior, 2000). In their initial stages both models 
emphasise the importance of determining barriers to change and ensuring that 
organisational members acknowledge that change is necessary. Implementing change 
in a soft system will be difficult unless the members of the organisation appreciate the 
need for change and any barriers to change are addressed. 
The literature regarding changing health care professionals' behaviour helps us to 
appreciate that actions that do not contribute to good medicines management must be 
replaced with those that do. Passive dissemination of information is not effective at 
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improving the general delivery of health care (Oxman et ai, 1995), prescribing 
behaviour (Grimshaw et ai, 2001) or adoption of clinical practice guidelines (Davis & 
Taylor-Vaisey, 1997). 
This resume of the literature shows that the interface is not simply a theoretical state 
and provides an insight into how poor medicines management can occur. The 
literature also highlights the importance of medication errors, financial issues and 
professional difficulties associated with transfer of clinical responsibility. 
Organisational change theory shows how change must be actively managed if it is to 
produce the desired results. Attention will now be focused on the findings of the 
present study and how they relate to the issues that have been identified in the 
literature. 
6.3 IMPACT OF THE INTERFACE ON EFFECTIVE MEDICINES 
MANAGEMENT 
In this section the problems raised within the present study concerning medicines 
management at the interface will be discussed. This will be done under the four key 
themes identified. 
• Poor inter- and intra-professional collaboration. 
• Misunderstanding of policy. 
• Flagrant violation of policy. 
• Inflexible or impracticable policy. 
6.3.1 Poor inter- and intra-professional collaboration 
The different perspectives of health care professionals of medicines management 
across the interface was a key finding from the data of the present study. Poor 
transfer of information across the interface frustrated all health care professional 
groups which meant that they wasted time finding information that could easily have 
been provided. General practitioners experienced difficulties in planning ongoing 
care for patients and community pharmacists were frustrated in not always being able 
to immediately dispense prescriptions. Whilst poor communication was a factor, the 
key reason for these problems resulted from a lack of inter- and intra-professional 
collaboration. 
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The present study identified poor professional collaboration both across the interface 
and within primary care. From the perspective of GPs, poor professional 
collaboration was of concern because this left them uncertain whether to accept the 
transfer of prescribing, and therefore clinical, responsibility from hospital colleagues. 
Clinical responsibility may be defined as 'whichever individual signs a prescription 
generally carries the legal liability for the consequences of prescribing the drug or 
item' (NPC, 1999 p40). Whilst the pharmaceutical industry is liable for adverse 
consequences resulting from defective medicines, the prescriber is culpable if the 
wrong medicine is prescribed for a patient or if it is used outside the terms of its 
product licence (Harman, 2003). Therefore, before prescribing a medicine, doctors 
need to be sure that it is appropriate for a patient's diagnosis and that it is being used 
within the terms of its product licence. This includes ensuring that any necessary 
monitoring requirements or contraindications have been taken into account. 
Sibbald et 01 (1992) undertook one of the first studies investigating the transfer of 
clinical responsibility between secondary and primary care. Nearly half of GPs 
surveyed said they had been asked by hospital doctors to prescribe medicines for 
which they felt unable to accept clinical responsibility because of difficulties detecting 
side-effects, explaining treatments to patients and monitoring dosages. In the present 
study, instead of being given a list of potentially problematic medicines to choose 
from, GPs were invited to raise issues that concerned them. This meant that they were 
not restricted to commenting on a specific list of medicines devised by the researcher. 
What emerged from the present study was an insight into the circumstances under 
which GPs feel uncomfortable accepting prescribing ,responsibility rather than a list of 
medicines that GPs did not wish to prescribe. The circumstances raised were 
medicines used outside the terms of their product licences and medicines with which 
GPs were unfamiliar. Transfer of prescribing responsibilities with the aim of 
transferring the costs of a medicine was also identified as a problem for GPs when 
accepting clinical responsibility. General practitioners are not necessarily concerned 
about the clinical aspects of the transfer of responsibilities but sometimes more so 
with the associated costs. This adds to the current understanding of what motivates 
doctors in primary and secondary care to be seriously concerned about their clinical 
responsibilities. 
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General practitioners expressed particular concerns about accepting clinical 
responsibility for medicines used outside the terms of their product licences or 'off-
label' uses. General practitioners interviewed for the present study were aware that 
by signing a prescription they were assuming clinical, and therefore legal, 
responsibility for any adverse outcomes. It is important to appreciate that GPs' 
concerns about prescribing medicines 'off-label' relate to how GPs understand the 
terms of product licences which mayor may not be a correct interpretation. General 
practitioners in the present study reported less discomfort in prescribing medicines for 
'off-label' uses ifit was clear that patients were fully informed of, and willing to 
accept, any associated risks. However, GPs reported that this type of information was 
not included in discharge information from hospitals. 
General practitioners in the present study were reluctant to accept clinical 
responsibility for unfamiliar medicines and two groups of medicines were identified. 
First, newly marketed medicines were problematic. For example, a GP expressed her 
concerns about being asked to prescribe mibefradil because she 'had never heard of, it 
had only just been launched' (App. 7.1, GP 4, para. 149). This was compounded by 
difficulties that GPs experienced obtaining any information about medicines that were 
not yet included in common primary care texts such as the British National 
Formulary. Data from the present study confirmed that GPs were unhappy about not 
being provided with essential information about new medicines prescribed in hospital. 
This supports the view of Jones et af (2001) who pointed out that hospital doctors 
expect GPs to be aware of new medicines or be able to find out more information 
themselves if necessary. The second group of medicines that was problematic was the 
'specialist' medicines. These have complex monitoring or prescribing arrangements 
and are prescribed on the advice of hospital doctors. Home et af (2001) included 
'high cost' in the definition of 'specialist medicine'. However, within the present 
study it was clear that, whilst some of the medicines were expensive, GPs were more 
concerned about the associated complex monitoring or prescribing requirements. 
Some of the medicines with attached issues of clinical responsibility were 
inexpensive. This contrasts with the views expressed by both hospital medical 
consultants and hospital pharmacists who perceived that GPs refuse to prescribe 
medicines primarily on grounds of cost. Until these different perceptions are resolved 
it is likely that hospital practitioners will remain unsympathetic to GPs refusing to 
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prescribe medicines because of clinical responsibility concerns. This could be 
achieved by removing financial incentives, such as prescribing incentive schemes, for 
GPs to refuse to prescribe expensive medicines. Since the introduction ofPCTs, GPs' 
prescribing budgets have been indicative rather than cash limited. However, PCTs 
still encourage GPs to prescribe within allocated budgets in order to achieve financial 
balance. It is perhaps easier for GPs to cope with the management of their prescribing 
budgets by refusing to prescribe expensive medicines rather than critically reviewing 
the cost effectiveness of their own prescribing. However, we have to bear in mind 
that GPs are perhaps prudent to be wary of prescribing new medicines or medicines 
used outside the terms of their product licences. Three of the medicines that GPs 
expressed clinical responsibility concerns about during the course of the present 
study, cisapride, mibefradil and tolcapone, were subsequently withdrawn from use in 
the UK (CSM, 2000; Anon, 1998a; Anon, 1998b). 
Consideration of the current processes for transferring patient care gives some 
indication why GPs may be reluctant to accept clinical responsibility. Hospital 
doctors generally send completed proformas or letters to GPs following hospital 
episodes which detail patients' medicine regimens. There is generally no prior 
consultation before this is done and so it is expected that GPs will comply and 
continue to prescribe patients' medicines. If a process could be introduced to enable 
two-way dialogue between hospital doctors and GPs, this might enable GPs to raise 
their concerns and improve the collaborative working relations between these groups 
of doctors working in primary and secondary care. 
Another way that the structure of the NHS contributes to poor medicines management 
is that the NHS is organised so that patient care is mainly the responsibility of GPs 
with referral to hospital medical consultants for specialist advice or treatment. Whilst 
this system is cost-effective, because it limits access to expensive secondary care 
resources, it is also inflexible. In particular it does not allow for any contingency to 
enable secondary care practitioners to continue to care for patients if GPs refuse to 
accept the transfer of clinical responsibility. Firstly, if the financial aspects of the 
structure of health care, as described in Chapter One, are considered, secondary care 
is only funded to pay for medicines for inpatients and limited quantities of medicines 
following hospital discharge or attendance at outpatient clinics. Since the 
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introduction of peTs this is relatively simple to resolve by virement of funds from the 
primary care prescribing budget to the secondary care budget. However this does not 
resolve the problem of how patients will obtain prescriptions. There is no provision 
within the secondary care system to issue repeat prescriptions to patients. This would 
mean that patients under the care of secondary care professionals would have to attend 
outpatient appointments. This might be inconvenient for patients and take up hospital 
appointments that could be freed for patients waiting for first appointments. In 
principle, this is against NHS policy which recommends that follow up for patients 
after hospital episodes should routinely be undertaken in primary care (NBS 
Modernisation Agency, 2004a). One has to accept that, given the current 
organisational arrangements, there is effectively no simple solution to enable hospital 
medical consultants, rather than GPs, to retain responsibility for prescribing 
medicines. 
Shared care guidelines have been proposed as a way forward to improve transfer of 
clinical responsibility (NHS executive, 1991). Duggan et al (2001) identified shared 
care protocols for 99 different medicines within the UK. This means that it is unlikely 
that there is a shared care protocol for every specialist medicine that GPs are asked to 
prescribe. If GPs are unhappy prescribing medicines with specific guidance on their 
use (Home et ai, 2001; Duggan et ai, 2001) it is not surprising that they will be 
unhappy about prescribing specialist medicines without provision of any information 
or guidance. It has already been discussed that GPs' discomfort with regard to 
prescribing specialist medicines relates to the circumstances surrounding a request to 
prescribe. The quality of any information provided is particularly important in 
making GPs feel more comfortable about accepting clinical responsibility. It is 
important to appreciate that individual GPs are likely to have different levels of 
comfort with prescribing depending on their previous experience and any special 
interests they might have. Therefore, one GP may be reluctant to prescribe a 
particular medicine whereas another GP might have no concerns. Taking this into 
account, it is difficult to devise a definitive list of medicines for which shared care 
guidelines are needed. An additional problem with shared care guidelines is that they 
do not necessarily improve the quality of patient care. Ashcroft et al (1998) found 
that patients reported that, despite a shared care guideline being in place, GPs were 
sometimes unaware when hospital practitioners had made dosage adjustments for 
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erythropoietin. This indicates that shared care protocols may not completely resolve 
the communication problems associated with transferring clinical responsibilities 
from hospital medical consultants to OPs. 
In the present study OPs issued prescriptions for medicines despite feeling 
uncomfortable. This was despite awareness that, by continuing to comply with 
requests to prescribe medicines they were uncomfortable with, OPs were perpetuating 
similar requests. They felt pressurised into prescribing medicines by patient 
expectations, patient convenience and, perhaps most importantly, the concern that 
patients would not be able to obtain medicines any other way. This is summed up by 
one OP's statement, 'you can't win, you can't establish the fact that you are unhappy 
and reluctant to prescribe and it should be done differently because there is no 
alternative if you don't do it' (App. 7.2, OP 7, para. 76). 
So far this discussion has considered issues raised by OPs associated with poor 
collaboration across the interface. Now the role of community pharmacists will be 
considered. It is recognised that adequate communication channels between hospital 
and community pharmacists are not yet in place (Sexton et ai, 2000). This problem 
has been neglected despite evidence to support the beneficial effects in terms of 
enabling a reduction in unintentional medicine changes in elderly patients (Binyon, 
1994; Law et ai, 1994; Pegrum, 1995) and in general medical patients (Choo & Cook, 
1997; Duggan et ai, 1998). Improved communication has also been shown to reduce 
medicine related problems when patients arrive home after discharge (Cromarty et ai, 
1998). The present study showed how this lack of c.ommunication has a detrimental 
impact upon community pharmacists' professional advisory role. Without such 
collaboration it is impossible for community pharmacists to properly check whether 
medicines are appropriate. Nor can the community pharmacist appropriately advise 
patients how to take their medicines or ensure the continuity of supply. 
The present study also illustrated how community pharmacists experienced many 
difficulties due to poor communication across the interface. These were mainly 
because they rarely received any information when a patient had been in contact with 
hospital services and were not involved in the discharge planning process. First, this 
makes it difficult for them to find out information they need to dispense prescriptions. 
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Additionally, lack of involvement in discharge planning means that patients may be 
prescribed medicines or dressings that are not legally permitted on a GP prescription 
and that solutions to medicines management problems devised by secondary care 
professionals may not be practical within a primary care setting. This shows that the 
wealth of knowledge of community pharmacists is being grossly undervalued and 
under-utilised especially with regard to the hospital discharge process and the 
undesirable impact this may have of the management of medicines. 
In the present study, community pharmacists complained about the lack of 
professional collaboration both within primary care and across the interface. Previous 
studies investigating the impact of liaison between hospital and community 
pharmacists have identified that the effectiveness of such liaison could be improved. 
It has been established that unexplained medication changes still occur despite liaison 
between hospital and community pharmacists (Binyon, 1994; Law et aI, 1994). 
Duggan et al (1998) found more positive effects of increased liaison between hospital 
and community pharmacists and that unintentional discrepancies were reduced. 
Whilst the differences in success rates may be due to differences in communication 
methods used in previous studies, there is an alternative explanation that emerged 
during the present study. This is that, although community pharmacists in the current 
study complained about the lack of information they received they were sometimes 
unsure about what to do with such information. Therefore community pharmacists 
faced dilemmas in making interventions that raise uncertainty as to whether they 
should take on a clinical role. These doubts were exacerbated by their concerns that 
any clinical interventions they make might damage their professional relationship 
with GPs. 
Some pharmacists in the present study commented that making interventions was not 
their priority. 'Lack of time' , is one explanation why community pharmacists do not 
intervene on prescriptions, despite perhaps being aware that particular medicines have 
monitoring requirements to ensure patient safety. This is a real issue because 
Hawksworth el al (1999) found that pharmacists with lower dispensing volumes made 
more clinical interventions. However, there is another factor identified within the 
present study that arises from the framework of the pharmaceutical services contract 
within which community pharmacists are required to practise. Community 
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pharmacists are remunerated for dispensing prescriptions, whereas making 
interventions costs money in terms of time, telephone and postage costs. Community 
pharmacists in the current study felt that there was insufficient remuneration within 
the existing pharmaceutical services contract to encourage them to make 
interventions. In particular, pharmacists complained that they would be financially 
penalised if they made interventions resulting in a reduction of prescribing. This may 
explain why schemes whereby community pharmacists are paid to make cost-
effectiveness interventions have been shown to be successful (Leach et aI, 2003). 
Whilst, the new community pharmacy contract (DoH, 2005) does place some 
emphasis on remuneration for clinical activities, such as medicines use review, the 
majority of remuneration will still come from the volume of dispensing. Therefore it 
is unlikely that the new contract will have much impact on encouraging community 
pharmacists to make prescription interventions. 
The second dilemma that arose, concerning community pharmacists' ability to deal 
with information they receive about patients, relates to uncertainties about their role. 
Community pharmacists in the present study recognised that they have a 
responsibility to check whether the dose of a medicine is correct but were reticent 
about whether it was their role to determine whether medicines were being monitored 
appropriately. This was felt to be a doctors' role but was partly due to the time 
constraints necessitated by a busy pharmacy. One of the difficulties for community 
pharmacists in developing a more clinical role and becoming more involved in 
monitoring outcomes is the lack of clinical information available to them. In a 
hospital setting patient records are easily accessible'to pharmacists and it is accepted 
practice that pharmacists need to check patient records. However, community 
pharmacists do not have access to records that are currently held within OP surgeries. 
It is neither feasible nor currently acceptable for community pharmacists to visit 
surgeries to check patients' notes. 
An additional consideration is that community pharmacists in the current study did 
not seem confident about taking responsibility for changes to medicines being made 
on their advice. This perhaps reflects the fact that clinical pharmacy is a relatively 
new development within community pharmacy and, with time, they may become 
more confident. What is perhaps more worrying is that the new pharmacy contract 
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(DoH, 2005) has given a clinical role to community pharmacists and this will not be 
successful unless they have the confidence to embrace this. It needs to be recognised 
that community pharmacists are not satisfied with their current role and feel that their 
skills are under utilised. Therefore, training is required to improve their clinical 
judgement in relation to medicines management so as to enhance their clinical role 
(Tweedie et ai, 2004). Community pharmacists in the present study did not only 
report inadequate collaboration with their hospital pharmacist colleagues but they also 
reported that relationships with GPs were often less than ideal. Therefore, in order to 
take advantage of community pharmacists' clinical skills there first needs to be a 
change in attitude of GPs in relation to their expectations of the role of pharmacists. 
The current resistance to increasing the clinical role of the community pharmacist 
needs to be overcome. 
Hughes and McCann (2003) found the main barriers for GPs to better collaboration 
with community pharmacists were the 'shopkeeper' image of community pharmacy 
and the perceived conflict between business and health care. The present study 
confirms that there is still a need to improve relationships between community 
pharmacists and some GPs. Community pharmacists reported different relationships 
with individual GPs which meant that they could confidently challenge prescriptions 
written by some GPs whereas, with other GPs, the dialogue would be more 
confrontational. The community pharmacists in the present study felt that contractual 
obligations have to take preference over local policies. This means, for example, that 
they may not enforce district formularies if their refusal to dispense a prescription 
might upset the delicate relationship with GPs. The dilemma, here, is that community 
pharmacists are contractually obliged to dispense any allowed NHS prescription item 
presented to them within a reasonable time. Also, if patients are turned away then 
they could simply take the prescription to another pharmacy where the pharmacist is 
either not aware of the non-formulary status of the medicine or is less concerned 
about ensuring compliance with it. Community pharmacists rely on GP prescriptions 
for the majority of their income and upsetting this relationship could be commercially 
detrimental. Whilst, legally, prescriptions cannot be directed either to or away from 
particular pharmacies pharmacists fear that GPs could influence their patients not to 
use particular pharmacies. This is a real dilemma for community pharmacists because 
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the sensitive commercial relationship between GPs and community pharmacists might 
encourage them to hold back from intervening on medicines issues. 
The improvement of collaboration and communication would be undoubtedly 
beneficial but it is difficult to see how the improvement of communication alone 
could improve the management of medicines. First, the poor control of repeat 
prescribing systems in general practice means that errors may be made transcribing 
information from hospital discharge communication into patients' records (Coleman 
et ai, 2001). This may be because unqualified reception staff make changes to 
patients' repeat prescription records without being checked by a doctor (Zermansky, 
1996). Another factor may also be relevant when considering the role of community 
pharmacists in improving medicines management across the interface. We do not 
know how much community pharmacists' failure to intervene is actually due to a lack 
of acceptance of interventions by GPs rather than a willingness to intervene. Previous 
studies looking at the effectiveness of liaison between hospital and community 
pharmacists have not reported the proportion of interventions accepted and 
implemented by GPs. However, Goldstein et al (1998) found that GPs agreed with 
58% of problems with repeat prescriptions identified by community pharmacists but 
only acted on half of the problems they agreed with. In particular, in the present study 
it was shown that community pharmacists may perceive GPs as being more likely to 
believe information received from the hospital as opposed to what they might suggest. 
Another important factor to take into account when considering the benefits of 
communication between hospital and community pharmacists is that, although 
pharmacists' interventions have led to a reduction in medication errors across the 
interface, the fact that community pharmacists are intervening means that 'near 
misses' are actually occurring. This could equally apply to interface issues other than 
medication errors, such as requests to GPs to prescribe non-formulary medicines. 
Therefore, systems need to be put in place to prevent medication errors occurring in 
the first place rather than simply expecting community pharmacists bridge the gap of 
poor information transfer (Cook et ai, 2000). This is because, if a community 
pharmacist fails to intervene, a patient may be harmed. 
216 
Community pharmacists would like to receive information about the source of non-
standard preparations (Brackenborough, 1997). Checklists are available to promote 
communication between hospital and community pharmacists, including the provision 
of information about suppliers for unusual medicines (RPSGB, 1993) but there has 
been little uptake of these (Cairns, 1994; Argyle & Newman, 1996; Sexton et ai, 
2000). Few hospitals involve community pharmacies in the discharge process 
routinely although a significant number claim to contact community pharmacists 
about patients on unusual medicines or using compliance aids (Sexton et ai, 2000). 
The present study confirms that community pharmacists experience problems 
sourcing unusual products. This demonstrates that the information required by 
community pharmacists is more than simply a list of medicines that patients are taking 
on discharge from hospital. With the production of extemporaneous preparations in 
pharmacies taken over by specials manufacturers there is often no difference in the 
dispensing process for ordinary licensed medicines and 'specials'. As community 
pharmacists dispense few items that are not available from usual wholesaler sources 
(Candlish et ai, 2003) they are unlikely to be familiar with medicines available as 
specials. In fact the present study showed that community pharmacists were only 
aware of the availability of unusual medicines if they had come across them 
previously. Even if information is given about formulations for extemporaneous 
preparations, because ofthe low volume of extemporaneous dispensing in community 
pharmacies it has been suggested that this practice should stop because pharmacists 
and their support staff are unlikely to maintain expertise and competence in this line 
of work (Rennison & Portlock, 2003a). It would perhaps be better for hospitals to 
stop discharging patients on extemporaneous preparations because of the inherent 
risks involved and the lack of evidence of efficacy of extemporaneously prepared 
medicines (Rennison & Portlock, 2003b). As the present study showed although 
community pharmacists are aware of the deficiencies in extemporaneous medicines 
they experience difficulty getting patients' medicines changed once they are 
established. This again supports an argument for not initiating extemporaneously 
prepared medicines in the first place. Another finding that arose from the present 
study were reasons why hospital pharmacists do not communicate with their 
community colleagues when patients are started on unusual medicines. This is 
because there are often no triggers to prompt communication particularly if a 
medicine is readily available on a dispensary shelf. 
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So far problems caused by lack of professional collaboration with community 
pharmacists have been considered when patients are discharged from hospital. 
However, issues also arise when patients are admitted to hospital. Community 
pharmacists are not involved when patients are admitted to hospital and so the wealth 
of information they have about how patients manage their medicines is not utilised. 
This may partly be explained because patients do not register with community 
pharmacists and therefore hospital pharmacists may experience difficulties identifying 
which community pharmacist to contact regarding information about patients' 
medicines. This causes problems particularly if hospital pharmacists do not take into 
account that patients use monitored dosage systems (MDS). There are several 
explanations for this, the first being that hospital pharmacists may not appreciate that 
patients are using MDS. This may be true if the MDS is not brought into hospital 
with the patient. Community pharmacists may discourage patients from taking MDS 
into hospital in case they go missing. Additionally, due to the large size ofMDS, they 
may be locked away and not available when a drug history is being taken. However, 
due to the increasing role of hospital pharmacists on admission to hospital (Foster, 
1995; Price, 1998; Doyle et ai, 1998) it is surprising that this information is not 
obtained on admission. What this means is that patients may be discharged from 
hospital on medicines that they are unable to take because they are dispensed in 
unsuitable packaging. Within the structqre of health care it was explained that 
hospital pharmacists practise solely in secondary care and therefore do not see 
patients in their home environments. This makes it difficult for them to appreciate 
how patients manage their medicines at home. 
6.3.2 Misunderstanding of policy 
A lack of awareness of knowledge of medicines management policies combined with 
various forms of misinterpretation in the present study led to the development of the 
theme 'misunderstanding of policy' . 
Primary care professionals misunderstood the hospital policy for the supply of 
medicines. The result of this was complaints that patients had not been provided with 
medicines at outpatient appointments or had been given less than the agreed quantities 
of medicines on discharge from hospital. Hospitals act appropriately by only issuing 
prescriptions to patients for new medicines that require immediate initiation and not 
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giving repeat prescriptions (NHS management executive, 1991). However, patients 
may not appreciate that whilst GPs and hospital doctors are part of the NHS, they 
effectively work within separate organisations. They therefore do not appreciate that 
hospital doctors are not allowed to issue repeat prescriptions. This means that patients 
could run out of medicines. General practitioners also complained that patients' 
desire to start new medicines immediately following outpatient appointments meant 
that they were pressurised into issuing prescriptions within a shorter timescale than 
usual. They felt it would be better if hospital doctors were able to issue prescriptions 
for all new medicines rather than just those that required starting immediately. 
The present study also highlighted the difficulty in keeping all health care 
professionals up to date with inclusions in a medicines formulary. General 
practitioners complained about being asked to prescribe medicines that they 
mistakenly believed were non-formulary. However, the present study also 
demonstrated that problems with formulary adherence can arise if health care 
professionals, other than doctors, are not kept informed of the reasons for, and content 
of, a formulary. At the hospital studied, non-medical health care professionals were 
excluded from communication channels about the medicines formulary. This perhaps 
reflects a lack of consideration that these health care professionals ask GPs to 
prescribe on their behalf because they cannot issue prescriptions themselves. In the 
future, as the number of non-medical prescribers increases, processes will have to be 
put in place to ensure that all relevant professionals are fully informed of mechanisms 
to control the use of medicines. 
Hospital pharmacists revealed their ignorance of the world within which their 
community colleagues practise by not appreciating that community pharmacists did 
not prepare extemporaneous medicines. Patients, therefore, had unrealistic 
expectations with regard to obtaining extemporaneous medicines from community 
pharmacies. This led to frustration on the part of hospital pharmacists when patients 
faced discontinuities in medicines supplies. However, community pharmacists in the 
study area were not dissimilar to other community pharmacists because other 
researchers have found that the frequency of extemporaneous dispensing in 
community pharmacies is low (Rennison & Portlock, 2003a; Candlish et aI, 2003). 
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6.3.3 Flagrant violation of policy 
In the present study, several ways were identified in which interface medicines 
management policy was flagrantly breached. These included the use of 'loss leader' 
medicines by hospitals in order to manage their own budgets and transferring the 
prescribing, and hence the cost, of expensive medicines to GPs. Hospitals also failed 
to adhere to policies on the return of patients' own medicines and they put pressure on 
GPs to prescribe non-formulary medicines. 
The long-standing practice by the pharmaceutical industry of introducing loss leaders 
into hospitals was described in Chapter One. General practitioners in the present 
study reported their frustrations that this practice was being perpetuated. It is easier to 
appreciate why this practice continues if this is considered within the context in which 
hospitals function. Hospital budgets have traditionally been cash-limited which 
means that increased expenditure on medicines has to be funded by reducing 
expenditure in another area. Hospitals also have annual efficiency targets imposed on 
them. This means that there is a strong incentive for hospital staff to purchase 
medicines cost-effectively, not least because hospital managers face serious penalties 
for failing to achieve financial balance. Conversely, there are no penalties for the 
continued use of loss leaders and so the practice continues. Moreover, for these 
reasons hospital managers are likely to b~ resistant to official guidance stating that the 
total costs to the NHS should be taken into account (NHS executive, 1994). 
Therefore, these sorts of policy violation can be explained, if not justified, by 
practitioners on each side of the interface attempting to maximise their budgetary 
performance. This undesirable practice understandably has a negative impact on 
inter- and intra-professional collaboration between primary and secondary care 
practitioners. 
General practitioners in the present study were resentful that prescribing was 
transferred to them in order to transfer the costs of expensive medicines from the 
secondary to primary care prescribing budget. Two scenarios were raised when they 
felt that prescribing responsibility was inappropriately transferred. First, when GPs 
had infrequent contact with patients with complex chronic conditions and took no part 
in clinical care other than to issue prescriptions. Second, when hospital doctors 
wanted patients to have expensive treatments which had not been approved for use by 
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hospital Drug and Therapeutics Committees. This was particularly irritating for GPs 
when the use of a particular medicine might reduce other areas of hospital 
expenditure. This confirms work published by Home et al (2001) and Duggan et al 
(2001) illustrating that GPs believe that this is simply a cost-transfer exercise and 
nothing to do with clinical effectiveness. 
The situation whereby hospital doctors, or other practitioners, may ask GPs to 
prescribe non-formulary medicines is more complex. Hospitals are encouraged only 
to provide medicines for patients attending outpatient clinics if they need to be started 
immediately (NHS management executive, 1991). For all other patients a 'medicines 
advice note' is written for the patient to deliver to the OP detailing any necessary 
changes to medicines. Whilst the use of medicines advice notes is compliant with 
national policy it is clear that this system can contribute to interface medicines 
management problems particularly if hospital practitioners decide to flaunt the rules. 
The problem with the use of medicines advice notes is that they bypass hospital 
pharmacists. Therefore, hospital pharmacists are unable to intervene if medicines 
advice notes are used to ask GPs to prescribe non-formulary medicines. The present 
study showed that OPs were reluctant to tum down such requests meaning that it is 
likely that patients will receive non-formulary medicines. This can also be related to 
the different roles of hospital and community pharmacists. Whilst pharmacists 
practising in hospitals are expected to intervene if non-formulary medicines are 
prescribed, this is not currently within the remit of community pharmacists. For 
contractual reasons discussed earlier in this chapter, community pharmacists normally 
do not question the prescribing of non-formulary medicines. This makes the managed 
entry of medicines difficult because medicines advice notes may be used to request 
medicines that have been rejected by Drug and Therapeutics Committees or that have 
yet to be considered. In the present study hospital doctors sometimes took advantage 
of this system by asking OPs to prescribe medicines they knew were non-formulary 
items. This demonstrates a lack of appreciation of the, need to manage medicines and 
the impact that failure to control expenditure on medicines can have on available 
resources in other parts of the health service. 
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6.3.4 Impracticable or inflexible policy 
Some medicines management policies, both local and national, create problems with 
the management of medicines because they are either impracticable or inflexible. 
These relate more to the strategies of cost-containment and budgetary management. 
In this section the strategies introduced by the secondary care sector will be discussed 
first. These relate to the management of expenditure on medicines through the use of 
formularies and secondary care doctors asking GPs to prescribe expensive medicines 
instead of these being funded out of hospital budgets. A further problem arises when 
policies for cost containment in primary care are not applicable in secondary care. 
Therefore, patients may be prescribed medicines in hospital that cannot be continued 
in primary care. 
The development of medicine formularies as a method of controlling medicines 
expenditure was identified in the introduction to this thesis. The problem with 
formularies is that they are mainly developed in either primary or secondary care and 
there is little published evidence of the successful application of joint formularies 
(Duerden & Walley, 1999). This means that, when patients come into contact with 
hospital services, their medicines may not comply with the hospital formulary. The 
GPs interviewed in the present study complained that patients' medicines were 
changed simply to comply with the hospi.tal formulary rather than for any clinical 
benefits. This could confuse patients but, additionally, GPs may sometimes have 
good reasons for their choice of medicine. The rationale for the choice of medicine 
has even greater significance when the financial aspects are taken into consideration. 
If a medicine is more expensive in primary care it puts pressure on the primary care 
prescribing budget. In the present study hospital pharmacists explained how they 
dealt with patients admitted on hospital non-formulary medicines. They would make 
a decision whether to purchase a medicine for an individual patient or to ask a hospital 
doctor to change their prescription to a formulary medicine. However, hospital 
pharmacists will obviously find it easier to change a prescription rather than go 
through the protracted process of purchasing a non-formulary medicine. This 
indicates that systems set up in hospital tend only to be concerned with the 
containment of hospital medicines expenditure rather than considering the total costs 
of medicines across a health economy. As previously mentioned, this is 
understandable given the emphasis on budgetary control within the secondary care 
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sector. Different pricing structures for medicines in primary and secondary care may 
therefore contribute to difficulties in collaborative prescribing across the interface. 
However, if hospital policies were more flexible and more sensitive to the needs of 
primary care, problems with formulary differences would diminish. 
The aim to achieve effective medicines management processes in secondary care may 
actually encourage rules to be broken. Hospitals may have good systems for 
formulary enforcement through hospital pharmacists but, in some hospitals, formulary 
adherence is only compulsory for junior doctors (Joshi et ai, 1994). The rigid 
secondary care formulary process may encourage hospital doctors to try to avoid this 
in order to get the medicines their patients need. Jones et al (2001) described how 
hospital doctors bypassed rigid policies for the introduction of new medicines into 
hospitals by asking OPs to prescribe them. One of the hospital medical consultants 
interviewed in the current study described the process as 'hoops to jump through' 
indicating that the process was unnecessarily bureaucratic and lengthy. It should be 
appreciated that whilst some hospital doctors are aware of the need for formulary 
control they may find the process restrictive. This may be compared with situations 
described in 6.6.3 giving rise to 'flagrant violation of policy' . In those instances 
hospital doctors did not appreciate the need to control medicines and felt this 
impinged on their clinical freedom. The frustration for some hospital medical 
consultants was that, when individual patients need specific non-formulary medicines 
for genuine clinical reasons, there is no quick way of obtaining these medicines 
through the hospital pharmacy. So it is understandable why some hospital doctors try 
to accelerate the process by asking OPs to prescribe non-formulary medicines. 
Another problem identified in the present study that arose from hospital systems to 
manage budgets was associated with the reluctance of hospital managers to transfer 
funds between hospital budgets. General practitioners expressed frustration that they 
were asked to prescribe expensive medicines which hospital management would not 
allow hospital doctors to prescribe. Whilst one of the objectives of formularies is to 
manage expenditure on medicines, OPs felt that in some cases the use of a medicine 
would reduce expenditure in other areas of secondary care. For example, OPs felt that 
allowing hospital gynaecologists to prescribe Mirena® intrauterine contraceptive 
devices would reduce the cost of sterilisation operations (App. 7.1, OP 2, para. 226). 
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They were frustrated at hospital management's failure to consider the 'whole system' 
of health care across both primary and secondary care and transfer monies from a 
surgical budget into the hospital prescribing budget to pay for the Mirena® devices. 
However, what GPs did not seem to appreciate was that, whilst it was true that the use 
of a medicine could reduce surgical admissions, in reality the hospital would not save 
this money because another patient would be admitted. So far, inflexible medicines 
management policies within secondary care have been considered. It is now 
appropriate to consider the impact of inflexible policies in primary care. 
Over time, primary and secondary care organisations have developed different 
mechanisms for controlling expenditure on medicines. The NHS 'blacklist' 
effectively only applies to primary care because community pharmacists are not 
reimbursed for dispensing blacklisted items. A loophole exists because hospitals are 
free to purchase blacklisted items. Blacklisted medicines prescribed for hospital 
patients may not legally be continued in primary care. In the present study hospital 
pharmacists showed that they were not aware of what was included in the 'black list' 
probably because they do not have to work within its terms. However, what this 
means is that hospital pharmacists will not intervene if they are not aware that a 
medicine or appliance is blacklisted. This may result in the patient potentially being 
unable to obtain further supplies of medi~ine at home. Some medicines, rather than 
being excluded from prescribing in primary care, may only be prescribed for specific 
conditions. General practitioners are required to endorse prescriptions with 'SLS' to 
indicate that a patient's condition fits the necessary criteria. Community pharmacists 
are not generally provided with information about patients on discharge from hospital 
which means that they would be unaware that patients fit the necessary SLS criteria. 
They are therefore likely to take the easy way out and dispense a product which is not 
suitable for the patient rather than returning the prescription to the GP for 
endorsement. In the present study an example of this practice was when a community 
pharmacist supplied an iron preparation for a baby but without including a dropper to 
enable easy administration (Appendix 6, Table 5, Case 1). The consequences of these 
different systems in place in primary and secondary care may be that patients have 
difficulty obtaining the medicines they need in the community. It would be far better 
for the list to apply to both primary and secondary care although this would have to be 
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enforced by local hospitals whereas in primary care the Prescription Pricing Authority 
enforces the black list. 
So far medicines management problems have been considered and how they result 
from deficiencies in the structure and process ofNHS health care at the interface. 
Now the problems that arise within the context of national policy will be discussed. 
6.3.5 Summary of key themes identified in the present study and their relevance 
to implementation of national policy 
At a national level, policy on the management of medicines at the interface is covered 
in four major documents. 'Discharge of Patients from Hospital' (DoH, 1989) and the 
'Hospital Discharge Workbook' (DoH, 2003) cover all aspects of the hospital 
discharge process and not just medicines. However, much of what is stated about 
general communication between health care professionals in primary and secondary 
care is relevant to the management of medicines. These documents emphasise the 
importance of ensuring that primary health care professionals are aware of, and able 
to meet, patients' potential needs before they are discharged from hospital. The 
present study did not set out to quantify the time taken for hospital communication to 
arrive nor does it consider the quality of information because this has previously been 
reported by other researchers such as Tulloch et a/ (1975) and Mottram et a/ (1994) 
and confirmed by more recent work by Foster et a/ (2002). However, the present 
study provides some insight into the problems that poor communication across the 
interface causes for health care professionals. General practitioners were frustrated 
that their time was wasted searching for information that, with some forethought, 
could have been provided. Even when information did arrive they complained that it 
did not fulfil their needs. This left them with difficulties in planning ongoing care for 
patients. Hospital medical consultants and hospital pharmacists also waste time 
searching for missing information. The specific problems of community pharmacists 
were discussed earlier in this chapter. In this respect, the problems associated with 
poor inter- and intra-professional collaboration that lead to difficulties in the 
management of medicines remain unresolved. 
The present study provided examples of GPs being expected to prescribe medicines 
for patients to whom they did not provide clinical care and in circumstances when 
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GPs felt they lacked the knowledge or expertise to accept clinical responsibility. This 
was discussed at the start of this chapter but it is important to emphasise, here, that 
guidance relating to prescribing and clinical responsibility across the interface has not 
been adequately implemented. Work by Sibbald et al (1991) showed that prescribing 
responsibility was transferred from hospital doctors to GPs only because of the 
priority to curtail hospital expenditure. This led to the development ofNHS guidance 
on clinical responsibility which emphasised that the person with clinical responsibility 
for a patient should prescribe any necessary medicines (NHS management executive, 
1991). It is clear, then, that the situation has not been resolved since publication of 
that guidance. Similarly, Duggan et al (2001) and Home et al (2001) found that, 
where shared care guidelines were established to clarify clinical responsibilities, these 
were still felt to be focused around transferring the cost of expensive medicines to the 
primary care prescribing budget. The continuation of this situation is partially 
explained by the way in which the NHS is organised. Hospital doctors are currently 
not permitted to prescribe for patients in the longer term because of funding issues 
and, in particular, the fact that repeat prescribing is not permitted in secondary care. 
One way to resolve this problem would be to implement 'repeat dispensing' in the 
secondary care sector. Repeat dispensing is being introduced in primary care as part 
of the new community pharmacy contract but will apply only to prescriptions written 
by GPs (DoH, 2005). 
The cost-effectiveness of prescribing across the interface became the focus of 
important guidance outlined in 'Purchasing and Prescribing' (NHS executive, 1994). 
In particular, reference was made to ensuring that hospitals took into account the 
primary care costs of medicines when making purchasing decisions. Effectively, this 
prohibits the use of 'loss leader' medicines but, as the present study shows, hospitals 
still take advantage of preferential discounts on medicines which cost significantly 
more when prescribed in primary care. 'Purchasing and prescribing' (NHS executive, 
1994) also stressed that the use of new medicines should be managed into the NHS. 
This requires consideration of their cost-effectiveness compared to existing medicines 
before being recommended for use. Hospitals have implemented this within 
secondary care through the use of formularies. However, the current study shows that 
hospital doctors may bypass the formulary process by asking GPs to prescribe non-
formulary medicines on their behalf. Not only does this mean that the entry of new 
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medicines is not being effectively managed (because community pharmacists do not 
enforce formularies) but GPs may be pressurised to prescribe a medicine about which 
they have no previous knowledge. 
So far the case has been made that the management of medicines continues to be 
problematic despite a raft of Department of Health guidance intended to alleviate such 
difficulties. In the next section, consideration will be given to the theories of change 
management in order to shed a different light on the subject that helps to explain why 
national policies have not been as effective as intended. 
6.4 APPLICATION OF CHANGE MANAGEMENT THEORY TO EXPLAIN 
WHY MEDICINES MANAGEMENT ACROSS THE INTERFACE HAS NOT 
BEEN EFFECTIVE 
In this section the problems with the management of medicines across the interface 
will be discussed within the context of change management theory. First, the gaps in 
the diagnosis of medicines management across the interface, identified in Chapter 
Three, will be discussed in the light of data that has emerged from the present study. 
Then consideration will be given to the forces driving and restraining change that 
have been identified. Finally, the findings of the present study will be discussed from 
the perspective of the requirements needed to bring about change in medicines 
management across the interface. 
6.4.1 Diagnosis of a situation requiring change 
In Chapter Three it was explained that a diagnosis of a situation requiring change is 
necessary before undertaking a change programme. This improves our understanding 
of a situation in its current state and provides background information useful to the 
change process. Nadler and Tushman's (1977) diagnostic model was applied to 
medicines management at the interface using data extracted from the literature and 
several gaps were noted. These were in the informal culture, shared vision of how 
things will look for the better in the future and leadership towards the goal of the 
shared vision. Findings that emerged within these areas during the present study will 
now be discussed. 
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6.4.1.1 Informal culture relevant to medicines management at the interface 
The findings from the present study give rise to three specific aspects that lead to the 
notion that an informal culture has evolved. First, there was the expectation that GPs 
accept the transference of responsibility for prescribing from their hospital colleagues. 
Second, was the perception that systems to manage the cost of medicines impacts 
adversely on hospital doctors' clinical freedom. Finally, health care professionals 
tend to consider patient care only within the context of primary or secondary care and 
not by taking account of the interface as a whole. 
With regard to the transfer of responsibility, what arose in the present study was that 
hospital doctors expected GPs to prescribe medicines without question and this has 
evolved into an informal culture. This traditional way of doing things has become 
entrenched in an informal culture despite the fact that over time medicines have 
become more complex and may no longer be appropriate for GPs to prescribe. 
General practitioners reinforce this informal culture by continuing to prescribe 
medicines with which they feel uncomfortable taking clinical responsibility. 
With regard to the cost versus clinical freedom dimension, hospital doctors may take 
advantage of loopholes in the processes of medicines management that enable them to 
initiate prescribing. This is exemplified ~y hospital doctors writing to GPs to request 
that they prescribe non-formulary medicines despite formulary alternatives being 
available. 
Finally, an informal culture has insidiously arisen whereby health care professionals 
consider patient care only within the context of the primary or secondary care 
environment within which they work. This is particularly pertinent for health care 
professionals in secondary care who do not consider whether patients will be able to 
obtain medicines in primary care or the budgetary impact of their prescribing 
decisions in the primary care setting. 
These informal cultural aspects have developed without much appreciation of what 
might be changed to improve the situation. The next section takes a look at these 
informal cultures and introduces a debate as to how barriers can be overcome and 
positive change introduced. 
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6.4.1.2 Shared vision across the interface 
Data from the present study indicates that there was no real evidence of a shared 
vision across the interface. First, attempts to manage the hospital prescribing budget 
through the use of 'loss leader' medicines and transferring costs to GPs illustrates a 
lack of regard for considering the impact on total medicines expenditure within the 
health economy. Second, both GPs and community pharmacists reported problems 
with being expected to prescribe or dispense unusual medicines without being given 
the information to enable them to do this safely and promptly. Whilst this is partially 
explained by a lack of awareness on the part of hospital practitioners of what their 
primary care colleagues need to know it also shows a lack of consideration of the 
information needs of primary care colleagues. 
6.4.1.3 Lack o/Ieadership in the vision/or improved medicines management 
A certain lack of leadership, particularly within secondary care, was exemplified by 
hospital doctors asking GPs to prescribe non-formulary medicines despite knowing 
that this was against the district policy. If hospital medical consultants defy policies 
then it will not be surprising to learn that junior members of medical teams follow 
their example. This is important because of the dominance of the medical model of 
health care within the NHS which means that doctors maintain significant control of 
resources. The cooperation of the medical profession is essential if the necessary 
changes in medicines management are to occur. Currently, doctors have most control 
of what happens to patients and the authority to over-ride the actions of other health 
care professionals (Baggott, 1998). 
Having identified the contributory factors to the continuation of poor medicines 
management at the interface, the theory of change management will now be 
considered in order to identify methods of counteracting these difficulties. The next 
step is to determine the factors that act as barriers to change or driving forces for 
change. These will be identified with the help of Lewin's (1947) force field theory. 
6.4.2 Force field analysis of factors driving and restraining change 
In Chapter Three Lewin's (1947) theory was used to explain that change can occur 
only if the driving forces are greater than the restraining forces. Examples of forces 
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found in the present study that may drive or restrain improvements or change in the 
medicines management process across the interface are shown in Table 6.1. 
Table 6.1 Forces driving and restraining change in medicines management 
Driving forces 
• OP refuses to prescribe and so hospital 
doctor continues to prescribe. 
• OP complains about request to prescribe 
non-formulary medicine. 
• All professional groups frustrated by 
poor communication. 
• Agreement that hospital medical 
consultant may prescribe new medicine if 
assistance is given with the managed 
entry of another, that is a 'win-win' 
situation. 
• Appreciation that an overspend on the 
prescribing budget reduces funds 
available for other health care areas. 
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• 
• 
• 
• 
• 
• 
Restraining forces 
OP prescribes a medicine despite feeling 
uncomfortable. 
Loophole in the medicines advice note 
system which means that hospital doctors 
can ask OPs to prescribe any medicine. 
Lack of awareness of the information 
needs of health care professionals on 
either side of the interface. 
Complicated process for the introduction 
of new medicines. 
Management pressure to manage hospital 
budgets seems stronger than in primary 
care. 
Use of 'loss leader' medicines and 'cost 
shifting' by hospitals is still allowed. 
• Lack of capacity and funding in 
secondary care to follow up patients on 
specialist medicines. 
• Reluctance by community pharmacists to 
take on a clinical role, including 
enforcement of district formularies. 
• Different medicines management policies 
operate in primary and secondary care 
and a lack of awareness ofthis in 
secondary care. 
• OP reluctance to change hospital initiated 
medicines. 
Table 6.1 above show the forces that act to drive and restrain change in the interface 
medicines management system. If the sum of driving and restraining forces are equal, 
change cannot take place. This means that in order to improve the interface medicines 
management system, driving forces must be strengthened or restraining forces 
weakened. Consideration will now be given to how these forces interact in a way that 
currently prevents improvements being made. 
6.4.2.1 Prescribing decisions 
A number of reasons were given to explain why, despite feeling uncomfortable, GPs 
complied with hospital practitioners' requests to prescribe. This provides a barrier to 
changing the situation because GPs who did refuse such requests reported that they 
did not continue to receive them. General practitioners were aware that the lack of 
capacity to follow up patients in secondary care meant that hospital practitioners, even 
if they preferred to retain clinical responsibility, had no option but to transfer clinical 
responsibility to GPs. It would be expected that if GPs rejected hospital practitioners' 
requests to prescribe non-formulary medicines then this practice would stop. Whilst 
GPs continue to agree to prescribe, hospital practitioners will take advantage of the 
medicines advice note system. This is because it is easier than going through the 
complicated processes for the introduction of new medicines. Community 
pharmacists could also help to stop inappropriate non-formulary requests but it has 
already been explained that this is not currently part of their role and there are 
disadvantages, not least financial, to them of starting to do this. 
6.4.2.2 Finance 
If the financial problems associated with medicines management across the interface 
are considered, a number of factors prevent change happening. Management pressure 
to control medicines expenditure seems to be stronger in secondary care than primary 
care. Therefore, hospital practitioners will be reluctant to change the medicines they 
use if this means that their costs increase. It is likely that the practice whereby 
hospitals take advantage of discounted medicines will continue until managers start to 
view medicines expenditure across the whole health economy rather than considering 
secondary care in isolation. A similar incentive exists to continue cost shifting 
expensive medicines to primary care and, again, until GPs stop complying with such 
requests, such practice is likely to continue. 
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6.4.2.3 Communication 
Barriers to improving communication across the interface relate to a lack of 
awareness of the needs of practitioners on the opposite side of the interface. Hospital 
practitioners in particular tend to remain unaware of the information requirements of 
their primary care colleagues. 
The reasons why change has not happened can also be explored using Camall' s 
(1999) 'change equation' EC = A x B x D. Where EC is the energy for change, A is 
the dissatisfaction with the current situation, B is the level of knowledge of the first 
steps to take towards change and D is the shared vision of what the future will look 
like following the change. 
Change will only happen if A, B and D are all greater than zero and if the energy for 
change is greater than the perceived cost of making the change. It is clear, then, that 
in order for medicines management across the interface to improve, there has to be 
dissatisfaction with the current situation. However, from the present study it appears 
that whilst secondary care consultants and pharmacists were frustrated with poor 
communication from primary care, it does not affect them sufficiently to create 
enough dissatisfaction to change the current situation. This is where the problem lies 
because improving medicines management at the interface requires hospital 
practitioners to change the way they practice and it may be difficult to motivate them 
to do this until they are dissatisfied with the current state. Conversely, primary care 
practitioners are unable to change the way things are done because this relies on a 
change in attitude of and practice of hospital practitioners. It has already been 
discussed how there is a lack of shared vision towards an improved system of 
medicines management across the interface. Now consideration will be given to how 
hospital practitioners can be encouraged to change the way they practise through what 
Lewin calls the 'unfreezing' of the current state. 
6.4.3 Unfreezing the current state oC medicines management across the interCace 
Carnell's (1999) 'change equation' tells us that change will not happen if stakeholders 
are satisfied with the current situation. First of all, an awareness of the need to change 
is required in order to overcome resistance to change. This is the first step in Lewin's 
(1947) three-step change model and is termed 'unfreezing'. 
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In order to improve medicines management across the interface there needs to be 
awareness that the quality of medicines management is poor across the interface. 
General practitioners were dissatisfied with being expected to accept clinical 
responsibility for specialist and unusual medicines and community pharmacists were 
dissatisfied with the lack of communication about patients who had been in contact 
with secondary care services. Both GPs and community pharmacists felt they wasted 
time searching for information that could easily have been provided for them and 
were left to explain to patients any problems in the transfer of their care. Whilst 
interface problems occurred infrequently, when they did occur they could take much 
time and effort to resolve. Conversely, hospital practitioners were frustrated with 
poor communication from primary care but this did not impact greatly on their daily 
practice. Second, the factors resisting change, whilst difficult to quantify, appear 
greater than the factors driving change. Driving forces for change were similar to the 
dissatisfaction expressed with the existing state of medicines management across the 
interface in that they mostly came from primary care practitioners. Resisting forces, 
however, were within the secondary care sector. Therefore, the key to improving 
medicines management at the interface lies in the hands of secondary care 
practitioners whose attitudes need to change if any real change is to occur. 
6.4.4 The need for change in behaviour and attitude of health care professionals 
Chapter Three concluded that the dissemination of guidelines, alone, did not result in 
a change in practice. This may explain why DoH guidance on medicines management 
has not been successfully implemented. Passive dissemination techniques such as 
mailing out the guidance were used. Health care professionals may not have 
appreciated how the guidance applied to them and of deficiencies in their current 
practice. Also, all practitioners who prescribe or influence prescribing must take 
account of the guidance otherwise the current situation will be perpetuated. 
Additionally, if health care professionals disagree with a guideline they may not 
adhere to it (Cabana et ai, 1999). In the present study this was demonstrated through 
the interface issues that arose because of a 'flagrant violation of policy'. In these 
cases the health care professional was aware that local policy was being breached but 
still chose to continue with the initial path of care. This again lends support to the 
proposal that barriers to change, particularly associated with secondary care 
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professionals, should be identified before attempting to introduce specific interface-
related policies. 
So far in this chapter the findings from the present study have been discussed in terms 
of reasons why medicines management problems occur at the interface and change 
management theory has been applied to show why national policy has been 
unsuccessful at improving the situation. This chapter finishes with a discussion of the 
key outcomes of the present study demonstrating how the study's aim and objectives 
have been achieved and how this contributes to existing knowledge about the 
management of medicines across the interface. 
6.5 KEY OUTCOMES FROM THE PRESENT STUDY 
Three key outcomes emerge from the present study. First, an improved understanding 
has been derived of the types of medicines management issues that arise when patient 
care is transferred across the interface. Second, it has been possible to identify some 
important reasons why medicines management is less than optimal and why DoH 
guidance has failed to improve the situation. Third, this thesis has led to the 
development of an improved understanding of the interface and its constituent 
dimensions which helps us to appreciate the type of interventions that may be 
necessary in order to ensure seamless car~. Each of these key findings will now be 
discussed in relation to the study's aim and objectives. 
6.5.1 Improved understanding of medicines management issues that arise at the 
interface 
The first objective of the present study was 'to describe and categorise problems 
relating to the care transfer process that lead to a deterioration in medicines 
management'. The data obtained during the study's fieldwork relates to the whole 
spectrum of interface medicines management in contrast with previous studies which 
have concentrated upon single aspects of the interface such as medication errors and 
the transfer of clinical responsibility. The present study has, therefore, improved our 
understanding of problems associated with the interface by considering the 
interrelated problems associated with poor communication and difficulties that 
practitioners experience when clinical and financial responsibility is transferred from 
primary to secondary care settings and vice versa. 
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Problems associated with poor communication arise, for example, when community 
pharmacists are not informed of where to obtain unusual medicines and this can lead 
to delays in patients receiving important medication. Similarly, financial drivers can 
be responsible for conflicting goals arising between primary and secondary care 
practitioners. The present study has illustrated this through the example of hospital 
practitioners asking GPs to prescribe non-formulary medicines that had not been 
formally considered by the hospital Drug and Therapeutics Committee or that had 
been rejected by the committee. Problems with respect to assuming clinical 
responsibility for medicines have been illustrated with reference to GPs who were 
concerned about accepting the transfer of prescribing responsibilities from hospital 
colleagues. Their underlying concern was that of the medico-legal consequences of 
prescribing a medicine with which the GP was unfamiliar or had little prescribing 
experience. Identification of the range of medicines management issues arising when 
patients were transferred across the interface showed where policy concerning 
medicines management was not being adhered to. This fulfilled Objective Two which 
was 'to critically appraise the local interpretation and implementation of health policy 
relevant to the needs of patients when clinical responsibility is transferred between 
primary and secondary care'. 
Medicines management issues were considered from the perspective of health care 
professionals rather than from the researcher's preconceived ideas. This correlates to 
Objective Three which set out 'to describe the staff communication and decision-
making processes when responsibility for care transfers from primary to secondary 
care and vice versa'. Communication across the interface was particularly 
problematic because this left health care practitioners on either side of the interface 
unsure of exactly which medicines patients should be taking. The study, however, has 
led to an important understanding that, rather than being concerned only by simple 
communication problems, the root cause of many of such difficulties emanate from 
poor inter- and intra-professional collaboration. This can result in health care 
professionals having insufficient information to make informed decisions about the 
continuing care of patients. The study also showed that different groups of health care 
professionals experienced different perspectives and problems with regard to the 
management of medicines across the interface. General practitioners, for example, 
were mainly concerned with attempts to inappropriately transfer, to primary care, the 
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responsibility for the prescribing of specialist medicines and the lack of collaboration 
between practitioners associated with this. General practitioners were also frustrated 
with the effect of prescribing decisions made by hospital practitioners on their own 
prescribing budgets without considering the knock on effect in primary care. 
Community pharmacists, on the other hand, were concerned with poor 
communication about patients across the interface but focused primarily upon the time 
that was wasted attempting to source unusual medicines or trying to find out exactly 
what medicines patients should be taking. Community pharmacists expressed 
frustration that this type of information could easily have been provided to them. 
Whilst the present study did not set out to quantify the frequency of medicines 
management problems it became clear that GPs and community pharmacists, in 
comparison with their hospital colleagues, were particularly dissatisfied with the 
current situation. The discontent expressed by practitioners, especially those within 
primary care, lead us to more closely examine the causes of sub-optimal medicines 
management across the interface. 
6.S.2 Causes of sub-optimal medicines management across the interface 
The identification of causes of the sub-optimal management of medicines across the 
interface was the second key finding arisjng from the present study. It was clear that 
the original data categorisation framework was too simplistic and did not provide 
sufficient explanation as to the causes of the interface issues. Therefore, a framework 
was developed to categorise the issues that arose according to whether they were 
associated with one of four identified causes. First, issues arose because of a lack of 
awareness of or misunderstanding of policy. This was when prescribing policy had 
not been followed due to the originator of the problem being unaware of or 
misunderstanding a policy rather than a will to deliberately violate a policy. There 
was some evidence that the lack of awareness or misunderstanding associated with the 
use of medicines sometimes resulted from complainants who incorrectly thought that 
policy had not been followed. They were, for example, not aware that the policy 
specifying quantities to be supplied on hospital prescriptions differed for medicines 
and nutritional supplements and that the quantities of medicines supplied on hospital 
discharge could vary provided it was not less than fourteen days supply. Another 
cause of sub-optimal medicines management across the interface was related to a lack 
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of inter- or intra-professional collaboration. For example, there were instances when 
health care professionals had failed to communicate when patients were being 
transferred or when there was a lack of collaboration between health care 
professionals before a patient was transferred to ensure that all the patient's needs 
would be met in the new care environment. Finally, there were some policies that 
practitioners felt were so impracticable or inflexible that they found it impossible to 
adhere to. For example, this occurred in the case of some national policies relating to 
the NHS blacklist and local policies such as those specifying the quantities of 
medicines to be provided for patients on discharge from hospital. In some instances 
practitioners even exhibited a total disregard for policy leading to flagrant violations 
such as when failing to comply with a district medicine formulary. 
The identification of the root causes of interface issues, presented in the findings of 
this thesis, helps us to understand the local interpretation and implementation of 
interface policy (Objective Two). The research has enabled the pin-pointing of where 
critical events happen and how these can trigger a chain of events resulting in an 
interface issue or problem. The mapping of these events shows where national or 
local interface policy can fail. 
Weak links in the process of medicines management were identified when OPs wrote 
referral letters to hospital practitioners, indicating a lack of awareness of the type of 
information required and the need for explicit descriptions of the medicines that 
patients are taking. Similarly, when patients are discharged back to the care ofOPs, a 
failure to accurately update the patient record in general practice may lead to the 
occurrence of medication errors. The lack of communication and collaboration with 
community pharmacists means that there may be insufficient information to dispense 
prescriptions following patients' discharge from hospital. Hospital pharmacists 
tended not to intervene when hospital doctors prescribed medicines that were not 
available for dispensing in the community. From the patient's point of view, it would 
be much better to prescribe a medicine that is known to be available in the community 
or to make arrangements to obtain it rather than to place the onus on OPs and 
community pharmacists to identify a source or find an alternative. This, perhaps, 
reflects the lack of awareness on the part of hospital pharmacists of the limitations 
within which their community colleagues have to operate. 
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For patients seen at hospital outpatient clinics, the main deficiency in the medicines 
management process was when non-urgent treatment was required and the hospital 
practitioner completed a medicines advice note or wrote to a GP requesting a change 
to a patient's medicine regimen. This results from a loophole in the medicines 
management process whereby hospital practitioners may ask GPs to prescribe non-
formulary medicines. Additionally, at this point there is an opportunity to provide 
GPs with complete information about why a different medicine is appropriate and 
whether there are any considerations, such as an 'off-label' use. Instead of this, 
secondary care practitioners tend only to provide standard information such as the 
name and dose of the medicine. 
The fourth objective of the present study was to explore reasons why DoH guidance 
regarding the management of medicines across the interface is not put into practice. 
This was achieved by considering medicines management across the interface within 
the context of organisational change management theory. This helps explain why 
previous attempts to ensure seamless care with regard to medicines have not been 
successful. A number of reasons have been identified that help to explain why 
medicines management across the interface has not improved. At the very least, there 
is a lack of shared vision for the aim of achieving seamless care across the primary 
and secondary care interface and consid~rable confusion with regard to where the 
responsibilities lie in terms of achieving this aim. Additionally, the barriers to 
changing the current situation rest mainly within secondary care and, until managers 
and practitioners within secondary care appreciate the need, there is unlikely to be any 
appreciable improvement. In Chapter Three it was ,demonstrated that medicines 
management across the interface represents a 'soft' problem, partly because of the 
large human element involved in the form of the health care professionals who 
provide care. This helps to explain why previous researchers have made some 
improvements in patient care with respect to medicines management across the 
interface but that much still remains in terms of developing truly seamless care. The 
next section considers how the definition of the interface itself might be revisited in 
such a way that will lead to strategies to improve the management of medicines. 
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6.5.3 Revised interpretation of the interface 
The third key finding arising from the present study relates to how the interface is 
understood. This section, therefore, reflects on how a reconsideration of the definition 
of the interface itself can lead to a better understanding of where the issues lie and 
subsequently how the management of medicines might be improved. It starts by 
considering the traditional view of the interface as a principally communication 
centred model. The model is then developed to include the influences on 
communication and decision making by and between health care professionals before 
progressing to the final model which takes into account the various components of the 
interface and how these impact on effective medicines management as considered 
within this thesis. Figures are used to illustrate the communication channels and 
inter-relationships between health care professionals on either side of the interface. 
6.5.3.1 Inter- and intra-professional collaboration regarding medicines across the 
intetface 
A traditional representation of the interface, shown in Figure 6.1, illustrates the 
physical separation of doctors and pharmacists in primary and secondary care 
environments and their links with colleagues. The principal communication channels 
about patients admitted to or discharged from hospital are shown between hospital 
consultants and GPs and hospital and community pharmacists. Problems at the 
interface occur when communication fails in some way. The findings from the 
present study, however, indicate that traditional communication-centred approaches to 
resolving medicines management across the interface are too simplistic because they 
do not take account of a wide range of external factors that influence communication 
and decision making associated with the management of medicines. Therefore, an 
important root cause of medicine problems at the interface results from poor inter- and 
intra-professional collaboration. This is, essentially, different, although subtly so, 
from 'miscommunication'. Ifpharmacists and doctors do not appreciate the needs of 
working environments on the 'other' side of the interface, then there will be situations 
arising that compromise communication and appropriate decision-making. For 
example, GPs may feel uncertain as to whether to accept the clinical responsibility for 
medicines requested by hospital medical consultants. Similarly, community 
pharmacists may feel unable to dispense prescriptions without being more fully 
informed of the needs of a particular patient. At best, these sorts of difficulties result 
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Figure 6.1 Traditional representation of communication regarding medicines across 
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in a waste of time and resources. At worst, such problems may result in the 
discontinuity of supply of medicine or the prescribing of an incorrect medicine, or 
incorrect regimen. 
6.5.3.2 The impact o/separate arrangements/or resource allocation 
The findings from the present study lead to a better understanding of the wider issues 
affecting medicines management across the interface. This more complex picture is 
portrayed in Figure 6.2 which illustrates the external factors that influence decision 
making in primary and secondary care environments. For example, hospital 
employees work within ground rules established for hospitals such as secondary care 
medicines expenditure budgets. Primary care practitioners, on the other hand, are 
independently professionally accountable for their decision making and are 
answerable to Primary Care Trusts and have separate budgetary ground-rules in 
relation to the funding of prescribed medicines. In this respect, the study confirms 
that a weakness remains within the NHS health care system that compromises 
resource allocation associated with the management of medicines. In secondary care, 
budgetary management is controlled via Drug and Therapeutics Committees, 
including the pressure to prescribe (often through pharmaceutical industry 
advertising) new medicines. In primary care GPs are allocated prescribing budgets 
that are controlled through prescribing advice and incentive schemes established by 
PCTs. The net impact of these separate policies is that there is still no accountability 
of practitioners within one sector for strategies introduced within the opposite sector. 
In partiCUlar, hospital managers tend to choose medicines that maximise their cost-
effectiveness in secondary care without considering the impact of such strategies in 
primary care. 
Some of the blame must also be apportioned to the pharmaceutical industry since it 
has, naturally, exploited the separate managerial arrangements in primary and 
secondary care. By heavily promoting to hospital staff the potential of new medicines 
there is a natural propensity for hospitals to take advantage of potentially beneficial 
advances in new medicines whilst remaining within their limited budgets. 
The strict enforcement of medicine formularies in secondary care raises another 
concern that has been brought to the fore by the present study. This is that secondary 
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Figure 6.2 Medicines management by primary and secondary health care 
professionals at the interface showing influences on communication and decision 
making 
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care professionals pressure, inadvertently or deliberately, GPs to prescribe non-
hospital formulary medicines. 
Secondary care professionals, who perhaps fundamentally disagree with the principle 
of formularies and believe that their clinical freedom is curtailed, may purposely take 
advantage ofloopholes in the system by asking GPs to prescribe non-formulary 
medicines. However, this loophole may also be exploited by those who appreciate the 
need for formularies but decide to use the loophole to circumvent their frustration 
with the rules governing the release of non-formulary medicines. 
The problems with managing expenditure on medicines are compounded because 
community pharmacists currently have no legal say in controlling the prescribing of 
non-formulary medication. Community pharmacists would be ideally placed to 
enforce formularies in primary care, especially if the system for remunerating 
pharmacists in primary care is changed to one that rewards clinical, as opposed to 
dispensing, activity. The recent introduction of the new pharmacy contract may 
provide scope for this particular problem to be addressed. Additionally, in order to 
improve inter-professional collaboration between GPs and community pharmacists, 
joint professional development of these two groups should be encouraged. 
Decisions around dispensing medicines are affected by the fact that there are certain 
national policies concerned with improving the efficient use of medicines that apply 
only in primary care. Remuneration for community pharmacists for dispensing 
prescriptions is controlled by the Prescription Pricing Authority. This means that 
systems for controlling medicines expenditure, such as the NHS blacklist are strictly 
enforced. Community pharmacists are not reimbursed for blacklisted medicines 
dispensed and so there is a strong incentive to enforce the blacklist in primary care. 
Conversely, expenditure on medicines dispensed in hospital pharmacies is taken from 
the overall budget allocated to hospitals. There is no involvement of the Prescription 
Pricing Authority and secondary care prescribers are not obliged to adhere to the 
limitations of the blacklist. This can lead to situations whereby patients may be 
started on medicines or appliances in hospital which cannot later be continued in 
primary care. 
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Figure 6.3 Medicines management across the interface showing how deficiencies in 
the structure and process of care give rise to poor inter- and intra-professional 
collaboration, miscommunication and mis-management of medicines 
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I Day to day clinical decisions affecting individual patients are normally delegated by the hospital chief 
pharmacist to the hospital pharmacy team. 
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The efficient functioning of the NHS relies upon responsibility for patient care being 
transferred back to GPs. This means that there is pressure on hospital doctors to 
discharge patients back to the care of GPs. Within the NHS system there is no facility 
for hospital doctors to maintain clinical and prescribing responsibility for patients. 
For GPs, this means that they may feel obliged to prescribe medicines despite not 
wishing to take clinical responsibility because there is no alternative if patients are to 
receive the medicines they need. 
6.5.3.3 Barriers to improving the management o/medicines across the interface 
It has already been shown how the systems and processes ofNHS care may be 
counterproductive to creating the seamless that is required. However, theories of 
change management also enable a clearer picture to emerge and, thus, illustrate how 
barriers might be tackled that currently prevent improvements in the management of 
medicines from being achieved (see Figure 6.3). 
Barriers to improving medicines management in primary care include the lack of 
awareness or understanding, by secondary care practitioners, of the difficulties that 
may be incurred by their primary care colleagues in procuring medicines and in 
relation to policy that places constraints on what can be dispensed (e.g. generic 
substitution can take place in hospital but not easily in primary care). Thus, there is a 
tendency for secondary care practitioners to focus only on the immediate needs of 
patients whilst they are in hospital without taking into account of their ongoing needs 
when discharged home. This problem is compounded by barriers to change 
highlighted in primary care and not withstanding the fact that GPs, in the main, tend 
to go along with prescribing medicines requested by secondary care colleagues. 
Findings from this study suggests that GPs feel aggrieved that some of these 
medicines are not cost-effective in primary care and that they are reluctant to accept 
clinical responsibility when they lack familiarity with the drug concerned. Another 
barrier to improving medicines management results from the professional isolation of 
community pharmacists. This means that they may be unaware of which medicines 
are included in a hospital formulary but perhaps, more importantly, they are inhibited 
from intervening when non-formulary medicines are prescribed because of a 
commercial reliance on maintaining good relationships with GPs. Complex 
relationships with GPs and a lack of information from secondary care may also hinder 
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community pharmacists from providing pharmaceutical care for patients who have 
been in contact with hospital services. 
6.6 SUMMARY 
In this chapter the key findings of the present study have been discussed in relation to 
the aim and objectives of the study. An improved understanding has been gained of 
the types of medicines management issues that arise and why they arise. It is clear 
that national guidance concerning medicines management has failed to sufficiently 
address the many issues that continue to arise at the interface. It is argued that this is 
because there are deficiencies in the structures and processes of health care that 
operate when patient care is transferred which contribute to the emergence of 
problems. Inter- and intra-professional collaboration within and across primary and 
secondary care requires extensive development. This means that, currently, health 
care professionals do not appreciate the needs of their colleagues. This leaves them 
inadequately prepared to ensure that the welfare of patients is maintained during and 
after the transfer of care across the interface. The separation of managerial 
responsibility for prescribing budgets in primary and secondary care means that, on 
each side of the interface, health care professionals are concerned only with how the 
cost of medicines impacts on their own side of the interface. This leads to an illogical 
and unacceptable situation whereby the expenditure on medicines across a whole 
health economy can be adversely affected. 
Consideration of interface issues within the context of change management theory 
provides an insight as to why national guidance has 'failed to improve medicines 
management at the interface. This is because, as exemplified by Lewin's driving 
forces for change, considerable barriers still remain that prevent change from taking 
place. Equally importantly, there is a lack of 'shared vision' as to how medicines 
management at the interface can be improved. In the final concluding chapter, the 
fmdings will be discussed with regard to the implications for pharmacy practice and 
further research relating to the management of medicines. 
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CHAPTER SEVEN 
CONCLUSION 
7.1 OVERVIEW 
The contribution to knowledge made by this thesis builds upon our understanding, 
derived from previous approaches documented in the literature. These previous 
approaches have largely concentrated on poor communication and poor record 
keeping and have tended to focus on either primary or secondary care rather than by 
tackling the interface as a whole from all of its different perspectives. 
Three key outcomes emerge from the present study. First, the main causes of 
interface issues affecting the management of medicines have been identified in terms 
of how the professional stakeholders, both in primary and secondary care, view their 
own world of practice and the research demonstrates that they are largely dismissive 
or ignorant of the perspectives of colleagues on the other side of the interface. These 
causes have been identified as: a) a lack of awareness or misunderstanding of policy 
where the ignorance of individuals means that their actions are pursued at the expense 
of other interface stakeholders; b) inadequate inter- or intra-professional collaboration 
where actions have been pursued mainly from a uni-professional point of view 
without consideration of the needs of colleagues within their own profession or 
outside their own discipline; c) the implementation of impractical or inflexible 
policies that have been poorly conceived and are difficult to put into practice without 
causing additional issues or inconvenience; d) individual flagrant violation of policy 
where practitioners have, themselves, decided that their needs in achieving a given 
outcome are more important than those outcomes identified and agreed by policy-
makers. Second, by drawing upon the theories of change management, this thesis has 
identified some key reasons to explain why much of the guidance published by the 
DoH has failed to make lasting improvements with regard to the management of 
medicines at the interface. Third, the contribution made by this research has led to the 
development of an improved understanding of the interface, itself, and its constituent 
dimensions that enables us to appreciate the driving and restraining forces that affect 
the process of change in managing medicines at the interface. 
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In this concluding chapter, after taking into account the limitations of this study, a 
forward-looking view is expressed with respect to the implications of the findings in 
the context of current policy making and practice 
7.2 LIMITATIONS OF THE PRESENT STUDY 
It is acknowledged that there are a number of limitations with the present study. 
Firstly, the cases studies and interviews drew upon the views of doctors and 
pharmacists with only a small representation from nurses. This means that the 
different perspectives of nurses and other allied health care professionals may not 
fully be taken into account. Since the professions allied to medicine all practise at the 
interface, it must be accepted that, due to the need to focus the study on the main 
stakeholders, this study could not fully take into account the views of all practitioners. 
However, this weakness arguably represents only a minor limitation for, although the 
role of non-medical prescribers is now coming to the fore, decisions regarding the 
procurement and use of medicines are still likely to be primarily governed by 
pharmacists and doctors. 
A second minor limitation of the study relates to the fact that the majority of data 
focused on medicines management within a single English Acute Trust and its 
associated Primary Care Groups. Howeyer, GP focus groups were undertaken in 
Gloucestershire and the hospital medical consultants interviewed worked in 
Gloucestershire and Manchester. Not withstanding this limitation, the qualitative 
findings derived from this study are considered to be generalisable because the issues 
that have been discussed are pertinent to a wide range of literature that rings a chord 
with the management of medicines in a range of English health economies. The 
strength of qualitative research comes from its ability to identify issues that are 
relevant to health care practice on a wide scale so long as the practitioners who give 
their views are representative of the type of practice that takes place in a wider 
geographical arena. Conversely, a contrasting alternative approach that might be 
taken by researchers who are more positivistically inclined, for example, to take 
random samples of stakeholders involved in managing medicines, would not only be 
practically difficult in terms of arranging focus groups in different parts of the 
country, but could have limitations of its own through not being able to engage the 
views of practitioners that have experience of specific problems (Greenhalgh & 
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Taylor, 1997). By contrast, the theoretical sampling, deployed in this research, has 
enabled an exploration of issues that reflect the range of experiences encountered in 
primary and secondary care and this lends itself to the generalisability that makes this 
research relevant beyond the boundaries of the specific hospitals and Trusts where 
data were collected for the present study. All NHS hospitals in England must comply 
with a common set of regulations and so the study of typical English health 
economies such as those in Southern Derbyshire and Gloucestershire means that the 
findings have wider implications than for the specific setting and popUlation studied 
(Parahoo, 1997). 
It must be accepted that the interviewing of only two hospital medical consultants 
does mean that the full range of perspectives from hospital doctors may not have been 
fully captured. However, in comparison with GPs and pharmacists, they seemed to 
experience fewer problems with medicines management across the interface and so 
interviewing more consultants would probably may not have generated much 
additional data. Nevertheless, the interviewing of more hospital medical consultants 
would, if the current themes could be confirmed, lead to greater confidence in 
understanding their decision-making processes. With hindsight, it WOUld, perhaps, 
have been beneficial to have interviewed junior members of medical teams in order to 
confirm their views. 
The choice of study methodology also has some limitations. The collection of case 
study examples of interface issues relied on reports being given to the researcher and 
for the researcher (also working as a pharmacist professionally) to personally have 
encountered these issues. It is, therefore, possible that some interface issues arose 
during the period of data collection that were not identified by this research. Access 
to complaints databases may have given further insight into other issues, particularly 
those experienced by patients. However, the range of problems identified through the 
collection of case study examples was backed up by data obtained from interviews 
with pharmacists and doctors. As the current study set out to categorise interface 
issues, rather than quantify them, the fact that individual issues may have been missed 
is of lesser importance. 
251 
7.3 IMPLICATIONS FOR CURRENT PHARMACY PRACTICE 
This study raises several issues that are relevant to pharmacy practice. Firstly an 
improved understanding of the types of issues and where in the medicines 
management processes things go wrong is important because it allows us to see where 
in the processes changes could be made or systems improved to prevent problems 
recurring. In particular there are many ways in which medicines management 
processes can fail by putting patients at risk of receiving the wrong medicines. Health 
care professionals clearly intervene on many occasions to ensure that patients obtain 
the correct medicines but communication systems must be improved to ensure that 
patient safety does not rely on health care professionals bridging communication gaps. 
It is important that improvements made to communication about patients apply to 
patients who have been seen at hospital outpatient clinics and not just those who have 
been admitted to hospital. Additionally unclear financial or clinical responsibilities 
are other important reasons why patients may experience a delay in obtaining the 
medicines they need when they are transferred between primary and secondary care. 
One of the major reasons why medicines management problems arise was identified 
as a lack of inter- and intra-professional collaboration. This is important because, 
until inter- and intra-professional collaboration is improved, medicines management 
across the interface is likely to remain problematic. However, it became clear, in the 
present study, that this was often due to a lack of awareness of the information needs 
of colleagues on the other side of the interface rather than an un will ingness to 
collaborate. The DoH continues to drive the expansion of non-medical prescribing. 
Soon nurses and pharmacists will be able to prescribe independently, within their 
competency, from an unlimited list of medicines. This policy shift from medical to 
non-medical prescribing increases the importance of developing a greater sense of 
inter- and intra-professional collaboration that has been argued in this thesis. The 
advent of non-medical prescribing will increase the number of professionals that are 
permitted to prescribe for a given patient which will, therefore, increase the 
complexity of the processes. This in turn is likely to make the management of 
medicines at the interface more difficult and, in all probability, will increase 
occurrence of the number of medication issues and problems at the interface. 
Furthermore, it is likely that the expansion of non-medical prescribing will have 
adverse consequences for the financial management of medicines. It is unclear, yet, 
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where the responsibility for primary care prescribing budgets will lie in terms of 
practice based commissioning. However, if, as seems likely, individual GP practices 
are to assume this responsibility, the management of expenditure on medicines is 
likely to face upward pressure as the number of different professional groups of 
prescribers rises. 
Secondary care professionals also need to give more consideration as to whether 
patients will be able to obtain further supplies of medicines in primary care before 
discharging them from hospital. There should be an on-going dialogue between 
health care professionals in primary and secondary care to ensure that, firstly, there is 
a willingness to accept the transfer of prescribing responsibility and, secondly, that 
medicines are available in the primary care sector for when the patient goes home. 
Whilst it is untenable, and not necessary, to do this for all medication, secondary care 
professionals should give special consideration to patients who are prescribed 
medicines that are unlicensed, used off-label, new on the market or likely to be 
uncommon in primary care. There also needs to be a system for maintaining 
prescribing responsibility in secondary care if GPs feel unable to accept clinical 
responsibility. Whilst hospital specialists would maintain clinical responsibility, 
repeat prescribing and monitoring could be undertaken by supplementary prescribers 
under a clinical management plan. In this way, should a medication issue arise, 
supplementary prescribers would have easier access to discuss and resolve such issues 
with the hospital specialist. 
Recent changes in NHS policy, in particular 'payment by results', make the transfer of 
prescribing responsibilities across the interface more complex. Through the 'payment 
by results' policy, hospitals will be paid a nationally agreed fee for each episode of 
care. The fee paid by peTs will depend on the 'health resource group' of the episode 
of care provided, with more complex episodes of care attracting a higher fee. Most 
importantly, within the context of this thesis, some medicines will be excluded from 
'payment by results' tariffs. This means that hospitals do not have to provide these 
medicines within the fee paid for the episode of care. Therefore, PCTs will have to 
pay an additional fee for the cost of the medicines or GPs will have to issue 
prescriptions in primary care. Primary Care Trusts are unlikely to want to approve 
invoices for each individual medicine excluded from payment by results, particularly 
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since the structures of peTs are currently under review with a view to reducing 
management costs. This makes it likely that the onus will be placed on GPs to issue 
prescriptions. The medicines excluded from 'payment by results' tariffs are what 
have previously been considered to be 'specialist' medicines so GPs are unlikely to 
want to accept clinical responsibility for them. By applying the theory of change 
management in a manner discussed earlier in this thesis, it will be appreciated that 
'payment by results' is likely to be counter productive due to resistance from GPs. 
The current research concentrated on the primary / secondary care interface although 
a number of issues were raised concerning patients who had been referred to tertiary 
care centres. Whilst the issues are similar at the primary / tertiary care interface, 
additional factors are likely to be relevant. First, the nature of tertiary care is such that 
the medicines that OPs are asked to prescribe are likely to be specialist or for rare 
conditions. Second, due to the additional distances that patients are likely to have to 
travel, GPs may feel obliged to prescribe so that travelling by the patient is kept to a 
minimum. 
In addition to showing deficiencies in the systems and processes ofNHS care with 
respect to medicines management, the present study has also identified some of the 
barriers to improving the situation. Perhaps most importantly, improving medicines 
management across the interface requires secondary care professionals to change the 
way they practise. Until awareness is raised of the need for change, this is unlikely to 
happen because secondary care professionals remain relatively satisfied with the way 
things are. This highlights the need for the application of proven change management 
strategies in order to successfully bring about the necessary changes in both primary 
and secondary care. 
7.4 RECOMMENDATIONS FOR FURTHER STUDY 
There are several areas that offer the potential for future study. The present study has 
identified some of the reasons why medicines management across the interface 
remains sub-optimal. The application of change management theory to medicines 
management across the interface has identified barriers to changes that are necessary 
to bring about improvements in medicines management. Therefore, it would be 
beneficial to apply a change management model across a health economy to find out 
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if this can be successful in bringing about the necessary changes. This would involve 
the identification of barriers to change from the perspective of all stakeholders in 
primary and secondary care, the development of a shared vision of how seamless 
medicines management should operate and clear leadership and accountability for 
achieving this vision. The responsibility for the management of medicines across 
both primary and secondary care could be the province of a specified health care 
professional. Such an individual would then have accountability for ensuring that 
medicines management activities in one setting do not compromise those on the other 
side of the interface. This does not necessary mean than it would be beneficial to 
have a single medicines budget across both primary and secondary care because this 
could create a situation whereby either primary or secondary care spend more than 
their fair share of the budget. 
One area of concern raised by OPs in the present study was the acceptance of clinical 
responsibility for prescribing specialist medicines. Shared care has been proposed as 
a way forward for dealing with difficulties with the transfer of clinical responsibility 
(NHS Management Executive, 1991). However, GPs remain unhappy about 
accepting clinical responsibility under shared care guidelines and there is a perception 
that this is just another method of transferring expenditure from secondary to primary 
care (Duggan et aI, 2001; Home et aI, 2001). There is an alternative solution, now 
that the transfer of funds between primary and secondary care budgets is permitted. If 
the current expenditure on 'specialist' medicines was transferred from the primary 
care to the secondary care prescribing budget, hospital medical consultants could 
continue to prescribe these medicines. However, rather than taking up time issuing 
repeat prescriptions, supplementary prescribers could be employed to monitor patients 
and issue repeat prescriptions. If this type of model was developed, the 
supplementary prescriber could ensure that GPs and community pharmacists were 
fully aware of patients' complete medicine regimens. This would confer an advantage 
of avoiding problems with the co-prescribing of interacting medicines. It would be 
useful to investigate whether a model of care like this was more satisfactory, in terms 
of patient safety and OP acceptance, than the current model of shared care between 
the hospital medical consultant and the OP. Any research in this area should take into 
account the recent changes in NHS commissioning arrangements, such as 'payment 
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by results', which mean that funds for medicines should flow into the organisation 
undertaking the prescribing. 
Finally, the present research touched on patients' perspectives of medicines 
management across the interface. However, due to the infrequency of interface 
issues, it was not possible to gain a full understanding of how patients are affected 
when responsibility for prescribing medicines is transferred between primary and 
secondary care. Ultimately, the whole literature base regarding the management of 
medicines across the interface is about improving the quality of patient care. 
Therefore, it is proposed that consideration of patients' perspectives could be the 
subject of a research project in its own right. 
7.5 THE WAY FORWARD 
Improving medicines management across the interface is mainly dependent on all 
health care professionals appreciating that they need to develop a better understanding 
of practice on the other side of the interface and how their current actions can create 
issues and difficulties that are difficult to resolve and can have a detrimental effect on 
patient care. At the current time there is little motivation for secondary care 
practitioners to consider the problems that are encountered by their colleagues in 
primary care. Whilst GPs continue to prescribe medicines requested, hospital medical 
consultants are able to bypass systems for formulary control and so have no 
restrictions on their clinical freedom. Perhaps, also, unless GPs complain, hospital 
medical consultants may be unaware that GPs feel uncomfortable taking clinical 
responsibility for certain medicines. Given that there is a perception that GPs only 
refuse to prescribe for financial reasons, this is another barrier that must be overcome. 
It is important to recognise that the tensions created by misunderstanding of the 
reasons why GPs refuse to prescribe certain medicines may be exacerbated by the 
implementation of 'payment by results'. Primary Care Trusts should ensure that there 
are systems in place to ensure that patients can obtain the medicines they need if GPs 
have genuine clinical responsibility concerns. This needs to be balanced against 
refusals to prescribe on financial grounds that could come about if responsibility for 
managing primary care prescribing budgets is returned to GPs with practice based 
commissioning. 
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The professional isolation of community pharmacists also provides a strong barrier to 
improving medicines management at the interface. Involving community pharmacists 
more in the care of patients who have been in contact with hospital services could 
result in the reduction of medication errors through the identification of transcription 
errors and advising patients how to take their medicines. However, this requires GPs 
to be more conducive towards accepting the advice of community pharmacists. 
Additionally, community pharmacists need to become more confident in their ability 
to provide a clinical role and communicate directly with other health care 
professionals rather than dealing with administrative staff. The increased involvement 
of community pharmacists could also improve the cost-effectiveness of medicines 
management across the interface. This is more likely to happen if they were to 
become more involved in formulary enforcement and the potential for this to 
adversely affect their income was removed. The new community pharmacy contract 
is currently in its infancy and it is, therefore, difficult to say whether this will affect 
the inclusion of community pharmacists within the primary health care team. 
However, PCTs could facilitate this by asking community pharmacists to target 
medicines use reviews, an advanced service within the new contract, at patients who 
have recently been in contact with hospital services. The present research showed 
that community pharmacists were sometimes unsure of how to deal with medicines 
management problems that arise. Positioning medicines management across the 
interface within the medicines use review framework could help to improve the skills 
and confidence of community pharmacists in this area. Primary Care Trusts could 
provide professional support and training specific to undertaking medicines use 
review in patients who have been in contact with hospital services. The formalising 
of this role within the contract framework might encourage GPs to accept an extended 
role for their pharmacist colleagues. 
The misunderstandings of policy that have been illustrated throughout this thesis 
could be improved by having one set of rules that applies across both primary and 
secondary care. Arguably, for example, it is unreasonable to expect community 
pharmacists to abide by the NHS blacklist when their hospital colleagues are not held 
to account in this way. Ensuring that all health care professionals work within the 
same set of policies should help to reduce the number of interface issues that arise. 
There also needs to be a more effective method of disseminating and explaining the 
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purpose of agreed medication policies to all professional parties. This would facilitate 
inter- and intra-professional collaboration and help to prevent the violation of policy 
which is likely to compromise patient care. 
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SoatItern DerbyshIre Health Authority 
PIeue reply to:- Jill Marshall 
SDEC Administrator 
I 
ext 6420 (direct dial/rom Derby hospitals 16-6420) 
Southern Derbyshire Health Authority. 
Derwent Court, Stuart Street, 
Derby DEI 2FZ. 
DX 709391 Derby 9. 
ThI: (01332) 626300. Fax: (01332) 6263~ 
website: www.sdhealth.demon.co.uk 
SOUTHERN DERBYSHIRE ETHICS COMMITTEE 
Your ReI 
OurReI AWAOJM 
22 July 1999 
MsJBrown 
Primary Care Liaison Pharmacist 
DCGH 
Dear Ms Brown 
SDEC REF: 9907173 
Chairman: Dr A W A Crossley MB ChB FRCA 
Direct/ax: 0/332 363963 
PHARMACEUTICAL CARE AT THE PRIMARY/SECONDARY INTERFACE - THE 
PATIENT'S PERSPECTIVE 
The Southern Derbyshire Ethics Committee considered the above protocol on 20 July 1999. I am 
pleased to be able to inform you that your study was approved on the understanding that you will follow 
the protocol as agreed. May I remind you that indemnity arrangements and financial implications need 
to be agreed with all appropriate Trust management(s) before commencing tbe trial. 
Please note that the SDEC will require: 
• to be advised immediately of any adverse report or changes to the protocol or if the study is 
abandoned; 
• a progress report on an annual basis or at the end of the study if this is a lesser time; 
• copies of all published reports. 
For your information, the SDEC complies with the Royal College of Physicians' guidelines for the 
composition and functioning of an Ethics Committee. 
, ~ ,,', t' ,'~, ,,' '",'-:;; ~ 
, v • t}<" /, { • • { I) , • I I III f j ( < J .' J " It i I .. I' ~ ::;. I J. ,; • ..-\ '1 ! ' f f I (I f.A , ¢ « f • (? (,;J f.' \{ t I (f ~ 'fj, ~ '~: ~ 
Yours sincerely 
A W A Crossley 
Chairman 
Southern Derbyshire Ethics Committee 
School of Health & Community Studies 
PATIENT INFORMATION SHEET FOR 
INPATIENT AND OUTPATIENT STUDY 
~ UNIVERSITY ~ of DERBY 
Kingsway House 
Kingsway 
Derby DE22 3HL 
United Kingdom 
Tei+44(0)1332622222 
Fax +44 (0) 1332622727 
Obtaining and Using Medicines following discharge from hospital or 
outpatient appointment: How do patients manage? 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with friends or relatives. Please ask if there is anything that is not clear or if you 
would like more information. 
Consumers for Ethics in Research (CERES) publish a leaflet entitled 'Medical 
Research and You'. This leaflet gives more information about medical research and 
looks at some questions you may want to ask. A copy may be obtained from CERES, 
PO Box 1365, London N16 OBW. 
Thank you for reading this information sheet. 
What is the purpose of the study? 
Before you can understand the purpose of this study, we need to provide a little 
background information. When patients have a spell in hospital, doctors, nurses, 
pharmacists and many other health professionals work as a team to provide the best 
possible care and treatment. Healthcare professionals are experts in their own right. 
So, staff are continually passing on information to other members of the team, making 
treatment as effective and efficient as possible. Sometimes communication breaks 
down because we live in a human world. This often results in nothing more than an 
inconvenience. But sometimes, the quality of care can be affected. Although this is 
widely known, it still remains very difficult to prevent mishaps that arise through poor 
communication. Often, staff in the hospital, or outpatients department are not aware 
of a problems experienced by patients. Sometimes, a problem occurring in hospital 
does not come to light until after a patient has gone home. 
Whilst in hospital, one ofthe most complicated stages is the preparation for discharge. 
At this time, it is very common for a patient to be prescribed new medication. 
Medication is often a very important part of hospital treatment. It is very important to 
make sure that treatment with medicines continues smoothly when a patient leaves 
hospital. But this process does not always work as smoothly as it should. For 
example, when patients return home we know that it is not always P~§i~JiJQh' exactly 
Dawn Forman MIlA PCOIp(IW' MDCJt TOCR 
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the same medicine to be prescribed in the community. Sometimes this sort of problem 
occurs simply because staff in the hospital have not been able to communicate 
adequately. with staff in the community (such as family doctors, community nurses 
and community pharmacists / chemists). 
The purpose of this research is to find out how patients manage their medication 
during the period from being discharged from hospital and for the first four weeks at 
home. We want to find out whether anything more can be done to help make sure that 
patients get the best use from medicines that have been prescribed in hospital and are 
able to continue receiving the benefit of medication, (if it is required) after leaving 
hospital. 
Why have I been chosen? 
You have been chosen because you are just about to be discharged from a hospital 
ward or because you have attended an outpatient department. We plan to invite about 
one hundred or so other patients who, like you, are being discharged from hospital or 
have attended an appointment in outpatients. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you 
are still free to withdraw at any time, without giving a reason. This will not affect the 
standard of care you receive. 
What will happen to me if I take part? 
If you do decide to take part, a researcher (Jane Brown) will contact you to make 
arrangements to ask you some questions about how you manage your medicines. She 
will ask you a few questions (for about 5 minutes) whilst you are in hospital or in the 
outpatients clinic. Jane may also want to contact you again on two further occasions 
within the next four weeks. Each time she will ask some questions about how you 
have managed your medicines (for example: Were you able to easily get a new supply 
when the hospital supply ran out?).If, at any stage, you prefer not to be interviewed 
again, just say so and you will not be contacted. The address of the researcher and 
supervisor can be found at the end of this information leaflet. 
What are the possible disadvantages and risks of taking part? 
The only possible disadvantage is that you will be giving up your free time to talk to 
the researcher. 
What are the possible benefits of taking part? 
You will not personally benefit from this research. But, by helping us finding out 
where communication breaks down we hope to improve hospital discharge and 
outpatient services for the benefit of future patients. 
Will my taking part in this study be kept confidential? 
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All information collected about you during the course of this research will be kept 
strictly confidential. Any information about you which leaves the hospital / 
outpatients department will have your name and address removed so that you cannot 
be recognised from. it. If, with your permission, a tape-recording has been made of 
any conversations you have with the researcher, the tape will be erased as soon as it is 
finished with. Any typed transcript made from such tape recordings will have names 
removed and, if appropriate, fictitious names substituted so that you cannot be 
identified. 
What will happen to the results of the research. 
The results from this study will be included in a Ph.D thesis which, if published, will 
be held in the library in the University of Derby and will be made available in the 
public domain in the usual way through the national library network. We hope that the 
results will also be published in an academic or professional journal. This, however, is 
unlikely to take place within one year. Your name will not be identified in any report 
or publication. 
Who is organising and funding the research 
This research is organised and funded by the Division of Integrated Care, School of 
Health & Community Studies, University of Derby. The work is carried out in 
collaboration with the Pharmacy Department, Derby City General NHS Trust. 
Who has reviewed the study? 
The Southern Derbyshire Ethics Committee bas reviewed this study. You should be 
aware, however, that review by an ethics committee does not necessarily mean that 
the aim of the research will be achieved. 
Contact for further information. 
!fyou would like further information about this study you can contact the following: 
Jane Brown (researcher) 
Pharmacy Department 
Derby City General Hospital 
Uttoxeter Road, 
Derby 
Telephone: 01332 625576 
Peter Rivers (Director of Ph.D study) 
School of Health and Community Studies, 
Kingsway House, 
Kinsgway, 
Derby 
DE223HL 
Telephone: 01332 622222 Ext. 3163 (please leave a message on the voice mail 
system if you receive no answer) 
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Information for community pharmacists 
The intravesical solution is an unlicensed formulation of oxybutynin 
which is available on a named-patient basis for patients in whom the oral 
formulation is not suitable. Patients will have been registered with the 
manufacturers by the hospital consultant. 
Administration 
The preparation comes as a 5mg in 50ml solution. Patients or carers 
will have been trained by the hospital in administration technique. 
Administration equipment should also be prescribed by the GP. 
The frequency of administration is usually once daily but it may only be 
necessary once, twice or three times a week. 
Supplier:- Pharmacia & Upjohn Ltd, 
Davy Avenue, 
Knowlhill, 
Milton Keynes, MK5 8PH 
Telephone:- 01908 603057 
Telephone orders usually take about 2 days to arrive. No orders are 
despatched on Fridays, Saturdays or Sundays. Therefore, orders placed 
after mid-day on Thursdays will not arrive until the following Tuesday. 
Storage requirements 
The solution should preferably be stored in a refrigerator at 2°C to 8°C. 
If this is not possible store in a cool place out of direct sunlight. The 
patient should remove the solution from the refrigerator about an hour 
before administration and allow it to reach room temperature. 
Hospital pharmacist contact number 
Dispensary - 625562 ext 5368 
Jane Brown (primary care liaison pharmacist) - 625576 
/e\.. 
~~ 
DERBY CITY GENERAL HOSPITAL 
U'ITOXETER ROAD DERBY DE22 3NE 
Oxybutynin intravesical 
solution 
Information for community pharmacists 
When you have obtained a prescription from your GP please 
give the prescription and this leaflet to your community 
phannacist (chemist). 
This preparation will have to be ordered. Please make sure 
you give the prescription to the phannacist at least a week 
before your supplies run out. 
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APPENDIX 3 
Report on interface prescribing issues 
Please report prescribing issues arising because of the primary / secondary care 
interface. 
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Practice name & address Reporting doctor .(~.~~ .. q. ... ~.f) .. 
Date ..... 1.~.J..~.1 .. ~ .. ~ ................ .. 
Please return completed forms to 
Prescribing Adviser via the health 
authority van. 
-----------------------------------------------------------------------------------------------------------------_. 
Reverse side of form 
Prescribing adviser 
Health Authority Name 
Health Authority Address 
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OUTPATIENTS INITIAL INTERVIEW (FACE-TO-FACE) 
Clinic date ...................................... . No ......... 
Hello, I'm Jane Brown, one of the pharmacists here. We're trying to make sure that 
everything to do with your medicines runs as smoothly as possible. I am doing some 
research to see if patients are managing their medicines alright. Would you mind 
spending about five minutes to talk about this? 
Negative response- end interview 
Positive response- continue. 
1. Is this your first visit to an outpatient's clinic 
2. Are you taking any prescribed medicines at the moment? 
(IfN, end interview, ifY, continue) 
YIN 
YIN 
3. Who writes the prescriptions for the medicines you are taking at the moment? 
a) GP 
b) Hospital doctor 
c) Other ( specify) 
4. Do you expect your medicines or doses to be changed by the hospital doctor? 
YIN 
5. Do you expect new medicines to be started by the hospital doctor? YIN. 
6. Does anyone help you with your medicine? YIN 
a) home help, 
b) partner, 
c) family member, 
d) neighbour, 
e) district nurse, 
f) nursing or residential home staft) 
7. Do you use any memory aids to help you to remember to take your medicines? 
YIN 
8. For how long will you need to take your medicines? YIN 
9. When will you need a further supply of medicines? YIN 
10. How will you get your next supply of medicines? 
a) GP appointment 
b) Repeat prescription 
c) Both 'a' and 'b' 
Outpatients initial interview (face-to-face) 1 
d) Home visit 
e) Organised by community pharmacist 
11. Who dhJps off your prescription request / picks up your prescription? 
12. Who takes your prescription to the community pharmacy (Chemist)? 
a) patient 
b) carer 
c) dispensing doctor 
d) community pharmacist collects 
Thank you for talking to me. 
Would you mind if I contact you by phone in about two weeks time so you can up-
date me on your experience with medication? 
Outpatients initial interview (face-to-face) 2 
OUTPATIENTS TELEPHONE INTERVIEW 
(ALL PATIENTS) 
Clinic date ...................................... . No ........ . 
Hello, this is Jane Brown from the Pharmacy at Derby City Hospital. I spoke to you 
about your medicines a couple of weeks ago at the outpatients clinic. Would you mind 
talking again about your medicines for about ten minutes? 
Negative response- end interview 
Positive response- continue. 
1. Did the hospital doctor make any changes to your medicines at outpatients? 
YIN 
a) change in dose 
b) medicine added 
c) medicine discontinued 
IfN, end interview. 
2. Were you given a prescription to get a new supply of medicines? YIN 
IfY, go to questions 3 and 4. 
2. How did you get your prescription dispensed? 
a) Self to pharmacy 
b) relative visited pharmacy (state who) 
c) friend visited pharmacy 
d) neighbour visited pharmacy 
4. At the pharmacy, did anyone explain? 
a) GP 
b) Hospital doctor 
c) Other (specify) 
5. Were you asked to get medicines on prescription from your GP? 
Outpatients telephone interview (all patients) 1 
IfN, go to question 9. IfY: Could you tell me about this? 
a) Was tqe.procedure to get repeat prescription explained to you? 
b) Were you given a letter ('flimsy') to take to your GP? 
c) Who took the 'flimsy' to the GP? 
d) How did you get in touch with your GP 
i) made appointment 
ii) called out GP 
iii) used GP' s repeat prescription procedure 
The next question is about how you got your prescription dispensed: 
6. Who collected the prescription from your GP and took it to a pharmacy? 
a) self 
b) relative (state who) 
c) friend 
d) neighbour 
e) community pharmacist via collection and delivery 
t) dispensing doctor 
7. Did anyone give you information about these medicines (e.g. what they are, how to 
use them, when and how to get more)? 
a) Counter Assistant 
b) Pharmacist 
c) Dispensing Doctor 
d) Friend 
e) Relative 
t) Neighbour 
Type of information given: 
8. Is there anything else you would like to tell me about your experience of using or 
obtaining medicines? 
9. Thank you for talking to me. May I contact you again in two weeks to give me an 
up-date on managing your medicines. 
If an important problem or issue arises 
I am really interested in what happened to you. Would it be possible to discuss this in 
more detail either now, or if it is more convenient, I could make an appointment to see 
you at home. 
Outpatients telephone interview (all patients) 2 
OUTPATIENTS FINAL TELEPHONE INTERVIEW 
(ONLY FOR PATIENTS WHO RECEIVED PRESCRIPTION MEDICINES FROM 
THE HOSPITAL PHARMACY) 
D.ate: ........................... . No ................ .. 
Hello, this is Jane Brown from the Pharmacy at Derby City General Hospital. When I 
spoke to you two weeks ago, you said you had received prescription medicines from 
the hospital pharmacy. Would you mind talking to me again about this for about ten 
minutes? 
Negative response: end interview 
. Positive response: continue. 
1. Have you finished the supply of medicines you got from the hospital pharmacy? 
YIN 
IfN, check why (e.g 'when required / or poor compliance?) 
2. Have you received a further supply of medicines? YIN. 
(IfN, check if short course) 
3. How did you obtain this further supply of medicines? 
a) made appointment with GP? 
b) called out GP 
c) used GP's repeat prescription procedure 
d) was the procedure for doing this explained? 
The next question concerns the dispensing of your prescription: 
4. 
a) Who collected your prescription from the GP? 
b) Who took your prescription to a Pharmacy? 
c) Did a community pharmacist provide a collection and delivery service? 
d) Did you receive your prescription from a Dispensing Doctor? 
Appendix D3 Outpatients final telephone interview 
5. Were you given any information about your medicines? 
a) No information given 
b) GP gave information 
c) Pharmacist gave information 
d) Counter Assistant gave information 
e) Information given but don't know who gave it. 
6. Did the information you received (in question 5) agree with any information given 
to you whilst at the hospital? 
Comment: 
7. Is there anything else you would like to tell me about your experiences with 
medicines? 
If a particular medication problem or issue arises: 
I am really interested to learn what happened to you. May I discuss this with you now 
or would it be more convenient to make an appointment to see you at home? 
Thank you very much for talking to me. 
Appendix D3 Outpatients final telephone interview 2 
INPA TIENT INITIAL FACE -TO-FACE INTERVIEW SCHEDULE 
.. 
Discharge Date ....................... . ID ......... . 
Hello, I'm Jane Brown, one of the pharmacists here. We're trying to make sure that 
everything to do with your medicines runs as smoothly as possible. I am doing some 
research to see if you are managing your medicines alright. Have you read the 
Information Leaflet about this? 
YIN 
IfY, proceed. IfN, provide information leaflet and return later. 
Would you mind spending about five minutes to talk about this? 
Negative response :- Stop interview and go to next patient 
Positive response: Continue 
1. Is this your first stay in hospital? YIN 
2. Have your medicines changed since you have been in hospital? YIN 
(IfY, go to question 3. IfN, go to question 4). 
3. Have these changes been explained to you? YIN 
4. Does anyone help you with your medicines? 
(prompt:. home help, partner, family member, neighbour, district nurse, nursing or 
residential home staff). YIN 
5. Do you use any memory aids to help you remember to take your medicines 
YIN 
6. Before you came to hospital, can you tell me what you did when you needed a new 
supply of medicines? 
(Prompt: GP appointment, Repeat prescription, home visit, dealt with by community 
pharmacist) 
7. Who drops off your prescription request or picks up your prescription? 
8. Who takes your prescription to a community pharmacy (Chemist)? 
(prompt: patient, carer, dispensing doctor, community pharmacist collects? 
Thank you for talking to me. Would you mind if! contact you by phone in 4 weeks 
time so that I can find out how you have been getting on with your medicines? 
Inpatient initial interview (face to face) 
INPATIENT HOME TELEPHONE INTERVIEW SCHEDULE 
Date ....................... . ID ......... . 
Hello, this is Jane Brown at Derby City General Hospital. I spoke to you about your 
medicines at the hospital a few weeks ago. Would you mind talking to me again about 
your medicines for ten minutes or so? 
YIN 
IfY, proceed. IfN, end interview. 
Negative response :- Stop interview and go to next patient 
Positive response: Continue 
1. Do you remember if you given a copy of your prescription to give to your GP? 
(Y = Can remember 
question: 
N = Can't remember). IfY, proceed with supplementary 
What did you do with it? 
a) Posted to GP 
b) Called GP out 
c) Gave to GP at appointment 
d) Did nothing 
e) Don't Know 
2. Have you finished the supply of medicines you got from the hospital pharmacy? 
YIN 
3. Have you got a further supply of medicines? YIN 
IfY, go to question 4. 
IfN, check if medicine was a self -limiting course (e.g. antibiotics) 
4. How did you get a further supply? 
a) was the procedure explained to you? 
b) GP appointment 
c) Repeat prescription 
d) Called out GP 
5. Tell me about when you got your prescription dispensed. 
Inpatient (at home) telephone interview 
a) who collected your prescription from the GP and took it to pharmacy or 
dispensing doctor? . 
b) Did anyone collect your prescription / deliver medicines to the door? 
.. 
6. Is there anything else you would like to tell me about your experience with 
medicines? 
Thank for talking to me. It has been very useful. 
q an interesting problem /issue arises 
Final question: 
I am really interested in what happened to you. Can you spare time to discuss this 
with me now, or would it be more convenient if! make an appointment to discuss it 
with you at your home? You are not obliged to discuss things further if you don't 
want to. 
If patient agrees, proceed with in-depth interview or make appointment. 
Inpatient (at home) telephone interview 

APPENDIX 5 
CASE STUDY EXAMPLES OF INTERFACE ISSUES 
Key 
CP community pharmacist 
GP general practitioner 
HC hospital medical consultant 
HP hospital pharmacist 
PM practice manager 
301 
302 
Table 1 Issues arising from lack of awareness or misunderstanding of policy (originated by hospital doctor) 
Complainant Problem I issue Counter argument Analysis Conseq uences 
I PM Hospital doctor Patients should only be given Lack of awareness of outpatient Practice rushing to issue a 
28 day supply recommended that a a hospital prescription at OPD supply policy, prescription only prescription immediately 
rule patient's medicine was if medicine must be started given if medicine is for immediate when medicine is not urgent. 
changed and did not give a immediately. initiation in line with EL(91)127. 
hos~ital ~rescri~tion. 
2 PM Complains that hospital Hospital does not provide Conflict resulting from hospital Patient could experience 
Azathioprine doctor told patient that GP repeat prescriptions for policy to reduce cost of repeat delay in obtaining further 
would give prescription for existing medicines. prescriptions against availability in supply due to time to order 
repeat supply of primary care. Patient may be medicine. 
azathioprine. Dispensing unaware only GP can give repeat 
> GP who does not keep prescriptions. Hospital policy in line 
"1:S 
azathio~rine in stock. with EL(91}127. "1:S (1) 
3 GP Asked to prescribe Misunderstanding by hospital No formal feed-back to doctors Risk management, medicine ::s P-o-. 
Mibefradil mibefradil, new drug. doctor over what had been requesting new medicines, withdrawn soon after because :x 
Formulary status was that agreed at Drug misunderstanding of what was of serious interactions with VI 
hospital should give full &Therapeutics Committee. agreed, against advice in EL(94)72. other medicines. 
su~~I~. 
4 GP Has received letter from Yohimbine is included in No transfer of additional information Delay in patient obtaining 
Erectile urologist asking him to district formulary. Usual with request to prescribe unusual medicine whilst GP finds out 
dysfunction prescribe yohimbine but practise to ask GP to medicine. Lack of awareness by GP more information. Risk 
GP does not know what it prescribe in this way. of what is included in district management issues if GP 
is. formulary. prescribes without full 
knowledge of the medicine. 
5 GP Hospital policy not to issue Patients should only be given Lack of awareness of outpatient Practice rushing to issue a 
28 day supply prescriptions to outpatients a hospital prescription at OPD supply policy, prescription only prescription immediately 
rule is putting pressure on his if medicine must be started given if medicine is for immediate when medicine is not urgent. 
w 
repeat ~rescribing s~stem. immediatel~. initiatio~ in line with EL(91)127. 
0 
w 
~ Table 2 Issues arising from lack of awareness or misunderstanding of policy (originated by hospital nurse) 
Complainant Problem I issue Counter argument Analysis 
1 lIP Prescription signed by SHO Continence adviser Continence adviser not aware that 
Bladder for tolterodine presented at cannot write tolterodine is non-formulary and of the 
instability hospital pharmacy. SHO had prescriptions herself. system for introduction of new 
been asked to prescribe by medicines, against advice in EL(94)72. 
continence adviser. 
2 GP Asked to prescribe tolterodine Continence adviser Continence adviser not aware that 
Bladder by continence adviser. cannot write tolterodine is non-formulary and of 
instability prescriptions herself. system for introduction of new drugs, 
against ~vice ill_~L(94 )72. 
Consequences 
Non-compliance with 
formulary or patient gets 
alternative medicine. 
Non-compliance with 
formulary or patient gets 
alternative medicine. 
i 
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Table 3 Issues arising from lack of awareness or misunderstanding of policy (originated by GP) 
Complainant Problem / issue Counter argument Analysis Consequences 
1 HC Complains that GP refuses to GP says hospital should GP unaware of or disagrees with 3 day Patient could run out of 
Dietetic prescribe gluten-free foods. provide 28 days supply hospital supply policy for dietetic gluten-free products or would 
products of gluten-free foods as products. Hospital policy is in line with have to buy at own expense. 
for other medicines. national guidance that only states Could lead to poor control of 
minimum quantities to be supplied for disease if does not obtain 
medicines & dressings [EL(91)127]. gluten-free foods. 
2 HP GP refusing to prescribe GP had checked with Misunderstanding over what is in the Delay in patient obtaining 
Nafarelin medicine which is included in Prescribing Adviser district formulary. further supply. 
the district formulary. who told him it was 
non-formulary . 
> 3 HP GPs refusing to prescribe GPs feel this is a Unclear if refusal is due to cost or Pressure on hospital budget if '"1:j 
Goserelin goserelin injection for specialist medicine & so clinical responsibility. GPs refuse to take over '"1:j ~ 
prostate cancer. Included in do not want to take prescribing. Plus may impact ::s 0-_. 
district formulary. clinical responsibility. on outpatient waiting lists if x 
patients have to return to VI 
hosEital for injections. 
4 He GP refusing to prescribe Feels unable to take Even if the local consensus is that a Pressure on hospital budget if 
Goserelin goserelin injection under clinical responsibility medicine is suitable for GP prescribing GPs refuse to take over 
shared care guidelines. for this specialist not all GPs will feel comfortable with prescribing. Plus may impact 
medicine. that decision. on outpatient waiting lists if 
patients have to return to 
hosEital for injections. 
5 HP Patient admitted with GP prescribed 5mg Different hospital and primary care Medication error - could 
Warfarin warfarin overdose. Dose was tablets to reduce policies for strengths of tablets have been very serious. 
5mg daily, hospital only quantity of tablets supplied. GP unaware of reason for 
supplies Img tablets. Patient patient had to take. hospital supplying Img tablets. 
was taking 5 x 5mg tablets 
w daily. 0 
VI 
loU Table 4 Issues arising from lack of awareness or misunderstanding of policy (originated by hospital pharmacist) 0 
0\ 
Complainant Problem I issue Counter argument Analysis Consequences 
1 Practice Several cases of patients not Hospital policy states Practice pharmacist misunderstood the Practice pharmacist thinks 
pharmacist getting 28 days supply of that patients must one-stop dispensing policy. hospital is not following 
28 day supply medicines on discharge from receive a minimum of policy. 
rule hospital. 14 days and a maximum 
of 42 days supply due to 
the use of 28 day patient 
packs. 
2 Nurse at Methotrexate prescribed at Usual policy is to Lack of awareness of exceptions to Delay in patient obtaining 
community community hospital dispense 2 weeks supply policy. Two week supply was in line further supply of medicine. 
hospital dermatology clinic for 8 for outpatients. with guidance in EL(91) 127 but local 
> Methotrexate weeks. Main hospital guidance superseded this. ~ 
pharmacy dispensed 2 weeks ~ 0 
instead of full supply. ::3 p.. 
.... 
3 Practice Patient discharged with only Five days supply of Hospital policy around using GP adds combination x 
VI 
pharmacist 5 days supply of Kapake® analgesic should be combination products changed in line analgesic to patient's records, 
Combination (co-cOOamoI30/500). No enough for post- with EL(94 )72, which states that total more expensive that separate 
analgesics longer on hospital formulary, operative analgesia. costs to the NHS should be taken into constituents. 
should have received separate account when choosing medicines, but 
constituents. Pre-packs of incompletely implemented. 
combination on ward. 
w 
o 
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Table 5 Issues arising from lack of awareness or misunderstanding of policy (originated by community pharmacist) 
Complainant 
HP 
Niferex elixir 
2 Mother 
Extemp-
oraneous 
preparation 
Problem I issue 
Complains that CP dispensed 
lOOml bottle which has no 
dropper. HP thinks that CP 
should have dispensed 30ml 
bottle which has dropper. 
Child taking suspension 
which has expired. CP does 
not make extemporaneous 
preparations on site. 
Counter argument 
30ml bottle cannot be 
dispensed on GP 
prescription unless for 
specific indication & 
endorsed 'SLS'. 
HP not aware that CPs 
do not make 
extemporaneous 
preparations on site & 
so time to dispense 
prescription will 
increase. 
Analysis 
HP unaware of difference in availability 
between hospital and GP prescription. 
No transfer of information to CP so CP 
would not be aware that patient fitted 
the criteria for SLS. 
HP lack of awareness of different 
hospital and community policies for 
making extemporaneous preparations. 
Consequences 
Mother cannot administer 
elixir to baby without 
dropper. 
Supply discontinuity. 
i 
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~ Table 6 Issues arising from inadequate inter- or intra-professional collaboration (originated by hospital doctor) 
00 
1 
2 
3 
4 
5 
6 
Complainant 
GP 
Olsalazine 
GP 
Octreotide 
GP 
Ciclosporin 
Patient 
Prednisolone 
CP 
Roaccutane 
GP 
Methyl-
phenidate 
Problem I issue Counter argument Analysis Consequences 
Asked by hospital doctor to Patient is intolerant of Lack of information to GP about the Patient may have been put 
prescribe olsalazine, non- formulary choice. reason for choosing a non-formulary back on original medicine 
formulary. medicine, against advice in EL(94)72. that he was intolerant of. 
Patient discharged on Usual practise to expect Inadequate transfer of information and Potential discontinuity whilst 
octreotide for unlicensed GPs to continue discussion prior to transferring care. responsibilities are decided. 
indication, no reason given to prescribing medicines Risk management issue if GP 
GP, no prior consultation. following discharge prescribes without full 
Confusion around indication. from hospital. knowledge of the medicine. 
Asked to prescribed Usual practise to expect No transfer of additional information Toxic medicine, risk 
ciclosporio for ulcerative GPs to continue with request to prescribe unusual management issues if GP 
colitis, unlicensed indication prescribing medicines medicine. prescribes, responsibilities 
& unfamiliar with use of following discharge for monitoring treatment are 
drug. from hospital. not explicit. 
Usually takes daily Most patients do stop Inaccurate drug history and poor Medication error, could have 
prednisolone for COPO but prednisolone on documentation on admission. been severe if patient had 
instructions on discharge discharge. followed instructions to stop 
medicines were to reduce to prednisolone. 
zero. 
Received GP written FPIO 
prescriptionforroaccutane 
(hospital only medicine), 
asking if she can dispense it. 
Concerned about taking 
clinical responsibility, unclear 
who will be responsible for 
monitoring the patient. 
Hospital medical 
consultant intended to 
continue supply. 
Normally expect GP to 
monitor medicines 
following discharge 
from hospital. 
Breakdown in communication, GP 
misunderstood that hospital medical 
consultant would continue to prescribe. 
Prescribing and clinical responsibilities 
not decided before care transferred back 
toGP. 
Delay in receiving medicine 
& patient inconvenience. 
Potential discontinuity whilst 
responsibilities are decided. 
Risk management issue if GP 
prescribes without full 
knowledge of the medicine. 
i 
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Table 7 Issues arising from inadequate inter- or intra-professional collaboration (originated by hospital pharmacist) 
Complainant Problem I issue Counter argument Analysis Consequences 
Practice ITO states Kapake®, policy is to Patient actually received Poor quality of information to GP through not Expensive combination 
pharmacist dispense separate constituents. separate paracetamol and endorsing medicine actually given on ITO. preparation could have 
Combination codeine tablets been added to patient's 
analgesics prescription. 
2 CP Received FPIO prescription for Named patient medicine Lack ofliaison between hospital & community This may result in supply 
Clobazam Smg clobazam Smg tablets & does not with system set up to order pharmacists around source of unusual discontinuity. 
tablets know where to get them from. in hospital. medicines (named patient) against 
recommendation in EL(91)127. 
3 CP Received FPlO prescription for Named patient medicine Lack of liaison between hospital & community This may result in supply 
oxybutynin oxybutynin intravesical solution & with system set up to order pharmacists around source of unusual discontinuity. 
intravesical does not know where to get it from. in hospital. medicines (named patient) against 
solution recommendation in EL(91)127. 
4 HP Complains that mother told by GP 2mg strength not listed in Lack of awareness in primary care of named- Delay in patient obtaining 
Captopril 2mg receptionist that only available from BNF or on GP computer patient medicines. Insufficient information medicine. 
tablets hospital. picking list. provided on discharge. 
5 CP Received GP for hydralazine New item recommended No opportunity for HP to liase with CP around Delay in patient obtaining 
Hydralazine 12.5mg suspension & does not from outpatient clinic and medicines not normally dispensed in medicine. 
suspension know how to make it. so not made by hospital community in line with EL(91)127 if 
pharmacy. recommended from outpatient clinic without 
hospital prescription being issued. 
6 HP No solution commercially available This process is relatively Impractical solution in primary care, CP Patient unlikely to obtain 
Omeprazole so informed CP to dissolve granules common in hospital. unlikely to keep Polyfusors, many CPs do not medicine in primary care. 
solution in 8.4% sodium bicarbonate make extemporaneous preparations on site. 
Polyfusor solution. Lack of aware!less by l!P of how CPs operate. 
7 HP Patient needs medicines in liquid Impractical in primary Could have been resolved before discharge if Patient unlikely to obtain 
Omeprazole form. Capsules dissolved in care, CP advised changing CP involved in discharge planning & medicine in primary care. 
solution sodium bicarbonate. to ranitidine. communication in line with EL(91)127. 
8 HP Child does not like the preparation Could not anticipate that Inadequate liaison with CP regarding actual May result in supply 
Chloral supplied by CP on discharge from child would dislike preparation supplied by hospital pharmacy. discontinuity whilst 
w hydrate hospital. different formulation. preparation ordered from 
~ solution specials manufacturer. 
i (D 
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Table 8 Issues arising from inadequate inter- or intra-professional collaboration (originated by GP) 
2 
3 
4 
5 
Complainant 
HP 
Phenytoin 
HP 
HP 
HP 
DigoDn 
HP 
Insulin 
Problem I issue Counter argument Analysis Consequences 
Inpatient prescribed 3 x 25mg No excuse for unclear Lack of clarity of admission Medication error, patient 
phenytoin capsules, should admission information. information. received wrong dose, could 
have been 3 x 25mg & 3 x have resulted in loss of 
sOmg. epileptic control. 
GP letter read by admitting No excuse for illegible Unclear admission letter. Medication error, patient may 
doctor as thyroxine 2S0flg, admission letter. have received the wrong 
should have been medicine. 
fluvoxamine 2SOmg. 
Query on patient's drug 
history, surgery closed until 
4pm so cannot check with 
GP. 
Admission letter says digoxin 
but no dose, no patient's own 
medicines. 
Not clear if patient is on pork 
or human insulin. 
Regular surgery hours 
include afternoon 
closures. 
No excuse for 
incomplete admission 
information. 
No excuse for unclear 
admission information. 
Difficulty in liasing with GPs. 
Incomplete admission information. 
Clarified with CP but not normally 
involved in admission drug history. 
Delay in determining correct 
medicine regimen. 
Delay in determining correct 
medicine regimen. 
Patient could have been 
given the wrong type of 
insulin - medication error. 
:g 
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Table 9 Issues arising from inadequate inter- or intra-professional collaboration (originated by community pharmacist) 
Complainant Problem I issue Counter argument Analysis Consequences 
1 Mother Child running out of HP not aware that CPs Patient not informed how long it will Patient may run out of 
Phenobarb- phenobarbitone suspension, do not make take to obtain a further supply. medicine. 
itone CP says it will take a week to extemporaneous Difference between hospital and 
suspension obtain as extemporaneous preparations on site & community policies for making 
preparations are not made on so time to dispense extemporaneous preparations. 
site. prescription will 
increase. 
2 HP Patient having difficulty Not available via usual Lack of liaison with CPs around source Delay in patient obtaining 
Magnesium getting supply of magnesium CP procurement routes. of unusual medicines against medicine. 
tablets glycerophosphate tablets in Did not know that they recommendation in EL(91)127. 
the community (started in can be imported by 
renal clinic). lOIS. 
3 Mother Difficulty obtaining medicine Dose and strength Medication error which could have Patient runs out of medicine. 
Extemp- in primary care. CP made specified on medicine been made during transcription of 
oraneous 151lg thyroxine susp bottle and discharge details from discharge letter to GP Medication error, patient 
preparation according to GP prescription, letter. records. No direct communication receives wrong dose. 
should have been 251lg & no between hospital & CP so CP unaware 
ingredients left to remake of error. 
correct strength. 
4 lIP Patient brought in an No excuse for not Inadequate labelling of medicines. Time wasted to clarify dose. 
Extemp- extemporaneous solution on labelling medicine with Risk of a medication error. 
oraneous admission, dose unclear as no strength. 
preparation strength on the bottle 
@iazoxide §uspension). 
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Table 10 Issues caused by impracticable or inflexible policy (originated by hospital doctor) 
-tv 
Complainant Problem I issue Counter argument Analysis Consequences 
1 PM GP asked to prescribe erythropoietin. Traditionally GPs continue to Unwillingness to accept transfer of high Delay in transfer of care. 
Erythro- PM wants to know who pays for it as prescribe after hospital cost drug which is against principles in 
poietin it is expensive. initiation. Funds for this EL(91)127 that expense should not inhibit 
medicine are in primary care. GPs in accepting prescribing 
responsibility. 
2 Community GP refusing to prescribe, no Concerned about taking Systems not in place to continue Inconvenient for patient 
paediatrician prescription pads in community, clinical responsibility for prescribing if GP refuses. to have to return to 
Methyl- must go to hospital to write hosp specialist drug. hospital to collect 
~henidate prescription. medicine. 
3 GP Feels this is a specialist drug and so Community paediatricians Systems not in place to continue GP pressurised into 
Methyl- hospital medical consultant should have no prescription pads. prescribing if GP refuses. prescribing although he > 
'0 ~henidate continue to prescribe. feels uncomfortable. '0 (1) 
4 GP Urology clinic recommending that Impractical to titrate dose in Inadequate transfer of care back to the Patient could be =' 0.. 
Erectile GPs prescribe MUSE® but not clinic due to time. Patients GP. prescribed the wrong 
_. 
:>< 
dysfunction titrating dose in clinic. Concerned know what to do if dose too dose. VI 
that incorrect dose may be high. 
~rescribed. 
5 HP GP refusing to prescribe cisapride for Unlicensed for children, side- Systems not in place to continue GP pressurised to 
Cisapride a child. effect concerns. prescribing if GP refuses. prescribe although 
uncomfortable. 
6 Mother Child has nephrotic syndrome, Hospital doctor not aware that Ifproduct is only available in hospital HC Delay in patient 
Urine testing cannot obtain blood & protein urine strips are blacklisted. should prescribe [EL(9l)127]. This obtaining product. 
strips testing strips on GP as they are requires awareness by hospital 
blacklisted. ~ractitioners of blacklisted ~roducts. 
7 Patient Hospital medical consultant Hospital medical consultant EL(91)127 states that if a product is only Patient must pay for 
Mucodyne® suggested patient try Mucodyne® to did not give hospital available in hospital, prescriptions should medicine if he wants to 
reduce sputum viscosity. GP can only prescription as not urgent & be supplied by hospital. Consultant try it but unhappy as he 
provide a private prescription as on non-formulary so not stocked unaware item blacklisted & should not 
was not informed this NHS blacklist by hospital pharmacy. ask GPs to prescribe non-formulary 
would be the case. items. 
w 
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Table 11 Issues caused by impracticable or inflexible policy (originated by hospital nurse) 
I 
2 
Complainant 
Prescribing 
adviser 
Plastics for 
feeds 
Mother 
Equipment to 
administer 
growth 
hormone 
Problem I issue 
Child discharged with 
gastrostomy, needs syringe to 
administer feeds, not 
available on GP prescription. 
Child started on growth 
hormone injection by hospital 
doctor. Injecting device and 
needles not available on GP 
prescription. 
Counter argument 
Not aware that syringes 
would have to be 
prescribed & not 
available on GP 
Gap in service as 
hospital specialist nurse 
on maternity leave and 
other staff unaware of 
process for ordering 
injecting equipment. 
Analysis 
Discrepancy between what can be 
prescribed in hospital and in primary 
care. 
Failure to adequately take into account 
the supply of injecting equipment when 
designing growth hormone shared care 
guideline. 
Consequences 
Feeds cannot be 
administered. 
Growth hormone cannot be 
administered. 
~ 
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-~ Table 12 Issues caused by impracticable or inflexible policy (originated by hospital phannacist) 
Complainant Problem I issue Counter argument Analysis Consequences 
1 HP (6 reports) Antibiotic syrups have short Hospital not fulfilling Not always practical to follow 28 day Cost / time implications for 
Re- expiry dates once 28 day supply policy. supply policy. OP to issue prescription for 
constitution reconstituted. Patients do not remainder of supply. 
of products want to return to hospital to 
collect remainder of supply, 
easier to get from OP. 
2 OP Relatives of inpatient have Patient admitted on non- Inconsistency between brand prescribed Brand switch (advised 
Modified written to GP asking for a hospital formulary in primary care & that prescribed in against in BNF) or patient 
release prescription for diltiazem. brand of diltiazem. Had hospital results in inability to supply on runs out of medicine. 
diltiazem enough PODs but discharge. This goes against EL(91)127 > discharge delayed & so which states that hospital must supply :g 
not enough for ITO. at least 7 days on discharge. (11 ::s 
Now too late for HP to 0-
order. 
~. 
VI 
3 OP Patient given hospital Hospital doctor not Little point in giving hospital Practice rushing to issue a 
prescription from outpatient aware that pharmacy prescriptions for medicines to be prescription immediately. 
clinic but hospital pharmacy would be shut. initiated immediately in line with 
closed for the day so OP had EL(91)127 if hospital pharmacy 
to write a prescription. opening hours are not aligned with 
outpatient clinics. 
4 HP Patient due to be discharged Hospital policy states Not always feasible to follow policy to Patient cannot take medicines 
MDS but medicines usually in an that medicines must be the letter, no point dispensing medicines as in unsuitable packaging -
MDS which HP cannot provided on discharge in unsuitable packaging. compliance problems. 
~rovide. from hos~ital. 
5 Patient's son Patient uses MDS at home, Hospital do not have the Lack of liaison with CP (1) to find out Patient cannot take medicines 
MDS discharge medicines not equipment to fill MDS. that patient uses MDS (2) to continue as in unsuitable packaging-
dispensed in MDS. 
____ _ ____ MQS_ on disch~g~"- compliance problems. 
w 
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Table 13 Flagrant violation of policy (originated by hospital pharmacist) 
Complainant 
1 CP 
Problem I issue 
Discharge medicines labelled 
with generic name but 
discharge summary has 
proprietary name. 
Counter argument 
Policy says that generic 
name should be 
endorsed on ITO form 
of which patient has a 
copy. 
Table 14 Flagrant violation of policy (originated by hospital manager) 
Complainant 
Hospital 
directorate 
business 
manager 
Interferon 
Problem I issue 
Asks ifGPs can prescribe 
interferon for hepatitis C 
instead of a hospital doctor as 
it is expensive. 
Counter argument 
Specialist treatment so 
GPs unlikely to want to 
take clinical 
responsibility. 
Table 15 Flagrant violation of policy (originated by GP) 
Complainant Problem I issue Counter argument 
Analysis 
Discharge counselling insufficient and 
pharmacy policy about endorsing ITOs 
not followed. 
Analysis 
Attempt at cost shifting from secondary 
to primary care budget. 
Analysis 
1 HP 
Diuretic 
Patient admitted on non-
formulary diuretic 
(Moducren®), insufficient 
PODs. 
Patient stable on this Non-adherence to district formulary in 
medicine, why change primary care. 
just to comply with the 
formulary? 
Consequences 
Patient confused, thought he 
had got the wrong medicines, 
may cause compliance 
problems. 
Consequences 
Delay in treating patients 
whilst financial arrangements 
are sorted out. 
Consequences 
Hospital had to purchase 
non-formulary medicine. 
;3> 
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Table 16 Flagrant violation of policy (originated by hospital doctor) 
(a) Medicine removed from formulary or rejected by Drug &Therapeutics Committee or Area Prescribing Committee 
Complainant Problem I issue Counter argument Analysis Consequences 
1 HP Hospital doctor prescribed Prefers to use modified Difficult to police loophole in system Non-compliance with 
Modified mlr isosorbide mononitrate, release nitrates. whereby hospital doctors can ask GPs formulary. 
release informed non-formulary but to prescribe non-formulary medicines, 
nitrates insisted on writing to GP. against advice in EL(94}72. 
2 Prescribing The hospital is initiating Hospital doctors think It is legally permissible for the hospital Huge expenditure in primary 
adviser patients on mlr nitrate modified release nitrates to prescribe 'loss leader' medicines but care for uncertain patient 
Modified preparations which are are better. against the spirit of national guidance benefit. 
release considerably more expensive EL(94)72. 
nitrates when prescribed in the :g community. 
3 HP Hospital medical consultant Patient has cancer, delay Difficult to police loophole in system Delay in patient obtaining 0 ~ 
Flutamide wants patient to have in initiating treatment if whereby hospital doctors can ask GPs medicine whilst sorted out. e. 
flutamide. Formulary status GP will not prescribe. to prescribe non-formulary medicines. 
><. 
Ul 
is 'not for GP prescribing' 
and not for hospital use until 
trials set up. Consultant 
refused HP's advice not to 
ask the GP to Erescribe. 
4 PM GP asked to prescribe Not available in hospital Loophole in system for managed Non-compliance with 
Flixonase® Flixonase@ nasal spray by pharmacy. introduction of new medicines, against formulary or patient gets 
nasal spray hospital doctor, non- advice in EL(94)72. alternative medicine. 
formulary. 
5 GP Request from locum ear, nose Not available in hospital Loophole in system for managed Non-compliance with 
Flixonase® & throat doctor to prescribe pharmacy. introduction of new medicines, against formulary or patient gets 
nasal spray Flixonase@ nasal spray, non- advice in EL(94)72. alternative medicine. 
formulary. 
Table 17 Flagrant violation of policy (originated by hospital doctor) 
(b) Medicine not considered by Drug & Therapeutics Committee 
Complainant Problem I issue Counter argument Analysis Consequences 
1 Prescribing GP asked to prescribe melatonin but Patient cannot have the No additional information with request Risk management issues if 
adviser does not know anything about it, non- medicine unless GP to prescribe unusual medicine. Hospital GP prescribes without full 
Melatonin formulary. prescribes. medical consultant should request that it knowledge of the 
is added to the formulary. Loophole in medicine. 
system for introduction of new 
medicines, against EL(94)72. 
2 HP TIO, non-formulary, not yet discussed Wants to use as may prevent Time lag between availability of new GP pressurised into 
Acamprosate at Drug & Therapeutics Committee. patient relapsing from medicines and formulary decisions. prescribing. 
Hos~ital doctor to ask GP to ~rescribe. alcohol abstinence. 
3 GP Asked to prescribe azelastine nasal Not available in hospital Loophole in system for managed Non-compliance with :> 
Azelastine spray, non-formulary. pharmacy. introduction of new medicines, against formulary or patient gets "tj 
"tj 
nasalseraI advice in EL(94)72. alternative medicine. (l) ::s 
4 GP Asked by hospital medical consultant to Not available in hospital Loophole in system for managed Risk management, p.. 
_. 
prescribe tolcapone for Parkinson's pharmacy. introduction of new medicines, against medicine was withdrawn :>< Tolcapone \Jl 
Disease, not yet approved by Drug & advice in EL(94)72. soon after because of 
Therapeutics Committee. adverse effects. 
5 HP Patient admitted on moxonidine, non- Started after request from Loophole in system causes problems in Hospital has to purchase 
Moxonidine formulary. hospital doctor. hospital if patients are admitted. non-formulary medicine. 
6 HP Hospital doctor prescribed tolterodine, Hospital doctor wants to use Loophole in system for managed Non-compliance with 
Bladder non-formulary. Hospital doctor said he this medicine so asks GP to introduction of new medicines, against formulary or patient gets 
instablity would ask GP to prescribe. prescribe. advice in EL(94)72. alternative medicine. 
7 GP Asked to prescribe Prowess (unlicensed Not available in hospital Loophole in system for managed Patient not able to obtain 
Erectile yohimbine product), non-formulary. pharmacy. introduction of new medicines, against medicine. 
dIsfunction advice in EL(94)72. 
8 Prescribing Hospital medical consultant asked GP to Consultant responds ifGPs Not adhering to introduction of new Non-compliance with 
adviser prescribe Zeraderm gel for scar, non- want patients treating they medicines policy, against advice in formulary. 
(2 cases) formulary, GP does not know what is it, should prescribe EI(94)72. Not providing additional 
IoN Zeraderm gel not stocked by CP. recommended items. information with unusual medicines. 
-.......:I 
w Table 18 Flagrant violation of policy (originated by hospital doctor) 
-00 (c) No funding in hospital 
ComplaiDaat Problem I issue Counter argument Analysis Consequences 
1 GP Asked to prescribe interferon No funding in hospital. Attempt at cost shifting from secondary Delay in treating patient. 
IDterferon for hepatitis C, not to primary care prescribing budget. 
appropriate for GP 
{!rescribing. 
2 GPs GPs registered complaints Traditionally GPs have GPs had been asked to prescribe a drug GPs pressurised into 
collectively that they lacked the continued to prescribe because there was no budget to fund it prescribing although they feel 
via the Area knowledge and experience to following hospital within secondary care. GPs were not uncomfortable. 
Prescribing prescribe erythropoietin initiation and so funds able to monitor therapy or adjust doses 
Committee following initiation by a for this medicine are in which is contrary to guidance :> Erythro- hospital medical consultant. primary care. EL(91)127. "0 
"0 
poietin 0 ::s 
3 UP Hospital medical consultant GP considers this a Difficult to obtain medicines for one-off Delay in initiating treatment p. _. 
Interferon wants patient to have specialist medicine & as whilst responsibilities sorted ~ uses. Vl 
interferon for unusual such should be out. 
indication, GP will not prescribed by hospital 
prescribe, no funding in medical consultant. 
hos~ital. 
4 Prescribing GP asked to prescribe and fit Expensive product, Attempt at cost shifting from secondary Pressure on GP prescribing 
adviser Mirena® interuterine device would overspend to primary care prescribing budget. budget. Risk management 
Mirena@RJD for menorrhagia, unlicensed gynaecology budget. issues in using device for 
use. unlicensed indication. 
S GP (2 cases) Asked to prescribe Expensive product, Attempt at cost shifting from secondary Pressure on GP prescribing 
Mirena@RJD Mirena®interuterine device would overspend to primary care prescribing budget. budget. Risk management 
for menorrhagia, unlicensed gynaecology budget. issues in using device for 
use. unlicensed indication. 
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Table 19 Flagrant violation of policy (originated by hospital doctor) 
(d) One-off use for individual patient 
1 
2 
Complainant 
GP 
Acetylcysteine 
bladder 
washout 
HC 
Anastrozole 
Problem I issue 
Asked to prescribe 
acetylcysteine for an 
unlicensed indication with 
little evidence of efficacy. 
GP had expressed 
considerable reluctance to 
continue the prescription. 
Counter argument 
Last resort to help with 
patient's symptoms. 
Anastrozole is very 
expensive and may 
mean that he overspends 
his prescribing budget. 
Analysis 
GP expected to continue prescribing 
even if he disagrees with treatment. 
This initially presented as a clinical 
responsibility issue. Confusion 
between the boundaries of clinical and 
financial responsibility is difficult to 
resolve. 
Consequences 
Delay in patient getting 
further supply of medicine. 
If response not adequately 
monitored there is the risk 
that the treatment may be 
inappropriately continued 
long-term which would be 
wasteful of resources. 
Delay in patient receiving 
treatment, very distressing. ~ 
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Table 20 Flagrant violation of policy (originated by hospital doctor) 
(e) Disagrees with policy 
1 
2 
Complainant 
Prescribing 
adviser 
Tamoxifen 
Practice 
pharmacist 
Enteric: 
coated aspirin 
Problem I issue 
Hospital medical consultant 
recommending that GPs 
prescribe branded medicine 
rather than the generic which 
is much cheaper. 
Hospital starting patients on 
enteric coated aspirin for no 
apparent reason, this is much 
more expensive that 
dispersible aspirin. 
Counter 
argument 
Consultant thinks 
generic version is 
of lower quality. 
Hospital doctor 
thinks it is better 
for patients. 
Analysis 
Hospital policy is to prescribe generically but 
may purchase brand cheaply through 
contracts. Problem when patients switched 
to the generic version in primary care. 
Inconsistency between product used in 
primary & secondary care. Hospital not 
taking into account total NHS costs when 
choosing medicin~s in line with EL(94 )72. 
Influence of hospital prescribing on primary 
care prescribing. There may be a lack of 
awareness by hospital doctors of price 
differentials between primary & secondary 
care. Hospital not taking into account total 
NHS costs when choosing medicines in line 
with EL(94 )72. 
Table 21 Flagrant violation of policy (originated by community pharmacist) 
Complainant 
HP 
Erytbro-
poietin 
Problem I issue 
CP told patient that 
erythropoietin prescription 
could not be dispensed. 
Counter argument 
Erythropoietin is 
expensive, CPs have to 
purchase medicines and 
are reimbursed later. 
Analysis 
CP putting needs of business before 
patient care. Refusal to dispense 
medicine is against terms of contract. 
Consequences 
Pressure on primary care 
prescribing budget. 
Reduced generic prescribing 
rates, a performance indicator 
for GPs. 
Pressure on primary care 
prescribing budget. 
Consequences 
Delay in patient obtaining 
medicine. Patient may run 
out of medicine. 
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Appendix 6 
Policy stating that hospital prescriptions should only be issued for medicines 
requiring immediate initiation results in supply discontinuity (Case 1.1) 
A practice manager complained that a patient's medicines were changed during a 
hospital outpatient appointment and the patient was not given a hospital prescription. 
He had used up his previous supply and was left with no medicines to take for his 
condition. 
Problem 
A practice manager felt that a hospital prescription should have been provided for 
medicines recommended by a hospital doctor during an outpatient appointment. 
Arising questions 
• Why was a prescription not given? 
The policy for issue of prescriptions to outpatients, which is agreed between 
secondary and primary care, is that prescriptions should only be issued for 
medicines that need starting immediately. In this case there was no need for an 
immediate prescription. 
• Why was this a problem? 
o The practice manager was not aware that the hospital doctor had complied 
with the outpatient supply policy. 
o The patient had finished his previous supply of medicines and so had no 
medicines to take. This put pressure on the practice to issue a prescription 
urgently rather than within the usual 24 to 48 hour time limit. 
• Could a hospital prescription have been dispensed in this case? 
No, because the medicine recommended (pantoprazole) was not included in the 
district formulary and so was not stocked by the hospital pharmacy. 
• Why was a non-formulary medicine recommended? 
The hospital doctor felt that pantoprazole was less likely to interact with the 
warfarin, that the patient was also taking, than the lansoprazole that he was 
currently on. 
Review of multifactorial dimensions of case 
• No indication on the medicines advice note to explain why the hospital doctor felt 
pantoprazole was more appropriate than lansoprazole. 
• No explanation given for recommending a non-formulary medicine. 
• The practice manager was unaware of the outpatient supply policy which stated 
that hospital prescriptions should only be given for medicines that must be started 
immediately. 
• The patient put pressure on surgery staff to provide a prescription immediately. 
Root cause 
When the medicines advice note was written in the outpatient clinic. 
Figure 5.4 Step 4b 
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Appendix 6 
Policy stating that hospital prescriptions should not be issued for 'repeat' 
supplies results in supply discontinuity (Case 1.2) 
A practice manager complained that a patient was not given a hospital prescription for 
azathioprine tablets that she took regularly but had run out of. 
Problem 
The patient informed a hospital doctor during an outpatient appointment that she had 
run out of azathioprine tablets. The hospital doctor explained that the patient's OP 
would issue a repeat prescription. 
Arising questions 
• Why was this a problem? 
The patient attended a Friday afternoon outpatient clinic and so presented a 
request for a repeat prescription to the surgery on a Saturday morning. 
• Why was this a problem? 
Saturday morning surgeries are usually for emergencies only and not for the issue 
of routine repeat prescriptions. This puts additional pressure on surgeries at a time 
when staffing is likely to be limited. 
• Was an exception made in this case? 
The practice was a dispensing practice and azathioprine was not stocked in the 
dispensary. Therefore, even if a prescription was written it could not be filled at 
the surgery. 
• Why was the patient not told to take the prescription to a community 
pharmacy for dispensing? 
It was not clear if patient was sent to a community pharmacy. However, the 
practice manager would not want this to happen because it would result in a loss 
of dispensing income. 
Review of multifactorial dimensions of case 
• No exception in the outpatient supply policy to allow hospital doctors to issue 
prescriptions for repeat medicines. 
• Rigid application of rules by hospital doctor without considering whether the 
patient would be able to obtain a further supply of medicines before the current 
supply ran out. 
• The person who signs a prescription takes clinical responsibility for any outcomes. 
Therefore, hospital doctors may be uncomfortable signing prescriptions for 
medicines, like azathioprine, which have potentially toxic side-effects if not 
monitored correctly. 
• Patients registered with dispensing practices may experience delays in obtaining 
unusual medicines. 
Root cause 
When the patient did not appreciate that she would not be able to get a repeat 
prescription from the hospital doctor instead of from her OP. 
Figure 5.4 Step 4a 
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Appendix 6 
Unclear communication following Drug and Therapeutics Committee meeting 
results in inappropriate transfer of prescribing responsibility to GP (Case 1.3) 
A GP complained that she had been asked to prescribe mibefradil following a 
patient's discharge from hospital. This was a new medicine that the GP had no 
information about, for example indications or side-effects. Initially the GP simply 
required more information but then discovered a Health Authority prescribing 
newsletter stating that GPs should not be asked to prescribe mibefradil. 
Problem 
A GP undertook a home visit to a patient recently discharged from hospital. The 
patient asked the GP for a prescription for a further supply of mibefradil that had been 
started during the hospital admission. The GP was concerned about issuing a 
prescription as she could not find any information about mibefradil in the BNF. 
Arising questions 
• Why was there no information in the BNF? 
Mibefradil was a new medicine on the market and was not yet included. 
• Would the GP prescribe if further information were supplied? 
Yes, until she saw the Health Authority prescribing newsletter stating that GPs 
should not be asked to prescribe mibefradil. 
• Why was this advice given? 
The Drug and Therapeutics Committee decision was that mibefradil was approved 
for use by a consultant cardiologist. This was on a six-month trial basis and all 
supplies were to be provided by the hospital. 
• Why did the hospital registrar insist that the GP issue further prescriptions 
when the GP contacted him? 
The registrar was not aware of the Drug and Therapeutics Committee decision. 
• Why was the registrar unaware that GPs should not be asked to prescribe 
mibefradil? 
Drug and Therapeutics Committee decisions are not formally communicated to 
other members of staff e.g. registrars, and so relies on the applying consultant to 
inform them of decisions. 
Review of multifactorial dimensions of case 
• Misunderstanding by consultant cardiologist of the exact details of the approval 
because no written response given to applicants. 
• Pharmacist checking discharge medicines should have picked up the potential 
problem and alerted the patient that further supplies would be provided by the 
hospital. 
• No system in place to issue repeat prescriptions from hospital pharmacy. 
• Difficult to keep GPs up to date with additions to medicines formulary. 
• Discharge process assumes GPs will be able to find out about unusual medicines. 
Root cause 
When Drug and Therapeutics Committee decision was communicated to applicant. 
Figure 5.6 
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Appendix 6 
General practitioners may not be aware of and confident to prescribe all 
formulary medicines (Case 1.4) 
A urologist asked a OP to prescribe yohimbine for a patient with erectile dysfunction. 
The GP did not know what yohimbine was or where it could be obtained from. 
Problem 
A OP has been asked to prescribe a medicine he has not prescribed before. 
Arising questions 
Why is there no information in the BNF? 
• Yohimbine is an unlicensed medicine which is not listed in the usual texts kept by 
OPs. It is available from a company who import it from Europe. 
• Why was further information not provided with the request to prescribe? 
No mechanism for transfer of additional information about unusual medicines. 
Review of multifactorial dimensions of case 
• Provision of additional information relies on hospital practitioner, either doctor or 
pharmacist, appreciating the need for additional information within primary care. 
Root cause 
When consultant asked OP to prescribe unusual medicine following patients' 
attendance at an outpatient clinic. 
Figure 5.4 Step 7 
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Appendix 6 
Pressure on GP practice workload caused by patients putting urgent requests in 
for non-urgent medicines (Case 1.5) 
A OP complained that the hospital policy not to issue hospital prescriptions to patients 
attending outpatient clinics was putting pressure on his repeat prescription system. 
This is because patients expect GP prescriptions to be issued as soon as medicines 
advice notes are presented. The GP also feels that medicines advice notes have been 
given for 'urgent' medicines and so should have been prescribed by hospital doctors. 
Problem 
Patients going straight to GP surgeries with medicines advice notes and expecting 
practices to immediately issue GP prescriptions. 
Arising questions 
• Why is this a problem? 
Practices are rushing to issue prescriptions immediately when medicines are not 
urgent. Practices require either 24 or 48 hours notice to prepare and issue repeat 
prescriptions. 
• Why are patients not told to come back in 24 or 48 hours when the 
prescription will be ready? 
General practitioners sometimes feel that medicines requested should be started 
immediately and so a 24 or 48 hour delay is not appropriate. 
Review of multifactorial dimensions of case 
• Disagreement between GPs and hospital doctors of what constitutes an 'urgent' 
medicine. 
• Patients inadequately informed of what to do with medicines advice notes. 
• Patient wishes to start new medicines as soon as possible. 
Root cause 
At outpatient clinic when patients are not informed that medicines are not urgent and 
that request for prescription should be put in as usual. 
Figure 5.4 Step 4a 
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Non-medical staff may initiate non-formulary medicines (Case 2.1) 
A hospital pharmacist received a hospital prescription for tolterodine written by an 
SHOo This had been approved by the hospital Drug and Therapeutics Committee but 
had not yet been approved for use in primary care by the Area Prescribing Committee. 
Problem 
A prescription was presented at the hospital pharmacy for a medicine not included in 
the district formulary. 
Arising questions 
• Why did the SHO prescribe a non-formulary medicine? 
He was asked to prescribe by the continence adviser. 
• Why did the continence adviser ask the SHO to prescribe? 
The continence adviser is a nurse and as such cannot prescribe herself. 
• Why did the continence adviser request a non-formulary medicine? 
She was not aware that tolterodine was not on the district formulary and also not 
aware of the process for the introduction of new medicines. 
• Why was the continence adviser not aware of formulary inclusions and the 
formulary making process? 
Poor communication from the Drug and Therapeutics Committee from the 
perspective of the process for the introduction of new medicines and the decisions 
made for individual applications. 
Review of multifactorial dimensions of case 
• Health care professionals other than doctors may influence prescribing decisions. 
These non-medical 'prescribers' may not be informed of systems for introduction 
of new medicines nor decisions made by Drug and Therapeutics Committees. 
• Complicated approval process for new medicines. Tolterodine had been approved 
by the hospital Drug and Therapeutics Committee for second line use but required 
approval also by the Area Prescribing Committee because of the potential impact 
on primary care prescribing. 
Root cause 
When choice of medicine was made without taking into account the medicines 
formulary. 
Figure 5.4 Step 4a 
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Non-medical staff may initiate non-formulary medicines (Case 2.2) 
A OP complained that he had been asked to prescribe tolterodine by the hospital 
continence adviser. The OP had been informed by the Health Authority Prescribing 
Adviser that, because this medicine had not yet been considered by the Area 
Prescribing Committee, it was non-formulary and so OPs should not be asked to 
prescribe it. 
Problem 
A OP has been asked to prescribe a non-formulary medicine by the hospital 
continence adviser. 
Arising questions 
• Why did the continence adviser ask the GP to prescribe? 
The continence adviser is a nurse and so cannot write prescriptions herself. There 
is no urgent need for this medicine to be started immediately and so it is 
acceptable for OPs to be asked to prescribe in this manner. 
• Why was a non-formulary medicine chosen? 
Continence adviser was not aware that tolterodine was not included in the 
formulary. 
• Why was the continence adviser unaware of the formulary status? 
Non-medical 'prescribers' are not informed of systems for introduction of new 
medicines and Drug and Therapeutics Committee decisions. 
Review of multifactorial dimensions of case 
• Health care professionals other than doctors may influence prescribing decisions 
across the interface. These non-medical 'prescribers' may not be informed of 
systems for introduction of new medicines nor decisions made by Drug and 
Therapeutics Committees. 
• There was some confusion as to whether tolterodine had been approved by the 
Area Prescribing Committee as the decision had not clearly been documented in 
the minutes. 
• Complicated approval process for new medicines. It had been approved by the 
hospital Drug and Therapeutics Committee for second line use but required 
approval also by the Area Prescribing Committee because of the potential impact 
on primary care prescribing. 
Root cause 
When choice of medicine was made without taking into account the medicines 
formulary. 
Figure 5.4 Step 4b 
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Appendix 6 
Different policies for the supply of medicines and dietetic products results in 
patient experiencing difficulty obtaining dietetic products (Case 3.1 ) 
A child had been discharged from hospital with a diagnosis of coeliac disease. A 
hospital medical consultant complained that the child's GP had refused to prescribe 
gluten-free foods. This meant that the child's mother was buying gluten-free foods at 
her own expense in addition to obtaining free samples from the hospital dietician. 
Gluten-free foods are expensive, for example a loaf of bread can cost around £3.00. 
Problem 
A mother is experiencing difficulties obtaining supplies of gluten-free foods on 
prescription for her child who has coeliac disease. 
Arising questions 
• Why is the mother having difficulty obtaining supplies? 
The child's GP is refusing to prescribe gluten-free foods. 
• Why is the GP refusing to prescribe? 
General practitioner believes that the hospital should provide 28 days supply of 
gluten-free foods on discharge from hospital as for medicines. 
• Why? 
General practitioner is unaware of, or disagrees with, the hospital seven day 
supply policy for dietetic products. That is, dietetic products are excluded from 
the usual 28 day supply process agreed for medicines. 
Review of multifactorial dimensions of case 
• Confusion may be caused by different policies for the supply of medicines and 
dietetic products. 
• Unwillingness of both GP and hospital doctor to back down resulting in patient 
having to purchase necessary gluten-free foods. 
• Patients may be caught in the middle of disputes around prescribing 
responsibilities. 
• Concern over managing budgets may be given priority over patient care. 
Root cause 
When child was discharged from hospital. It was not clear to the GP that the policy 
agreed across the district was that only seven days' supply of dietetic products would 
be given. 
Figure 5.3 Step 8b 
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Appendix 6 
Lack of awareness of formulary status of medicines may create difficulties for 
patients in obtaining prescriptions (Case 3.2) 
A hospital medical consultant reported that a patient was having difficulties obtaining 
supplies ofnafarelin from her GP. Nafarelin was included in the district formulary 
and so was considered appropriate for transfer of prescribing responsibilities to OPs. 
Initially the patient saw a OP locum at the practice who issued a prescription. 
However, a OP principal refused to provide a repeat prescription. 
Problem 
A GP is refusing to prescribe a medicine which is included in the district formulary. 
Arising questions 
• Why is GP refusing to prescribe? 
The GP believes that nafarelin is not included in the district formulary and so he 
should not be asked to prescribe it. Additionally, because of the specialist nature 
of the medicine, he requires shared care guidelines before he will take over 
prescribing responsibility. 
• Why does the GP think that nafarelin is non-formulary? 
The GP contacted the Primary Care Group Prescribing Adviser who incorrectly 
informed him that nafarelin was non-formulary. 
• Why was this advice given? 
The Prescribing Adviser could not find any evidence that the Area Prescribing 
Committee had approved the medicine. 
Review of multifactorial dimensions of case 
• It is difficult to keep all interested parties informed of amendments to formularies. 
• Reference to or copy of the agreed shared care guidelines was not enclosed with 
request to prescribe from hospital medical consultant to GP. 
Root cause 
When Prescribing Adviser gave incorrect information about the formulary status of a 
medicine. 
Figure 5.6 
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General practitioners may refuse to prescribe formulary medicines (Case 3.3) 
A hospital pharmacist complained that some GPs were refusing to prescribe goserelin 
injection for men with prostate cancer discharged from hospital. Goserelin was 
included in the district formulary and a shared care protocol had been agreed 
suggesting that the majority of GPs would feel comfortable accepting the transfer of 
prescribing responsibilities. 
Problem 
General practitioners are refusing to prescribe goserelin injection for patients 
discharged from hospital. 
Arising questions 
• Why are GPs refusing to prescribe? 
They feel unable to take clinical responsibility due to the specialist nature of the 
treatment. 
• Why is it a problem for hospital doctors to continue to prescribe? 
Hospital funding only covers the immediate discharge period. 
• Are there any other problems with the hospital continuing to supply? 
There are no systems set up for issuing repeat prescriptions in hospital outpatient 
clinics. There is also no staff capacity to administer the injections in a secondary 
care setting. 
Review of multifactorial dimensions of case 
• Despite the local consensus being that goserelin is suitable for GP prescribing not 
all GPs will feel comfortable with that decision. 
• Goserelin is an expensive medicine; sometimes there is confusion between 
refusals to prescribe for clinical responsibility issues as opposed to financial 
issues. 
• There is no transfer of additional infonnation about specialist medicines (e.g. a 
shared care protocol) along with requests to prescribe. 
Root cause 
When the GP's agreement to accept clinical responsibility was not gained prior to 
transfer of prescribing responsibility. 
Figure 5.4 Step 7 
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General practitioners may refuse to prescribe formulary medicines (Case 3.4) 
Goserelin is a gonadorelin analogue used in the treatment of endometriosis, breast and 
prostate cancer amongst other conditions. This is administered by monthly 
subcutaneous injection. The injection should be given into the anterior abdominal 
wall and so is given by a health care professional rather than self-administered by 
patients. Goserelin was included in the district formulary and a shared care protocol 
had been agreed suggesting that the majority of GPs would feel comfortable accepting 
the transfer of prescribing responsibilities. A hospital medical consultant complained 
that a GP refused to prescribe goserelin injection for a woman under shared care. 
Problem 
A GP refuses to prescribe goserelin injection for a woman discharged from hospital. 
Arising questions 
• Why is the GP refusing to prescribe? 
He feels unable to take clinical responsibility due to the specialist nature of the 
treatment. 
• Are GPs permitted to refuse to prescribe continuing treatments? 
Shared care guidelines do state that GPs can refuse to prescribe on clinical 
responsibility grounds. This particular GP has never prescribed goserelin 
previously and so may be unfamiliar with it. 
• Will the GP prescribe if he is educated about the medicine? 
No, he feels this should be provided in secondary care and does not agree with 
secondary care procedures being transferred to primary care when he is not paid 
for them. 
• Is the refusal to prescribe really due to clinical responsibility concerns? 
Unclear, but it seems like the refusal is due to resource issues regarding the 
administration of the medicine in primary care. 
Review of multifactorial dimensions of case 
• Despite the local consensus being that goserelin is suitable for GP prescribing not 
all GPs will feel comfortable with that decision. 
• No consideration given to the workload associated with the transfer of prescribing 
responsibilities from secondary to primary care for medicines with complex 
administration or monitoring requirements. 
Root cause 
When the GP's agreement to accept clinical responsibility was not gained prior to 
transfer of prescribing responsibility. 
Figure 5.4 Step 7 
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Different policies across the interface may result in medication errors (Case 3.5) 
A woman was admitted to hospital after accidentally taking five to six times the 
prescribed dose of warfarin. Her usual dose was Smg per day and her GP prescribed 
Smg tablets for her. The dose had recently been changed to Smg on one day and 6mg 
the next day. Her anticoagulant booklet had been returned with the following 
instructions: 
M 
S 
T 
6 
W 
S 
Th 
6 
F 
S 
Sa 
6 
Su 
S 
Problem 
A patient was admitted to hospital after taking an accidental overdose of warfarin. 
Arising questions 
• Why did the patient take too many tablets? 
The patient noticed that her tablets were a different colour and telephoned the 
biochemistry laboratory for advice. She was incorrectly informed that the number 
in her anticoagulant booklet corresponded to the number of tablets to take. 
• Why was the wrong advice given? 
The laboratory staff member assumed that the patient would have Img tablets. 
• Why did the member of starf assume that the patient had Img tablets? 
The hospital policy was that only Img warfarin tablets were supplied. The 
member of staff was unaware of the different warfarin policies in hospital and 
primary care. 
• Why did the GP prescribe 5mg tablets? 
The GP was unaware of the reasons for the hospital only providing I mg tablets 
and thought that the patient would be helped by reducing the number of tablets to 
be taken. 
Review of multifactorial dimensions of case 
• Lack of awareness of other policies operating within the area. 
• Laboratory staff member did not check which strength of warfarin tablets the 
patient had before giving advice. This raises issues about which staff should 
advise patients about their medicines. 
• Difficulties with introducing consistent policies across health authority boundaries 
as two neighbouring hospitals in different health authorities dispense only 3mg 
warfarin tablets. 
• The patient warfarin booklet gave the dose as a numerical figure and did not state 
'milligrams' or 'tablets'. 
• The community pharmacist did not intervene to enforce the district policy of 
supplying only lmg warfarin tablets and did not counsel the patient about how to 
take warfarin tablets. 
Root cause 
When policy decision was made to keep only I mg tablets in hospital and not 
communicated to all relevant practitioners resulting in incomplete implementation. 
Figure S.5 Step 3 
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Misunderstanding of the intricacies of policies causes complaints (Case 4.1) 
A policy was agreed between the hospital and the Health Authority, through the Area 
Prescribing Committee, to increase the quantities of medicines supplied to patients on 
discharge from hospital and following attendance at outpatient clinics. The result of 
this was that outpatients would be given 28 days supply of medicines that required 
starting immediately. However, the supplies issued on discharge from hospital were 
more complex because they were linked to a 'one-stop' dispensing scheme. The 
scheme meant that patients requiring medicines during an inpatient stay were issued 
with 28 days supply labelled with directions for discharge. These packs of medicines 
were then used to fill discharge prescriptions. This meant that some patients would be 
discharged with less than 28 days supply if medicines had been administered during 
the inpatient stay. A practice pharmacist complained about several examples when 
the hospital had not provided 28 days supply of medicines on discharge from hospital. 
Problem 
The hospital is not dispensing 28 days supply of medicines for patients on discharge 
from hospital. 
Arising questions 
• Why? 
The hospital policy, agreed by the Area Prescribing Committee, states that patients 
must receive a minimum of 14 days supply and a maximum of 42 days supply, 
due to the use of 28 day patient packs. 
• Why did the practice pharmacist complain? 
She misunderstood the intricacies of the policy. 
• Why? 
Poor communication about the details of the policy to all interested parties after it 
had been agreed at the Area Prescribing Committee. 
Review of multifactorial dimensions of case 
• The hospital 'one-stop' dispensing policy is sometimes incorrectly referred to as 
the '28 day' prescribing policy. 
• Not all wards started the 'one-stop' dispensing programme at the same time 
meaning that some wards were still only issuing one weeks' supply of medicines 
on discharge from hospital. 
• Discharge prescriptions are sometimes not endorsed with the quantities of 
medicines dispensed. 
Root cause 
When the outcome of the policy decision was communicated to stakeholders. 
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Different policies for quantities of medicines to supply creates confusion 
(Case 4.2) 
Dermatology clinics were held at community hospitals as well as in the main district 
general hospital. The community hospitals did not have their own dispensaries and so 
prescriptions were faxed through to the district general hospital pharmacy and the 
medicines returned with a hospital driver. 
Problem 
A dermatologist prescribed methotrexate for a patient attending a community hospital 
outpatient clinic. Two weeks supply of methotrexate was dispensed by the hospital 
pharmacy. The patient then requested a further supply from her GP who refused and 
sent the patient back to the community hospital. 
Arising questions 
• Why did the GP refuse to prescribe methotrexate? 
The agreement was that the hospital would supply all immunosuppressants for 
dermatological conditions and that GPs should not be asked to prescribe. 
• Why did the dermatologist not prescribe tbe full supply until the next 
outpatient appointment? 
He did prescribe eight weeks supply but only two weeks was dispensed by the 
hospital pharmacy. 
• Wby? 
The hospital policy at that time was to provide only two weeks supply for 
outpatients with the GP to prescribe further supplies. 
• What about the agreement that all immunosuppressants should be dispensed 
by the hospital pharmacy? 
The dispensary staff dealing with this prescription were not aware of this 
agreement. 
Review of multifactorial dimensions of case 
• Confusion may be caused by different supply policies for different clinics. 
Root cause 
When the outpatient prescription was dispensed and staff were not aware of the 
policy. 
Figure 5.4 Step 6 
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Incomplete implementation of policy results in continued use of 'loss leaders' 
(Case 4.3) 
Kapake® (co-codamol 30/500) tablets were removed from the district formulary 
because, whilst they were inexpensive to supply within the hospital setting, they were 
expensive when continued in primary care. Kapake® was considered a 'loss leader' 
medicine which had no clinical benefits over prescribing the separate components. 
Therefore, a policy was produced stating that patients requiring this combination 
would be prescribed separate codeine and paracetamol. 
Problem 
A practice pharmacist complained that a patient had been discharged from hospital 
with Kapake® tablets when he should have received the separate components. Only 
five days supply was given contravening the 28 day supply policy 
Arising questions 
• Why is this a problem? 
Kapake® is significantly more expensive when prescribed in primary care. This 
expensive preparation could have been added to the patient's repeat prescription 
record. 
• Why was the patient given Kapake®? 
Although the hospital policy had changed, some of the wards still had stocks of 
Kapake® 'take home' pre-packs which could be issued by nursing staff on 
patients' discharge from hospital. 
• Why had pre-packs not been removed from the wards? 
No-one had thought to do this when the policy was implemented. 
• Why was only five days supply given? 
This was the agreed size of the pre-pack and should have been enough for post-
operative pain control. Patients requiring longer than five days analgesia require 
clinical review. 
Review of multifactorial dimensions of case 
• Post-operative analgesia plans are not clear to GPs. Patients should not require 
longer than five days supply of analgesia and so these medicines should not be 
added to patients' repeat prescription records. 
Root cause 
When the switch from Kapake® to paracetamol and codeine was implemented 
without taking into account all departments holding stocks of Kapake®. 
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Different policies Cor dispensing extemporaneous preparations may result in 
supply discontinuities (Case 5.2) 
A child was discharged from the children's hospital several months previously. Her 
mother has just noticed that the amiodarone suspension her child was taking expired 
the previous day. She obtained a prescription from her OP and took it to a community 
pharmacy for dispensing. The community pharmacist did not make extemporaneous 
preparations and had to order amiodarone suspension from a specials manufacturer. 
This meant that it would be several days before he could dispense the prescription. 
Therefore the mother approached the hospital pharmacy for help. 
Problem 
A child's amiodarone suspension has expired and there will be a delay before the 
community pharmacist can dispense the prescription. 
Arising questions 
• Why does the community pharmacist not make extemporaneous 
preparations? 
Extemporaneous dispensing is becoming less common in community pharmacy. 
• Why can the community pharmacist not dispense this prescription as it is 
urgent? 
He does not keep the required diluent in stock. 
• Why did the mother not order the medicine earlier? 
She did not appreciate that the prescription would not be dispensed immediately 
and had not realised that the current supply had expired. 
Review oC multiCactorial dimensions oC case 
• The expiry date on extemporaneously prepared medicines is much shorter than 
commercially prepared medicines. 
• Community pharmacist expects mother to resolve own supply problems. 
• Lack of awareness on the part of hospital pharmacists of dispensing process in 
community pharmacies. 
Root cause 
When child was discharged and mother was not adequately informed of the potential 
difficulties with obtaining extemporaneous preparations. 
Figure 5.3 Step 8b 
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Appendix 6 
Difficulty transferring clinical responsibility for unusual medicine (Case 6.2) 
Octreotide is an analogue of somatostatin which is licensed for the treatment of 
acromegaly and neuroendocrine tumours. It may also be used to reduce gastric 
secretions but is unlicensed for this use. A GP complained that a patient had been 
discharged on octreotide following treatment for pancreatic cancer. There was no 
prior consultation between the hospital medical consultant and the GP and no reason 
was given why the patient required octreotide. 
Problem 
The GP thinks that a patient has been discharged on an inappropriate treatment. 
Arising questions 
• Why does the GP think that octreotide is inappropriate? 
The patient has pancreatic cancer. The GP checked the indications for octreotide 
in the BNF and found that pancreatic cancer is not included in the list of 
indications, although it may be used for other cancers. 
• Why did the GP think the octreotide was prescribed to treat the cancer? 
The only information provided to the GP was included in the interim discharge 
summary. This did not state why octreotide had been prescribed. Unlicensed 
indications are not listed in the BNF and so the GP assumed that it was a cancer 
treatment rather than for symptom relief. 
• Why was more information not given? 
There is no system for provision of further information when prescribing 
responsibility for a specialist medicine is transferred. 
Review of multifactorial dimensions of case 
• Octreotide is uncommonly seen in primary care, particularly for unlicensed uses, 
whereas it is not unusual in hospital. 
• Information about unlicensed uses of medicines is not included in the usual texts 
kept in primary care. 
• Poor information transfer from secondary to primary care. 
• Interim discharge summaries are written by junior medical staffwho may also be 
unaware of the reasons for unusual medicines being prescribed. 
Root cause 
When discharge information was prepared without taking into account that the OP 
might require additional information about an unusual medicine. 
Figure 5.3 Step 6c 
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Appendix 6 
Difficulty transferring clinical responsibility for unlicensed medicine (Case 6.3) 
A OP was telephoned by a gastroenterology SHO and asked to prescribe ciclosporin 
for a patient with ulcerative colitis. The patient had been seen at an outpatient clinic 
that day. Ciclosporin is an immunosuppressant which requires careful monitoring to 
prevent serious toxicity. It is unlicensed for use in ulcerative colitis. 
Problem 
The OP is unwilling to take over prescribing responsibility for ciclosporin. 
Arising questions 
• Why is the GP unwilling to take over prescribing responsibility? 
He is unfamiliar with the use of the ciclosporin and it is for ulcerative colitis 
which is an unlicensed indication. 
• Would the GP prescribe if further information were supplied? 
No because evidence for the use of ciclosporin in ulcerative colitis is uncertain. 
Additionally the medicine is potentially toxic with a narrow therapeutic index and 
large inter-patient variability. 
• Why was the GP asked to prescribe? 
It is usual practice to transfer prescribing responsibilities from secondary to 
primary care without regard to the characteristics of the medicine. 
Review of multifactorial dimensions of case 
• Ciclosporin is uncommonly used as a final option for patients with ulcerative 
colitis not responding to other licensed medicines. Therefore, the appropriateness 
of transferring clinical responsibility to GPs had not been considered by the Area 
Prescribing Committee. 
• No systems to maintain prescribing responsibilities in secondary care. 
Root cause 
When decision was made to use ciclosporin within the hospital setting without 
considering whether OPs would be willing to take over prescribing responsibility. 
Figure 5.4 Step 4b 
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Appendix 6 
Inadequate recording of drug history on admission to hospital (Case 6.4) 
A patient with COPD was admitted to hospital with an infective exacerbation. His 
usual prescription was two to three 5mg tablets of prednisolone each day. However, 
this was not taken into account when the hospital discharge prescription was written. 
The patient was instructed to gradually reduce the dose of prednisolone and then stop 
taking the tablets. 
Problem 
A patient was given insufficient prednisolone tablets on discharge from hospital. 
Arising questions 
• Why? 
The house officer wrote the discharge prescription for a regimen reducing to zero. 
• Why? 
Prednisolone started when patients are admitted to hospital with acute 
exacerbations of COPD is usually discontinued once patients' conditions have 
stabilised. 
• Why did the hospital doctor not appreciate that the patient was on a 
maintenance dose of prednisolone? 
Failure to check the admission drug history when the discharge prescription was 
written. 
Review of multifactorial dimensions of case 
• Most patients do not continue on oral corticosteroids following treatment of an 
acute exacerbation of COPD. 
• Discharge prescriptions are sometimes written without reference to patients' 
notes. 
Root cause 
When patient was admitted to hospital it was not clearly stated on the inpatient 
medicine chart that prednisolone should only be reduced to the pre-admission dose. 
Figure 5.2 Step 3 
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Appendix 6 
General practitioner misunderstands that hospital medical consultant will 
maintain prescribing responsibility (Case 6.5) 
Isotretinoin is used for the treatment of severe acne. It is a toxic medicine which 
should only be prescribed by, or under the supervision of, a consultant dermatologist. 
A community pharmacist received a prescription for isotretinoin prescribed by a GP 
and is not sure whether she is able to dispense it. 
Problem 
A community pharmacist is unsure whether she can dispense a prescription for 
isotretinoin written by a GP. 
Arising questions 
• Why is community pharmacist unsure whether she can dispense the 
prescription? 
The BNF states that isotretinoin should only be prescribed by, or under the 
supervision of, a consultant dermatologist and the prescription presented was 
written by a GP. 
• Why did the GP prescribe isotretinoin? 
The GP received a letter from the consultant which she thought requested her to 
continue prescribing for the patient. 
• Why did the consultant ask the GP to prescribe? 
The hospital medical consultant is aware that GPs cannot prescribe isotretinoin 
and intended to continue to prescribe. 
Review of multifactorial dimensions of case 
• Normal practise for GPs to take over prescribing responsibility once initiated by a 
consultant for most medicines. 
• Lack of explicit communication across the interface leaves GPs unclear about 
their continuing responsibilities for patient care. 
• General practitioner trusted the information provided by the hospital medical 
consultant rather than researching the medicine herself. 
Root cause 
When letter was sent to OP from consultant describing the treatment initiated. The 
OP misunderstood that the hospital medical consultant would retain prescribing 
responsibility . 
Figure 5.4 Step 7 
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Appendix 6 
General practitioner has concerns over accepting clinical responsibility for a 
specialist medicine (Case 6.6) 
A GP is concerned about increasing prescribing of methylphenidate by child 
psychiatrists for children with behavioural problems. This medicine requires 
monitoring and it is unclear whether GPs or hospital medical consultants should take 
clinical responsibility. 
Problem 
A GP is uncomfortable accepting prescribing responsibility for methylphenidate. 
Arising questions 
• Why? 
Methylphenidate is a specialist medicine which requires monitoring to be used 
safely. It is not clear whether GPs or hospital medical consultants will be 
responsible for undertaking the necessary monitoring. 
• Why are monitoring responsibilities unclear? 
No additional information is provided along with a request to prescribe. There are 
no shared care guidelines in place. 
Review of multifactorial dimensions of case 
• Increasing volume of prescribing for children with behavioural problems which 
increases workload for monitoring in primary care. 
• Some controversy regarding the use of methylphenidate for the treatment of 
attention-deficit hyperactivity disorder (Consumers' Association, 1995). 
Root cause 
When request to prescribe was sent to GP without clearly stating which doctor would 
be responsible for each aspect of patient care. 
Figure 5.4 Step 7 
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Appendix 6 
Incomplete implementation of policy could result in continued use of 'loss 
leaders' (Case 7.1) 
Kapake® (co-codamol 30/500) tablets were removed from the district formulary 
because whilst they were inexpensive to supply within the hospital setting they were 
expensive when continued in primary care. Kapake® was considered a 'loss-leader' 
medicine which had no clinical benefits over prescribing the separate components. 
Therefore, a policy was produced stating that patients requiring this combination 
would be prescribed separate codeine and paracetamol. 
Problem 
A practice pharmacist complained that a discharge summary from the day case unit 
stated that a patient had been supplied with Kapake® tablets when she had actually 
been supplied with separate paracetamol and codeine tablets. 
• Why is this a problem? 
Kapake® is significantly more expensive when prescribed in primary care. This 
expensive preparation could have been added to the patient's repeat prescription 
record. 
• Why did the confusion arise? 
The day case unit used pre-printed discharge letters indicating which medicines 
patients had been supplied with on discharge from the unit. The discharge letters 
had not been updated to reflect the new policy. 
• Why had old stationary not been removed from the wards? 
No one had thought to do this when the policy was implemented. 
Review of multifactorial dimensions of case 
• Failure to consider the whole system when implementing a change. 
Root cause 
When switch from Kapake® to paracetamol and codeine was implemented without 
taking into account all stationary describing Kapake®. 
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Community pharmacist not informed how to obtain unusual medicine (Case 7.2) 
A community pharmacist contacted the hospital dispensary because a child recently 
discharged from the children's hospital had been prescribed 5mg clobazam tablets by 
a GP. The pharmacist wanted to know where the hospital pharmacy obtains this 
strength of tablet. 
Problem 
The community pharmacist has received a prescription for 5mg clobazam tablets and 
does not know where to obtain them. 
Arising questions 
• Why did the community pharmacist not know where to obtain the tablets? 
This strength of c10bazam in not listed in any of the usual texts kept by 
community pharmacies or stocked by wholesalers. 
• Why? 
Clobazam 5mg tablets are only available on a 'named patient' basis directly from 
the manufacturer. 
• Why was this information not passed onto the community pharmacist? 
There was no mechanism within the hospital pharmacy department for passing on 
procurement details for named patient medicines. 
Review of multifactorial dimensions of case 
• Hospital practitioners may not appreciate that community colleagues will not 
know how to obtain unusual medicines. 
• The community pharmacist was in another health authority area to the hospital 
and so would not have been aware of local policies. 
• 'Named patient' medicines are not uncommon in hospital pharmacies and may 
actually be kept in stock. 
• There is no system for communicating information to community pharmacists. 
Root cause 
When responsibility for care was transferred back to the OP and no information 
provided about a medicine with an unusual supply route. 
Figure 5.3 Step 7 
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Appendix 6 
Community pharmacist not informed how to obtain unusual medicine (Case 7.3) 
Oxybutynin is an antimuscarinic drug with a direct relaxant effect on urinary smooth 
muscle and is used to treat urinary incontinence caused by detrusor muscle instability. 
Its use is limited by antimuscarinic side-effects, such as dry mouth and constipation. 
Before the advent of similar medicines with improved tolerability, oxybutynin was 
used as a topical application to the bladder. This was an unlicensed medicine 
available from the manufacturer on a named patient basis. A community pharmacist 
contacted the hospital pharmacy department after being presented with a prescription 
for oxybutynin intravesical solution. 
Problem 
A community pharmacist has received a prescription for oxybutynin intravesical 
solution and does not know where to obtain it. 
Arising questions 
• Why is there no information in the BNF? 
The preparation is unlicensed and only available on a named patient basis from the 
manufacturer. 
• Why was this information not passed onto the community pharmacist? 
There was no mechanism within the hospital pharmacy department for passing on 
procurement details for named patient medicines. 
Review of multifactorial dimensions of case 
• This was the first time the consultant urologist had asked a GP to prescribe this 
preparation so it may not have been used in primary care previously. 
• In order to obtain supplies patients must be registered with the company. In this 
case the patient had not been registered when the supply was made from hospital 
pharmacy stock which further delayed the process. 
• Hospital practitioners may not appreciate that community colleagues do not know 
how to obtain unusual medicines. 
• 'Named patient' medicines are not uncommon in hospital pharmacies and may 
actually be kept in stock. 
• There is no system for communicating information to community pharmacists. 
Root cause 
When prescribing responsibility transferred to GP without consideration of the 
information needs of primary care practitioners. 
Figure 5.4 Step 6 
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Appendix 6 
Patient experiencing difficulty obtaining unusual medicine in primary care 
(Case 7.4) 
Captopril is widely available as 12.5mg, 25mg and 50mg tablets licensed for the 
treatment of hypertension and heart failure amongst other indications. An unlicensed 
2mg tablet is also available from the manufacturer and is used when small doses are 
required, for example when children are being treated. 
Problem 
A mother contacted the hospital pharmacy department reporting that a GP surgery 
receptionist had told her that she could only obtain 2mg captopril tablets for her child 
from the hospital pharmacy. 
Arising questions 
• Why was the mother given this information? 
The receptionist would not be able to find the 2mg strength of captopril tablets in 
the BNF or on the practice computer drug dictionary. 
• Why did the receptionist not realise that even though 2mg tablets are not 
listed they are available in primary care? 
She thought they were a 'special order' medicine available only through the 
hospital. 
Review of multifactorial dimensions of case 
• Captopril 2mg tablets are relatively uncommon in primary care. 
• Hospital practitioners may not appreciate that community colleagues are not 
aware of the availability of unusual medicines. 
• 'Named patient' medicines are not uncommon in hospital. 
• No additional information provided to GPs about unusual medicines when patients 
are discharged. 
• Patient not informed that medicine is unusual in primary care but is available. 
Root cause 
When discharge summary was written for GP without including information about an 
unusual medicine. 
Figure 5.3 Step 7 
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Appendix 6 
Community pharmacist not informed of formula for extemporaneous 
preparation (Case 7.5) 
Hydralazine is an antihypertensive commercially available in tablet and injection 
form. If a patient has swallowing difficulties and requires a liquid formulation then 
this would have to be made as an extemporaneous preparation. 
Problem 
Community pharmacist received a prescription for hydralazine suspension and wanted 
to know how the hospital pharmacy department had been making it. 
Arising questions 
• Why did hospital pharmacy staff not pass on the information when the initial 
prescription was dispensed? 
This preparation had not been made in the hospital pharmacy department as the 
patient was seen in the outpatient department and given a medicines advice note to 
obtain a supply through his GP. 
Review of multifactorial dimensions of case 
• No opportunity for hospital pharmacists to intervene if patients are given 
medicines advice notes at outpatient clinics as these are taken straight to a GP 
surgery and therefore bypass the hospital pharmacy. 
• Hospital doctors may not be aware which preparations are not commercially 
available. 
Root cause 
When medicines advice note was written asking OP to a prescribe suspension without 
taking into account that this preparation was not commercially available. 
Figure 5.4 Step 4b 
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Appendix 6 
Patient initiated on formulation of medicine which is impractical to prepare in 
primary care (Case 7.6) 
Omeprazole was originally only available in capsule fonnulation although there is 
now a dispersible tablet. The capsules contain enteric-coated granules of omeprazole. 
In the hospital setting a solution of omeprazole was prepared by opening the capsule 
to release the granules and mixing them with a solution of sodium bicarbonate to 
dissolve the enteric coat. Then the freshly prepared solution could be administered to 
patients with swallowing difficulties. 
Problem 
Impractical method for preparing omeprazole solution in primary care. 
Arising questions 
• Why is this preparation impractical in primary care? 
The hospital pharmacy department used sodium bicarbonate from a Polyfusor® to 
dissolve the enteric coat surrounding the granules in omeprazole capsules. 
Polyfusors® are not routinely kept in community pharmacies. This is quite a 
complex process for carers to undertake. 
• Would another medicine be more suitable? 
Possibly, although this was not considered before the patient's discharge from 
hospital. 
Review of multifactorial dimensions of case 
• This process is relatively common in a hospital pharmacy setting. 
• Lack of awareness with the hospital of how community pharmacists operate. 
• Failure to consider alternative medicines before starting an unusual formulation of 
medicine. 
• If community phannacist had been involved in the discharge planning process 
potential problems may have been identified before the patient was discharged 
from hospital. 
Root cause 
When medicine chosen which would be complicated to supply in the community. 
Figure 5.2 Step 4c 
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Appendix 6 
Patient initiated on formulation of medicine which is impractical to prepare in 
primary care (Case 7.7) 
As described in Case 7.6, omeprazole was originally only available in a capsule 
formulation. A solution could be prepared by opening the capsule to release the 
enteric-coated granules inside and mixing them with a solution of sodium bicarbonate 
to dissolve the enteric coat. Then the freshly prepared solution could be administered 
to patients with swallowing difficulties. 
Problem 
A practice pharmacist felt that the process for making omeprazole solution was too 
complex in primary care and wondered if ranitidine suspension would be suitable. 
Arising questions 
• Why is the process for making omeprazole solution impractical? 
It requires dissolving the omeprazole granules in sodium bicarbonate solution 
which is not routinely kept in community pharmacies. The solution must be 
freshly prepared which puts an additional burden on carers. 
• Would an alternative ulcer healing medicine be appropriate? 
The patient has a gastrostomy feeding tube and lansoprazole suspension is 
probably too viscous to go down the tube. Ranitidine syrup would be suitable for 
the tube. 
• Why was ranitidine not considered before discharge? 
There are no problems making omeprazole solution in a hospital setting and so an 
alternative was not considered. 
Review of multifactorial dimensions of case 
• This process is relatively common in a hospital setting. 
• Failure to consider how carers would cope with preparing medicines before 
discharge from hospital. 
• Failure to critically review medicines on discharge from hospital. In retrospect it 
was considered that ranitidine would provide sufficient suppression of gastric acid 
for the patient's condition once discharged from hospital. 
• Lack of liaison with community pharmacist around whether it would be possible 
to prepare medicine in primary care. 
Root cause 
When patient was discharged without considering whether it would be practical to 
make omeprazole solution in the community. 
Figure 5.2 Step 4c 
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Appendix 6 
Change in formulation of medicine when patient discharged to primary care 
(Case 7.8) 
An infant had been initiated on chloral hydrate suspension at a hospital clinic. The 
hospital pharmacy ordered this from a specials manufacturer. When the patient was 
discharged from hospital the community pharmacist prepared further supplies 
extemporaneously. 
Problem 
A child does not like the chloral hydrate suspension obtained from a community 
pharmacy. 
Arising questions 
• Why? 
Community pharmacist is manufacturing from chloral hydrate powder whereas the 
hospital pharmacy bought the preparation from a specials manufacturer. 
• Why did the community pharmacist not supply the same preparation? 
There was no communication between hospital and community pharmacists and 
so the community pharmacist was unaware of the preparation dispensed 
previously. 
Review of multifactorial dimensions of case 
• Could not anticipate that infant would dislike a different formulation of medicine. 
• No system for communicating information about unusual medicines to community 
pharmacists. 
Root cause 
When child was discharged back to the care of the OP and no transfer of information 
to community pharmacist about the preparation used. 
Figure 5.3 Step 7 
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Appendix 6 
Inadequate information provided by GP when patients are admitted to hospital 
(Cases 8.1 to 8.5) 
These five cases have been grouped together because they all relate to drug history 
problems when patients were admitted to hospital due to unclear admission 
information. 
Problem 
Patients' current medicines incorrectly prescribed on admission to hospital: 
8.1 Patient prescribed phenytoin 75mg instead of 225mg daily 
8.2 Patient prescribed thyroxine 250flg instead of fluvoxamine 250mg 
8.3 Type and dose of inhalers not known 
8.4 Digoxin prescribed without a dose 
8.5 Insulin prescribed but unclear if pork or human insulin 
Arising questions 
• Why were medication histories unclear? 
Poor admission information provided by GPs. 
Review of multifactorial dimensions of case 
• Difficult for hospital practitioners to access surgeries due to limited opening 
hours, particularly in the afternoon. 
• If patients are admitted as emergencies the admitting GP may not have access to 
the full patient record. 
• Patients do not always bring their own medicines into hospital with them. 
• Patients who self-refer to hospital will not have a GP referral letter. 
Root cause 
When patient was referred to hospital by GP. 
Figure 5.2 Step la 
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Appendix 6 
Patients experiencing difficulties obtaining further supplies of medicines in 
primary care (Case 9.2) 
Reports of two patients having difficulty obtaining further supplies of magnesium 
glycerophosphate tablets from community pharmacies. This is an oral preparation 
used to prevent recurrence of magnesium deficiency in patients who may have been 
treated initially with magnesium sulphate infusion. In one case the community 
pharmacist informed the patient that he could not supply magnesium 
glycerophosphate tablets but that he could sell her a tonic containing magnesium. 
Problem 
Patients having difficulty obtaining further supplies of magnesium glycerophosphate 
tablets from community pharmacies. 
Arising questions 
• Why could community pharmacies not obtain the tablets? 
They did not know where to get them from. 
• Why? 
It is unclear because these tablets and their supplier (a medicines importer) are 
mentioned in the BNF, although the only magnesium monograph included is for 
magnesium sulphate injection. 
• Why was an alternative preparation recommended? 
The community pharmacist was unaware of the importance of taking a specific 
amount of magnesium. 
Review of multifactorial dimensions of case 
• Community pharmacists are not used to dealing with suppliers other than their 
regular wholesalers. 
• Community pharmacist was unable to source intended medicine and failed to find 
out where it could be obtained. 
• Community pharmacists do not receive any clinical details about patient and so 
are unaware of the reasons medicines are prescribed. 
Root cause 
No communication from hospital to community pharmacist around sourcing unusual 
medicine and the need for a specific product to be supplied. 
Figure 5.4 Step 6 
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Appendix 6 
Wrong strength of extemporaneous preparation prescribed (Case 9.3) 
Extemporaneously prepared medicines typically have short expiry dates, one week for 
this example of thyroxine suspension. Therefore, if an error is made in the 
prescription or dispensing of an extemporaneous preparation, patients risk a 
discontinuity in supply unless a further supply can be prepared quickly. 
Problem 
A community pharmacist dispensed thyroxine suspension 15J..lg in 5ml for a child 
when the strength should have been 25J..lg in 5ml. 
Arising questions 
• Why was the wrong strength prepared? 
The prescription written by the GP specified the wrong strength. 
• Why was this not noticed before suspension was prepared? 
The mother did not notice until she read the bottle label. The only information 
accessible to the community pharmacists was what was written on the FP 1 0 
prescription. 
• Why can the pharmacist not make up another supply? 
He has run out of ingredients and so there will be a delay whilst these are 
obtained. 
• Why is this a problem? 
The previous supply from the hospital pharmacy has expired because the 
suspension only has a seven day shelf life. 
Review of multifactorial dimensions of case 
• Extemporaneously prepared medicines are not listed on GP computer picking lists 
and so there is a risk that an incorrect strength may be manually prescribed. 
• There is no communication between hospital and community pharmacists about 
patients and so they prepare medicines as prescribed by GPs. 
• Extemporaneous preparations often have short expiry dates. 
• The community pharmacist did not confirm the strength before making the 
preparation. 
Root cause 
Careless addition of medicine to patient's prescription record meant that a prescription 
was issued for an incorrect strength of suspension. 
Figure 5.5 Step 3 
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Appendix 6 
Patient admitted with inadequately labelled medicine (Case 9.4) 
It is important that any extemporaneously prepared suspensions have the strength of 
the medicine included on the label. This is so that anyone caring for the patient in the 
future can calculate the dose of medicine being taken. A child was admitted to 
hospital with a bottle labelled 'Diazoxide suspension. Take 2mls three times a day'. 
There was no indication of the strength of the suspension on the label. 
Problem 
The dose of diazoxide that the child is taking is unknown. Nursing staff cannot 
administer the suspension to the child because there is no strength on the bottle label. 
Arising questions 
• Why is there no strength on the label? 
Omitted in error by dispensing pharmacist. 
Review of multifactorial dimensions of case 
• The prescription only stated 'diazoxide 50mg tablets x 18 in 1 OOml' although the 
pharmacist could have calculated the strength from this information. 
• Inadequate checking procedures in place in the community pharmacy to ensure 
that all information is present. 
• Lack of appreciation on the part of the community pharmacist that another health 
care professional might need to calculate the child's dose of medicine. 
Root cause 
During the dispensing process when the medicine label was generated. 
Figure 5.5 Step 8 
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Appendix 6 
Difficulty transferring responsibility for expensive medicine (Case 10.1) 
Erythropoietin is used to treat anaemia associated with renal disease. It requires 
specialist knowledge to prescribe and monitor safely and so some GPs are reluctant to 
accept clinical responsibility. However, it is also an expensive medicine costing 
several thousand pounds a year. The cost of a medicine is charged to the prescriber's 
budget so if a GP prescribes erythropoietin this can have a significant impact on the 
practice budget. Fundholding practices received incentives to manage their budgets 
and this could provide a disincentive to accept prescribing responsibility for expensive 
medicines. 
Problem 
A fundholding practice manager enquired about funding arrangements for 
erythropoietin. There was a delay in the patient obtaining supplies whilst this was 
resolved. 
Arising questions 
• Why is practice manager enquiring about funding arrangements? 
A hospital doctor has asked a GP to prescribe erythropoietin. This is an expensive 
medicine which will be charged to the GP's prescribing budget ifhe prescribes. 
• Why was the GP asked to prescribe? 
Traditionally GPs continue to prescribe all medicines after hospital initiation. 
• Why? 
Hospital budgets only funded for small supplies of medicines and not ongoing 
treatment. 
Review of multifadorial dimensions of case 
• Usual process is to assume GPs will prescribe on receipt of a request from a 
hospital doctor. 
• Funding arrangements assume that prescribing responsibility, and therefore the 
cost of medicines, will be transferred to GPs. 
• Incentives to manage prescribing budgets may deter GPs from prescribing 
expensive medicines. 
Root cause 
When prescribing responsibility was transferred without prior consultation with GP. 
Figure 5.4 Step 7 
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Appendix 6 
Community doctors ask GPs to prescribe medicines because they do not have 
access to community prescriptions (Case 10.2) 
Within the Health Authority area community doctors did not have access to FP 1 O(HP) 
prescriptions. These are prescription forms used by NHS employed doctors that may 
be dispensed by community pharmacists. Community clinicians may prescribe in 
environments outside a hospital setting. Therefore, unless patients are willing or able 
to travel to have prescriptions dispensed at the hospital pharmacy, GPs must prescribe 
on FP 1 0 prescriptions. 
Problem 
A GP is refusing to prescribe methylphenidate for a child. The community 
paediatrician only has access to hospital prescription forms and so the child's mother 
must travel some distance to get the prescription dispensed at the hospital pharmacy. 
Arising questions 
• Why will GP not prescribe methylphenidate? 
He is unwilling to take clinical responsibility. 
• Why does the mother have to travel to the hospital pharmacy to have the 
prescription dispensed? 
The community paediatrician only has access to hospital prescription forms which 
cannot be dispensed by community pharmacists. 
• Why do community paediatricians not use FPI0(HP) forms? 
It was the policy of the community trust policy not to use FPlO(HP) forms due to 
the lack of control of medicines prescribed and the payment of dispensing fees to 
community pharmacists. 
Review of multifactorial dimensions of case 
• No system in place for community paediatricians to continue prescribing if GPs 
refuse. 
• Hospitals must reimburse community pharmacy dispensing fees if FP I O(HP) 
prescriptions are dispensed by community pharmacists. Prescriptions dispensed 
by the hospital pharmacy department fall within existing funding arrangements. 
• FPIO(HP) forms could be misused by doctors to prescribe non-formulary 
medicines as community pharmacists do not enforce the district formulary. 
Root cause 
When prescribing responsibility was transferred without prior consultation with the 
GP. 
Figure 5.4 Step 7 
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Appendix 6 
Difficulty transferring clinical responsibility for a specialist medicine (Case 10.3) 
A OP is unwilling to prescribe methylphenidate because he feels it is a specialist drug 
and that the community paediatrician should prescribe. 
Problem 
A GP is refusing to prescribe methylphenidate. 
Arising questions 
• Why is the GP unwilling to prescribe? 
He feels that methylphenidate is a specialist medicine and that he is unable to take 
clinical responsibility. 
• Why did the community paediatrician ask the GP to prescribe? 
It is usual practise to ask GPs to prescribe as community paediatricians have no 
prescription pads. 
Review of multifactorial dimensions of case 
• The community paediatrician felt there was no point issuing a prescription until 
the staff at the child's school had agreed to administer the lunchtime dose. 
Therefore, if the community paediatrician had prescribed once agreement with the 
school had been reached the child's mother would have had to return to hospital to 
collect the medicine. 
• Community paediatrician felt it would be more convenient for the mother to 
obtain prescriptions in the community. 
• No system in place for community paediatricians to continue prescribing if GPs 
refuse. 
• No additional information issued to GP along with request to prescribe. 
Root cause 
When prescribing responsibility was transferred without prior consultation with the 
GP. 
Figure 5.4 Step 7 
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Appendix 6 
Difficulty transferring responsibility for unusual medicine (Case 10.4) 
MUSE® is device containing alprostadil for urethral application for the treatment of 
erectile dysfunction. The device is available in four strengths and the dose must be 
titrated depending on the effect on each individual patient. The BNF recommends 
that medically trained personnel give the first dose. 
Problem 
A GP complained that the erectile dysfunction clinic staff were recommending that 
GPs prescribe MUSE® but that the dose was not being titrated in the clinic. He was 
concerned that an incorrect dose might be prescribed. 
Arising questions 
• Why is the correct dose not found in clinic? 
Only one dose can be given during a clinic appointment. Therefore, if the dose is 
only partially effective patients are given a higher strength device to try at home. 
• Is this safe? 
Patients are informed what to do if effects do not wear off after a few hours. 
Review of multifactorial dimensions of case 
• Not clear if clinic procedure was followed for all patients. This may mean that 
some patients are referred back to GPs before an effective dose has been 
determined. 
Root cause 
When the clinic staff sent a letter to the GP that did not fully explain the process 
carried out within the hospital setting. 
Figure 5.4 Step7 
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Appendix 6 
Different policies operational in primary and secondary care creates difficulty 
for patient in obtaining medicines (Case 10.6) 
There is a difference between hospital and community pharmacy dispensing policies 
whereby hospital pharmacies may dispense any available product but community 
pharmacies may not dispense products included on the NHS 'blacklist'. This means 
that patients could be started on medicines or devices that are not available in the 
community. 
Problem 
Mother cannot obtain protein and blood urine-testing strips for child with nephrotic 
syndrome in the community. 
Arising questions 
• Why can mother not obtain test strips? 
The child's OP issued a prescription but the community pharmacist cannot 
dispense it. 
• Why can the community pharmacist not dispense the prescription? 
Multi-purpose testing strips may not be prescribed on the NHS in primary care 
because they are included on the NHS 'blacklist'. 
Review of multifactorial dimensions of case 
• Hospital doctor was unaware that some test strips are not available on NHS 
prescription in primary care. 
• Different policies operational in primary and secondary care. 
Root cause 
When mother was told to obtain a further supply of test strips via her OP without 
appreciating that this was not possible. 
Figure 5.4 Step 4a 
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Appendix 6 
Different policies operational in primary and secondary care (Case 10.7) 
At the time of the study Mucodyne® capsules were included in the NHS 'blacklist' 
and so were not prescribable under the NHS by OPs. A hospital medical consultant 
recommended that a OP prescribe this for a patient to reduce sputum viscosity. 
Problem 
A patient complained that a consultant had recommended that he take Mucodyne® 
capsules but he is experiencing problems obtaining them on the NHS. 
Arising questions 
• Why can the patient not obtain Mucodyne® on the NHS? 
The OP told the patient that it was blacklisted and so he could not write an NHS 
prescription for it. 
• Why can the hospital consultant not prescribe? 
Mucodyne® was not included in the district formulary and so the hospital 
pharmacy will not dispense it. 
• Are there any other supply routes? 
This could be dispensed as a private prescription at a cost of around £40 per 
month. The patient is not prepared to pay for his medicine. 
Review of multifactorial dimensions of case 
• The hospital medical consultant was not aware that Mucodyne® was blacklisted 
and so OPs would not be able to prescribe it. 
• Different policies operational in primary and secondary care may mean than 
secondary care practitioners are unaware of policies operational in primary care 
and vice versa. 
• Even if hospital pharmacy departments do not stock blacklisted items patients may 
be led to believe they can obtain them in primary care. 
• There is a loophole in the system for formulary enforcement whereby hospital 
doctors may ask GPs to prescribe non-formulary medicines. 
• Rigid enforcement of the formulary by hospital pharmacy management means the 
patient is unable to obtain medicines he has been told may reduce his symptoms. 
Root cause 
When hospital doctor asked OP to prescribe non-formulary medicine. 
Figure 5.4 Step 4b 
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Appendix 6 
Different national supply policies for consumables in primary and secondary 
care (Case 11.1) 
A five year old child was discharged from hospital after insertion of a gastrostomy 
feeding tube. The nutritional products he required could be prescribed by his GP but 
syringes required to administer the feeds could not. Therefore, there is a need to 
establish an alternative supply route. 
Problem 
A child is being fed via a gastrostomy tube and his mother cannot obtain syringes 
necessary to administer the feeds from her GP. 
Arising questions 
• Why can the GP not prescribe the syringes? 
This type of syringe is not available on GP prescription 
• Why? 
It is not listed in the Drug Tariff as available for prescribing by GPs. 
• Why did the GP practice not order a supply of syringes? 
The majority of equipment and medicines must be individually prescribed in 
primary care. There is no budget within practices for purchasing this type of 
equipment. 
• Could the district nurse supply from the community budget? 
No, because the mother provides all care for her child and district nurses are not 
involved. Additionally they are not trained in paediatrics and so involvement in 
this case would be outside their competencies. 
• Could the paediatric liaison nurse provide syringes? 
No, because they do not have a budget for supplying equipment and so would 
have to take from hospital ward stocks. This is not appropriate because the 
hospital budget would be used for a patient in primary care. 
Review of multifactorial dimensions of case 
• Lack of awareness on the part of hospital practitioners of policies applicable to 
primary care, for example that certain equipment is not available on prescription 
and that GP practices do not keep stocks of equipment to issue to patients. 
• Inability to access budgets for community services unless community nurses are 
providing nursing care. 
• Budgets for services sometimes exclude necessary equipment (e.g. paediatric 
liaison nurses). 
• Lack of liaison and consistency even within hospital departments. 
Root cause 
When patient was discharged back to the care of the GP without ensuring that all 
medicines and equipment could be supplied. 
Figure 5.3 Step 8a 
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Appendix 6 
Syringes necessary to administer an injection may not be prescribed in primary 
care (Case 11.2) 
Growth hormone injection is used to treat deficiency of the hormone in children and 
adults. The medicine is packaged in a cartridge fitted into an injecting device. A 
needle must be attached to the device before the medicine can be given by 
subcutaneous injection. Whilst growth hormone cartridges may be prescribed under 
the NHS the injecting device and needles are blacklisted and so may not be prescribed 
in primary care. Hospital clinics obtain supplies of injecting devices and needles and 
these are given to patients. 
Problem 
A child is taking growth hormone injection and his mother is experiencing difficulty 
obtaining a further supply of needles. 
Arising questions 
• Wby? 
The needles are not prescribable under the NHS. 
• Wby can she not obtain the needles from the hospital clinic? 
Prescribing responsibility has transferred to the GP under a shared care 
arrangement and so the child is not attending the hospital clinic as frequently as 
previously 
Review of multifactorial dimensions of case 
• Different mechanisms for supply of consumables in primary and secondary care. 
• Growth hormone initiated and monitored by tertiary centre, child also under the 
care of a secondary care paediatrician and a GP. 
• Specialist growth hormone nurse on maternity leave, therefore gap in service and 
other staff not clear how patients can obtain needles. 
• Failure of arrangements for shared care to take into account supply of 
consumables. 
Root cause 
Prescribing responsibilities may be transferred to GPs under shared care arrangements 
without ensuring that patient are able to obtain further supplies of consumables. 
Figure 5.4 Step 4a 
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Appendix 6 
Restrictive hospital policies for quantities of medicines to supply (Case 12.1) 
Antibiotic syrups have short expiry dates once reconstituted. This means that if an 
antibiotic course extends beyond the expiry date of the product patients must return to 
collect the remains of the course from the hospital pharmacy. This is often 
inconvenient for them due to the distance between their homes and the hospital. It is 
often easier for patients to obtain the remainder of the supply via their GPs although 
this means that the hospital is not fulfilling their obligations around supplying 
complete antibiotic courses. 
Problem 
Hospital pharmacy cannot fulfil their contractual agreement to supply full courses of 
antibiotics due to short expiry dates of reconstituted products. 
Arising questions 
• Why? 
Patients prefer not to return to the hospital pharmacy to collect remaining supplies 
of antibiotic syrup. 
• Why is it a problem to obtain further supplies from GPs? 
There are cost implications to primary care budget, although these are small, and 
also the time involved for GPs to issue prescriptions for the remains of an 
antibiotic course. 
Review of multifactorial dimensions of case 
• Patient reluctance to return to hospital. 
Root cause 
When policy for supply of medicines from hospital was agreed without taking into 
account possible exceptions and patient preferences. 
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Appendix 6 
Hospital pharmacy department opening hours not aligned with outpatient clinic 
hours (Case 12.3) 
A GP complained that he was asked to prescribe for a patient because they could not 
get their hospital prescription dispensed because the phannacy had closed. 
Problem 
General practitioner rushing to issue a prescription that should have been dispensed 
by the hospital pharmacy. 
Arising questions 
• Why did the hospital pharmacy not dispense the prescription? 
Hospital pharmacy closes at 5.30pm and some outpatient clinics run until 7pm. 
• Could the patient not take the hospital prescription to a community 
pharmacy? 
No, because he was given a hospital prescription which can only be dispensed by 
the hospital pharmacy. 
• Could patient come back when hospital pharmacy was open? 
Yes but this would be inconvenient for the patient and involve another trip to the 
hospital. 
Review of multifactorial dimensions of case 
• Pharmacy opening hours are not aligned with outpatient clinic times 
demonstrating a lack of liaison between outpatient and pharmacy department 
management. 
• Outpatient clinic staff not aware of the opening times of the hospital pharmacy. 
Root cause 
When hospital prescription was issued without taking into account that the pharmacy 
department would have closed. 
Figure 5.4 Step 4a 
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Appendix 6 
Lack of consideration of 'whole system' when medicines supply policy written 
(Case 12.4) 
The hospital policy was that patients should be given at least fourteen days supply of 
medicines on discharge from hospital. The hospital pharmacy department did not 
have the equipment to dispense medicines in monitored dosage systems (MDS). 
Therefore, patients requiring monitored dosage systems to assist with compliance 
problems could not be supplied in this way by the hospital pharmacy. Patients' 
medicines would be dispensed in the usual way in original packs or tablet bottles. 
Problem 
A patient is due to be discharged from hospital and requires medicines dispensing in a 
monitored dosage system. The hospital pharmacy department cannot do this as they 
do not have the necessary equipment. 
Arising questions 
• Why does the patient need medicines in MDS? 
Patient is visually impaired and so home carers assist with medicines. Social 
services policies state that staff may only do this if medicines are in MDS 
dispensed by a pharmacist. 
• Why does the hospital pharmacy department not have the necessary MDS 
equipment? 
Several different systems are in use and the hospital would still have difficulty 
supplying medicines for some patients if only one system was purchased. 
Review of multifactorial dimensions of case 
• Community pharmacists cannot dispense hospital prescriptions and so it was 
necessary to obtain a prescription from the patient's GP in order to get the 
medicines dispensed in an MDS. 
• No single MDS used across the area, if this had agreed hospital pharmacy might 
have purchased the necessary equipment. 
• Failure to take into account action to be taken for patients requiring MDS when 
the medicines supply policy was agreed. 
Root cause 
When the hospital pharmacist reviewed patients own medicines without taking any 
action to ensure that MDS would be provided on discharge from hospital. 
Figure 5.2 Step 4c 
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Appendix 6 
Lack of consideration of 'whole system' when medicines supply policy written 
(Case 12.5) 
The hospital does not have the equipment to dispense medicines in monitored dosage 
systems (MDS). Therefore, patients requiring MDS to assist with compliance 
problems could not be supplied in this way by the hospital pharmacy. Patients' 
medicines would be dispensed in the usual way in original packs or tablet bottles. 
Problem 
A patient's son pointed out that his mother's discharge medicines had been dispensed 
in bottles when she normally uses an MDS at home. He wanted to know how she 
would manage her medicines. 
Arising questions 
• Why were discharge medicines supplied in bottles when patient uses MDS? 
It was not appreciated that the patient used an MDS when the discharge 
prescription was prepared. 
• Could the hospital pharmacy supply the medicines in an MDS 
No because they do not keep the necessary equipment. 
Review of multifactorial dimensions of case 
• There were several different types of MDS in use across the district which 
deterred hospital pharmacy staff from purchasing the necessary equipment. 
• It is not really appropriate for community pharmacists to re-dispense hospital 
dispensed medicines in MDS due to lack of funding for dispensing. 
Root cause 
The patient's use ofMDS was not clearly documented on admission to hospital. 
Figure 5.2 Step 4c 
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Appendix 6 
Breach of policy to endorse prescriptions with generic names of medicines 
creates confusion (Case 13.1) 
Patients are given a copy of their discharge prescription on discharge from hospital. 
The hospital policy stated that hospital pharmacists should endorse prescriptions with 
generic names if they have been prescribed by brand. 
Problem 
Community phannacist complained that a patient had thought that his medicines had 
been wrongly dispensed. 
Arising questions 
• Why did the patient think a mistake had been made? 
The medicines that the community pharmacist dispensed were labelled as 'co-
amilofruse' and 'diclofenac' and the copy of the discharge prescription said 
'frumil' and 'voltarol'. 
• Why had the prescription not been endorsed with the generic names? 
Breach of policy by dispensing pharmacist. 
Review of multifactorial dimensions of case 
• Lack of appreciation on the part of the hospital pharmacist of the importance of 
endorsing prescriptions. 
Root cause 
When discharge prescription was dispensed and policy regarding prescription 
endorsements not complied with. 
Figure 5.3 Step 7 
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Appendix 6 
Transfer of prescribing in order to transfer the cost of expensive medicines 
(Case 14.1) 
The most appropriate doctor should write prescriptions. Prescribing responsibility 
should not be transferred from hospital doctors to GPs simply to transfer the costs of 
treatment. 
Problem 
A hospital directorate business manager enquired whether prescribing responsibility 
for interferon could be transferred to GPs. 
Arising questions 
• Why? 
Interferon is an expensive medicine costing several thousand pounds per patient 
per year. 
• Why is it not appropriate to transfer prescribing responsibility to GPs? 
This is a specialist treatment and GPs are unlikely to want to take clinical 
responsibility. It also requires monitoring to assess patient outcomes and this will 
continue to be undertaken by hospital doctors meaning that it is more appropriate 
for hospital doctors to prescribe. 
Review of multifactorial dimensions of case 
• Hospital budgets are cash-limited with yearly cost improvement targets. This 
gives an incentive to transfer the cost of expensive treatments to primary care. 
• At the time interferon was unlicensed for the treatment of Hepatitis C. 
Root cause 
Inappropriate transfer of prescribing prevented before it occurred. 
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Appendix 6 
Limited enforcement of the district formulary in primary care (Case 15.1) 
The district formulary was closely monitored and enforced with the hospital setting. 
Hospital pharmacists ensured compliance by intervening when non-formulary 
medicines were prescribed. The situation is different in primary care whereby GPs 
may prescribe non-formulary medicines and it is not within the current role of 
community pharmacists to question this. This means that non-formulary medicines 
taken by patients admitted to hospital may not be stocked by the hospital pharmacy. 
Problem 
Patient admitted taking Moducren®, a combination product for hypertension 
containing timolol, amiloride and hydrochlorothiazide. This is not included in the 
district formulary and so not stocked by the hospital pharmacy department. 
Arising questions 
• Why could the hospital pbarmacy department not purchase a supply? 
Non-formulary medicine which is relatively expensive compared to alternatives. 
• Why was the patient not changed to a formulary alternative? 
The patient was stable on Moducren®. Changing the medicine might have 
affected her blood pressure control. Therefore, blood pressure would require 
monitoring following change of medicine. This would be more appropriately 
done by the patient's GP. 
Any contributing factors? 
• Patient did not bring any of her own medicines into hospital. 
• Adherence to district formulary is enforced less strongly in primary care than in 
hospital. 
• Community pharmacists do not intervene when non-formulary medicines are 
prescribed by GPs. 
• Community pharmacists have no incentives to enforce formularies. Firstly they 
are not remunerated to do this and secondly it might actually be commercially 
detrimental if intervening upsets their relationships with local GPs. 
• The patient may have been taking this particular antihypertensive for a long time. 
This raises the question of whether patients' medicines should be changed simply 
to comply with a formulary. 
Root cause 
When non-formulary medicine prescribed in primary care. 
Figure 5.2 Step la 
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Appendix 6 
Hospital doctor insists on asking GP to prescribe non-formulary medicine 
(Case 16.1) 
Modified-release isosorbide mononitrate preparations are approximately ten times the 
cost of standard release preparations in primary care. However, modified-release 
preparations are sold as 'loss leaders' to hospitals at a fraction of the real price to 
encourage their use. Across the Health Authority it was realised that significant 
savings could be made if there was a switch to the use of standard-release 
preparations across both primary and secondary care. This policy was agreed by the 
Area Prescribing Committee. 
Problem 
A hospital doctor insists on writing to a OP asking him to prescribe a modified-release 
isosorbide mononitrate preparation. 
Arising questions 
• Why? 
The hospital doctor had written a hospital prescription for modified-release 
isosorbide mononitrate. This had been intercepted by a hospital pharmacist who 
had informed the doctor about the new policy. 
• Why did the hospital doctor not accept the pharmacist's advice to use 
standard-release isosorbide mononitrate? 
The doctor prefered to use modified release isosorbide mononitrate and did not 
agree with the new policy. 
Any contributing factors? 
• Loophole in the system whereby hospital doctors may ask OPs to prescribe 
non-formulary medicines. 
• Failure to gain commitment from all stakeholders when policy was changed. 
Root cause 
When letter was written to OP to request prescription. 
Figure 5.4 Step 4b 
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Appendix 6 
Hospital use of 'loss leader' medicines impacts on primary care prescribing 
budget (Case 16.2) 
Modified-release isosorbide mononitrate preparations are approximately ten times the 
cost of standard release preparations in primary care. However, modified-release 
preparations are sold as 'loss leaders' to hospitals at a fraction of the real price to 
encourage their use. The Health Authority Prescribing Adviser proposed that 
significant savings could be made if there was a switch to the use of standard-release 
preparations across both primary and secondary care. This policy was agreed by the 
Area Prescribing Committee. 
Problem 
Hospital use of modified-release nitrates is causing a significant cost pressure in 
primary care. 
Arising questions 
• Why do hospital doctors prescribe modified-release preparations? 
There is a perception that these are clinically more effective and improve 
compliance. 
• Why have hospital pharmacists not challenged these perceptions? 
The hospital pharmacy department is able to purchase modified-release 
preparations cheaper than standard-release preparations and so this strategy 
actually saves the hospital money. 
• Why? 
Modified-release preparations are sold as 'loss leaders' to hospitals at a fraction of 
the real price. This is because pharmaceutical companies appreciate that once 
patients are started on medicines they are unlikely to be changed and hence their 
initial expenses will be recouped. 
Review of multifactorial dimensions of case 
• Hospital budgets are cash-limited with yearly cost-improvement targets. This 
gives an incentive to take advantage of' loss leaders' despite this being against the 
spirit of national guidance. 
• It is legally permissible both for pharmaceutical companies to offer medicines to 
hospitals at significantly discounted prices and for hospitals to accept these. 
• It is sometimes more expensive for hospitals to prescribe standard-release than 
modified-release preparations. 
Root cause 
Failure to review medicines included on formulary with regard to their cost-
effectiveness across the whole health economy. 
372 
Appendix 6 
Poor feedback about Drug and Therapeutics Committee decisions (Case 16.3) 
A surgeon wanted to prescribe flutamide for a patient with pancreatic cancer. This 
was an unlicensed indication. This had been previously discussed at the hospital Drug 
and Therapeutics Committee following an application from another consultant. The 
decision was that this medicine should not be used within the hospital setting until 
appropriate trials had been established. The Area Prescribing Committee had also 
discussed the medicine and agreed that it was not appropriate for prescribing by GPs. 
Flutamide was written on the hospital discharge prescription but not dispensed by 
hospital pharmacy. 
Problem 
A hospital doctor was going to ask a GP to prescribe flutamide because the hospital 
pharmacy department had not dispensed the discharge prescription. 
Arising questions 
• Why is this a problem? 
The Area Prescribing Committee decision was that flutamide was not suitable for 
GP prescribing. 
• Why was the hospital prescription not dispensed? 
The Drug and Therapeutics Committee decided that flutamide should only be used 
as part of a clinical trial and trials had not been set up. 
• At which point did things go wrong? 
The Drug and Therapeutics Committee decision was not communicated 
adequately to the hospital medical consultant and he did not accept the decision. 
Review of multifactorial dimensions of case 
• Patient has cancer, delay in obtaining medicine whilst problem is resolved. 
• Loophole in the system for the managed introduction of new medicines whereby 
GPs may be asked to prescribe non-formulary medicines. 
• No way of enforcing Area Prescribing Committee decisions outside the hospital. 
• Individual practitioners may disagree with committee decisions. 
• General practitioners may be coerced into prescribing as patients have cancer and 
they feel they can do little else although the true benefits have not been 
established. 
Root cause 
Hospital medical consultant did not accept the Drug and Therapeutics Committee 
decision and was going to take advantage of a loop hole in the medicines management 
process by asking a GP to prescribe on his behalf. 
Figure 5.3 Step 9 
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Appendix 6 
General practitioners asked to prescribe non-formulary medicines via medicines 
advice notes (Cases 16.4 and 16.5) 
Hospital doctors write hospital prescriptions for patients requiring medicines that 
must be started immediately. For most other medicines a medicines advice note is 
written for patients to deliver to their GPs. This states which medicines GPs should 
prescribe. 
Problem 
A OP complained that he has been asked to prescribe Flixonase® nasal spray via a 
medicines advice note. This preparation is not included in the district formulary. 
Arising questions 
• Why is this a problem? 
The district formulary was developed to ensure effective and efficient prescribing 
in primary and secondary care. If GPs comply with non-formulary requests there 
may be inefficient use of resources. 
• Are there any other problems with GPs complying with non-formulary 
requests? 
It may appear as if GPs are not complying with the district formulary when their 
prescribing data is analysed although the initial request to prescribe the medicine 
came from a hospital doctor. 
Review of multifactorial dimensions of case 
• Loophole in the medicines advice note system whereby GPs may be asked to 
prescribe non-formulary medicines. 
• One of the hospital doctors was a locum who might not have been aware of 
inclusions in the district formulary. 
• No hospital pharmacist involvement when medicines advice notes are written. 
Root cause 
When medicines advice note was written. 
Figure 5.4 Step 4b 
374 
Appendix 6 
Difficulty sourcing information about unlicensed medicines (Case 17.1) 
Melatonin is an unlicensed medicine used for the treatment of sleep disorders in 
children with behavioural problems. It is not listed in the BNF and so primary care 
practitioners may have difficulties finding out clinical or procurement information 
about melatonin. 
Problem 
A GP has been asked to prescribe melatonin by a hospital consultant but he has no 
previous experience of it and cannot find any information. 
Arising questions 
• Why can the GP not find any information? 
Melatonin is an unlicensed product which is not included in the BNF. 
• Why was further information not sent with the request to prescribe? 
It is not usual practice to send clinical information along with prescribing requests. 
Review of multifactorial dimensions of case 
• The Area Prescribing Committee had only recently approved the medicine for use; 
previously the hospital medical consultant had been prescribing. 
• The shared care guideline had not been completed and so there was no prepared 
information to issue to GPs. 
Root cause 
Hospital practitioners may not take into the account the information needs of GPs 
when asking them to prescribe unusual medicines. 
Figure 5.4 Step 7 
375 
Appendix 6 
Separate formulary mechanisms between acute hospital and mental health trusts 
(Case 17.2) 
Acamprosate may help patients abstain from drinking alcohol. At the time this 
medicine had recently been marketed and an application had not yet been submitted to 
the acute hospital Drug and Therapeutics Committee. 
Problem 
Acamprosate prescribed on a patient's discharge prescription. 
Arising questions 
• Why is this a problem? 
It was a non-formulary medicine and so not stocked by the hospital pharmacy 
department. 
• Why was acamprosate prescribed on the discharge prescription? 
A psychiatrist who reviewed the patient suggested this might help with alcohol 
abstinence. 
• Why is there a problem if the hospital doctor asks the GP to prescribe? 
General practitioners should not be asked to prescribe non-formulary medicines so 
that the district formulary is complied with and the entry of new medicines is 
managed. 
Review of multifactorial dimensions of case 
• Different formulary management processes between the acute hospital and the 
mental health trust with the result that some medicines might be approved in one 
setting and not the other. 
Root cause 
When a psychiatrist recommended a medicine that was approved for use by the 
mental health trust but non-formulary in the acute hospital trust. 
Figure 5.3 Step 6c 
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Appendix 6 
Loophole in the process for managed introduction of new medicines whereby 
hospital doctors may ask GPs to prescribe non-formulary medicines (Case 17.3) 
A process for the introduction of new medicines had been agreed between primary 
and secondary care at the Area Prescribing Committee. Medicines for use solely 
within the hospital setting would be approved via the hospital Drug and Therapeutics 
Committee. Those medicines which GPs would be expected to prescribe would also 
need approval by the Area Prescribing Committee. Until approval had been gained 
for new medicines GPs should not be asked to prescribe them. Similarly GPs should 
not be asked to prescribe medicines rejected by either of the committees. 
Problem 
A GP was asked to prescribe azelastine nasal spray which is non-formulary. 
Arising questions 
• Why is this a problem? 
Reduces compliance with district formulary which has been implemented to 
ensure prescribing is effective and efficient across primary and secondary care. 
Review of multifactorial dimensions of case 
• Loophole in the medicines advice note system whereby GPs may be asked to 
prescribe non-formulary medicines. 
• No hospital pharmacist involvement when medicines advice notes are written. 
Root cause 
When GP was asked to prescribe non-formulary medicine. 
Figure 5.4 Step 4b 
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Appendix 6 
Loophole in the process for managed introduction of new medicines whereby 
hospital doctors may ask GPs to prescribe non-formulary medicines (Case 17.4) 
Tolcapone was the first ofa new class of medicines for the treatment of Parkinson's 
Disease. It had not been approved by the Drug and Therapeutics Committee and so 
GPs should not have been asked to prescribe it. Additionally it required careful 
initiation due to necessary adjustments in the dose of levodopa. 
Problem 
A GP was asked to prescribe tolcapone and he feels this would be more appropriately 
started by the hospital medical consultant. 
Arising questions 
• Why is this a problem? 
This was a completely new class of medicines and so the GP had no previous 
experience of the medicine. There was a requirement for liver function tests to be 
monitored. Additionally, adjustment of patients' levodopa dosage was necessary 
and the GP did not feel confident to take clinical responsibility for this. 
• Why did the hospital medical consultant not prescribe tolcapone? 
The drug had not been approved by the Drug and Therapeutics Committee and so 
was not stocked by the hospital pharmacy department. 
Review of multifactorial dimensions of case 
• Loophole in the medicines advice note system whereby GPs may be asked to 
prescribe non-formulary medicines. 
• No hospital pharmacist involvement when medicines advice notes are written. 
• Time lag between availability of new medicines that might benefit patients and 
formulary decisions. 
Root cause 
When hospital medical consultant asked OP to prescribe a non-formulary medicine. 
Figure 5.4 Step 4b 
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Appendix 6 
Loophole in the process for managed introduction of new medicines whereby 
hospital doctors may ask GPs to prescribe non-formulary medicines (Case 17.6) 
An outpatient prescription for tolterodine was presented at the hospital pharmacy 
department. Tolterodine had not been considered by the Drug and Therapeutics 
Committee and so was non-formulary. The hospital pharmacist informed the hospital 
doctor about the formulary status and suggested alternatives. Tolterodine is a new 
medicine for bladder instability with allegedly increased tolerability. 
Problem 
A hospital doctor was going to ask a GP to prescribe a non-formulary medicine. 
Arising questions 
• Why is this a problem? 
The policy agreed between primary and secondary care stated that GPs would not 
be asked to prescribe non-formulary medicines. 
• Why is the hospital doctor going to ask the GP to prescribe a non-formulary 
medicine? 
The hospital prescription has not been dispensed because tolterodine is not 
stocked by the hospital pharmacy department as it is non-formulary. 
• Are there any formulary alternatives? 
Yes, but hospital doctor believes that these are unsuitable for the patient and so 
wants to try tolterodine. 
• Is he aware that GPs should not be asked to prescribe non-formulary 
medicines? 
Yes, he was informed by the hospital pharmacist but refused to accept the advice. 
Review of multifactorial dimensions of case 
• Hospital pharmacists have no control over what hospital doctors ask GPs to 
prescribe. 
Root cause 
When hospital doctor refused advice not to ask GP to prescribe non-formulary 
medicine. 
Figure 5.4 Step 4b 
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Loophole in the process for managed introduction of new medicines whereby 
hospital doctors may ask GPs to prescribe non-formulary medicines (Case 17.7) 
Prowess is an unlicensed medicine for the treatment of erectile dysfunction. It is a 
combination product containing yohimbine amongst other things. Yohimbine was 
included in the district formulary but the Prowess preparation was not. Being non-
formulary, Prowess was not stocked by the hospital pharmacy department. 
Problem 
A GP complained that he was asked to prescribe Prowess by a hospital doctor. 
Arising questions 
• Why is this a problem? 
Prowess is non-formulary. 
• Why did the hospital medical consultant ask the GP to prescribe? 
He regularly asks GPs to prescribe non-formulary medicines. 
• Why? 
He does not think he has to adhere to the formulary. 
Review of multifactorial dimensions of case 
• Loophole in the medicines advice note system so that GPs may be asked to 
prescribe non-formulary medicines. 
• No mechanism for stopping hospital doctors requesting GPs prescribe non-
formulary medicines. 
• Hospital medical consultants may feel that formularies impinge on their clinical 
freedom. 
Root cause 
If hospital medical consultants do not support the idea of a district formulary they 
may take advantage of loopholes in medicines management processes in order to 
obtain the medicines they want for their patients. 
Figure 5.4 Step 4b 
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Loophole in the process for managed introduction of new medicines whereby 
hospital doctors may ask GPs to prescribe non-formulary medicines (Case 17.8) 
Zeradenn is a silicone-based paste for application to the skin for the reduction of 
specific types of scars. It was not included in the district fonnulary nor listed in the 
BNF. It was not available in the UK but could be imported from the Netherlands. 
Problem 
A OP complained that he was asked to prescribe Zeradenn. 
Arising questions 
• Why is this a problem? 
o Not included in the district fonnulary therefore GPs should not be 
asked to prescribe. 
o Not listed in the BNF and so the OP does not know what it is. 
o The community pharmacist told the OP that it was not available for 
dispensing. 
• Why did the hospital medical consultant ask GPs to prescribe a non-
formulary product? 
Product was too new to be included in the fonnulary and so had not been 
submitted to the Drug and Therapeutics Committee. 
• Is the consultant going to apply to the Drug and Therapeutics Committee to 
consider Zermaderm for addition to the formulary? 
No, he considers that OPs should prescribe what he suggests if they want their 
patients treating. 
Review of multifactorial dimensions of case 
• Loophole in the medicines advice note system whereby OPs may be asked to 
prescribe non-formulary medicines. 
• The consultant did not think Zeraderm could be prescribed in primary care and so 
thought that patients would purchase it. However, patients were not informed 
how to obtain Zeraderm when they were seen at the outpatient clinic. Also it is 
expensive and so patients are unlikely to want to buy it. 
Root cause 
If hospital medical consultants do not support the idea of a district formulary they 
may take advantage of loopholes in medicines management processes in order to 
obtain the medicines they want for their patients. 
Figure 5.4 Step 4b 
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Attempt at avoiding the process for introduction of new medicines by asking a 
GP to prescribe a non-formulary medicine (Case 18.1) 
Interferon had recently been introduced for the treatment of Hepatitis C. Prior to this 
there had been no drug treatment options. The use of interferon in the treatment of 
Hepatitis C was discussed at the Area Prescribing Committee where it was decided 
that due to the specialist nature of the treatment this was unsuitable for prescribing by 
GPs. However, no funding had been identified within secondary care to allow 
hospital medical consultants to prescribe interferon. This effectively meant that 
patients could not be treated. 
Problem 
A GP complained that he was asked to prescribe interferon for the treatment of 
Hepatitis C. 
Arising questions 
• Why was the GP unhappy to prescribe interferon? 
He felt unable to take clinical responsibility for prescribing this medicine because 
of its specialist nature. 
• Is this different to other GPs' perceptions? 
No, it was agreed at the Area Prescribing Committee that interferon was 
unsuitable for prescribing by GPs. 
• Why did the hospital medical consultant ask the GP to prescribe? 
No funding had been identified within secondary care and so the hospital 
pharmacy department would not dispense any prescriptions. 
Review of multifactorial dimensions of case 
• Doctors want to provide the best care for their patients so there is sometimes 
tension between what is affordable and the medicines doctors want to prescribe. 
• If the GP had complied with the request to prescribe, a new medicine would have 
been introduced putting a pressure on the primary care prescribing budget. 
• There is a perception in secondary care that funding will be provided by primary 
care for new treatments provided treatments are shown to be clinically effective. 
Root cause 
When a medicines advice note was written for a non-formulary medicine. 
Figure 5.4 Step 4b 
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General practitioners collectively decide that they no longer wish to prescribe a 
specialist medicine (Case 18.2) 
Erythropoietin is used to treat anaemia associated with renal disease. Historically, 
whilst hospital nephrologists had initiated erythropoietin, continued prescribing was 
undertaken by GPs. This meant that although there had been no specific funding 
allocated for erythropoietin the funding effectively lay in the primary care prescribing 
budget. 
Problem 
General practitioners feel that prescribing of erythropoietin would be more 
appropriately undertaken by hospital doctors. 
Arising questions 
• Why do GPs not wish to carry on prescribing erythropoietin? 
General practitioners feel that they have insufficient knowledge and experience of 
erythropoietin to allow them to take clinical responsibility for this medicine. 
• Why do hospital doctors not prescribe erythropoietin? 
Funds for this medicine lie within the primary care prescribing budget. 
• Why are funds within the primary care prescribing budget? 
No specific NHS funding was allocated for erythropoietin when it was introduced. 
As hospital doctors initiate the treatment but ask GPs to prescribe, expenditure is 
taken from the primary care prescribing budget. The primary care prescribing 
budget is increased annually to take into account inflation. This effectively means 
that increased expenditure on expensive medicines like erythropoietin is taken into 
account when primary care budgets are set. 
Review of multifactorial dimensions of case 
• Poor managed introduction of a new medicine through not considering the funding 
implications when the medicine was approved through the Drug and Therapeutics 
Committee process. 
• Failure to take into account that the number of patients requiring erythropoietin 
treatment would increase over time. 
• Not considering the most appropriate location for prescribing when the medicine 
was introduced. 
• Difficulties in moving budgets between primary and secondary care to allow 
prescribing to take place in the most appropriate location. 
• Lack of clarity over who maintains clinical responsibility. 
• No additional transfer of information when request to prescribe was made. 
Root cause 
When GPs refused to prescribe medicine recommended by hospital doctors via 
medicines advice notes. 
Figure 5.5 Step 3 
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Difficulty in gaining approval to prescribe a medicine for use in an individual 
patient (Case 18.3) 
A hospital medical consultant wanted to prescribe interferon for an unusual indication 
for an individual patient. Interferon was not stocked by the hospital pharmacy and the 
GP refused to prescribe. 
Problem 
The hospital medical consultant cannot obtain interferon to treat his patient. 
Arising questions 
• Why did the GP not prescribe interferon 
This is an unusual medicine for an unusual indication and the GP did not wish to 
take clinical responsibility because of a lack of experience of prescribing 
interferon. 
• Why did the hospital medical consultant not issue a hospital prescription? 
Interferon was not stocked by the hospital pharmacy because it was non-
formulary. 
• Why did the hospital pharmacy department not purchase interferon for this 
individual patient? 
Treatment was likely to be ongoing and as interferon is an expensive medicine it 
could not be purchased until funding had been identified. 
Review of multifactorial dimensions of case 
• There is a delay in initiating treatment whilst funding and clinical responsibilities 
are resolved. 
• Hospital funding arrangements only include provision for 28 days treatment. 
There is no provision for extra funding if prescribing remains the responsibility of 
a hospital doctor. This means that hospitals are financially penalised if GPs refuse 
to prescribe ongoing treatment. 
Root cause 
When hospital medical consultant presumed that GP would prescribe the medicine 
requested. 
Figure 5.4 Step 4b 
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General practitioners unhappy to prescribe interuterine device for unlicensed 
indication (Cases 18.4 and 18.5) 
Mirena® is a progestogen eluting interuterine device which at the time of the 
complaints was only licensed for use as a contraceptive. However, the progestogen 
released from the device made it an effective treatment for menorrhagia and it has 
since been licensed for this indication. 
Problem 
General practitioners complained that hospital doctors were asking them to prescribe 
Mirena® interuterine devices for the treatment of menorrhagia. 
Arising questions 
• Why are GPs complaining about being asked to prescribe Mirena® 
The device was only licensed for contraceptive use at that time and GPs were 
reluctant to take clinical responsibility for an unlicensed use. 
• Would GPs be happy to prescribe for contraception, the licensed indication? 
No, because they feel that if hospital doctors are recommending devices that will 
be fitted in hospital then the hospital should provide the device. 
• Why are the devices not provided by the hospital pharmacy? 
The Mirena® interuterine device had been discussed at the hospital Drug and 
Therapeutics Committee and a decision made that they would not be supplied by 
the hospital pharmacy for contraceptive purposes. The gynaecology Clinical 
Management Team had recently decided that they did not wish to use Mirena® 
interuterine devices. 
• Were there any exceptions to this policy? 
The hospital pharmacy department would purchase and supply Mirena interuterine 
devices for individual women with menorrhagia in exceptional circumstances on 
the request of consultant gynaecologists. 
• Why were GPs asked to prescribe then? 
Some hospital consultants wished to use Mirena® interuterine devices more 
widely for women with menorrhagia. 
Review of multifactorial dimensions of case 
• There is a loophole in the process for formulary control whereby hospital doctors 
may ask GPs to prescribe medicines for unapproved indications. 
• The device may be used for different indications and so confusion may arise over 
which indications are covered by hospital funding. 
• Funding restrictions in secondary care encourage hospital doctors to attempt to 
transfer the costs of expensive medicines to the primary care prescribing budget. 
• Individual hospital doctors may not agree with decisions made by Clinical 
Management Teams. 
Root cause 
When hospital doctor wrote to OP requesting prescription of device for unapproved 
indication. 
Figure 5.4 Step 7 
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General practitioner asked to prescribe medicine for unlicensed indication with 
uncertain evidence of efficacy (Case 19.1) 
A patient had undergone cystoplasty whereby a bladder had been created out of a 
section of gastrointestinal tract. Mucus secreted by the gastrointestinal tract tissue 
was making bladder emptying difficult for the patient. Before discharge from hospital 
the patient had been started on acetylcysteine solution for instillation into the bladder 
via a catheter. Acetylcysteine is a mucolytic and the aim was to break down mucus 
secreted by the gastrointestinal tract tissue. However, it is unlicensed for use via the 
intravesical route and for this indication. 
Problem 
General practitioner was unhappy to prescribe acetylcysteine for intravesical use for a 
patient discharged from hospital. 
Arising questions 
• Why was GP unhappy to prescribe acetylcysteine? 
There are several reasons why the GP was unhappy to continue prescribing 
acetylcysteine for the patient: 
o It is for an unusual use and is unlicensed and so the GP was unwilling 
to take clinical responsibility. 
o There is little evidence of the efficacy of acetylcysteine for this use. 
o It is expensive. 
• Why was the GP asked to prescribe in such an unusual situation? 
It is usual hospital policy to transfer prescribing responsibility to GPs following 
discharge from hospital. 
Review of multifactorial dimensions of case 
• Small quantities of medicines supplied on discharge from hospital leave little time 
for resolving issues that arise with the transfer of responsibilities. 
• No additional infonnation provided to help the OP prescribe confidently when the 
patient was discharged from hospital. 
• Poor discharge planning meant that the patient's ability to access medicines in 
primary care was not considered. Acetylcysteine is not stocked by community 
pharmacies and so even if the GP had written a prescription there would have 
been a delay in the patient obtaining a further supply. 
Root cause 
When new medicine was started and no consideration given to pharmaceutical 
discharge planning. 
Figure 5.2 Step 4c 
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Hospital consultant experiencing difficulty obtaining a non-formulary medicine 
for a patient (Case 19.2) 
A hospital medical consultant complained that he was having difficulty getting a OP 
to prescribe anastrozole for a woman with breast cancer. This had been recommended 
by an oncologist as an alternative to tamoxifen, the usual treatment, because the 
woman was experiencing side-effects. The GP claimed that he could not take clinical 
responsibility because this was a relatively new medicine of which he had no 
experience. 
Problem 
A OP refused to prescribe anastrozole for the treatment of breast cancer and this was 
delaying treatment. 
Arising questions 
Why was the GP refusing to prescribe? 
The OP said he was unable to take clinical responsibility for prescribing this medicine 
as he had no previous experience of it. 
Did other GPs hold a similar view? 
No, other OPs had taken over prescribing, and hence clinical responsibility, with no 
previously reported problems. 
Why could the hospital medical consultant not prescribe? 
Hospital contractual arrangements mean that hospitals are only funded to provide one 
month's supply of medicines to outpatients. Also, systems are not set up to issue 
repeat prescriptions in hospital outpatient clinics. 
Could the hospital doctor prescribe if the GP funded the treatment? 
Yes, but this was unusual and difficult to set up. 
Review of multifactorial dimensions of case 
• Incentives put in place with OP fundholding may perversely affect GPs 
willingness to accept the transfer of prescribing of expensive medicines. 
• Difficult to set up systems whereby hospital doctors prescribe when funding for 
continued prescribing of medicines is within primary care. 
• No time in outpatient clinic schedules for issuing repeat prescriptions. 
• Patient had breast cancer and this dispute delayed her obtaining appropriate 
treatment which was most distressing. 
• Sometimes funding disputes can cause discontinuities in patient care. 
Root cause 
When GP realised the cost of medicine he was being asked to prescribe. When he 
realised that the health authority adjusted OP budgets for high cost drugs the clinical 
responsibility issue disappeared. 
Figure 5.5 Step 3 
387 
Appendix 6 
Hospital medical consultant recommending that GPs prescribe branded 
medicines (Case 20.1) 
By using generic medicines the NHS can purchase more medicines from limited 
resources. Within hospitals, pharmacists may substitute generic medicines when 
proprietary medicines are prescribed. However, in primary care, if a proprietary 
medicine is prescribed, community pharmacists must dispense the exact brand 
specified. 
Problem 
A hospital medical consultant is recommending that GPs prescribe branded tamoxifen 
instead of the generic preparation. 
Arising questions 
• Why is this a problem? 
Proprietary medicines are generally more expensive than generic medicines which 
means that there may be adverse consequences for the primary care prescribing 
budget. 
• Why is the hospital medical consultant recommending a proprietary 
preparation? 
The hospital medical consultant believes that generic tamoxifen is of a lower 
quality. 
Review of multifactorial dimensions of case 
• Hospital pharmacy departments are sometimes able to purchase proprietary 
medicines cheaper than generic medicines through contracts. This means that 
patients may be started on a proprietary medicine in hospital but then switched to 
a generic medicine in primary care. 
• Community pharmacists are not able to substitute generic medicines in the way 
that their hospital colleagues can. 
• Hospital pharmacists do not see recommendations that are made on medicines 
advice notes which means that hospital doctors may ask GPs to prescribe 
inappropriately. 
Root cause 
When a hospital medical consultant completed medicines advice notes specifying that 
GPs should prescribe proprietary medicines. 
Figure 5.4 Step 4b 
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Hospital doctors starting patients on expensive formulation of medicine 
(Case 20.2) 
Phannaceutical companies may introduce modified formulations of medicines at 
increased cost in order to increase their profits. Some modified formulations may 
have limited patient benefits and cost significantly more than standard preparations. 
If these are continued in primary care following hospital discharge there is a cost 
pressure for the primary care prescribing budget. 
Problem 
Hospital doctors were prescribing enteric coated aspirin rather than dispersible aspirin 
for hospital inpatients. 
Arising questions 
• Why is this a problem? 
Enteric coated aspirin is much more expensive when prescribed in primary care 
than dispersible aspirin. 
• Why are hospital doctors prescribing enteric coated aspirin? 
There is a belief that enteric coated aspirin is better for patients. 
• Why do hospital doctors think it is better for patients? 
They perceive that it causes less gastrointestinal side-effects. 
• Is this perception valid? 
Enteric coated aspirin may be of use in patients experiencing dyspepsia with 
dispersible aspirin but does not reduce the risk of a gastrointestinal ulcer or bleed. 
Review of multifactorial dimensions of case 
• Hospital pharmacy departments are sometimes able to purchase premium price 
formulations cheaper than standard medicines through contracts. 
• Hospital doctors may be unaware of the cost differentials between enteric coated 
and standard formulations. 
• Hospital doctors may have incorrect perceptions about the value of modified 
formulations and this may be encouraged by the phannaceutical industry. 
Root cause 
When new medicines were started for hospital inpatients without taking into account 
the future impact on the primary care prescribing budget. 
Figure 5.2 Step 4c 
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Patient experiencing difficulty obtaining expensive medicine following discharge 
from hospital (Case 21.1) 
Community phannacists purchase the medicines necessary to dispense prescriptions 
and are then reimbursed by the Prescription Pricing Authority (PPA). There is a time 
delay between purchasing expensive medicines, such as erythropoietin, and 
reimbursement by the PPA which may have financial consequences for community 
phannacists. 
Problem 
A patient has taken a prescription for erythropoietin to several community 
phannacists and all have said they are unable to dispense the prescription. 
Arising questions 
• Why would the community pharmacists not dispense the erythropoietin 
prescription? 
Erythropoietin is an expensive medicine and community pharmacists may be 
concerned about the impact of this on their phannacy finances. 
• Can community pharmacists refuse to dispense prescriptions? 
No, the regulations state that they should dispense prescriptions presented with 
reasonable promptness. 
Review of multifactorial dimensions of case 
• Business interests of community phannacists may sometimes over-ride patient 
care issues. 
• Phannacists sent the patient away rather than trying to resolve the problem. This 
may reflect the fact that community phannacists are not remunerated for 
undertaking interventions. 
• Erythropoietin is relatively unusual in primary care and so the pharmacists may 
not have come across this before. 
• No infonnation was provided for community pharmacists when patients were 
prescribed erythropoietin. 
Root cause 
When community phannacist unreasonably refused to dispense a valid prescription. 
Figure 5.5 Step 6 
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Appendix 7.1 (1 st GP focus group) 
So, first of all I really just wanted to get you talking, just to talk about 
what happens about the process that happens when patients are 
discharged from hospital. I only want to spend a couple of minutes on 
this, about the information you get and ... " does anyone want to start? 
I think that it's quite frustrating sometimes that you get patients asking 
for repeat prescriptions of their discharge medications before you've got 
any notification through of what they were discharged on or sometimes 
even that they'd been in hospital or had been discharged. That can be 
quite frustrating sometimes. 
And because there's none of the, even when you get a proper discharge 
summary, there's often none of the sort of erhm thought processes, the 
decision making processes that have gone on to end up with that list of 
drugs so you don't actually know that they've definitely been stopped. 
They may go in on some drugs and then come out on others and the 
patients says 'oh I don't remember, I don't know if I'm supposed to still 
be on that anymore'. So you never actually, unless you speak to the 
doctors you often don't know why certain things have happened. 
2 
15 
You mentioned about hospitals, perhaps what they're prescribing, does 48 
GP2 
anyone else find that that might influence them? 
It's often the way that you get to hear about new drugs when the 
consultant's start to use them, some of them seem to die a quick death, 
the weird and wonderful ( ) and but yes I think the other thing is if 
they're getting the experience with using a drug then we're likely to 
follow. 
49 
What about other grades of hospital staff, or non-medical members of 50 
GPI 
GP2 
GPI 
GP2 
GPI 
GP2 
staff doing their clinics? 
I can't think of any. 
Continence adviser, you have to be quite specific and it will often be the 
most expensive drug. 
Oh, now that's a sore point. 
For what? 
Bladder instability. 
Urinary incontinence. That's an interesting example actually isn't it? 
She hasn't normally mentioned the name to the patient but she will often 
put it in the letter saying she wants Detrusitol as opposed to what we 
might start with I. 
I Interesting that hospital drug information pharmacist had worked with continence advisers and 
consultants to produce guidelines on when these newer, more expensive drugs should be used 
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Right. So what does she say to the patient? What's the patient 
expecting when they? 
I have no idea what she says to the patient. 
The patient must have been given the idea that there was something 
different that they could be having other that the oxybutinin that I have 
already given them. But I think you're right she hasn't actually 
mentioned it by name. But it is awkward because they've been given 
the impression that there is something else that they could try and if I am 
going to turn round and say well I am sorry this is not in the practice 
formulary or I don't actually want you to have anything different it's 
quite a difficult situation. 
I have actually been in that situation and refused to give the continence 
adviser's drug on grounds of cost. 
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Right so now I'd like to move onto erhm the issues that arise when 80 
patients have been in contact with hospital services. I mean, I didn't 
want to call them problems because they might not always be a problem 
as such but just anything you've had when a patient's been to hospital 
and erhm I mean anything, obviously I want to concentrate on drugs but 
if there 's any other issues apart from drugs. 
One of the most annoying things is the fact that they do discharge them 
with just a weeks worth of medication and the other thing is that if 
patients do what we always used to say and take their medication in with 
them they just take it so they can go in with a full bottle of aspirin and 
come out with just days worth which I think is a bit frustrating for them 
and for us as well. 
81 
The question was just really to ask if you'd got any experiences of 96 
problems that happen when people have been in contact with hospital 
services. 
The common problem is that they go in on say felodipine and because 
the hospital don't have it in their formulary perhaps they'll come out on 
a different calcium channel blocker and then the patient's are completely 
confused. 
And you wonder whether to change them back again or not. 
And then that's not on our formulary and you want to change them back, 
same goes with statins, go in on one statin and come out on another and 
it's just a nightmare, particularly the patient gets confused. It means an 
awful lot more work for us at the practice, the receptionists sorting it all 
out. 
And we could do with clearly being told what has been stopped whilst 
they're in erhm and why. 
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100 
What about any specific drugs or specific patients? Have you ever been 119 
asked to prescribe something that you have perhaps not felt comfortable 
about? 
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Yes. 120 
Erythropoietin. 121 
Yes, that's what I was hoping would come up! And why is that. 122 
Why did we refuse it? 123 
Well, why did you, can you just tell me a bit about what happened, about 124 
the story behind it? 
Well, he was going, he went in through, for a second renal transplant 
and I forget who the consultant is over there but the patient was rather 
hoping, he was told, that his OP would be able to prescribe it. 
Right. 
And at a practice meeting we decided that this wasn't acceptable and so 
we in fact contacted the consultant and said that we weren't going to 
prescribe and in fact it was resolved at that stage. They were happy but 
they'd tried it on us. 
On the grounds of cost or that it was a secondary care drug? 
Oh yes mainly on the grounds of cost because it's huge, and also 
because we had no experience of prescribing it and it needs monitoring 
doesn't it? 
I remember a while back the drug mibefradil, Posicor, that was the new 
calcium antagonist that was withdrawn after about sort of six or eight 
months or something because I had a patient come out of hospital on it, 
I'd never heard of it, it had only just been launched, he was already on 
maximum other therapy and he was discharge on it. I couldn't find any 
information about it, not in the BNF, pharmacies didn't know anything 
about it because it was so new erhm and yet I was you know having to 
take the responsibility for carrying on with the drug and I spoke to Dr X 
(consultant) and he said oh it was a marvellous, marvellous drug and it 
would be fine. So I prescribed it but erhm I think if patient's are being 
started on very new drugs then they ought to be sent out with data for us 
about the drugs, if it's even too new for the BNF. It was even before the 
reps were starting to push it. 
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Would you be happy with just additional information or do you think ISO 
that perhaps that ought to stay in the hospital settingfor a certain 
period o/time? 
I think it was a very, it wasn't a drug that was likely to cause problems 
but I mean I didn't know that without consulting him about it. But I 
mean there are drugs which, you know, because they are so new you 
don't know and I suppose it did cause problems in the end because it 
was withdrawn. So maybe it should stay in the hospital domain for 
maybe six months or something. 
Some of the oncology drugs, for breast cancer and prostate cancer, they 
are being prescribed. We don't really have much experience. 
151 
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Yeah. 153 
GP3 But we do prescribe them. 154 
Do you get any support in prescribing them or do you generally get any 155 
information? 
GPI No. 156 
GP3 No we get no information at all. 157 
Have you got any experience of any other interventions that perhaps 215 
have been put into place to try and transfer prescribing responsibility 
apart from shared care guidelines which the rheumatologists are good 
at but no-one else is? 
GP2 Depends what you mean by trying to transfer prescribing I mean one 216 
issue is the Mirena issue. We refer people for sterilisation and the letter 
comes back saying there is a much better treatment called Mirena, see 
your GP. And when they're seen in the gynae outpatients they're told 
Mirena will sort this out, see your GP. (Trying to give it back to us.) 
GP4 And the family planning clinic's asking for the prescription for Mirena 217 
because they haven't got .. 
GP2 A budget. 218 
GP 1 ... any funding for. 219 
So they're asking you to prescribe it and the patient actually takes it in 220 
with them. 
GP 1 And Mrs (name of consultant) does the same for Mirenas ifshe'sjust 221 
fitting them for menorrhagia rather than contraception, she'll ask you to 
provide the prescription. If you are willing, it's not a demand, it's a 
polite request. It's really difficult to tum it down. I haven't felt able to 
tum it down. 
GP2 (nods). 222 
GPI You do, do you? What happens next? Does the patient end up not 223 
having Mirena? 
GP2 Erhm, well basically we don't fit coils, there is no-one in our practice 224 
who fits coils and there actually aren't that many GPs, we don't really 
have enough coils per year to actually do it. I mean if you've only got 
half a dozen women in the practice for coils. 
GP4 That perhaps because you don't have any coil fitters! 225 
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No, because if people ask for them we sent them to family planning 
clinic and they get them done. But it's partly, we discussed it and we 
felt that it wasn't appropriate again supplying the prescription to 
somebody that we're not overseeing the treatment of. But it was also 
because we felt that it shouldn't be happening like that and sort of try 
and put pressure to get the system changed that you know for things like 
sterilisation you know the cost of a Mirena is going to be cheaper than 
the sterilisation if it's a cost issue the hospital should be looking at that 
and changing their budget allowance rather than trying to shove it back 
onto us and the same with family planning. Ehrm I mean our feeling is 
that most of family planning we provide for our patients, the one thing 
we don't provide is coil fitting because we don't do enough and you 
know it would be more sensible if it's a budgetary thing for the people 
that are getting pills with the family planning clinic, pills and injections 
to come back to us. 
Yes, it's rather a back-door way of coping with the situation as far as the 
hospital is concerned isn't it? 
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Appendix 7.2 (2Dd GP focus group) 
Right just to start you off sort of get you talking a bit really, I'd just like 
to ask you about the process erh what happens when people are actually 
discharged from hospital? What information do you get? 
Well, you can get nothing. 
Yes. 
Erhm which seems irritatingly common. You can get the patient turning 
up clutching the packets that they were given in hospital saying what are 
these, erhm and I think they need some more and am I supposed to carry 
on taking them. That's the most irritating. Am I supposed to carry on 
taking these? And sometimes it works and you actually get the green 
form that says what you're supposed to be prescribing them but you may 
not actually get the other form that tells you what they've been in 
hospital with. 
And I think your comment was actually very good [name of participant]. 
Are they actually supposed to carry on taking it? I have had people 
come in having stopped their medication because they've only had 
seven days .... 
Mmmmm. 
... saying oh it's only seven days worth so I assumed it was a week's 
course and obviously they should be continuing with it. 
I think the same, sometimes patients have no idea erhm and some things 
that we consider it's obvious they are going to want to continue like 
aspirin, beta blockers post-infarct or something. Other things may be 
not so obvious proton pump inhibitors, ifthey've had a gastroscopy and 
we think they probably need to continue them for what length of time 
and the patient hasn't been told. 
You mentioned seven day's supplies and patients stopping after that 
seven days, does the short supply cause any other difficulties? 
Urgency of prescription, they've had it for two or three days and, and 
there's a weekend in the middle and 
Bank holiday weekends. 
Absolutely. Absolutely, and you know the person's regular doctor is 
away. I find it a real nuisance. I think, seven days of lots of things is 
entirely inappropriate, aspirin, cheap beta blockers, things like 'Go in 
and see them' you know, a fortnight, make an appointment to see your 
doctor sometime in the next fortnight and take these tablets with you. It 
would be so easy and then people would always be so much better 
managed rather than you know people ringing up, sending in bits of 
paper, often it's not a doctor who knows the patient properly. Often 
you've got no discharge summary. you can't question the patients about 
whether they're still taking their other tablets or not because you know 
often things will be changed, silly things like erh I've seen statins 
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changed when people have been into hospital, not because of it's a 
better statin because .. 
Its not formulary. 
.. that's right. It because that's the policy in that particular hospital and 
that's the cheapest statin. So, so you know and on occasions that's 
happened, they've already had that one in the past and it's not suited 
them or something like that so that's why they're on statin X rather than 
statin Y. And you've got, you're faced with do you issue a prescription 
for another month or whatever if it's tablets not knowing whether or not 
anybodies sat down with this person and said oh you do know of course 
these didn't suit you last time, you know perhaps you'd be better off on 
the ones you've already got or the ones you've got three packets of in 
the cupboard . 
... you know time costs money as well, and as [name of participant] 
says it's the sort of time side of, it's having to scout around to find 
useful or relevant information prior to seeing someone who you've, may 
not be overly familiar with. 
You can make a big deal about it but it leaves a bad taste in everybody's 
mouth and doesn't actually achieve anything and I, you know I don't 
agree with it. I don't spend, sort of go through life just agreeing with 
everybody to make life easy but that's one case where you just, you are 
hardly doing anything are you. You can't win, you can't establish the 
fact that you are unhappy and reluctant to prescribe and it should be 
done differently because there is no alternative if you don't do it, within 
the Trust. 
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Is that a worry then, the fact that patients don't get the medicines if you 77 
say no it's not appropriate for me to prescribe it then the patient ... 
Then they wouldn't get it so you prescribe it so the worry is actually that 
you're prescribing, it is actually the prescribing because the moment you 
sign the prescription the, any problem lands in your lap. Not in the 
person who said that they should take it in the first place but the person 
who actually signs the prescription and so the problem is actually being 
coerced into a position where you have to prescribe something where 
you don't feel that you've got the either the contact with the patient, the 
expertise to supervise the drug concerned or for some other reason 
you're unhappy to prescribe but there's nowhere else to send the patient 
to get the things that you feel they need and you're in a corner. You 
have to prescribe for them because nobody else is going to and they are 
already established on treatment so if you say well I'm not signing this 
then they'll end up with no treatment and then just as [name of 
participant] said it just leaves a nasty taste in the mouth for everybody. 
We've just had a guy who's got severe peripheral vascular disease, and 
he was on a calcium channel antagonist he was on something else and X 
wrote me a letter and wanted him to start on beta blocker and I just felt 
really uncomfortable about putting him on a beta blocker. I had a chat 
with the pharmacist, the ones down at X pharmacy are really helpful and 
really good. And they were saying well yes I think that is a problem or 
there is a potential problem to that but because it was a private patient, 
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batting him back, he was reluctant to write a private script because the 
patient was insured, he didn't actually have very much money and it 
was all who's actually going to take the responsibility for this 
prescription for this person. I'm unhappy to do so and of course it 
looked a little like I didn't believe him and I didn't trust him and I felt 
uncomfortable about that. 
Let me just tell you .. 
Yeah, he had a prescription, I think he had a private prescription, and he 
was fine and I continued to do his. 
But the received wisdom is actually in the supplement about treating 
ischaemic heart disease is that it doesn't, it isn't supposed to worsen 
claudication but it will worsen skin perfusion so if they have got critical 
ischaemia you can't use it but if it, if they haven't got critical ischaemia 
then you try and get everybody you can on a beta blocker and this idea 
that we were taught at medical school where people with intermittent 
claudication shouldn't have beta blockers is actually not, the whole 
answer. 
HRT. Treatment of breast cancer and she was asking and we wrote back 
and said, 'Yes, we're quite happy for you to prescribe it'. (laughs) 
If a letter came saying I have discussed with the patient the pros and 
cons and whilst it is recognised that, gave you the extra information .. 
That would be fine wouldn't it. 
.. or in the case of the HRT if they put you know we have discussed with 
her the pros and cons or HRT. She appreciates there may be an 
increased risk but she feels, that's much better when it's in writing from 
them that they have had a full and informed discussion. 
I think that's a very good point, I think that's quite correct. It was a 
phone message, it wasn't even a letter, it was just a phone message 
please will you do a prescription for this person for this drug and ... 
You can see the reasoning behind it. 
Yes, sure and at least you know that he's thought about it and it hasn't 
sort of come through as an error just hasn't realised. 
Can't there be some system in place where, for the nurse to fax surgeries 
at the end of clinic of the patients they want to start on something? 
Because it is so unrealistic the expectation, 'Oh, go and see your doctor, 
the letter will be there next week.' You feel a real prat sitting there. 
I have a particular bug-bear about people being put on Tylex. 
On Tylex? 
And then being on it forever. I find it very hard to get people off 
branded erhm codeine, paracetamol, dihydrocodine, paracetamol 
combinations and just personally don't like them anyway because I 
think that ifsomebody's in a lot of pain you can't give them more than 
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eight a day anyway and what's the point of giving them paracetamol, if 
they're going to over, you know if you're giving them so that people 
can't overdose then that's a bit pointless. You know I personally tend to 
give people either whatever either codeine or dihydrocodine by itself, 
because it's a lot cheaper, because it's a lot more flexible because they 
can use it up to two hours instead of up to four hours if they want to. 
But all the patients that I've got that are on Tylex or Solpadol or 
whatever they've got just such faith in that name and that packet and 
that strength. Halfofthem we change, perhaps half of them but a lot of 
them you just never can so you end up with these repeat prescriptions 
year on year and I find that very difficult to stop. And I also think, one 
knows full well that it is only done because the hospital are getting it at 
a real knock-down price compared to, you know, general practice. I 
personally find that a problem. 
And you know the names, the trade names are all very short and catchy 
and so that's what everybody talks about because it's a lot easier to say 
co, erhm you know Tylex rather than co-codamol500 and 30mg you 
know so even if people aren't, are having generic prescriptions they still 
come in and say please can I have my Tylex when it says on their repeat 
prescription co-codamol 500 and 30mg. They will actually say please 
can I have some Tylex. 
Is this, there was something else I was going to ask, I don't know if you 
were going to mention it later, things like consultants wanting you to 
provide a prescription for something that's expensive. 
I raised it because as I say, to me and my patients, it's no problem 
because, like you, I fit [Mirena intrauterine devices] but I know there are 
other practices where maybe they don't fit and I've had the situation 
where, I think it's also inequitable that if you're fitting them obviously it 
affects your drugs budget, I think it's a very good, useful drug so I don't 
mind but obviously it affects it. Whereas if your patient ends up having 
a hysterectomy or an endometrial resection then it doesn't have any 
effect on your drugs budgets. I think it is a shame sometimes that useful 
things that are, on the surface, pricey are sometimes, there seems to be a 
two-tier system. 
Right, and you're saying that because of the separation of the 
prescribing and sort of hospital budgets .. 
You can't, in legal terms you can't sign your name on a prescription and 
then give it to the patient and say you take this to the family planning 
clinic and they will fit it because you will be responsible for any 
misadventure that the patient suffers at the family planning clinic. 
The same goes for goserelin for endometrial resection. 
Now that's interesting because I don't have any problem with goserelin. 
What's the problem there? Because the letter just comes saying please 
give them you know three doses of goserelin at monthly intervals and so 
you prescribe it. 
I think it's very much a budget transfer they don't even give the first one 
do they? They get somebody to do it to transfer budgets. In a way. 
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GP7 ( ) whatever we are we're the second most overspent. I'm a great fan 158 
of things like Mirena, I'm quite happy to prescribe, we would consider 
that if it was appropriate for the patient you know that if by not doing it 
you would just be being a stroppy practice. It's a bit like the Ritalin 
prescription, it just leaves a bad taste in everybody's mouths and the 
patients tend to suffer. 
GP8 Whilst I raised this I think it's particularly the Mirena's which are so 159 
useful for so many people I mean I do think they need counselling and 
it's not necessarily the best thing since sliced bread but, but they are 
proven to be so worthy and yet because of all this budget conflict I 
suspect a lot of people aren't getting them who would benefit from 
them. 
GP5 And then you get () but also once you've signed the prescription you 165 
then have the conflict about whose responsibility it is to follow-up the 
person with this Mirena. Is it the person who signed the prescription or 
is it the person who fitted it. Who's going to see them? 
GP8 Well, you're not saying your average GP isn't capable of following up 166 
someone with an interuterine system? 
GP5 No, but whose the, whose responsibility is it? You see if you .. 167 
GP8 I think it's the GP's, in the same way as someone who's had a coronary 168 
artery bypass they get followed up for a while at the hospital and then it 
gets transferred back doesn't it? 
GP8 ... certain practices have cottoned on that it won't affect their budget if 175 
the M irena is fitted from ... 
GP7 Saves them money ..... 176 
GP8 But I think it is iniquitous because (a) they are not being quite fair 177 
because they're not using their budget ... 
GP9 They're not writing a prescription either. 178 
GP8 .. and (b) it's unfair on other practices who, who are providing 179 
prescriptions. 
GP8 In a way, just an idea, I don't know ifit would necessarily work but if 190 
you looked at the number of Mirenas fitted countywide 
. .. . . . . . . . . . . . . . . . . . . . . .. I mean personally I don't see why some budget 
shouldn't be used. Transferred. 
GP7 We are all quite happy just to write these prescriptions for things purely 192 
to endorse them when really we shouldn't be. 
GP5 People going to tertiary centres, it is a problem. I've got a girl who goes 243 
to, she used to go to GOS and now she's got an adult tertiary 
rheumatologist now and she's on subcutaneous methotrexate. 
GP7 Wow. 244 
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OP 5 This is wildly unlicensed and I write prescriptions for this every month 245 
for her to have an injection a week, every month. So here am I 
prescribing cytotoxics in general practice for injection erhm but I do all 
the monitoring, I get the letter, I am told what we are aiming for, in what 
circumstances to reduce the dose erhm I've written to the professor 
before now and said, 'You know, I'm worried about this.' I get a very 
nice sensible letter back telling me the pros and cons and all the rest of it 
and, you know, and I just wind the dose up by 2.Smg every six weeks 
like I'm supposed to until I get to 20mg and that's all fine because I feel 
I am really involved with the process and I see her every month and I 
am actually monitoring her treatment and I know what I am supposed to 
be doing. And it's an unlicensed drug and well you know erhm let's not 
get too worried about it but on the other hand you can get patients who 
are in tertiary care who are having things, in fact I've got a very good 
example is a cystic who sees [name oflocal paediatrician] and goes to 
[name of tertiary children's' hospital. I never see her from one year's 
end to the next but every month I get these letters from [name of local 
paediatrician] saying, 'Please will I prescribe this, this, this, this, this 
and this?' It's cost-shifting. I'm not involved in that child's care and 
they're all, almost, unlicensed drugs. Some of them are things, when 
they get, some of the antibiotics and nebulisers, and the other get a bit 
more you know esoteric but most of it's fairly tame stuff. And I'm not 
monitoring her, I'm not supervising her treatment, I am just expected to 
sign the prescriptions. 
OP9 And that contrasts so much with the AIDs patients, the HIV patients, 246 
you never see them but you don't get asked to prescribe. 
So did they, going back to this methotrexate patient, did they erhm, the 261 
hospital started it did they or were you asked to initiate? 
GP5 I gave the first injection. 262 
Really. 263 
OP7 That's quite impressive! 264 
OPS I taught her mother. I taught her mother how to do the injections and so 265 
the mother now does the injections. 
Oh. Did you find that a bit unusual? Would you not expect them to .. ? 266 
OPS It's very unusual and I wrote back to them saying come on you know 267 
give us some more information. You know I want, you know just 
telling me that this is what we're going to do won't do I want to know 
where do you put the injection, you know, how do I do it, you know 
etcetera and so they got somebody from the injection clinic to ring me 
up and they spoke to me on the phone and told me about where to place 
the injections, how to put the needle in and all this sort of stuff and. 
OP7 What if you'd have refused, if you'd said no. 271 
GP5 Then either she would have not had the methotrexate because she'd 272 
been having it orally and then it was shown that she didn't absorb it 
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orally. 
Ah, right. 
I was going to say why doesn't she just take it orally. 
So, she, if I'd have said, 'No, we're not doing this' then either she'd 
have to go to London every week to have her injection which clearly is, 
you know, impossible because she's got such disabling disease, or she 
wouldn't have had it, she have had something else. 
But, but actually they could have started. I bet they would have had a 
nurse specialist attached to them. 
They could have initiated it, they could have done the first one. 
It's a bit naughty isn't it, I think? 
It's taking advantage .... 
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Appendix 7.3 (lst community pharmacist focus group) 
CP2 Urn, occassions when I've seen that would be a few patients that have 10 
got a lot of contact with them perhaps using urn erh compliance aids. 
I've got one chap that comes in quite regualarly urn he'll then come out 
with his (either) 28 days supply, urn he doesn't read urn and he won't 
take anything unless it's in a compliance aid so I, you know usually all 
this gets wasted and he goes back onto weekly scripts for his 
compliance aid. 
Right ............................. Why do you think that happens erh II 
CP2 Why what happens? 12 
Why er what sort of compliance aids are you talking about the .. 13 
CP2 He has a Nomad. 14 
Right ..... which obviously we don '( have in the hospitall suppose, well IS 
we don't 
CP2 You mean why do I think he's got a compliance aid? 16 
Well, no l just wondered why you thought that he sort of got sent home 17 
with 28 days 
CP2 I don't know because in his case it's very wasteful because the stuffs 18 
just coming out and he's not using it at all ..... but there doesn't ........ I 
mean I'm thinking of a particular patient communication can be 
difficult with him and I mean it's not with me because I know him quite 
well but as I say he doesn't read urn and obviously he's not been able to 
tell the hospital that it's no use you giving me anything because he, he 
just won't take it unless it's, it's right there the days of the week and he 
just takes one day after the other and you know won't have anything 
really from a bottle of tablets. 
CP3 1.. .... .1 suppose we're lucky really working with one practice but we're 70 
lucky in that we have a sort of very good relationship urn I suppose we 
are very, very lucky because we don't get that if we need to fill a 
medidose we do get the weekly prescriptions but when we first sort of 
started setting up our we found it was a waste of time trying to 
contact any doctors or get them to do it because he just didn't want to 
know because he just didn't have time and it would never have got done 
whereas if you could get the receptionist who normally churns out the 
prescriptions, if you can get her on side to actually produce a form so 
that every week all she's got to do is she produces a form and doctors 
only got to sign it urn and that actually helped quite a lot and so they 
now they actually do the forms and send us the forms and leave for us to 
send back 
CP2 Well in my situation the district nurses have been vital in that because 71 
it's taking, reducing their work 
CP3 .... I was going to say it was the district nurses, yeah they were 72 
instrumental in wanting it to start. It's actually saving the NHS money 
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by the time a district nurse goes in to see a patient house just for that 
when it actually costs our bill, the practice directly for fundholders or 
the health authority indirectly it can be quite persuasive. 
Now I want to move onto what problems do you think when you know 73 
what's your experience of pharmaceutical care problems when patients 
get admitted to or discharged from hospital and I'd like to know 
personal experiences andjust things that youfeel might go wrong if you 
haven't had personal experiences of them. 
I've got a couple of good ones from the last couple of weeks. Someone 
was, erhm it was a lady who actually has a medidose and has got quite a 
number of items in fact so many it's actually physically difficult to 
actually get them into the medidose itself but one thing she was on was 
lithium, the Camcolit brand and she'd started suffering from 
dehydration. She was admitted to hospital, when she came out a week 
later it had been swapped to Priadel but nobody seemed to know why 
and then it was left to me and she came out on a Friday afternoon to try 
and sort out on a Friday well what are we going to do now. Has she had 
the Priadel in hospital or has she had the Camcolit in hospital? What 
are we going to do now? In the end we decided to leave the Priadel 
because that's what she'd been discharged on and obviously arranged 
for blood level checks. And she was also on chlormethiazole and had 
been for like a number of years and they weren't in at all er in her 
medidose. Needless to say she was a bit worried about that. They'd 
also changed a couple of other things which weren't sort of major 
problems but when she'd been sent out, now she'd actually gone in with 
ordinary paracetamol tablets and somebody had obviously decided that 
she'd be better off with soluble paracetamol and so she'd been 
discharged with a month's worth ofparacetamol but of course they're 
too big to go in a medidose ... five or six boxes. And then they'd also 
put her on omeprazole and they'd decided that rather than put those in a 
medidose they'd give her boxes of those as well. So in the end, and also 
she was on .. 
Everyone laughs 
It gets worse. She was also on calcium and the didronel and erh we just 
like supplied a little tub with several calcium tablets in for the 
appropriate number of weeks and then the didronel tablets for the two 
weeks went straight in the medidose. But they supplied a whole load of 
those. It was, in the end she'd, she literally came in with almost a 
carrier bag, most of it was paracetamol soluble. When I spoke to the 
CPN I don't know why on earth they've done that she's got no problem 
at all with paracetamol, she knows entirely what she's doing. In fact 
she knew one day a week she goes to a day hospital, so she knew to take 
her paracetamol out of her middle dose because she'd need it when she 
was at the day hospital. 
Its's not that long ago either we had a child on a Hickman line 
chemotherapy transferred to do five days at home and then go back to 
the children's and so we had this fraught, frantic district nurse comes 
running in wanting Opsite veneguard dressings and I said well you 
won't get them on an FPIO and I doubt if the wholesalers would have 
them and the ward that had discharged the child to go home for a home 
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visit said 'No, no we can't give you those out of our budget. Get the 
doctor to prescribe them. So we were trapped in this loop erhm and of 
course when it happened it's after 5 and no-ones in the pharmacy at the 
Children's. 
I've got a child on, with er kidney failure, quite bad and she gets a 
fortnightly script with several items. She's also on azathioprine that for 
some reason she has to get from the hospital and I don't know if it's 
because the GP won't prescribe it or I don't really know why. I mean if 
the parent hadn't told me I wouldn't even know that she was on 
azathioprine. Her mother said that the last time she got a supply from 
the pharmacy they said why don't you get this from your GP and as she 
points out it's sometimes difficult because if she gets an appointment 
cancelled at the hospital there's a chance that she runs out of 
azathioprine. But as I say I don't know ifit's because the GP won't 
agree you know to take responsibility for the child on that. I don't 
know why that is because she's getting the Adalat, the Innovace, 
everything else from the GP. 
77 
You said that unless mum had said you wouldn't even have known that 78 
the child was on azathioprine. 
That's right, she's never got it from me. 
What do you think about that? 
I do find that disturbing. I mean for something like azathioprine I really 
think I ought to know that a six year old child is on it. Definitely. 
And some GPs, ifit's not in the BNF they don't believe it exists. 
Right, yes 
Lots of stuff and lots of unlicensed stuff in the hospitals. I had a GP 
ring me up last week well erhm, again it's a young child, a three year 
old with kidney impairment and she's on captopril suspension but 
because she's going on holiday we wanted her to go with something 
unbreakable in case the bottle of captopril gets smashed on the plane or 
whatever. I said oh I'll get you some 2mg tablets and the doctor went 
oh well they don't do a 2mg tablet, they're not in the BNF. 
How did you know they were 
I was going to say I didn't know they were 
Er I've just been around a long time. 
I think I might be catching you up as I've come across them. It's like 
Imuran lOs, it's er 
Sorry what was that? 
Imuran } Omg, the azathioprine } Omg, nobody knows they exist and if 
you ring Glaxo you can get 
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I don't know they exist, it's just what you come across in your practice. 
A GP reg we had and all the hospitals I've worked at they've existed. 
They seem to be following me wherever I work in clinical practice 
somewhere they appear. Here comess the Imuran, the Imuran 10 script 
has turned up. I've been here eight years and it's caught up with me. 
I mean some of the hospital consultants, not come across them 
personally but through a patient is they're very often I think perhaps 
don't see that, always see the problems that families have to cope with 
at home and again this particular child on the captopril, where it's made 
as a special it only, it actually now is only the special will only make it 
up with a fortnights expiry date on. It used to be a month um and I 
think with all the other worries that these families have got with the 
children as sick as this to remember to get a prescription every month 
you know for something like this and I said you know, you know tablets 
would be much easier, you can crush them, you can put them on a 
dollop ofice-cream. They've got two or three years expiry, you're not 
going to be worried all the time about running out. Talk to your 
consultant next time you go. Well she's doing very well on the 
captopril suspension I don't, they don't want to change her. And I think 
well the variability in the suspension even though it's made by the same 
company all the time. How he can say that that's a more acceptable 
product for the child I just don't know. 
Well we have this with the tacrolimus because it's usually prescribed as 
a powder but quite often the dose is I mg and you may as well just open 
a Img capsule and know that you've got Img, because it'll go down an 
NG tube. No problem with it at all but the biggest faff was she was on 
omeprazole 10 dissolved in two and a half mls of sodium bicarbonate 
8.4% solution. So I rang up and said 'how are you making this?' Oh 
we use polyfusors, we open them, pour then into a 200ml bottle and 
give them an expiry of a week. I said fine I've just got to explain this to 
the GP. So I explained it to the GP, the script arrived along with a note 
saying 'can you get smaller bottles, it seems rather expensive to me'. 
So I though this is going to tum nasty if we're not careful, so I talked 
the community liasion paediatric nurse into getting a tablet crusher so 
now they crush the granules and it suspends in a little bit of milk and 
you don't have to worry about it. I was thinking oh god no, and the 
GP's happy. 
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Do you ever, you know you were saying about the captopril and you 155 
know mum had spoken to the consultant and he wasn't really happy, do 
you ever yourself get in touch with the hospital consultant or 
Erhm, I thought about it that time but I don't know it's just reading the 
situation really, knowing the parent and reading between the lines, I 
don't know, I decided on that occassion that it probably wouldn't be 
productive. I think the child was doing well on it and so I was in the 
back of my mind thinking oh if this change is made on my insistence 
you know you've got to carry the can and pharmacists are used to, 
coming back to pharmaceutical care and taking responsibility for the 
patient, pharmacists aren't used to carrying the can for that extent. I 
think we've probably got a long way to go before they do. 
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CP3 I did once attempt to contact a consultant but I just couldn't contact 157 
him, he just wasn't around. So in the end I settled for, I can't remember 
what the detail was, I don't think it was something particularly 
important but in the end I managed to contact his medical secretary and 
said 'oh yes I do that in letters all the time' for this particular, he does 
that a lot ( ) and I thought I'm just going to have to settle with that. I 
can't remember exactly what it was, it was a long, long time ago. I 
think it may have just been a strength or a particular dosage or 
something like that. I can't remember what it was but why it sticks in 
my memory was it seemed to be almost impossible to get in contact 
with him, especially within the limitations of the time and I had only 
just qualified at the time. Maybe my inexperience my decision would 
have been different. 
We've talked about erhm people coming out with compliance aids and 193 
they've got them but the drugs aren't in them you know things like the 
soluble paracetamol you mentioned, dressings that you can't get on 
FP lOs, erhm drugs that aren't actually prescribed by the GP, they're 
getting from the hospital even though GP's supplying other medicines 
erh people getting discharged at weekends, erhm and 'special' 
preparations. Can you think of anything else that causes a problem? 
CPI You could expand the dressings to include all non-drug tariff lines 194 
because hospitals, though they try and stick to things that aren't black-
listed, might use things that are erh and it can leave you in a situation 
when the patient doesn't understand why they have to get it from the 
hospital, why he can't have it on a prescription even though the locum's 
written a prescription for 150 of them so he doesn't have to go back 
regularly but erh 
CP 3 Are hospitals aware of what's in the drug tariff'? I mean do they 195 
actually have a copy of the drug tariff'? Or perhaps better an actual, it 
would be easier if they had an alphabetical list of dressings they can 
prescribe. Or can discharge people on, rather than actually giving them 
a copy of the drug tariff. 
You mentioned your ethical dilemmas I suppose, with you know, not 203 
giving a patient something that they actually need. What about, do you 
have any other sort of ethical concerns about any unusual drugs that 
you might get transferredfrom hospital? 
CP I I had actually, we have a very young child with GORD, who's on erhm 204 
cisapride and because we've had that letter come round from the CSM 
and the GP's not too happy about prescribing it but the consultant won't 
budge but I do wish they'd go somewhere else because I ..... 
CP3 don't really want to dispense it! 205 
CPl .. I don't really, I really feel awkward about it and you get that feeling, I 206 
really feel I should say something but I could destroy the trust that the 
patient has with the consultant because the child is so much better at the 
moment and is putting weight on. You know it's just something that, it 
might not happen but it could be a cardiac event waiting to happen. It's. 
CP2 I mean with children, a lot of the things are unlicensed and the way that 207 
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they use them I think you just get used to it. 
I think some things there's a history of usage which is a bit more 
reassuring as well. There's a provinence like with captopril erhm and 
erhm say atenolol syrup you know that's been used for quite a while and 
what's the other one that's sticking in my head but won't come up? 
Erhm, Innovace as well, there seems to have been a fairly, almost since 
the, it Innovace became available you have seen paediatric scripts for it. 
And there's not really been anything in the CSM pointing out that when 
you simply target something that's being used in a child that's 
underage, under weight erh your thinking (groan) should we really be 
doing this? 
I think erhm, I think my biggest complaint is the fact that in hospital the 
compliance problem isn't really dwelt on enough and even if they're 
aware that patients have got compliance aids, which they're not always. 
they don't really know, you know like I've got a lady on compliance 
aids and she, the hospital put her on dipyridamole three times a day and 
then, she has three times a day dosages in the compliance aid but she 
knows she's supposed to take the dipyridamole before, half an hour 
before meals and so I said right let's move everything to before your 
meals. No, no the rest of them upset me ifI take them before meals so 
she's in fact got horrendous complaince problems because she's taking 
dipyridamole out of a bottle before her meals and then her compliance 
erhm times out of the aid after her meals erhm you know really she 
should perhaps have been put straight on the Persantin MR. And things 
like that really. You know when you actually get there and try and sort 
the problem out it's difficult to backtrack and then through the GP, back 
to the hospital. GPs can be very reluctant to change hospital's 
recommendations, very reluctant. You know when one does for good 
reason you really do feel like applauding them. 
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Appendix 7.4 (2nd community pharmacist focus group) 
One idea which would, may be easy to implement would be to actually 
to stick, from the pharmacy side to stick on the bottom copy on the 
reverse of it copies of the labels of the stuff that they're issued and then 
at least we would, if the patient did bring that discharge letter into the 
pharmacy we would be actually able to see what actually went out and 
how it was written because as I said previously there have been times 
when the brand name has been transcribed by the registrar or whoever's 
discharged the patient, by the time it's gone through the pharmacy it's 
been transfered into generics and the discharge note's not been amended. 
Because they don't appreciate the differences between a branded 
prescription that's written in OP land will be, the patient will be issued 
with Tenormin ifTenormin is written whereas in hospital the registar 
can write, or whoever is prescribing it can write a brand product but 
whatever's kept in the pharmacy gets given so you could write 
Tenormin, whatever, you will only get that product that's on the shelf. 
It could also be that the hospital have the ..... 
patient's own 
..... contract for say Frumil so Frumil is issued because it is the cheapest 
co-amilofruse. 
Co-amilofruse, yes, yet if we for co-amilofruse we would give co-
amilofruse. 
We wouldn't have it at contract price to be able to give it at that price. 
Have you had any experiences of this? 
Patients asking for reasons why their medication has changed? Yes, oh 
yes. I'm just trying to think of an example. Oh also I think if we're very 
busy you can say to someone 'have you had this before?' and they might 
say yes because they've just had it from the hospital but if we're very 
busy and we don't stop to say well has anybody explained to you, are 
you happy with your medication or whatever, that opportunity if you 
like would be missed ......... . 
I think the point is ..... 
........ and then to get the most out of their medication 
.... if they come in with a typed prescription because it's been put on 
repeat if they come in with that, they've done the right thing, gone to the 
doctor first, they've got a prescription, they come in you just, I mean it 
might be a new product but you know it's not as obvious as if you had 
an indication 'this person has been in hospital' you know flag this 
person please ask them that they're quite happy to take everything. 
Because I don't, I think they just go to the doctor who says 'oh yes lets 
change it, there you are receptionist, just type this into the repeat thing, 
it's done by the hospital so therefore it's all ok'. 
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CP 5 That's right yes. 124 
CP4 And therefore I don't have to look at it. I mean they're not going to 125 
question, very few would question a letter from the consultant saying 
'this patient needs such and such' and so it just gets put on the computer 
and then, from then on no-one has a chat to them about it. 
CP6 The other ... 126 
CP 5 The number of times that I've had a prescription when it's come 127 
through, like in that case when it's come straight from the GP and 
you've looked at it and looked at their past records and realised that 
there's a contraindication or an interaction and erh you check with the 
patient 'oh yes I'm still taking that' and you ring up the GP 'oh yes it's 
initiated by the hospital, it's got to be alright she must have been on it 
from the hospital' well it may have been but erhm yes. 
CP4 Proton pump inhibitors is a good example of that. Where they come out 147 
on the highest dose or even when it was Losec the 20s and yet they don't 
need the 20s forever but that, I mean that really is the thing with the GP, 
the GPs are very bad at that. They will prescribe 20s just forever. 
They'll put it on repeat and they'll get it for the next three years. 
CP6 Yeah and there's no diagnosis so we, we can't then challenge that 148 
prescription to say well you know it's three months now how about 
reducing it. 
CP7 I had quite a bad miscommunication erhm the patient had been in 149 
Macmillan I think and there was a communication from the doctor at the 
hospital by telephone I think to the GP and I think the GP must have 
misheard and I got a prescription for what was an overdose so I went 
back to the GP and the GP said 'oh that's what the hospital said' so I 
was so unhappy about it I actually managed to get hold of the hospital 
and check the dose with them. 
Who did you speak to in the hospital? 150 
CP7 Erh I think the, I can't remember, it was a year or two ago now. 151 
A doctor was it or? 152 
CP7 Yeah, it was from the original prescriber and they told me what the dose 153 
should have been. 
How did you feel about doing that though? 154 
CP7 I felt like I was going over the GP's head. Because he believed what the 155 
hospital had, what he thought he had been told but that was a verbal 
communication I think from the hospital. 
CP4 At the end of the day you did more than you probably had to do because 156 
I mean, all you could do, all you really had to do was just refuse but I 
mean obviously none of us would actually ever do that but you know 
what I mean. 
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It was incredibly expensive what the doctor had actually prescribed on 
the prescription as well. 
I think they don't realise the time it takes, in community phone calls cost 
as well and it's, if you phone from a GP's practice the health authority 
pay for it. If we phone it comes from our bills. 
The stupid thing about stamps I mean at the end of the day if they make 
a mistake that's the hospital's fault or whatever because it came out 
wrong we have to send the prescription back to the GP by you know 20p 
And it all comes out of95 pence. It all comes out of95 pence. 
That's what I'm saying. And one to post back, that's 40p. 
There's no recompense for interventions. There's no recompense for 
interventions out of your 95 pence though really. You can't say 
telephone call 5 pence. 
Well, theoretically you can but I don't know how. 
You can put it down as out of pocket expenses and just. 
I don't know people that do but I don't know whether we just write it 
down or whether you would have to prove that that's what you'd spent 
on it. Even then you would probably spend more of your time that it's 
worth to reclaim 40p. 
It's the same as specials isn't it because you've got to do it as a 
telephone call you get invoice as, with an adhoc expense but you don't 
claim the telephone call. 
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So what about any specific, can you think of any specific times when 167 
you've had patients come into your pharmacy who've just come out of 
hospital with a, that's caused you a particular problem. 
Very recently, this was an A and E discharge, it was on a Friday night 
for eye drops and it was a special antibiotic mixture for eye drops, 
cefuroxime 5% in snotears. A and E didn't issue a prescription 
presumably because the pharmacy was shut, they'd gone to the GP to 
get, they'd been told to go to the GP to get this prescription written up, 
they'd got an FP 1 0 prescription which they brought to me on a Saturday 
morning and I said there's no way I can do this erh I'd have to order it 
erh specially made. Oh yeah that'll be alright I've got a few drops left 
from a previous time when it'd occured. How long ago was that? 
(Everyone laughs) 
Oh well, only about three weeks ago. Alright OK as long as it's only 
three weeks that's fine you can use them. And I said it'll by the time 
I get it through. In the meantime, I faxed it through to our specials 
department and they contacted me on Monday morning to say they 
couldn't issue that combination because they didn't deal with or had no 
snotears in and so they couldn't give that brand they could only give 5% 
cefuroxime. Of course then I found out that it's actually a special that 
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the DRI keep in and deal with themselves. But that should have been 
issued, that should have come through the hospital service it shouldn't 
ever have been issued as an FPl O. Anyway the patient's mother went 
back to the GP, got another script, another FPIO which is no doubt come 
up to the LPC next time because he told her to go and stand in the 
pharmacy department and demand that they issue that prescription for 
her. 
I suppose it's useful, might be useful for children because they're often 
on liquid specials but I think it might be more useful with the elderly 
population so that we knew what they were on and we could counsel 
them because they're more likely to be confused, they're more likely to 
not be able to ask the right questions to get the right answers erhm 
they're more overawed by the hospital situation whereas they might you 
know if they come in a quiet time to us people that they know, people 
you know the pharmacy that they've been to for years it might be easier 
for them to access the pharmaceutical care that they need. 
I think it's like, and the other thing is some, specially the, going to the 
elderly they may have turned up at the DRI or the City with a stroke and 
then got carted off to Babbington for rehab and then they get discharged 
so they, before they have been discharged there's very little input and 
also you tend to find, I find that Babbington discharges, they don't 
everything that they're supposed to be on and then there's a frenzied 
phone around to the GP and to us to make sure they're on everything 
and we, I had one lady who was on valproate, Epilim, everything and 
they couldn't figure out the strengths, you know 500mg in 5ml and the 
dose was 325mg and they couldn't figure out how many mls it was 
going to be and for how long and I ended up regurgitating it over the 
phone to them, with a calculator and calculating it, but the patient was at 
home at this stage so I don't know what had happened with the 
discharge erhm. 
They hadn't got the medicines baSically? 
No, and the husband was really in a frenzy because he didn't know what 
to do. He came to our door wanting help and that's how we got 
involved but I think that stems from the elderly, you've got to keep. 
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What about, we talked about problems when patients have been 284 
discharged can you think about any problems that there might be when 
patients are actually admitted to hospital. 
Yeah I can think of a big problem, give me back my monitored dosage 
systems please. 
Yeah, I'm glad that one's come up. 
I've told my nursing homes that they're not to hand anything over to the 
ambulance drivers at all because the amount of times they just 'bye bye 
£16 Nomad tray'. You know so I basically said it's my property, well it 
is theirs if they want to pick it out and put it in a paper bag for them, but 
as far as I am concerned it is my property it does not go in the 
ambulance. 
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CP 5 I don't deal with Nomad but with monitored dosage, the MDS system I 288 
tell my nursing homes if they're sending any of the drugs they just open 
the plastics and keep the plastics to send back to us. 
CP4 Yeah, that's not too bad. 289 
CP 5 Because, obviously that's the throwaway bit, obviously with Nomad 290 
there isn't a throwaway bit. 
CP4 I mean at the end of the day it's hard, I mean the ambulance arrives, it's 291 
very often a bit of an emergency so you know 'can I have the 
medication?' 'yes, there you go' but I mean I, if you get a rush of it it 
gets very annoying because its a lot of money. I just told them that 
they're not to do it. With Manrex it's a bit easier because they can take 
take them out of the actual things 
CP4 I mean there are things where there are shared care guidelines where the 328 
GPs have turned round and said we're not happy dispensing this. But 
how many times a day do you see things being used by a GP in an 
unlicensed indication or length of time and they're unaware. I mean as 
far as I'm aware it does, the onus lies on the GP and so it's not our 
problem. 
Do you not think it is? 329 
CP4 Well, I don't think legally it's our problem because basically they've 330 
signed it to say they are giving it. Eh because it can be used for that, it's 
just unlicensed. 
CP6 They've made that clinical decision. 331 
CP 5 It's their clinical decision therefore it's their responsibility. 332 
CP4 As long as the dosage is reasonable for that, I mean at the end of the day 333 
we don't the condition half the time so it's very hard for us to make a 
decision erhm. 
CP6 Are they using Cozaar for hypertension or heart failure? 334 
CP4 What was the betacardone one they've got erh reviewed not long back. 335 
Erh how many time I still see that. Now that's not used for, is that 
hypertension it's not meant to be used for now. I know it's one 
indication it was used for a fair bit. 
CP6 I think it is hypertension. 336 
CP 5 You've only got to look into the malaria leaflet, you've got doxycycline 337 
CP6 Unlicensed. 338 
CP 5 ... there's a recommendation for that erhm and it says it's unlicensed for 339 
that recommendation so it's acceptable to do it. Providing the doctor has 
signed the prescription and therefore he's taking the clinical 
responsibility. 
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I'd say it's a professional thing for us that if we, that ifI knew and was 
worried about it I would ring to make sure that the doctor knew that he 
was doing it unlicensed. 
yeah 
But erh I suppose that does make it a sort of ethical issue but legally it's 
not an issue because the doctor has signed to say that he is happy to give 
that and I think as long, where it stands with us, as long as we are happy 
that the dose is correct for that person, it isn't going to do them any 
harm, then I think that's all we can do with the information that we 
know at present. 
See, that's the problem. It's all tied in with communication. Are we 
confident enough to challenge the GP with that prescribing? And 
unfortunately we're not because we don't have the whole picture and 
that's why we find it very difficult to challenge the GP, you know for a 
start we don't even know whether it's, half the time whether it is an 
unlicensed indication and if it is we don't know whether they have 
spoken at great lengths to various bodies and they've actually agreed on 
that and then we end up phoning and 'yes it is' put the phone down. 
Ethically, what do we do because we've been told, and again it's not 
blacklisted so we can't refuse it. 
We can accept it. 
You have to accept it. If you're presented with an FPI0 you must 
dispense it within a reasonable time or make provision. You cannot 
refuse under your terms of contract. 
We will be paid, it's not a blacklisted line therefore we are paid for it, 
the GP's the one that will be questioned as to why he's prescribed it and 
that will only be through Derbyshire it won't be through the National 
Health Service. 
This has come up and what was said at the Prescribing Advisory Group 
was ........ I think it was Viagra that we were discussing, and we said 
that you know, we were saying no we're not going to fund this, it isn't 
going to be funded it isn't going to be in the formulary and therefore we 
forgot about it. And what I said was well actually we are seeing scripts 
for Aricept, we are seeing scripts for Viagra, if they're not prepared to 
fund it there should at least be some sort of guidelines there, because it 
will happen. 
It is happening. 
It is happening, absolutely yes. And Viagra's another example of that. 
Viagra is being prescribed and we're dispensing it. 
And this new obesity drug is going to be another one. 
You can't refuse it. 
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I've never had a prescription for that. 
I must admit all my Aricept and all my Viagra scripts have all been 
private to date. 
I've had one FPl 0 Viagra and we spoke to the prescriber and he said, 'In 
my', and he is one of these decent GPs who if you actually confront him 
he will tell you exactly the path that he has taken to reach that decision, 
and he said'ln my opinion everything's failed, he's been on alprostadil, 
he's been on everything and he's come to me, I'm prescribing it and I'll 
take the ownership of it.' So we obviously dispensed it. 
I think it's a very fine line we're put on, you know like everyone else we 
have limited time, we have limited, so you have to, you do have to say 
this is a priority, this isn't a priority. Now to myself, finding out 
whether someone's being monitored on something, unfortunately is not 
a priority. And to be honest I think in the big scope of things I don't 
think it would be a priority. As far as I'm concerned the GP has, I'm 
there to make sure that what's been given is correct, correctly given, that 
theoretically is correct for what they were originally diagnosed for but 
the actual monitoring etcetera would be down to the GP and the 
consultant. 
It's like taking clinical responsibility. 
Well, we're not mentioned anywhere in the guidelines, in shared care 
guidelines at all. 
Because this is taking clinical pharmacy into the community but we 
actually haven't been given the responsibility to do it. You know if 
someone comes in and they take allopurinol, do we ring up the GP 'have 
you done a creatinine clearance? You know have you adjusted the 
dose?' you know how far do you take it. And it's again the 
communication set up hasn't been, is not there yet. Well you know 
we're linked up via computer ... 
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Appendix 7.5 (Ist hospital pharmacist focus group) 
HP2 Now, we've got those boxes we tend not to hold up the process of 55 
discharge as long as all the medicines are the same as they are on the 
chart. It's when they suddenly change on discharge that they need to go 
to pharmacy to sort them out. But then it depends whether or not they've 
planned ahead or not. 
HP6 The thing about the discharge process is most of it is nurse led with the 56 
exception of the prescription and that's the bit that causes a lot of 
problems in that they can plan social services and meals-on-wheels and 
pet care you know several days before the patient goes home because the 
nurses can get on with that they're not restricted in any way. The rate 
limiting step is the generation of the prescription by the medical staff. 
HP2 That usually happens after a six o'clock ward round. 57 
HP6 On Sunday. 58 
HP3 And then the late people end up, but it's been less of an issue now we've 59 
got patient boxes. But it does happen with new items, or things they've 
just changed, like doses they've changed. 
HP6 Or things they've actually just run out of because the nurses check the 60 
lockers to varying degrees and depending on their need for the bed they 
may discharge them with less than the optimum amount if there's a bed 
crisis or they may elect to send the prescription down to pharmacy to 
make up a full 28 days supply. 
HP8 I think ideally we're meant to check lockers aren't we twice a week or 61 
something? 
HP7 But also sometimes the prescription that the doctor writes bears 88 
absolutely no resemblance to what the patient, the labels on the bottles or 
what the patient is actually doing. 
HP2 Because sometimes the bottles are old bottles or they don't say, say it 89 
says 'take two a day' and the patient actually takes one a day. Actually 
speaking to the patient you get a better history but sometimes you can't 
speak to the patient if they're very poorly. 
HP7 Or if they say 'take as directed'. 90 
HP2 The blister sheets. 100 
Why are they a problem? 101 
HP7 Because you can't keep them in the locker for a start. 102 
HP6 The nurses aren't used to them because of the way some of them are they 103 
have separate sheets for the morning, separate sheets for lunchtime, so 
the same drug can be in three separate plastic sheets. 
HP2 And you don't know what, the colour blue is morning and yellow is 104 
afternoon but you don't know what blue and yellow mean. They do in 
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the nursing home but they don't here and when they get discharged you 
can't discharge them on just boxes of tablets because they can't use 
those, they can only use the blisters so you end up ringing the nursing 
home and the pharmacy. 
What do you do about that then? 
I would ring the pharmacy and the nursing home. Because there's 
usually a sticker on isn't there saying which chemist dispensed them and 
which nursing home they're in, so you'd have to speak to them and they 
have to organise between themselves. Because you can supply the 
medicines but then there's no point supplying the medicines if the 
pharmacy's already got the new packs made up and then you've got to 
talk to the, if the tablets that they're being discharged on are different to 
what they came in on erhm there's no point in us giving boxes and 
bottles because they can't really use them. 
105 
106 
You mentioned about patients admitted on non-formulary drugs. What I 16 
do you do about that? 
It depends what it is. 
Yeah. 
You use the patient's own, if an alternative's not appropriate you buy 
them in. 
.... Buy some 
You never start a non-formulary drug but a couple of them come in and 
if the physicians won't change. 
I try and assess whether it's a, I mean if it's something for say to control 
blood pressure or antidepressants then I don't think you'd look to change 
them to something else. But say if it was a nonformulary antihistamine I 
wouldn't go out of my way to get it purchased. I think you make a value 
judgement as to the medication and as I say if it was blood pressure or 
depression, something serious then I think we would make every attempt 
to continue it. But if it was something say for symptomatic relief you 
know antiacid, antinausea, analgesic then we would probably change 
them, well certainly I would change them to something that was 
comparable unless there were other over riding reasons. 
Has anyone else got any differing views on that? 
Yeah, sometimes you try and get them to bring some in from home, or 
they've got a prescription at home. 
Or they've got, instead of giving them 28 days supply they've got 
enough for three or four days and they've got plenty at home to carry on 
with so as long as we discuss with the patient and they're aware that they 
supply the rest themselves and they're happy to do that. 
Most of the patients are alright if you explain that it's something that we 
don't keep routinely and if they have got a means of getting more when 
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they get back home, they don't expect us by and large to supply large 
amounts. As long as they've got enough for their stay and a few to get 
back home they're normally quite happy. 
HP8 Or things have been added on but they've been on similar things that 176 
haven't been removed. Like Imdur, we've had somebody readmitted 
who we've swapped in the hospital to isosorbide mononitrate, that's 
been added on but the Imdur hasn't been removed. And they've been 
taking both. 
And you've had a patient admitted on both. 177 
HP8 Dispensed by the same pharmacist. 178 
By the same community pharmacist? 179 
HP8 Yes. 180 
HP8 And we've had problems as well because we do generic TIO letters, it's 181 
all generic. So even if they're on a branded version of it, they'll come in 
on the branded version that they were on before and then because we've 
given them a generic name as well they come in on that as well. 
You mentioned quite afew problems that you thought the community 196 
pharmacists might have with sort of supplying medicines when the 
patients have been discharged from hospital, things like your specials, 
your opthalmic specials, extemps, named patient things, what about the 
GP? Do you think the GP ever has any difficulties with continuing the 
prescription? 
HP4 I think they rarely realise that there's a problem. It is the patients or the 197 
chemists who have to sort it out. Either the chemist will try and sort it or 
some of them will say 'I haven't got it' and send them on their way. 
And some just send them here with an FPl 0 in their hand. It's quite 
common at weekends isn't it chaps. 
HP9 Yes, yes. 198 
HP2 I mean the OP I suppose could say, oh, what's this and they'd have a 199 
look in the BNF and they can't find it. If it's a special it won't be in 
there will it so I can see that being a problem unless they've got a letter, 
a hospital discharge letter telling them a bit about it, you know how long 
it takes for instance. 
HP9 1 think you're right but I don't think they would know what's a special 200 
they wouldn't know that a particular strength ofhypromellose eyedrops 
we buy from Moorfields and opposed to one off the shelves. 
HP 1 I think on the whole I tend to talk to in the dispensary community 201 
pharmacists about this patienfs been discharged on these from your 
hospital what are they, how do I get hold of them? We rarely speak to 
OPs about these it's mainly the community pharmacists. I don't know 
whether the OP would see the discharge letter I reckon the receptionists 
just add it on. 
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We've talked about, well these have mainly been supply problems 208 
haven't they really. Do you think the GP or the community pharmacist 
have any other difficulties when patients have been transferred from the 
care of the hospital. 
I think if we send somebody home on something for an unlicensed 
indication and the pharmacist is there checking doses and they, you 
know a dose may be appropriate for a particular condition whereas they 
don't even know what the condition, what the indication is because they 
don't get that information on the FPI O. And things that require 
monitoring they don't get. 
Yeah, new drugs, difficult drugs and expensive drugs. 
Expensive for who? Is that a problem for the GP or community ... ? 
The GP yeah, they pass it off as 'I don't know enough about this drug or 
this condition, we'd sooner have the hospital at least get people started 
on it' but there is an element ofit's an expensive product and they don't 
want it on their budget. I think there's an element on both sides of 
course. 
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So what sort of information do you think is important, first of all for a 223 
GP when a patient is dischargedfrom hospital. 
They need to know if we've stopped something, why we've stopped it, if 
we've started something why we've started it. 
And is it going to be ongoing treatment or not. 
I think they're quite good in ticking GP continue, yes or no, but there's 
on the TIO form a box for indication isn't there and they never fill that 
in. 
There really ought to be some way of communicating what the intentions 
are with regard to treatments. I mean we talk about ( ) and the patient 
has hypertension or liver dysfunction but item by item there's no 
communication one way or the other as to what the long-term plan is. I 
mean you think about things like ACE inhibitors and statins, is there 
really any intention to increase the dose, is there any intention with H2 
antagonists or with PPIs to actually reduce the dose when the patient is 
controlled or with inhalers. There doesn't seem to be any way of 
communicating the intent, the therapeutic intention is long term of the 
treatment, so we end up with people on ACE inhibitors who are on low 
doses and never actually achieve a clinically significant dose. 
We could do with better links as well, we don't really know the 
community pharmacists. 
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Just to finish off, [name of participant] mentioned about ringing up a 240 
community pharmacist when a patient was going home on a Manrex 
system do any of you do anything like that, sort of anticipating problems. 
Nods. 
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What sort of things do you do? 242 
HP6 Similar sorts of things to methadones, but you know you can have a 243 
monitored dosage system. I have to say I rarely ring up about supply, to 
tell them where to get things from. Like if it was a special, I would 
rarely think to ring them up about a special. 
Does anyone think to do that? 244 
HPI Usually I do. 245 
HP3 Usually tell the patient. 246 
HP4 I would say with outpatients I would make the assumption that if we ( ) 247 
as long as they understand they've got to give the chemist some notice 
and the chemist can talk to us if they need to. I mean some do, some 
don't. 
HP 1 In an ideal world it would be nice to think all that way ahead but you've 248 
just got so many patients that it's difficult to do. 
HP6 And also () the discharge, the nurses on the ward, you know it wasn't 249 
planned they'd be going, there's a bed crisis and you go up the next day 
and they've gone so you've never even had the opportunity to intervene. 
Because people are turned round so quickly? 250 
HP6 Nods 
Just one last thing I'd like to mention is, I mean you've talked about 252 
extemps and specials and things like that but what about things that 
aren't actually on the Drug Tariff? Do you ever .... 
HP6 Such as? 253 
Such as .. 254 
HP4 Mainly dressings, we tend to give the full supply. One that causes no 255 
end of problems is Cicacare. It costs us a fortune and patients get fed up 
with coming back every month for another piece, so we give them five or 
six months worth at a time. (plastic surgery) 
HP 10 In community pharmacy you just give what's in the drug tariff on FPIO. 256 
HP 1 I'm not aware really of what's not on the Drug Tariff. 257 
HP4 This is becoming less ofan issue now, there are very few. 258 
HP8 You tend to see it the other way round, people come in from community 259 
on things that we don't keep. 
HP4 Or they're on dressings trials .... 260 
HP8 Things like dressings it is a problem because if we're following the 261 
district formulary you know that it's going to be on an FPl 0 apart from 
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obviously some dressings but generally. 
When I used to do the admissions ward as well, when you phoned a GP 
you'd find that the computer records aren't always kept up to date. Very 
frequently the receptionist won't actually let you speak to the GP she 
will pull it off the computer so you'll be getting all the information to 
start the treatment here as well. 
But what you do, what I've found is totally bamboozle them with 
something and they say well what is the query about and you make it 
sound so technical that they say, 'Just a moment, oh I'll put you through 
to the doctor'. 
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Appendix 7.6 (2Dd hospital pharmacist focus group) 
So now I'd like you to talk about what happens when patients are 22 
discharged from hospital. And what I really want to try and get to the 
bottom of is what you perceive the discharge process to be. 
Yeah, well I'd say crap ............ it's haphazard isn't it. If it's coming 
from the ward it's the last thing on their mind to get them out. And they 
suddenly realise that the ambulance is on it's way and they go 'erh we 
need medicines'. It's not always the case but a lot ofthe time that 
happens. 
Or it's they're desperate to go. People want to take them home. 
They've been told they can go so you're right it is the last thing on their 
minds. It's all rush, rush. 
I suppose what is supposed to happen is they're supposed to have sat 
down with them a while before they go home and counselled them about 
all their medicines. 
But that you can do but you can't actually prepare the medicines and 
remind them on discharge because it's all such a ... 
Or it's a nurse telling them. 
If the decisions are made at the last minute, there's an awful lot oflast 
10 minute 'do they need the laxatives, do they need this, oh my god 
they're still on nebules and they should be on an inhaler' decisions. 
This is a case example of where I've been this afternoon is that the 
doctors have happily written in the notes 'home today' told the patient 
she can home today, haven't done anything about the TIOs and so she's 
sitting there with the relatives going so what time are we going home. 
And so they having to bleep the doctor to get them to come back and 
write TTOs. 
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What about other medicines and their availability in the community, do 57 
you ever think about that? 
Dressings. 
Well, yeah. Dressings. 
I sort of try and think about it because I think that's the sort of thing 
there's problems with, I know about problems, other things I don't. 
I don't know ifthere's problems with feeds are there? 
I never think about that. Well, we don't deal with feeds much do we, the 
dieticians organise that. 
We have problems with some of the unlicensed things we see. But 
hopefully that's odd enough for us to sort out a supply in advance. 
I think we're very good at thinking about it if it's obvious. Like we've 
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stood there crushing the tablets down but if it comes in a box or is in 
blister packs I think we just tend to assume that they will get hold of it. 
HP 15 Yes. 65 
HPI6 Well surely it shouldn't be a problem getting hold of it if it's on the 66 
formulary because therefore the GPs should, shouldn't have a problem 
prescribing it. 
HPI4 Yeah, the problems arise where it's not prescribable or it's a special or 67 
we're making it specially in Keltrol and things like that. 
HP 11 But usually these days we've had to fill in that many differerent forms to 68 
get it, it sort of twigs! 
Can you tell me about any pharmaceutical care issues which arise when 109 
patients are admitted to hospital? 
HP II Drug history, if patients don't bring in their own drugs it's very difficult 110 
isn't it, especially at night. 
HP 13 There's often very, very, very inadequate GP letters. That example of I) ) 
was it thyroxine that looked like something totally different and so for 
days they got this thing because it looked like that and we had no way of 
checking their drugs over the weekend while we were waiting for a GP. 
HP II ... carbamazepine? 112 
HP 13 No, that was just because our doctor couldn't write. 113 
HPI5 I had one when a patient came in from clinic on Monday and he drew his 114 
inhalers for me but it still didn't make any sense, they were Easibreathes 
but he'd drawn them upside down but we phoned his GP today and it 
transpires he's been on dothiepin, but he didn't bring it in, he's no idea 
about it, he doesn't remember his tablets and he came straight in from 
clinic so there's no GP notes and he said he wasn't taking any tablets. 
HP12 Isn't there problems with things like Medidoses where you can't ... 115 
HP II If they don't write a little card then it's difficult isn't it? 116 
HP 13 But we can at least identify them if they're in a Medidose. 117 
HP 12 Well what was that problem you had last night, or the other night with 118 
syrups? 
HPI3 Yeah, the syrups came in from the community and they rang me up to 119 
say what dose is this child on is doesn't say on the syrup, I was like 
hello. 
HPI2 It was actually Primidone and it just said 3mls whatever, I mean there is 120 
only one strength of Primidone but they didn't know. 
And what was the directions, the directions were so many mls ... ? 121 
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HP 13 Take 3 mls x times a day. 122 
HP 12 They were on clonazepam which is a special made from Nova which 123 
had a different dose, well that had the right dose, they had erhm 
Primidone which they didn't have any milligrams in but it just had 3 mls 
or something, they didn't know what it was and what was the other one? 
They were on something else where the dose is oh baclofen, the bottle 
said 5mls four times a day, it had been prescribed three times a day, 
there's no mum there to ask. It's kind of a special needs child and the 
notes aren't clear but there's nothing from the home, and all of it was 
just wading through checking what they had and what should they have 
been on and. 
HP 11 There one's we get here are they're as flat as a pancake and they're on 124 
steroids or something and they go missing for days or whatever. I do 
think that patients should register with a community pharmacist in the 
same way as they do with GPs and so you've got someone to refer to so 
you've got an up to date list. 
So we talked about discharge planning earlier, can you tell me about 156 
any difficulties you have experienced for individual patients in trying to 
plan their discharge? 
HP 13 I'm having problems getting hold of community chemists and find out 157 
which chemist they are to direct the information to erhm. 
HP 11 It's always that Chad one. 158 
HP 13 Yeah. 159 
HP 16 Or the Tesco's one. 160 
HP 12 Or you phone up and it's a locum there and you know. 161 
HP13 And if it's syrups there's a big problem and there's often not enough 162 
time if you can't get hold of them on the phone to actually send them the 
information. 
HP 16 Yeah, erhm because it was me that handled the prescription in the first 226 
place and the doctor had erhm I don't know which one he decided to 
use, but I said to him, you know, 'We use this instead' and he said, 'Oh 
well, just tell the patient, give the patient a note and send them to their 
GP and tell them that this is what I want them to prescribe.' And I was 
just thinking what. 
So did you do that then? 227 
HP 16 And eventually. What did I do in the end? I think I had written it on the 228 
prescription card and given it back to him to take to his GP. And then 
the GP had rung me up which is just as well. I was so thankful she had 
got me because I don't think anyone else would have had a clue. And 
then I was able to explain to her what had happened because there was a 
whole issue about blood pressure and whether the patient could tolerate 
it or not and the doctor in clinic wanted this to be monitored. 
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Right, so. 
And didn't have time to do it in clinic and didn't want to send the patient 
back to clinic. 
Right, so did the GP prescribe it in the end? 
Not the non-formulary one but the alternative. 
So they just wanted tamlusosin and they wouldn't take alfluzosin. 
I can think of loads. Sodium bicarbonate when it's oral solution and we 
use the Polyfusor. That seems to cause, even if you tell chemists it 
always seems to cause a delay and problems and I've had questions from 
where do you get the Polyfusors from? to where do you get the sterile 
bottles that you put it in? Erm, we had someone with carnitine even 
though it's commercially available we still seem to have problems with 
that. 
Is that unlicensed though or? 
No it's normal. I mean all the unlicensed things hopefully you can have 
pre-empted and made an attempt at communicating and letting them 
know. 
Have you still not had 'phone caIls where you've let them know and 
you've told them the supplier, the phone number of the supplier and the 
patient still rings back saying my pharmacist says they can't get it and 
now I've run out. 
Yeah, oh yeah, numerous and erhm there's one particular chemist who 
seems incapable of doing those erhm it drives me mad, suspensions, 
making suspensions with strength on so they're always ringing you up or 
there's always a problem with that. Do you know who I'm talking 
about? 
There's one community pharmacist phoned about Fosex when it first 
came out, I don't think he wanted to have something on his shelves that 
he might not ever use again so he was phoning up asking if we could use 
something else instead, like Calcichew or something. 
Right. 
He wasn't keen on that. 
Does he not read his BNF? 
I tried to explain to him that it wasn't quite appropriate. 
I would like to see you trying to convince Dr [name of nephrologist] to 
use something else. 
This was after of course the patient had been referred back, the patient 
said he hadn't got hold of any and then he phoned up. Well I phoned 
him I think. 
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So was he going to suggest to the GP to change it do you think? 251 
HP 11 No he sent the patient away I think at the time. 252 
HP 13 They [community pharmacists] do seem to make things inordinately 274 
difficult when it's not necessary, like buying in Fosex, I mean how 
expensive is that and can't they claim broken bulk or anything like that. 
But they always seem to want to put it back on you if it's something 
slightly unusual. 
HP 16 I guess because that's they're more financially orientated whereas we 275 
don't have to think about that side of things a huge amount. 
HP 11 Yeah. 276 
HP13 But it's their shop. 277 
HP13 But haven't they thought about that by looking at the formulary in the 278 
first place. 
HP 11 Yeah, limit the number of drugs they should keep in. If GPs would stick 279 
to the formulary. 
HPI5 That's the issue isn't it. 280 
HP 11 Yeah, I think they should be made to stick to the formulary if we've 281 
decided it across the trust. 
HP13 There would still need to be a mechanism for those one-offs where you 282 
do want something that's not on the formulary. 
HPll Yeah, but they should apply in the same sort of way that we do. There's 283 
nothing really emergency, they should go to PAG [area prescribing 
committee] or whatever and sort it out. 
HP 15 Yeah there is the great potential for having a district formulary between 284 
hospitals and community. 
HP 11 Yeah, I think community pharmacists should try and enforce it more. 285 
think that should be part of their role. But then they could keep a 
narrower number of drugs couldn't they, they wouldn't have to keep all 
these hundreds of obsure things that keep going out of date and throwing 
them away. 
You talked about some of the problems that community pharmacists 308 
might have with the sort of cost of the stock on the shelves and things 
like that and then turning patients away but what about GPs, have you 
any experience ofOPs? 
(Someone laughs) 
Not mentioning any names! 309 
HP13 Yeah, are we allowed to start on that one in particular? 310 
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HP 12 As in OPs not prescribing expensive things? 311 
Yes, well .. 312 
HP 12 I think we've all had experience of that. 313 
Not just expensive things but .. 314 
HP 15 I had a problem where I happened to be running through the dispensary 315 
and someone was looking for something to do with urology where the 
patient, it transpired after a lot of, actually after just retrieving their notes 
that they'd been prescribed cyproterone alongside their Zoladex 
injection which of course you take cyproterone for three weeks after 
your first Zoladex injection to conteract the tumour flare, and the patient 
had had a supply from us for the three weeks and then they'd gone back 
to their OP who said 'oh no you need a whole month's supply go back to 
the pharmacy to get the rest of it' and pharmacy had said no we would 
have arranged with you at the time of dispensing. And it literally took 
me to go back to the notes to find out that it was only to cover his 
Zoladex and that was me thinking I'm going to check before we arrange 
any further supplies. And it was just an absolute nightmare. I don't 
know where the problem had occured but the OP obviously hadn't 
received the letter from clinic to say 'patient has started on Zoladex'. 
So do you think he didn't know that the patient had had Zoladex then at 316 
all? 
HP 15 I don't know, I didn't speak to the OP myself. 317 
HP 13 Some of them appear to be very obsessed with the 28 day issue don't 318 
they. Even when we give everything we've got and the patient doesn't 
want to come back to us. 
HP12 But they don't know that that's what we've done. 319 
HP 13 Well, if we do it we're supposed to write it on the TIO .... 320 
HP16 Yeah, total supply. 321 
HP13 .. which I think happens. I think we do endorse the prescription. 322 
HP12 What total supply? 323 
HP13 Yes, this is every thing we've got. 324 
HP12 I've got a reaJly good one but I can't remember the drug. 339 
Tell me about it anyway. 340 
HP 12 I can't remember the drug. It was someone ringing up saying, oh I know 341 
what it was! Methotrexate! Methotrexate for a child for rheumatoid 
arthritis. Ehm so the child had come in to see one of our consultants and 
then seen one of the, liaised with the know arthritis, rheumatologist over 
at the [sister hospital], so started methotrexate and then the mum rings 
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up erhm saying it says on the package it's not for children and how am I 
supposed to give this and spent ages saying about it being unlicensed 
and blah di blah di blah and the whole issue about it. But I think there's 
a whole issue particularly in paediatrics of patient information leaflets 
when they're used off-label and unlicensed that people don't, you know 
it's all very well you go and put your trust in the hospital and then you 
get these tablets and you open up the box and in there it says don't give 
to children or don't use for this or I don't know there must be things. 
There's loads of obscure things. 
Or you are using this for a certain thing, and you think I'm not using it 
for this, it must be wrong or you know and she was absolutely 
distraught, and eventually she went back and saw doctor and it was all 
fine and explaining about, but you had someone on call about, because I 
saw one of your on-call sheets saying 'counselled mum'. 
Yeah, I, we do get quite a lot of calls here from parents of children 
because like [HP 12] says it is an issue and they just ring up wanting 
reassurance that it says do not use in the under 12' s and they've got it to 
use in the under 12's. And it's all very well when we give it from here 
because we can, we know to talk to them at the hatch and say look 
we've checked it out but it does say in the leaflet this but we do it all the 
time it's fine, don't worry. But perhaps, I don't know, they're not as 
conscious of it elsewhere. Because we lucky enough that we've got a 
paediatric hospital. 
The other thing of course is that we're, we often open our original packs 
to supply you know smaller supplies of tablets, perhaps in community 
they don't actually open the original packs so they haven't a clue what's 
on the patient information leaflet in the first place. They just stick the 
label on the outside. 
Isn't that part of their responsibility if they're giving something to a 
patient they should at least know what they're giving them? 
They might be quite happy giving it without realising that in huge letters 
across the middle of the leaftlet is 'do not give to children under 12'. 
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Do you think that that's a worry for community pharmacists though, the 348 
fact that they're .. 
I don't know they even think about it do they? 
But also to be fair to them, they don't have the information to know 
what they're using it for. So they could get a prescription for 
methotrexate, now they don't know if that kid's got cancer, if they've 
got arthritis, got psoriasis, what they're using, they don't have it so how 
can they check ifit's right. 
But they can check to see whether it says 'don't give to a child under 
12'. 
No, but then they're still stuck, they don't have the clinical knowledge 
that, or clinical insight that we get. At least we know what they're using 
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it and they don't have that. 
Do you think we meet the information needs of the GPs and the 
community pharmacists? 
Obviously not otherwise they wouldn't phone us up. 
But we kind of need more information from them to know what they 
need to know about. 
So what are we going to do about it then? 
Tell them to buy an ABCD. 
So do you think there is anything that we could do? 
I mean quite a few of them are aware of what's not on the formulary and 
what they're not, try and be a bit more aware of what they're not likely 
to have because we just say, octreotide, we assume that because it's on 
our shelf it's fine. And then you could send that information direct but 
again it's us (a) thinking about it for every prescription and (b) knowing 
where to send the information if they haven't got a set chemist. 
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Just one thing that came to me as well really I mean we talked about 441 
non-formulary drugs and the fact that the GPs obviously don't stick to it, 
is that a problem for you when patients come into hospital? 
All Yes. 442 
HP 15 It's particularly a problem in surgery where the surgeons don't give two 443 
hoots about what they're on and as we all know, actually don't believe 
that there should be such a thing as a formulary or a drug budget or 
anything like that and they don't want to get involved and so they won't 
do the monitoring for example converting from long-acting nitrates to 
short acting nitrates and I feel that with my limited resources it is 
difficult for me to implement that hence the reason I don't if they have 
enough of their own patient's own supply, which is not helping the 
district in the long term. 
HP II Well it's difficult if it's for these people who are on drugs out of the arc 444 
anyway. They've been on it forever, barbiturates erhm methyldopa, all 
those rubbish things. 
HP 13 These funny combination preparations that are listed as 'unsuitable for 445 
prescribing' and they go 'but my doctor told me it was the best thing'. 
HP II Because they've been on it forever and it's working. 446 
HP 13 You can't say, yeah... 447 
HP 15 It's a bit different that when they've only started it in the last few 448 
months. When they're on something really new that we haven't 
approved yet. When they're on one ofthe 15 hundred ACE inhibitors 
that we just don't happen to keep. 
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HP 13 ..... I wouldn't have any qualms about changing someone's ACE 449 
inhibitor because it's pointless keeping all of those but if it was pscychy 
drugs or something then you wouldn't. 
HP12 But that's because you understand what you're confident in what you're 450 
changing. 
HP13 No it's not because it's different with psychy drugs isn't it? 451 
HPll Yeah, they take longer to kick in and so on. 452 
HP13 Different things work better for different people and you don't know 453 
how long they've spent trying to get them settled on. 
HP 15 They could have tried everything but they've never got the best drug 454 
history. 
HP 16 Because you don't know what they've tried before. There's the other 455 
issue of hospital doctors thinking they can get round the formulary by 
saying that the GP can prescribe a non-formulary drug when in actual 
fact they shouldn't. That is a major issue that has appeared. 
Have you had experience of that? I mean you mentioned at the start the 456 
urology thing. 
HP15 The urologists are dreadful. I honestly think they have no concept and 457 
they won't listen to me when I tell them that they can't do that. 
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Appendix 7.7 (Ist hospital medical consultant interview) 
So you said that the outpatient discharge communication is probably better 21 
because it is produced by more senior doctors rather than the discharge 
summaries that are written by house officers. 
Mmm. 22 
I mean how could you, how could we actually improve that, make it better, why do 23 
you think it's not so good? 
Because they don't have the experience and they don't, you know, have the feel of 24 
what it's like for primary care. Not that we do as much as GPs so I think it's 
experience erhm knowing what the key issues are, what's a straight-forward 
admission and what's less straight-forward. You know I think a lot of the time 
some of the junior staff have only got a rough idea of what the admission's all 
about. And also sort of areas of follow-up, and I think also that the more 
temporary the staff are, the less you know they don't have this feeling of 
responsibility you know they've dealt with the acute episode and their 
responsibility ends there. And now we have some moving at three month intervals 
so they don't have a sense offeeling, you know, if this doesn't work out well for 
the patient then they, you know it's not my problem, it's going to be someone 
else's problem. Whereas if things don't work out well for my outpatients then it 
bounces back on me later erhm so erhm you know what you call it? An incentive 
to get it right. It's the same with my SpRs and my SHOs, you know they don't see 
the consequences of their problems. Well some of them do! 
So we've talked about sort of communication from the hospital to the GPs what 25 
about what you get from GPs when patients are admitted? 
Now that's a very variable feast. The problem there is that the ones that are 26 
admitted are normally admitted as an emergency and the doctor who sees them 
isn't the regular doctor of the patients, so you know why the hell should they, you 
know, know what's going on. So erh, you know you can't really blame the GPs. 
Sometimes if the GP knows the patient you get a very comprehensive letter with 
all the information that you need but the letters are very often, they don't have all 
the drugs in them, and erhm they don't have the past medical history etcetera and 
that's OK if the patient's compos mentis but very often the patient can't give you 
that information. Ifwe look at GP letters erh, you know there's a huge range of 
letters and I think that they suffer from the same thing that the letters from us to 
them suffer from. It's not really knowing what the person wants. 
Erhm, well it depends on how sort of commonly I'd expect it to used and whether 54 
I'd expect the GPs to know about it. Erh if it's one that's likely to be in common 
use erhm I would after an initial period, I wouldn't necessarily make a point that I 
am giving a new drug. I'm trying to think of some examples. The main one is the 
proton pump inhibitors and they seem to be used so universally amongst GPs, 
most GPs seem to know them but they don't always understand the dosage of 
them. Erhm I think it's fair to say we probably presume a bit too much that they 
do know. I try to avoid using new drugs. I mean if it's something very rare like 
say infliximab for Crohn's, then if ever I mention infliximab in a you know, in a 
GP letter then I would write a few words about it. 
And who would prescribe that then? 
55 
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Well that would have to be us but there is an issue about who's doing the 56 
prescribing and monitoring in certain things like azathioprine and methotrexate. 
And erh you know try to make it clear in the letter where the responsibility's left. 
It doesn't always work out. 
Have you experienced problems with that in particular? 57 
Well, not really no. No, that's perhaps it isn't done in a very sort of systematic 58 
way. 
Do you carry on prescribing azathioprine or do you pass that over to the GPs? 59 
Well, we've only just started the methotrexate and what we're doing with the 60 
methotrexate is a bit more organised because we've got an advanced nurse 
practitioner to sort it out for us. And that is that any patient commenced on 
methotrexate, the GPs would be sent an information leaflet erhm and that we 
would not pass over care without getting their permission first. But azathioprine 
we don't have an information leaflet and I do ask them to do the monitoring of 
blood tests mainly because it is logistically easier for the patient and a quarter of 
the time I get the patients to monitor their own blood tests, rather than the GPs. 
Otherwise the results go back to the GP surgery. Now, it isn't a perfect system. I 
think the best system is if most patients monitor their own blood tests regularly. 
Or that we have some sort of central system for monitoring blood tests. 
Have you ever had difficulty in erh, say you've discharged a patient and they have 67 
been on any medicine, have you ever had problems with a GP not wanting to 
prescribe medicines. 
Erhm, a couple oftimes. Er octreotide, erhm we got round it in the end, not for 68 
clinical reasons but financial reasons. 
You definitely feel that that was financial reasons rather than? 69 
Oh, yes. Why did you ask that? 70 
Well, I just wondered because sometimes, I feel that sometimes they do have 71 
genuine clinical reasons for not wanting to take responsibility for it whereas 
sometimes the issue does get clouded by the high cost of a lot of these medicines. 
I didn't think they did. I don't think erhm I don't think I've ever had a GP query, I 72 
can't remember when they queried a script that wasn't for financial reasons. 
Not in my gastro practice. I think in, in you know patients leaving the ward and 74 
things that's different. 
So what happened with the octreotide then? Who actually did prescribe it? 75 
Well, erhm in actual fact the problem really actually came from the area, the sort 76 
of, the old pharmaceutical adviser for the FHSA. 
Right. 77 
And then, you know, in the end it was a question of well who's responsible for 78 
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giving this? And the way it was resolved in the end was the was the patient was in 
primary care and we were only providing nominal supervision for that. So they 
paid for it in the end. 
So they paid for it, and did they prescribe it as well? 79 
Yes. 80 
Yes, so, but the GP was quite happy to prescribe it? 8 I 
Yes, with some guidelines from me. 82 
Did that take a long time to sort out? 83 
It wasn't too bad. There weren't any major problems. Not like being, wanting to 84 
use a new drug that's too expensive. Like infliximab. That is a huge problem. 
What happened then? 85 
Well, well we had to submit to the health authority and then I don't know what's 86 
happening but you know, there are sort of committees that it has to go through and 
erhm you know so you've got a drug with a license, with an NNT of3 and you've 
got some very ill patients and you can't use it because of funding. We have to go 
through all these hoops. So there's an issue there. You know it gets resolved at 
the end of the day, it just takes an awful long time to sort out. 
And when you've probably got a patient who needs it there and then? 87 
Yes, I mean I think the whole thing, that particular example's complicated because 88 
what are our exact circumstances when we are going to use it? You just know that 
certain people would probably hugely benefit from it, you can't just write a script 
for it and so you know that's a bit of a nuisance but it's fair enough because you 
are signing a cheque for so much money. 
You mentioned with this octreotide that the GP didn't want to prescribe it because 89 
it was expensive and does that ever concern you about, you know sort of your 
prescribing within the hospital? 
Oh, all the time. Yeah, I think I'm more budget, I'm more conscious of it. But 90 
you know does one withhold medication that one has learnt to prescribe because 
it's expensive? The answer is no. I don't do that. So erhm you know like an 
expensive antibiotic or something one tries not to think about price and what one's 
spending when, when, when one perceives there's a clinical need. I did hear that 
at a drug savings committee that tried to look at things that didn't need to be given, 
you know when there were alternatives erm and it's apparent that there are lots of 
things that could be done a bit more cheaply. The question is, is there a big 
enough pay-back for the effort of changing people's practice? And very often 
there isn't. 
Just one last thing, you mentioned about giving, about being only able to give 95 
seven days supply and you said that that was a nuisance. Why is that a nuisance? 
Well, in the outpatient clinics for example I might prescribe a course of steroid 96 
therapy. Well I've now got agreement with the pharmacy to ignore the two week 
rule and I can give a six week course of prednisolone or I want to give a short 
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course of something that is longer than two weeks. And if a patient needs to be 
restocked with their sulphasalazine and they would normally get a month's script 
from their GP, shy can I only give them two week? It's anomalous really and it's a 
nuisance for them. 
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Appendix 7.8 (2Dd hospital medical consultant interview) 
What about when erhm treatments are changed? Do you initiate that treatment or 5 
do you ask the GP to do it? 
It depends upon the drug. If it's a drug that I feel that the GP would be happy to 6 
prescribe and that might depend on the drug, it might depend on my knowledge of 
the GP then I would leave it to them. If it's a drug that I think they are unlikely to 
be familiar with then I would tend to prescribe it. Or if it's an outpatient 
attendance and I feel that they need the drug urgently and there might be some, 
you know, reason for them not to be able to attend the GP then I prescribe. 
So how do you make those decisions about you know the drug, what do you take 7 
into consideration when you are thinking about whether a GP might or might not 
be happy to prescribe? 
Well, there would be some drugs that I would feel that the GP would be much 8 
more able to make a decision on prescribing than me, hormone replacement 
therapy would be an example for that which I prescribe mainly as a rheumatologist 
for prophylaxis and treatment of osteoporosis but it's a classic drug for which the 
reasons for prescribing are much broader than that and the reasons to prescribe or 
not and perhaps more likely to be known to somebody in primary care than myself. 
There would be other classes of drugs, lets say prescriptions of things like 
antidepressants and proton pump inhibitors where I feel that I would maybe have 
preferences but that I wouldn't feel strongly about and I feel it's probably more 
appropriate for the GP to make that decision. Also that the GP might be better 
informed about previous drug treatments and other, other issues which might 
influence that prescription. 
So what recommendation do you make to the GP, do you just say prescribe HRT 9 
for this patient for that, whatever reason and you leave it to the GP to decide. 
Yes. Absolutely and often the same with antidepressants or things like proton 10 
pump inhibitors where you can make advice generically. 
What other things do you think the GP needs to know apart from what the 11 
diagnosis is and what the treatment's going to be? 
Erhm, I, I mean just knowing the diagnosis covers a fairly kind of wide range of 12 
things in itself. I mean, with the, within in a diagnosis you might be able to give 
an impression of prognosis and that would obviously determine what kind of 
treatment you might offer, the aggressiveness of the disease. Erhn and I think it 
needs to be in context as well. The impression that you've considered developing 
disease X in the context of you know lets say heart disease and diabetes rather than 
just a disease in isolation. 
What about when patients are referred to you? What do you think's, what 13 
information do you needfrom the GP? 
Erhm, a brief history of the reason for the referral and some idea of what the 14 
expectations from the referral are and a brief past medical history and not just of 
events, not just cholecystectomies and appendicectomies but also relevant, 
particularly psychosocial information often left out of the GP's letter because that 
very much helps to put the patient in their context. I like to know what medication 
they're taking currently and any relevant medication they've taken previously 
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particular thinks, particularly things that have been used to treat the reason why the 
patient is being referred and which maybe haven't worked or have produced 
problems and if it's relevant drug allergies as well. 
Do you give GPs any additional information about drugs at all? 19 
It would depend on the drug, I mean if, an example of a drug like leflunomide 20 
erhm which as a rheumatologist you might use now quite a lot but most GPs would 
still I think be unfamiliar with. You might just give a kind of potted vignette of 
what the drug is, how it's thought to work and what the problems associated with 
it are and I think you make the assumption for lots of other classes of drugs that 
the GP's knowledge ofthat drug would be at least as good as yours. 
Would you include the other disease modifying drugs in that or do you give other 21 
information? 
I mean I would send them less information in the letter about disease modifying 22 
drugs with which I felt they might be familiar but I still tend to include information 
about drug monitoring and drug side-effects. Maybe not quite so much 
explanation. Erhm and we also give the patient a shared care book if we are 
asking the GP to be involved with blood monitoring which (a) will give 
information about the drug and the patient's treatment with that drug and (b) the 
schedule for monitoring. 
Is that, that's held by the patient? 23 
That would be held by the patients, yes. 24 
At which point do you ask the GP to share care? Do you start the patients and 25 
stabilise them or? 
Erhm, yes sometimes is the answer to that because it depends on the drug, I mean 26 
take leflunomide again, I feel that most GPs are unlikely to be familiar with 
leflunomide so I'd probably do the initial prescribing for most patients starting that 
drug. GPs are more likely to be familiar with, for example methotrexate, so I 
would often ask the GP to prescribe methotrexate. Although that would depend on 
the GP as well, I mean I know that some GPs would be very happy with that, 
would be keen for you to do that and other GPs would be less happy so that would 
depend on personal knowledge. 
Yes, so that's just something you've learnt as you've been working here? 27 
Yes. 28 
What about erhm things like lejlunomide, have you had problems trying to transfer 29 
care back to the GP or? 
I've had one GP out of several dozen people starting leflunomide who was not, 30 
initially not happy at continuing prescription and monitoring under a shared care 
basis and in fact for reasons apart from that the patient discontinued treatment with 
leflunomide so I don't know whether that would have continued to be a problem 
but I wrote explaining the position and the protocol and so on and he didn't write 
back to say that he wouldn't prescribe but in fact by that time we'd already taken 
the woman off. But by and large I don't have problems with people in primary 
care not wanting to be part of a shared care system, which I think is probably 
438 
Appendix 7 
relatively unusual but that may be because we've historically been, had to take on 
a lot of the actual monitoring ourselves here. And which not all hospital 
departments have been able to or have ( ). 
Do you think the GPs are quite happy with that, they're prescribing the drug and 31 
you doing the monitoring? 
Historically they have been happy or lots ofGPs have been happy but I think it's 32 
something that I have come to feel increasingly uneasy about because there's the, 
there's erhm it's held on trust that the results are being looked at by the person 
who's doing the prescribing and although we've not had any problems with that 
system that I'm aware of, I think it's going to have to be the case that in future that 
the person who prescribes actually is able to have sight of the results. It may be 
that that means that the GPs, if they're going to prescribe have to do more ofthe 
monitoring, it may mean that we have to do more of the prescriptions. It may also 
be possible for us to actually physically carry out having the blood taken here and 
yet supply the GP in parallel with a copy of the results. 
I mean personally I take the view that you can't separate the cost of drug 52 
prescriptions from the cost of everything else that you do and if you chose to spend 
a quarter of a million on anti-TNF drugs or you chose to spend the million on cox 
II inhibitors across the health authority then that's a quarter of a million less that 
you've got to spend on physiotherapy or whatever. So I think, I mean I find 
personally ... 
(interruption from someone coming into office) 
So you think it would actually be better to look at drug costs as part of the whole 54 
costs rather than erhm just sort of isolating them because I think this is the 
problem that we've had with GPs in the past that their, the only part of their 
budget that's really been separately defined and monitored has been the 
prescribing budget so that's the one that they're always looking at. 
Yeah, I mean I feel it needs to be seen in a very broad context that it's all taken 55 
ultimately from the same budget and you know you can argue at a high level how 
big that budget should be but within a given financial year you've only got a given 
amount of money to work with and if you spend more on cox II inhibitors or 
whatever then you're going to have less money to spend on other things so I don't 
think you can ignore that or I think you ignore it at your peril. 
Have you had any problems arising when you've had a patient transferred to you 56 
from a GP at all? 
What sort of things? 57 
Well if you 've not had sufficient information or anything like that or have you 58 
managed tofind out what you wanted to know? 
Erh I think the standard of information in lots of referral letters in primary care is 59 
not high, again it varies very much from practice to practice that I couldn't really 
put a figure on it but I'd say probably 50% of referral letters don't contain 
adequate information about why the patient has been referred or about specifics 
with regard to the drugs that they're taking. 
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Does that impact on patient care do you think or does it just waste your time? 60 
I mean partly it wastes my time but, in a busy clinic you can more usefully spend 61 
your time doing something other than trying to dig out the details of what it might 
be relatively easy to provide anyway. I mean some practices, I mean not in this 
end a good, a good referral letter but also send a copy of their computerised 
practice records you know for the last, well however long really so you've really 
got a very comprehensive picture of the patient's background. And while that 
sometimes might be too much information, by and large it's very useful. 
Can I just go back again to this business about you know if GPs do refuse to 62 
prescribe erhm to continue medicines? Why do you think they do that have you? 
I mean they may be unfamiliar with the drug and unhappy about prescribing 63 
themselves and feel very clearly that it's the hospital's responsibility to prescribe 
you know they'll not perhaps have their name on a prescription for a drug when 
they're not familiar with that drug's actions, it's side-effects, monitoring which I 
think is reasonable, very reasonable. They may also feel that the drug that you're 
prescribing that they may be familiar with is not appropriate, that the wrong 
decision's been made. 
Do you think cost ever comes into that? 64 
I think cost probably does come into it sometimes, I think may be they sometimes 65 
feel that inappropriately expensive drugs are being prescribed in large numbers in 
secondary care without really any thought to the costs to the primary care budget. 
But it think that's probably less than, that's probably less of a perception than it 
was and it's certainly not something that I've had a problem with. 
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